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Abstract 
The intracellular second messenger InsP3 is a vital molecule in the regulation of 
Ca2+ signalling.  Ca2+ mediates a wide range of cellular activities from 
fertilisation and cell differentiation through to apoptoisis.  Using X-ray crystal 
structure data and molecular modelling, a series of novel InsP3 analogues were 
designed as selective InsP3R-antagonists.  Two novel synthetic routes have 
been developed for the synthesis of these analogues.  The first route uses a 
Ferrier-II rearrangement to provide enantiopure inositol intermediates, whereas, 
the second route employs a diastereomeric resolution to obtain the enantiopure 
inositols.  The successful synthesis of InsP3 and a series of 5-position modified 
analogues are reported herein. 
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1. Introduction 
1.1. Biological overview of inositol phosphates and Ca2+ signalling 
Calcium (Ca2+) signalling is recognised as one of the most fundamental 
signalling systems in all living organisms.  Ca2+ signals are the first signals, 
which are sent after fetilisation.1  These signals arise by the sperm injecting 
phospholipase C zeta (PLC!, believed to be the sperm factor) into the egg, 
which hydrolyses PtdIns(4,5)P2 2, releasing InsP3 1 into the egg cytosol.
2  The 
InsP3 then activates its complementary receptor (InsP3Rs), releasing Ca
2+ from 
the stores on the endoplasmic reticulum that trigger development of the 
embryo.  It is also a Ca2+ signal that will be the last signal sent before you die, 
as excessive release of Ca2+ initiates programmed cell death (apoptosis).1  
However, Ca2+ also mediates many other cellular functions throughout the 
whole of life; including cell differentiation and proliferation, gene transcription 
and muscle contraction.3  
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Figure 1.1.1.  Key compounds of the secondary messenger pathways associated with Ca
2+
 release as a result of GPCR 
activation.  InsP3 1.  PtdIns(4,5)P2 2.  DAG 3. 
For some years, it was suspected that inositol phosphates were responsible for 
mediating the Ca2+ signalling cascade.3  However, it was not until 1983 that 
Berridge and co-workers demonstrated that D-myo-inositol 1,4,5-trisphosphate 
(InsP3) 1 (Figure 1.1.1) mobilised distinct intracellular Ca
2+ stores.4  This 
discovery led to an explosion of research into Ca2+ signalling, which has led to 
the synthesis and characterisation of many natural and unnatural intracellular 
signalling molecules based around the myo-inositol core.5  It is now widely 
accepted that InsP3 1 is the key intracellular secondary messenger that 
mediates intracellular Ca2+-release. 
Introduction – InsP3 Biology 
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1.2 InsP3 as a key second messenger 
1.2.1 Identification of InsP3 as key Ca
2+-releasing secondary messenger 
The work in the field of inositol signalling can be traced further back than the 
discovery made by Berridge and co-workers.  In 1953, Lowell and Mabel Hokin 
were investigating what they believed to be the incorporation of radio labelled 
32P into RNA, following the stimulation of isolated pancreatic slices by acetyl 
choline (ACh).6  It was discovered that there was no incorporation of 32P into the 
RNA, but rather that it was incorporated to the inositol-based 
phosphatidylinositol (PtdIns) and phosphatidic acid (PA).6 These observations 
became known as the “phosphoinositide effect” (PI effect) and were the subject 
of much comprehensive research over the following 20 years.3 
Durell and Garland were the first researchers to suggest that metabolism of the 
inositol phospholipids by phospholipase C lay downstream of receptor 
activation.7  Michell then observed coincidence of inositol lipid metabolism and 
Ca2+ homeostatic changes, and proposed a link between the two.8  Berridge 
demonstrated this link experimentally, by showing that phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2) 2 was the principal substrate for the PtdIns 
specific PLC,9 rather than PtdIns, as previously thought.  As a result of the 
metabolism of PtdIns(4,5)P2 2, InsP3 1 accumulated in the cytosol and effected 
release of Ca2+ from distinct intracellular stores,4 proving the link between the 
phophoinositides and Ca2+ signalling. 
The discoveries made by Berridge and others have led to much research into 
the detailed mechanisms of inositol pathways and their role in Ca2+ signalling.  
A range of naturally-occurring polyphosphorylated inositols have all been shown 
to have key biological activities,10 but the focus of this dissertation will remain 
on the interaction of InsP3 with its receptors. 
 
1.2.2. InsP3 signalling cascade 
The pathways that link InsP3 to Ca
2+-signalling are now well established at a 
cellular level, but some of the specific details about receptor activation on a 
molecular level still remain elusive. 
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The Ca2+ signalling cascade, mediated by InsP3, is related to the G-protein 
coupled receptors (GPCRs), which are transmembrane proteins found 
traversing the outer cell membrane.  These receptors are linked to the 
secondary messaging cascade via the interaction of the G-protein complex with 
the hydrolytic enzyme phospholipase C (PLC), as shown in Figure 1.2.1. 
 
Figure 1.2.1. Schematic diagram of the InsP3 signalling cascade, which leads to release of Ca
2+
 from the intracellular 
stores located on the endoplasmic or sarcoplasmic reticulum.  Reproduced with permission.
5 
External signals - such as hormones, neurotransmitters or growth factors - 
arrive at the cell surface and bind with their complimentary GPCR, inducing 
agonist activation of the receptor.  The binding of the ligand confers a 
conformational change in the entire receptor, leading to dissociation of the G-
protein complex.  The !-subunit of the G-protein then moves to activate the 
membrane bound phospholipase C.  PLC hydrolyses the membrane bound 
PtdIns(4,5)P2 2, releasing diacylglyceol (DAG) 3 and InsP3 1, both of which are 
second messengers. 
The bifurcating nature of the InsP3 signalling cascade is demonstrated by the 
release of Ca2+ through two different pathways, each mediated by one of the 
second messengers released through hydrolysis of PtdIns(4,5)P2 2.  The 
lipophilic DAG 3 remains bound in the membrane, where it can mediate its 
cellular actions through the activation of protein kinase C (PKC) enzymes, 
Introduction – InsP3 Biology 
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which can lead to the opening of voltage-gated Ca2+ channels.  The hydrophilic 
InsP3 diffuses into the cytosol, where it moves to bind with the InsP3 receptors 
(InsP3Rs), located predominantly on the endoplasmic (ER) or sarcoplasmic 
(SR) reticulum.  The InsP3Rs are ligand-gated Ca
2+ channels, which open when 
InsP3 binds, releasing Ca
2+ from the distinct intracellular stores on the ER or 
SR.  These controlled releases of Ca2+ then trigger further cellular events to 
mediate their actions. 
 
1.3. Structure and function of the InsP3 receptors (InsP3Rs) 
1.3.1. Identification of the InsP3R subtypes 
The InsP3Rs were first isolated and cloned in 1989 by Mikoshiba and co-
workers.11  The InsP3Rs are ubiquitous throughout higher organisms, including 
mammals and humans.  Their primary function is the regulation of the levels of 
cytosolic Ca2+ (in addition to the RYRs), by controlled release of Ca2+ from the 
stores located on the endoplasmic reticulum (ER) or sarcoplasmic reticulum 
(SR) (in smooth muscle cells) in response to extracellular stimuli via the G-
protein coupled receptors (GPCRs). 
There have been three isoforms of the InsP3Rs identified,
12 that share high 
sequence homology (60-70% conserved amino acid sequences), but differ in 
their affinity for InsP3 and their physiological distribution.  The ratio of 
expression of the isoforms differs by cell type.  High levels of the type-1 
receptor (InsP3R-1) are expressed in the central nervous system (CNS).  The 
type-2 receptor (InsP3R-2) is prevalent in many cell types, particularly in spinal 
cord and glial cells.  The type-3 receptor (InsP3R-3) is more typically expressed 
in the kidney, brain, gastrointestinal tract and pancreatic islets.  The disparity in 
the distribution and homology of the receptor subtypes suggests that each may 
have a distinct cellular role and that interaction between them may be required 
for spatial and temporal control of Ca2+ signalling. 
Of the three receptor-subtypes, the most studied are the InsP3R-1, which were 
isolated from mouse. 
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1.3.2. Structure of the InsP3Rs 
The InsP3R-1 is a homotetrameric structure, composed of four identical 
subunits arranged in a symmetrical fashion.  This four-fold symmetry and the 
overall architecture of the receptor has been confirmed by 3D electron 
microscopy studies.  These studies have shown two distinct domains within the 
receptor: the large cytoplasmic portion and the smaller transmembrane (TM) 
channel region.13-17  
 
Figure 1.3.1.  Schematic diagram of domain structure of subunit of mouse InsP3R-1.  The protein is 2749 amino acids 
long and composed of five distinct domains (from the N-terminus): the suppressor domain; the InsP3 binding domain; 
the modulatory domain; the transmembrane (TM) channel domain; and the coupling domain. 
Each subunit is 2749 amino acids long, made up of five distinct domains: (from 
the N-terminus) the inhibitory suppressor domain (1-224); the InsP3 binding 
domain (225-578); the modulatory domain (579-2100); the TM channel domain 
(2100-2590); and the coupling domain (2591-2749).  A cross-sectional 
representation of the receptor is shown in Figure 1.3.2., indicating these distinct 
regions and their relative locations. 
 
Figure 1.3.2.  Cross sectional representation of InsP3R-1 receptor, showing two of the four identical subunits, forming 
the central pore through which the Ca
2+
 is released. 
Introduction – InsP3 Biology 
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1.3.3. X-ray crystal structures of InsP3Rs 
In recent years Bosanac and co-workers have elucidated the structure of the 
two N-terminal domains of the InsP3R-1, by solving the X-ray crystal structures 
of the suppressor domain and the InsP3 binding domain (in complex with InsP3 
itself).18, 19  The suppressor domain (residues 1-224) found at the N-terminus is 
composed of two subdomains, displaying a hammer-type shape (Figure 1.3.3.). 
 
Figure 1.3.3.  PyMol (www.pymol.org) representation of the X-ray crystal structure of InsP3 suppressor domain of 
mouse type 1 InsP3Rs (PDB accession number 1XZZ).  Head subdomain in red; Arm subdomain in gold.
19 
The Head subdomain (shown in red) forms a !-trefoil fold; and the Arm 
subdomain (shown in gold) forms a helix-turn-helix structure, which protrudes 
away from the !-trefoil folds.  Although this region is not required for InsP3 
binding, it decreases the affinity of the receptor for InsP3, hence was termed the 
suppressor domain (SD).20  However, the SD is necessary for the Ca2+ channel 
gating, as InsP3 will bind to an InsP3R without a SD, but will no longer open the 
pore to release Ca2+.20, 21  The links between InsP3 binding and channel 
activation are still not fully understood at present, and without a structure of the 
entire InsP3R-1 at sufficient resolution, it will be difficult to deconvolute the 
gating mechanism.  
Adjacent to the SD is the InsP3 binding domain, consisting of 354 amino acids 
(residues 224-578) organised into two subdomains.18  Bosanac and co-workers 
solved the structure of this domain, using a slightly extended construct 
(residues 224-604), which was found to bind InsP3 with high affinity (Kd 
0.09 nM).22 
head 
subdomain 
arm 
subdomain 
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Figure 1.3.4. PyMol (www.pymol.org) representation of the X-ray crystal structure of InsP3 binding domain of mouse 
type 1 InsP3Rs with InsP3 bound (PDB accession number 1N4K).  !-subdomain in blue; "-subdomain in green.
18 
The structure was solved with InsP3 bound, as the apo-protein was not 
amenable to crystallisation.  The InsP3 binding domain is boomerang shaped, 
consisting of two subdomains: the !-helical, C-terminal !-domain (residues 437-
604) contains an ‘armadillo-repeat’ like fold; and the N-terminal, "-domain 
(residues 224-436) containing the "-trefoil fold (Figure 1.3.4.).  These two 
subunits form a deep cleft lined with basic residues, into which InsP3 binds. 
 
1.3.4. Summary 
Much is now understood about the overall pathway of Ca2+ release, induced by 
stimulation of the GPCRs.  However, the mechanism of InsP3R activation by 
InsP3 is still unclear.  Small molecule tools, in conjunction with the known X-ray 
structures of the InsP3Rs, are therefore required for closer study of this 
mechanism on a molecular level. 
 
!-subdomain "-subdomain 
InsP3 
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1.4. Inositol structure and nomenclature 
myo-Inositol 4 is the most common of the nine possible stereoisomers of 
cyclohexane hexanol (Figure 1.4.1.).  Five of the nine stereoisomers are 
naturally occurring (myo-inositol 4, neo-inositol 6, D-(+)-chiro-inositol 11, L-(-)-
chiro-inositol 12, scyllo-inositol 5) and four are unnatural synthetic products (cis-
inositol 8, epi-inositol 7, allo-inositol 10, muco-inositol 9).  Of these nine 
stereoisomers, five (myo, scyllo, neo, cis, muco) are meso with an internal 
plane of symmetry between C-2 and C-5, therefore, are not optically active.  
Two stereoisomers, D-(+)-chiro-inositol 11 and L-(-)-chiro-inositol 12, are a pair 
of enantiomers with no internal symmetry elements. 
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Figure 1.4.1.  The nine stereoisomers of inositol. 
myo-Inositol 4 is the most abundant stereoisomer in nature; when literature 
refers to ‘inositol’ without a prefix, it is generally accepted that this refers to 
myo-inositol.  Whereas, the general term ‘inositols’ refers to all of the nine 
stereoisomers.  scyllo-Inositol and neo-inositol are found in small quantities in 
neuronal tissues and D-(+)-chiro-inositol 11 is found as a motif in some 
biological molecules.23 
The naming of these molecules was confused in earlier publications, due to 
their highly symmetric nature and the strict adherence to IUPAC rules.24  Under 
these naming conventions, the addition of a single phosphate group would 
change the priorities of the substituents around the ring and required a swap 
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between D- and L- numbering systems.  Therefore, in an effort to circumvent 
these issues Agranoff’s Turtle has been used (Figure 1.4.2.).10  Subsequently, 
Agranoff’s rules were officially recommended by the International Union of 
Biochemistry Nomenclature Committee as the method for numbering inositol-
based molecules.25, 26 
 
Figure 1.4.2.  Agranoff’s turtle rules for the numbering of inositol ring systems.  (Figure adapted from Irvine and Schell 
with permission)
10 
Agranoff states that the turtle represents the most thermodynamically stable 
chair conformation of myo-inositol.  The axial 2-position hydroxyl group is the 
head and the other five equatorial hydroxyl groups are the flippers and the tail.  
For the D-numbering system, the turtle is right flippered, so position 1 is the right 
flipper.  Position 2 is always the head, regardless of numbering system.  
Therefore, following in an anticlockwise manner, the left flipper is position 3 and 
so on.  Alternatively, for the lesser used L-numbering, the turtle is left flippered, 
so it would regard position 1 as the left flipper.  As the head is still position 2, 
the numbering would continue in a clockwise fashion, defining the right flipper 
this time as position 3.  To avoid confusion, the D-numbering system is now 
used predominantly in both chemistry and biology literature. 
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1.5. Synthesis of InsP3 and inositol polyphosphate analogues 
1.5.1. Introduction 
In the synthesis of inositol-based compounds, formation of the correct inositol 
ring configuration is essential (there are nine stereoisomers).  It is therefore of 
key importance to ensure that the inositol core is generated in an unambiguous 
manner. 
Commencing a synthesis from the parent inositol molecule by subjecting it to a 
range of manipulations to achieve the target molecule is the most typical 
method.  An alternative approach is to build up functionality on a non-inositol 
skeleton and then transform it into the appropriate inositol core via a 
carbocyclisation or dihydroxylation reaction.  In both of these aforementioned 
strategies, there is the further complication in the requirement for advanced 
enantiopure intermediates, rather than just racemic ones.  Chemical or 
enzymatic resolutions can achieve this, although typically at the cost of yields.  
Alternatively, some synthetic routes will commence from chiral pool materials, 
which can be transformed directly into enantiopure inositol intermediates 
without the need for resolution steps by retention of the chiral information. 
The methods surveyed in the following sections of this chapter principally apply 
to the synthesis of myo-inositol rings and InsP3 1, rather than other inositol 
isomers.   
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1.5.2. Ozaki’s synthesis of InsP3 
Ozaki and co-workers were the first group to report a synthetic route to InsP3 1 
in 1986.27  Their synthetic route started from the commercially available myo-
inositol (Scheme 1.5.1.), thus fixing the ring configuration immediately. 
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Scheme 1.5.1.  Ozaki’s total synthesis of InsP3 1.  Reagents and conditions: i. BnCl, NaH, DMF, 90% yield;  ii. ethylene 
glycol, 4-TsOH, CHCl3, RT, 80% yield;  iii. AllBr, NaH, DMF, 100% yield;  iv.  AcOH, H2O, 90 ˚C, 88% yield;  v. 1-
menthoxyacetylchloride, pyridine, 39% yield of 19;  vi. NaOH(aq), MeOH, 98% yield;  vii. AllBr, NaOH, benzene, reflux, 
76% yield;  viii. BnCl, NaH, DMF, 98% yield;  ix. RhCl(PPh3)3, DABCO then HCl, MeOH, 58% yield;  x. (PhNH)2P(O)Cl, 
4-DMAP, pyridine, 41% yield;  xi. i-AmONO, AcOH, pyridine, Ac2O;  xii. 5% Pd/C, H2, MeOH, H2O.
27 
myo-Inositol was bis protected as the cyclohexylidene acetal, affording the diol 
13, which was perbenzylated to give the dibenzyl ether 14.  Selective cleavage 
of the more strained 4,5-trans acetal was achieved under conditions reported by 
Tate.28  The ether 14 was treated with ethylene glycol in the presence of 4-
toluenesulfonic acid in chloroform, precipitating the 4,5-diol 15 before the less 
reactive 1,2-cis-acteal was cleaved.  Allylation of the two hydroxyl groups, 
followed by removal of the cis-acetal provided the racemic 1,2-diol 17.  The 
racemate 17 was optically resolved by treatment with 1-L-menthoxyacetyl 
chloride to give a pair of diastereoisomers 18 and 19, which were separated by 
fractional crystallisation and silica gel chromatography.  The desired 
enantiomerically enriched diastereoisomer 19 was obtained in 39% overall 
yield.  Cleavage of the chiral auxiliary from 19 by alkaline methanolysis, 
followed by selective allylation of OH-1 afforded the alcohol 21, which was 
protected as the benzyl ether 22.  Removal of the allyl groups from 22 with 
Wilkinson’s catalyst, followed by acidic methanolysis provided the 1,4,5-triol 23, 
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which was phosphorylated with dianilidophosphoric chloride to give the 
protected trisphosphate 24.  Deprotection of the phosphate groups with isoamyl 
nitrite, followed by hydrogenolysis afforded D-InsP3 1.  Yields for the two 
deprotection steps were not published, as they were unoptimised at the time of 
publication. 
Ozaki’s synthetic route provided a method by which the L-enantiomer of InsP3 1 
could be synthesised, by using the antipodal diastereoisomer 18 from the 
resolution step.  Whilst not significantly biologically active, L-InsP3 is an 
important control compound for biological assays. L-InsP3 contains all the 
elements of D-InsP3, however, it only binds to the InsP3Rs with vastly reduced 
affinity (cf. D-InsP3), and has a poor Ca
2+-releasing potential.29 
 
1.5.3. Potter’s early syntheses of racemic InsP3 
Subsequent to Ozaki’s work, Potter and co-workers published a racemic 
synthesis of InsP3 using a phosphite chemistry approach for the 
phosphorylation step (Scheme 1.5.2.).30  The racemic 1,4,5-triol 23 was treated 
with diisopropylamino(2-cyanoethyl)chlorophosphine, yielding the 1,4,5-
trisphosphoramidite 26.  1H-Tetrazole-catalysed substitution of the amine 
moiety by 2-cyanoethanol afforded the trisphosphate 27.  Subsequent oxidation 
of 27 with t-butyl hydroperoxide gave the protected trisphosphate 28, which was 
subsequently deprotected by Birch reduction to give racemic InsP3 1.  Some 
other inositol-based phosphate impurities were observed during the dissolving 
metal deprotection, which could only be separated after ion exchange 
chromatography and preparative HPLC. 
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Scheme 1.5.2.  Potter’s racemic synthesis of InsP3 1 from triol 23.  Reagents and conditions:  i. ClP(OCH2CH2CN)N
i
Pr2 
(3.3 eq), Hünig’s base, CH2Cl2, 90% yield;  ii. 1H-tetrazole, HOCH2CH2CN, CH2Cl2 (no yield quoted);  iii. 
t
BuOOH, 
100% yield;  iv. Na, NH3(l), -78 ˚C, ~50% yield.
30 
Whilst Potter’s synthesis was racemic, methodology was shown to be available 
to obtain triol 23 in an enantiopure form by Gigg and co-workers.  Using similar 
methodology to Ozaki, they could prepare the enantiopure triol 32 via 
isopropylidene acetals and regioselective allylation (using stannylene acetal 
chemistry).31   
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Scheme 1.5.3.  Resolution to obtain D-1,2,4-tris-O-benzyl myo-inositol 32.  Reagents and conditions: i. (-)-!-
Camphanic acid chloride, pyridine, RT, 18 h, 86% yield of 30;  ii. NaOH, MeOH, reflux, 1 h, quant. yield;  iii. HCl in 
MeOH (1 M), reflux, 20 min, quant. yield.
32 
The resolution of the 2,5,6-triol was achieved by coupling a !-camphanate unit 
onto the isopropylidene analogue 29, affording 30.32  Basic hydrolysis of the 
chiral auxiliary on 30 afforded alcohol 31, which was subjected to acidic 
hydrolysis to remove the acetonide, yielding 1-D-1,2,4-tris-O-benzyl-myo inositol 
32.  This triol 32 was the antipode of 1-L-1,2,4-tris-O-benzyl-myo inositol 23 (or 
1-D-2,3,6 tris-O-benzyl-myo inositol 23), which was required for the InsP3 
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synthesis.  This triol 23 could be obtained by hydrolysis of the other 
diastereoisomer from the mother liquors of the resolution step. 
 
1.5.4. Ley’s enantiopure synthesis of InsP3 from benzene. 
Ley and co-workers approached the synthesis of InsP3 and phosphatidyl inositol 
derivatives from a very different viewpoint, which would see the six stereogenic 
centres of inositol being introduced in a sequential manner starting from 
benzene.33  Ley had previously published work on the strategic importance of 
microbial oxidation using Pseudomonas putida to convert benzene into cis-
cyclohexadiene-1,2-diol 33.34  These vicinal alcohols would ultimately become 
(OH-2 and OH-3). 
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Scheme 1.5.4.  Ley’s route to InsP3 from benzene (part 1).  Reagents and conditions:  i. (MeO)2CO, NaOMe, MeOH;  ii. 
mCPBA, CH2Cl2, 47% yield over 2 steps;  iii. HBF4·OEt2 (cat.), CH2Cl2, 67% yield;  iv. BnBr, Ag2O, DMF, 100% yield;  v. 
Et3N, MeOH, H2O, 3 days, 99% yield.
33 
The cyclic carbonate 34 was readily synthesised from the diol 33, obtained from 
the microbial oxidation.  Selective epoxidation of 34 with mCPBA afforded the 
!- and "-epoxides (35 and 36) in a 4.6:1 ratio (Scheme 1.5.4.).  This epoxide 
would give rise to OH-4 and OH-5 of the inositol.  Ring opening of the epoxide 
35 with alcohol 37, derived from (S)-(+)-mandelic acid, provided a pair of 
diastereomeric alcohols 38 and 39.  After careful separation, the free hydroxyl 
group of 38 was protected as the benzyl ether 40 and the carbonate group was 
removed, furnishing diol 41.  Hydroxyl-directed epoxidation gave almost 
exclusively the "-epoxide 42 (leading to OH-1 and OH-6) (Scheme 1.5.5.).  
Protection of the cis-diol as the acetinide 43, followed by regioselective epoxide 
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opening with alcohol 44 afforded a mixture of myo-46 and muco-45 inositol 
rings.  Removal of the chiral auxiliary and the benzyl group from the myo-
inositol ring by hydrogenolysis furnished the 1,4,5-triol 47, which was 
phosphorylated to give the protected trisphosphate 48.  Final global 
deprotection of 48 by hydrogenolysis and acid hydrolysis afforded D-InsP3 1. 
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Scheme 1.5.5. Ley’s route to InsP3 from benzene (part 2).  Reagents and conditions:  i. mCPBA, CH2Cl2, 87% yield;  ii. 
2,2-dimethoxypropane, CSA, CH2Cl2, 89% yield;  iii. alcohol 44, NaH, TMEDA, 110 ˚C, 72 h, 95% yield (of 46 (58%) 
and 45 (37%) combined);  iv. H2, 10% Pd/C, EtOH, 16 h, 100% yield;  v. 
n
BuLi, 
i
Pr2NH, tetrabenzylpyrophosphate, THF, 
-30 ˚C to RT, 67% yield;  vi. a. H2, 10% Pd/C, EtOH, 48 h;  b. 80% aq. TFA, 4 h, 88% yield over 2 steps.
33 
Ley showed that through careful stereocontrol of epoxidations and their 
subsequent ring openings that each position of the myo-inositol ring could be 
set and controlled in an individual manner.  However, this method was not 
readily amenable to syntheses of analogues, due to the restricted arrangement 
of the protecting groups.  Subsequently, Trost35 and Altenbach36, 37 have shown 
that the dihydroxylation concepts proposed by Ley can be used to synthesise D-
InsP3 1 from Conduritol B derivatives. 
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1.6. Improved synthetic strategies employing orthoesters 
1.6.1. First reported use of myo-inositol 1,3,5-orthoformate 49 
Kishi and Lee were interested in the synthesis of cyclohexane derivatives 
bearing three axially protected hydroxyl groups on the 1-, 3- and 5- positions as 
part of an ongoing research project.  Their attention was focused on the 
synthesis of the adamantane-like mono orthoester of myo-inositol 4.  This 
racemic material was derived from myo-inositol in a single step by acid 
catalysed reaction with triethylorthoformate in 76% yield (Scheme 1.6.1.).38  
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Scheme 1.6.1.  Formation of myo-inositol orthoformate 49 and the triacetate derivative 50.  Reagents and conditions: i. 
CH(OEt)3, 4-TsOH·H2O, DMSO, 100 ˚C, 76% yield;  ii. Ac2O, pyridine, RT, yield not reported.
38
  
Analysis of the orthoformate 49 and its corresponding triacetate derivative 50 by 
1H NMR clearly demonstrated that there was a symmetry element present in the 
molecule, supporting the proposed adamantyl caged structure.  Subsequently 
this has been confirmed by numerous groups using 13C NMR, where only 4 
signals are observed for the inositol ring. 
Billington and co-workers realised the potential of the orthoformate 49 as the 
starting point for the synthesis of several inositol polyphosphates.39  Having 
previously encountered problems with the low-yielding selective formation of the 
1,2:4,5 bis acetal 13 reported by Ozaki,27 Billington looked to the orthoformate 
as an alternative protecting group strategy (Scheme 1.6.2.)  
Formation of the orthoformate 49 was achieved in high yield from myo-inositol, 
using a modification of Kishi’s original method.38  Switching the solvent to DMF 
provided a cleaner product and more readily reproducible yields of 49.  
Selective allylation of OH-4, desymmetrised the molecule to afford the racemic 
diol 51.  The selectivity of the alkylation was derived from the stabilisation of the 
alkoxide intermediate, by formation of a sodium chelate bridge between the 
alkoxide and the remaining axial hydroxyl group.  On quenching with allyl 
bromide, the allyl ether 51 was exclusively formed 
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Scheme 1.6.2. Racemic synthesis of myo-inositol 1,3,4,5-tetrakis(phosphate) 56.  Reagents and conditions: i. Triethyl 
orthoformate, 4-TsOH·H2O. DMF, 90 ˚C;  ii. NaH (1 eq), AllBr (1 eq), DMF, RT, 80% yield;  iii. NaH (2.5 eq), BnBr 
(2.5 eq), DMF, RT, 86% yield;  iv. Rh(PPh3)3Cl, diazabicyclo[2.2.2]octane, EtOH, reflux;  v. 0.1 M HCl-MeOH, reflux, 
15 min, 53% yield over 2 steps;  v. NaH, ((BnO)2PO)2O, imidazole (cat.), THF, 25 ˚C, 66% yield;  vi. 10% Pd/C, H2, 
EtOH:H2O (80:20), 88% yield.
39
 
Perbenzylation of the diol 51 afforded 52, hydrolysis of which furnished the 
1,3,5-triol 53.  Removal of the allyl group from the 4-position, using Wilkinson’s 
catalyst followed by acid hydrolysis of the vinyl ether, afforded the tetrol 54.  
Phosphorylation with tetrabenzylpyrophosphate and imidazole, furnished the 
protected tetrakisphosphate 55.  Subsequent global deprotection of 55 by 
hydrogenolysis afforded racemic D-myo-inositol 1,3,4,5-tetrakisphosphate 56 
(Ins(1,3,4,5)P4). 
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Figure 1.6.3.  myo-Inositol 2-phosphate 57 (meso), myo-inositol 4-phosphate 58 (racemic) and myo-insoitol-1,3-
bisphosphate 59 (meso) synthesised by Billington from the orthoformate precursor 49.
39 
Using similar techniques, the total syntheses of racemic D-myo-inositol 2-
phosphate 57, D-myo-inositol 4-phosphate 58 and D-myo-inositol 1,3-
bisphosphate 59 were effected via the orthoformate 49 (Figure 1.6.3.).  These 
synthetic routes were considerably higher yielding and more reliable than those 
published previously.  However, the main drawback to the methodology used by 
Billington was that these routes yielded only racemic or meso compounds. 
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1.6.2. Development of enantioselective route to inositol polyphosphate
 derivatives via myo-inositol orthoformate 
Holmes and co-workers developed an elegant solution to address the problems 
of enantioselective syntheses of inositol derivatives via the orthoformate 49.40, 41  
Building on the previous methodology demonstrated by Billington,39 Holmes 
developed a route that could provide enantiopure intermediates, which were 
used to synthesise a range of inositol polyphosphates.  All these intermediates 
were derived from a common material, obtained from a diastereoisomeric 
resolution, outlined in Scheme 1.6.4. 
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Scheme 1.6.4. Synthesis of enantiopure inositol intermediate 65.  Reagents and conditions:  i. CH(OEt)3, 4-TsOH·H2O, 
DMF, 100 ˚C, 63% yield;  ii. NaH (1 eq), PMBCl (1 eq), DMF, RT, 67% yield;  iii. NaH (2.5 eq), BnBr (2.5 eq), DMF, RT, 
99% yield;  iv. DIBAL-H (2.5 eq), CH2Cl2, RT, 96% yield;  v. NaH (1.0 eq), AllBr (1.5 eq), imidazole (0.1 eq), DMF, RT, 
85% yield;  vi. HCl, MeOH, reflux, 78% yield;  vii. 1-(S)-(-)-Camphor dimethylacetal (3.5 eq), 4-TsOH·H2O (0.05 eq), 
CH2Cl2, reflux, 31% yield.
41 
Formation of the orthoformate 49 from myo-inositol was achieved under 
Billington’s conditions,39 followed by the axial-selective alkylation of OH-4 as the 
PMB ether to afford diol 60.  Perbenzylation of the diol 60, afforded the fully 
protected orthoformate 61.  The orthoformate was opened in a regioselective 
manner using DIBAL-H to reveal the 5-position alcohol 62, whilst maintaining 
the protection of the 1- and 3-positions as a methylidene bridge.  Detailed 
studies on the mechanism of this deprotection were conducted by the Holmes 
group,42, 43 and are discussed further in Chapter 4.2.  Allylation of the 5-position 
hydroxyl group of 62 gave the fully protected inositol 63, which was then 
subjected to acidic methanolysis to remove the acetal bridge and the PMB 
group, affording triol 64.  The racemic triol 64 was then subjected to an optical 
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resolution, by protection of the vicinal 3,4-diol using the camphor acetal strategy 
first described by Bruzik.44 Treatment of 64 with 1-(S)-(-)-camphor 
dimethylacetal, produced a mixture of four diastereoisomers, one of which 65 
could be isolated from the others by rigorous silica gel chromatography in 31% 
yield.  This enantiopure alcohol then used to effect the synthesis of the 
PtdIns(3,4,5)P3 and several other myo-inositol phospholipids.
41 
 
1.6.3. Use of the Holmes’ resolution methods 
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Figure 1.6.5.  PtdIns(4,5)P2 66 and immobilised PtdIns(4,5)P2 67 synthesised via the resolution method.
45 
Subsequent to the resolution work, Lim et al. used the resolution methodology 
to synthesise PtdIns(4,5)P2 66, which is the natural membrane-bound precursor 
to InsP3 within cells.  The work was extended for the synthesis of an affinity 
matrix of PtdIns(4,5)P2 immobilised on Affi-Gel 10, used for binding experiments 
to identify proteins that interact with this phospholipid.45  A similar technique 
was reported by Painter et al. for the immobilisation of PtdIns(3,4,5)P3.
46 
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Figure 1.6.6.  Membrane permeant derivatives D-InsP3/BM 68 and L-InsP3/BM 69 synthesised from the respective 
enantiomers of alcohol 65 (obtained by resolution of triol 64 with either 1-(S)-(-)- or 1-(R)-(+)-camphor dimethyl acetal). 
Conway et al. have also used the resolution chemistry for the synthesis of both 
enantiopure membrane permeant derivatives of D-InsP3 68 and L-InsP3 69,
29 
which were first reported by Tsien and co-workers in racemic form.47  These 
derivatives have short lipophilic butyryloxymethyl (BM) ester chains, which 
protect the phosphate groups, enabling them to diffuse across the cell 
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membrane, without the need for mechanical or chemical damage to 
permeablise the membranes.  Once in the cell, the protecting groups are 
removed by lipase enzymes in the cytosol, releasing the parent inositol 
phosphate.   
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Figure 1.6.7. Caged, membrane permeant derivative cm-D-InsP3/PM 70.  The photolabile dimethoxynitrobenzyl group 
(DMNB) is cleaved by excitation with UV light (345-355 nm). 
Tsien and co-workers have used different resolution methodology to synthesise 
a membrane permeant photo-labile caged InsP3 derivative 70.
48  The 
compound was synthesised using vicinal acetonide and a resolution with 
camphanic acid chloride, similar to the work of Gigg (vide infra).  The 
photolabile dimethoxynitrobenzyl (DMNB) caging group could be cleaved in 
vitro using UV light, allowing site-specific release of InsP3 within the cell.  All 
these membrane permeant compounds are very important for the study of the 
role of the InsP3Rs in Ca
2+-signalling pathways, as they enable whole, 
undamaged cells to be used for studies rather then permeabilised ones. 
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Figure 1.6.8. 4-Position analogues of InsP3 synthesised as potential antagonists of InsP3Rs.
49
 
More recently Bello et al.49 have employed the enantiopure alcohol 65 as a key 
intermediate for the synthesis of 4-position analogues of InsP3.  The synthesis 
made use of the ability to easily differentiate the 1-, 4- and 5-positions of 
inositol, enabling facile synthesis of the analogues.  These analogues have 
been evaluated as antagonists of the InsP3Rs and are discussed further in 
Chapter 2.3.1. 
Overall, the enantiopure alcohol 65, developed by Holmes has provided a good 
platform for the synthesis of a wide range of enantiopure inositol 
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polyphosphates with different substitution patterns.  The arrangement of 
protecting groups that 65 offers, allows for individual functionalisation of the 1-, 
3-, 4-, and 5-positions in an independent manner.  By using the enantiopure 
alcohol 65, the products of subsequent steps should be similarly 
enantiomerically enriched, provided racemisation of the ring does not occur. 
 
1.7. Alternative uses and resolution of orthoester derivatives 
In addition to the orthoformate 49, other orthoesters of myo-inositol such as 
orthoacetate 71 and orthobenzoate 72 have been used in the synthesis of InsP3 
and inositol polyphosphate derivatives (Figure 1.7.1.).50 
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Figure 1.7.1.  myo-Inositol orthoesters: orthoformate 49, orthoacetate 71 and orthobenzoate 72. 
In order to obtain enantiopure compounds, these esters are resolved using 
various chiral auxiliaries outlined in this section.  Extensive strategies for 
protecting group manipulation of orthoesters have been published by 
Shashidhar and co-workers,51 who, along with others, have demonstrated the 
synthetic utility of these molecules. 
 
1.7.1. Orthoformate 
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Scheme 1.7.2.  General method for optical resolution of orthoformate 49 with camphor or mandelic acid-derived 
auxiliaries. 
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The groups of Potter and Watanabe have separately published optical 
resolutions of orthoformate 49 with camphanic acid chloride52 and 
acetylmandeloyl chloride respectively.53  Each approach installs two chiral 
auxiliaries onto the 2- and 4- (or 6-) positions of the orthoformate (Scheme 
1.7.2.).  The diastereoisomeric mixtures are then separated by column 
chromatography, affording the 2,4- 73 and 2,6-isomers 74 of the orthoformate.  
These methods are, in effect, chiral desymmetrisations of the orthoformate.  
Potter employs this methodology for the rapid synthesis of D-Ins(1,3,4,5)P4 56,
52 
while Watanabe synthesises D-Ins(4)P.53 
 
1.7.2. Orthoacetate 
Potter has employed an optical resolution of the orthoacetate 71 using 
camphanate esters for a rapid synthesis of InsP3 1 (Scheme 1.7.3.).
54  He 
reported that the orthoacetate was advantageous over the orthoformate, as the 
corresponding diesters from the resolution could be separated by crystallisation 
from different solvents. 
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Scheme 1.7.3.  Potter’s rapid synthesis of InsP3 from orthoacetate 71.  Reagents and conditions: i. 1-(S)-(-)-
Camphanoyl chloride, DMPA, CH2Cl2, 0 ˚C to RT, 37% yield of 75;  ii. 80% aq. TFA, 7 days, 25% yield of 76 (40% yield 
of 77);  iii. a. (BnO)2PN(
i
Pr)2, 1H-tetrazole, CH2Cl2, RT, 1 h;  b. mCPBA, -78 ˚C to RT, 72% yield over 2 steps;  iv. a. H2, 
10% Pd/C, MeOH, H2O, RT, 12 h;  b. NH3(aq), 60 ˚C, 4 h, then HCl (5 M), MeOH, H2O, reflux, 14 h, 70% yield over 3 
steps.
54
 
Resolution of the orthoacetate 71 afforded the 2,4- (not shown) and 2,6-diesters 
75.  Selective cleavage of the orthoacetate with TFA afforded an equal mixture 
of the triols 76 and 77, with no control over placement of the acetate group.  
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Separation of the triols was achieved readily by chromatography.  The 1,4,5-
triol 76 was then phosphorylated using the phosphoramidite method, affording 
trisphosphate 78, which was deprotected by hydrogenolysis and aminolysis to 
provide InsP3 1. 
 
1.7.3. Orthobenzoate 
The orthobenzoate 72 offers the same synthetic advantage as the orthoacetate 
in that, the diesters that arise from the chiral desymmetrisation with camphanic 
acid chloride are readily separable by crystallisation.  Potter has reported 
resolution of 72 in the same manner to the orthoacetate 71, citing that the 
cleavage of the orthobenzoate provides a more stable ester on O-1 or O-3 (cf. 
acetate).55  Using intermediates generated from 72, Potter has synthesised 
PtdIns(3,4,5)P3 analogues,
56 and showed that 1,4,5-triols can be derived from 
72, similar to 76 and 77 from the acetate series.55  Potter has also 
demonstrated that 72 can be selectively cleaved, affording 2-benzoyl-myo-
inositol.  This compound was used in the synthesis of the anticancer agent 
Ins(1,3,4,5,6)P5.
57 
O
O
O
BnO
OH
BnO
79
Ph
4 5
1
BnO
BnO
OH
OH
OBn
OH
82
i iiO
O
O
BnO
O
BnO
80
Ph
4
BnO
BnO
O
O
OBn
O
P
O
OBn
OBn
P
O
BnO
BnO
P
O OBn
OBn
83
O
O
O
BnO
OH
BnO
81
Ph
CH3
iii
iv, v
CH3
4
HO
HO
O
O
OH
O
P
O
OH
OH
P
O
HO
HO
P
O OH
OH
84
iv, v
CH3
CH3
 
Scheme 1.7.4.  Racemic synthesis of 4-C-Me InsP3 84.  Reagents and conditions:  i. Dess-Martin periodinane, CH2Cl2;  
ii. MeMgBr, Et2O, -78 ˚C to RT, 3 h;  iii. DIBAL-H (4 eq), CH2Cl2, -78 ˚C to RT, 4 h, 55% yield;  iv. a. (BnO)2PN(
i
Pr)2, 
1H-tetrazole, CH2Cl2, RT, 1 h;  b. mCPBA, -40 ˚C to RT, 57% yield over 2 steps;  v. H2, Pd Black, NaHCO3, 36 h then 
DOWEX H-100 resin, 100% yield.
58 
Gaffney has investigated alternative selective cleavages of an orthobenzoate 
derivative 79, for the synthesis of 4-C-methyl analogues of InsP3 and 
Ins(1,3,4,5)P4.
58  Oxidation of the 4-position of racemic alcohol 79 afforded 
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inosose 80, that underwent stereoselective addition of an equatorial methyl 
group,59 furnishing the myo-inositol alcohol 81.  Cleavage of the orthobenzoate 
with a large excess of DIBAL-H (4 eq) afforded the 1,4,5-triol 82.  When 2 eq of 
DIBAL-H were used, the orthobenzoate was only partially cleaved to reveal the 
5-position alcohol; 4 eq were required to affect complete opening to the 3-O-
benzoyl, which was further reduced to the 3-O-benzyl group.  No induction of 
the ester onto the 1-position was observed.  Phosphitylation of 82 using the 
phosphoramidite method furnished the trisphosphate 83, which was 
deprotected by hydrogenolysis to provide racemic 4-C-CH3 InsP3 84. 
 
1.7.4. Resolutions of alternate substrates 
Watanabe has demonstrated improved protocols for optical resolutions of mixed 
cyclohexylidene and disiloxaniyl acetals with acetyl mandelic acid,60, 61 building 
on the original syntheses demonstrated by Ozaki (vide infra).  This allowed for 
the convergent synthesis of D-PtdIns(4,5)P2 2 from the two enantiomers 
obtained from the resolutions.  These routes use the same optical resolution 
techniques described for the orthoformate, but offer alternate order of protecting 
groups.   
 
1.8. Carbocyclisation reactions towards inositol phosphates 
The methods surveyed above show syntheses that commence from the parent 
inositol molecule.  An alternative approach to the synthesis of such inositol 
molecules, is to build up functionality on a non-inositol core then transform it 
into the appropriate inositol stereoisomer via a carbocyclisation reaction.  Within 
this category, there are examples of the Ferrier type-II rearrangement, ring-
closing metathesis and a pinacol-type rearrangement.  These methods offer a 
different approach to protecting group strategies and orders, which would not 
be readily available when commencing a synthesis from myo-inositol. 
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1.8.1.  The Ferrier-II rearrangement for synthesis of inositol rings 
In 1979 Ferrier was studying carbocyclic ring closure as a method to synthesise 
cyclohexane derivatives via a biomimetic approach, akin to the enzymatic 
conversion of D-glucose-6-phosphate to D-myo-inositol-1-phosphate.62  A late 
step in this pathway was assumed to be an enzyme-assisted aldol ring closure, 
providing an inosose that would be reduced to the inositol.  Ferrier achieved 
such a reaction in a non-enzymatic system by the mercury-mediated ring 
closure of pyranoside 85 to the corresponding cyclohexanone 86 (Scheme 
1.8.1.).62 
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Scheme 1.8.1.  Ferrier’s original system for the Ferrier II carbocyclisation reaction.  Reagents and conditions:  i. HgCl2, 
acetone:water (2:1), 4.5 h, reflux, 83% yield.
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The transformation of 85 to 86 was achieved using stoichiometric amounts of 
mercuric(II) chloride and proceeded in a stereoselective manner, forming only a 
single product 86.  Subsequently a second minor epimeric product 93 was 
identified, where the stereochemistry at the C-2 position was inverted.63  
Investigations through control reactions showed that it was the mercury ions 
that were responsible for mediating the reaction, rather than simply acidic 
conditions, as no rearrangement was observed at the same pH as the reaction 
in the absence of mercury.  This reaction is now commonly known as the 
Ferrier-II rearrangement. 
Several groups have reported improvements to Ferrier’s original protocol, by 
altering the metal salt used to promote the rearrangement.64  Ferrier found that 
mercuric(II) acetate improved the yield of his original system to 89% and 
effected several other rearrangements that did not occur with mercuric(II) 
chloride.63  Chapleur reported mercuric(II) trifluoroacetate was effective at 
converting azide-containing pyranosides into their corresponding inososes.65  
Machado showed that the rearrangement was possible using substoichiometric 
amounts of mercuric(II) sulfate in the presence of acid, representing a 
significant improvement in the method.66  Ogawa showed that a range of 
acetate and benzyl protected 5-enopyranosides could be rearranged to 
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cyclohexanones using catalytic mercuric(II) trifluoroacetate or mercury(II) oxide 
(as low as 5 mol%).67  In his synthesis of the antibiotic, Hygromycin A,68 and the 
natural product, (+)-Lycoricidine,69 Ogawa demonstrated that 1 mol% of 
mercuric(II) trifluoroacetate was sufficient to effect Ferrier-II rearrangements. 
 
1.8.2. Mechanism of the Ferrier-II rearrangement 
To elucidate the mechanism of the rearrangement, Ferrier was able to isolate 
organo-mercury intermediates from the reaction pathway by using anhydrous 
methanol as the reaction solvent, thereby the preventing hydrolysis step.  The 
presence of these intermediates indicated that the reaction proceeded via an 
oxymercuration of the pyranoside double bond, acetal hydrolysis, then an aldol-
type ring closure to furnish the cyclohexanone.63  Kakinuma and co-workers 
conducted deuterium-labelling studies on similar organo-mercury intermediates, 
which showed that racemisation of the sugar C-6 position, ascribing this to 
possible radical processes.70  Whilst the exact mechanism remains elusive,64 an 
accepted mechanism, which accounts for most of the experimental 
observations was published by Machado and co-workers (Scheme 1.8.2.).71 
On treatment of the deoxyhex-5-enopyranosde 85 with a mercury(II) salt, 
oxymercuration of the double bond occurs, introducing the hydroxyl group at the 
most substituted end of the double bond in a Markovnikov fashion.  The 
mercuric intermediate 88 then coordinates to the aglycone portion of the 
molecule, initiating ring opening of the pyranoside with loss of the aglycone to 
afford the ketoaldehydes 89 and 91.  Whilst these two intermediates are in 
equilibrium with each other, the equilibrium position is thought to lie far to the 
left in favour of 89.  The major cyclohexanone product 86 is derived via the 
pseudo chair intermediate 90 by an intramolecular aldol-type reaction.  The 
minor, epimeric product 93 is formed via the less thermodynamically favoured 
twist-boat transition state 92. 
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Scheme 1.8.2. Proposed mechanism of the mercury(II)-mediated Ferrier II Rearrangement.
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More recently, the group of Cleophax and co-workers have investigated various 
mercury(II) salts (acetate, sulfate, nitrate, and chloride) for the conversion of D-
galactose precursors to deoxy myo-inositols in the presence of thiourea.72  
Detailed NMR studies of the reaction show similar steps to those proposed by 
Machado, however, the presence of a cyclohexylidene acetal on the substrates 
appeared to hinder ring closure when no thiourea was present. 
 
1.8.3.  Use of the Ferrier Rearrangement 
Several groups have utilised the mercury-mediated Ferrier-II rearrangement for 
the synthesis of a wide range of inositol and inositol polyphosphate analogues.  
Ferrier used the rearrangement to synthesise pseudo-!-D-glucose, the 
carbocyclic variant of glucose, where the oxygen atom has been replaced by 
carbon.73  Bender was the first to report a Ferrier rearrangement with six 
substituents, using the enol acetate 94 in place of the unsubstituted enol ethers, 
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which had been used previously.74  This rearrangement furnished an inosose 
95 with an acetate group at the O-1 position in good selectivity (over the C-2 
equitorial OH 96), which could be further manipulated (Scheme 1.8.3.).  
Bender’s work showed that it was possible to use the rearrangement for the 
synthesis of fully oxygenated inositol rings rather than the 1-deoxy inositol rings 
previously synthesised. 
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Scheme 1.8.3.  First report of Ferrier II rearrangement of enol acetate 94.  Reagents and conditions:  i. Hg(O2CF3)2, 
acetone:H2O (4:1), 0 ˚C, 10 min then NaCl(aq), 20 h, RT, 59% yield (85:15 95:96).
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In the following paper, Prestwich reported the synthesis of a P-1-tethered 
Ins(1,3,4,5)P4 affinity label, using a similar Ferrier-II rearrangement to transform 
an enol acetate to the fully oxygenated inosose.75  Prestwich has continued to 
exploit the synthetic utility of the reaction for the synthesis of numerous 
phosphatidylinositols,76 their affinity tagged and photoactivatable derivatives. 77, 
78 
Potter has made good use of the stereoselectivity of the Ferrier rearrangement 
for the synthesis of 2-deoxy-myo-Ins(1,3,4,5)P2 from D-glucose by using the 
minor epimer (formed though the twist-boat TS) from the Ferrier-II reaction.  
The minor epimer was chosen after establishing that the configuration of the 
axial OH-2 in the major epimer could not be readily inverted.79 
Cleophax and co-workers synthesised 6-deoxy D-InsP3 from D-galactose via a 
Ferrier rearrangement of an olefinic derivative of the sugar.72, 80  This compound 
was thought to have been of interest in the study of Ca2+-signalling, as it was 
known to be an InsP3R-agonist, but with considerably lower activity than InsP3.   
Chapleur and co-workers were the first group to demonstrate that allyl 
protecting groups were tolerated in the mercury-mediated Ferrier-II reactions, 
with no sign of chelation of the metal ions.81  They used the protecting group in 
the synthesis of 3-deoxy muco- and myo- Ins(1,4,5)P3. 
There have been many other uses of the Ferrier II-rearrangement for the 
synthesis of various inositol derivatives other than just the myo-configuration.  
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The rearrangement allows for a wide variety of protecting groups to be placed 
onto an inositol ring, which facilitates the synthesis of numerous inositol 
analogues with varying substitution patterns.64, 82 
 
1.8.4. Palladium-mediated Ferrier-II rearrangements 
Although many groups continued to research mercury-mediated Ferrier-II 
rearrangements, others were considering alternative metals to promote the 
reaction.  Whilst exploring new routes towards amino cyclitol antibiotics, Adam 
found that the rearrangement of aminodeoxyhex-5-enopyranoside 97 to inosose 
98 was possible by using catalytic amounts of palladium(II) salts in the 
presence of acid.83  This reaction (Scheme 1.8.4.) was found to occur rapidly, in 
an analogous manner to the Ferrier-II rearrangement, however, it was 
acknowledged that it was likely to proceed by a different mechanism. 
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Scheme 1.8.4.  Palladium-mediated Ferrier II rearrangement of aminodeoxyhex-5-enopyanoside 97.  Reagents and 
conditions:  i. Pd(OAc)2 or PdCl2 (10-20 mol%), dioxane or acetone, water, H
+
, 60 ˚C, 40-60 min.
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Ikegami and co-workers extended the investigation into palladium-mediated 
rearrangements through a series of studies towards the synthesis of all nine 
stereoisomers of inositol.84  Screening of palladium salts and solvents identified 
that the Ferrier-II reactions of 6-deoxypyranosides could be achieved with PdCl2 
(as low as 5 mol%) in dioxane-water mixtures.85  This work was extended to the 
rearrangement of 6-O-acetylpyranosides (glucose, mannose, galactose) under 
similar conditions.86 The yields of these reactions were found to be higher than 
for the mercury-mediated rearrangements, however, a greater number of 
isomeric products were also observed, most of which could be separated by 
chromatography.86  An alternate mechanism for the palladium reaction was 
proposed to rationalise the different levels of stereoselectivity observed 
between mercury- and palladium-mediated reactions (Scheme 1.8.5.). 
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Scheme 1.8.5.  Proposed mechanism for the palladium-mediated Ferrier-II rearrangement of a glucopyranoside 99.
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Oxypalladation of the enol acetate 99 affords the unstable hemiacetal 100, 
which loses methanol to afford the dicarbonyl intermediate 101.  101 can 
rearrange to the palladium enolate 102, which then undergoes an aldol-type 
ring closure to provide the inosose 104.  Formation of the enolate 102 has not 
been confirmed, but is thought to be the crucial step in the reaction.84  The 
relatively open enolate 102 allows for a greater number of possible 
stereoisomeric products, compared to the mercury-method, where both the Hg 
atom coordinates to oxygen to hold a more rigid transition state 
A further study by Ikegami surveyed conditions to reduce the inosose molecules 
from the palladium-mediated rearrangements in a stereoselective manner.87 
Ikegami showed it was possible to attain high levels of stereocontrol, enabling 
all permutations of the inositol stereoisomers to be synthesised by the reduction 
of the inososes derived from only glucose, mannose or galactose.87  Typically, 
the selectivity of the ketone reduction to the axial or equatorial hydroxyl group 
was controlled by the size of the reducing agent.  This work culminated in the 
report of the synthesis of all nine inositol isomers through a systematic 
approach.84  The group also demonstrated synthetic utility in their arrangement 
of protecting groups by the synthesis of D-InsP3 1 and Ins(1,3,4,5)P4 56. 
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1.8.5. Alternative carbocyclic ring closures 
Sinaÿ and co-workers have shown that other metals can mediate Ferrier-type 
rearrangements, but with retention of the aglycone portion of the carbohydrate 
(Scheme 1.8.6.)  
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Scheme 1.8.6.  Novel carbocyclisation reaction of 6-deoxypyranosides.  Reagents and conditions: i. 
i
Bu3Al, toluene, 
40 ˚C, 70% yield;  ii. AlMe3, toluene, 80 ˚C, 100 min, 72% yield;  iii. Ti(O
i
Pr)Cl3, CH2Cl2, -78 ˚C, 15 min, 98% yield. 
On treatment of !-6-deoxypyranoside 105 with iBu3Al, the deoxy myo-inositol 
106 is formed, with complete retention of the anomeric information (Scheme 
1.8.6.).  Similar treatment of the "-anomer of 105, afforded the epi-inositol 
product.88  If AlMe3 is used in place of 
iBu3Al, a methyl group is introduced at 
the equatorial C-2 position, forming the 2-C-Me myo-inositol 107 
stereospecifically.89  Further studies showed that treatment of the pyranoside 
108 with Ti(OiPr)Cl3 afforded a Ferrier-like myo-inositol product 109 in high 
yield, again with retention of the anomeric stereochemistry.90 These reactions 
represent a novel carbocyclic ring closure that could be used in a similar 
manner to the Ferrier rearrangement, for the synthesis of highly substituted 
inositol molecules.  
 
 
1.9. Desymmetrisation approach to inositol phosphates 
All of the methods surveyed in this chapter have involved optical resolutions or 
transformations from chiral pool materials to obtain enantiopure inositol 
molecules.  These routes typically have involved multiple steps and can suffer 
from poor yields at the critical step where the enantiopure material is obtained. 
Miller sought to circumvent this problem by proposing a catalytic 
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desymmetrisation of myo-inositol to obtain an enantiopure inositol in a single 
step and high yield.91  Previous work in Miller’s group had shown that this type 
of reaction attained high levels of enantioselectivity in non-polar solvents.  Thus, 
2,4,6-tribenzyl myo-inositol 111 was chosen as the substrate over the more 
polar myo-inositol; reducing the number of potential reaction sites from six to 
three.  111 was synthesised in two steps from the orthoformate 49 by 
exhaustive perbenzylation to form 110, followed by deprotection of the 
orthoformate 110 to provide the racemic 1,3,5-triol 111 (Scheme 1.9.1.) 
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Scheme 1.9.1.  Synthesis of screening substrate 111.  Reagents and conditions: i. BnBr, NaH, DMF, RT;  ii. HCl, 
MeOH, reflux.  Yields not quoted.
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Miller’s aim was to site selectively phosphorylate 111 at the 1- or 3-positions, 
thereby desymmetrising the meso molecule.  Such a reaction, by virtue of the 
symmetry of the triol 111 substrate and the chirality of the catalyst, would also 
be enantioselective. 
 
1.9.1. Screening of peptide catalysts 
A small library of random peptides, based around modified His residues, were 
screened for regio- and enantioselectivity for the monophosphorylation of triol 
111.  These peptides were designed to be small kinase mimics, which were 
expected to behave as nucleophilic catalysts.  Peptide 112 was shown to have 
excellent selectivity for phosphorylation on the 1-position in >98% ee.92 
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Figure 1.9.2.  Peptide catalysts 112 (selective for 1-P) and 113 (selective for 3-P). 
 To obtain selective phosphorylation on the 3-position, Miller did not look to 
synthesise the enantiomer of 112.  Instead, a more focused library of peptides 
were synthesised, based on results that favoured 3-position phosphorylation 
(over the 1-position) from the both the original screen and an expanded random 
screen.  When this focused library was screened, 113 was identified as highly 
selective for phosphorylation of the 3-position in >98% ee.93 
 
1.9.2. Concise syntheses of D-1-InsP and D-3-InsP 
Miller and co-workers used the two newly discovered catalysts to complete the 
synthesis of D-1-InsP 117 and D-3-InsP 115 (or L-1-InsP) in a divergent manner 
from the triol 111 (Scheme 1.9.3.).92, 93 
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Scheme 1.9.3.  Synthesis of D-1-InsP 117 and D-3-InsP 115 by catalytic desymmetrisation.  Reagents and conditions: i. 
DPCP, Peptide 113 (2.5 mol%), Et3N, toluene, 0 ˚C, 56% yield (>98% ee);  ii. Li, NH3(l), THF, -78 ˚C, 95% yield;  iii. 
DPCP, Peptide 112 (2.0 mol %), Et3N, toluene, 0 ˚C, 65% yield (>98% ee);  iv. Li, NH3(l), THF, -78 ˚C, 96% yield. 
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Treatment of the triol 111 with diphenylchlorophosphate (DPCP) and 
triethylamine in the presence of 112 or 113, afforded the protected D-1-InsP 116 
and D-3-InsP 114 respectively.  Global deprotection by Birch reduction afforded 
the two known enantiomeric products D-1-InsP 117 and D-3-InsP 115.   
 
1.9.3. Synthesis of D-Ins(3,5,6)P3 – the antipode of D-InsP3 
Miller extended his desymmetrisation methodology for the synthesis of a range 
of myo-inositol polyphosphates.  Of special interest was D-Ins(3,5,6)P3 124, 
which is the enantiomer of D-Ins(1,4,5)P3 1.  The synthesis of this molecule 
allows formal access to InsP3 when the opposite desymmetrisation catalyst is 
used. 
3
1
BnO
HO
OPMB
OH
OPMB
OH
118
i
3
1
BnO
O
OPMB
OH
OPMB
OH
119
P
OPhO
PhO
BnO
O
OPMB
OBOM
OPMB
O
P
ORO
RO
P
OBn
OBn
O
ii
R = Ph   120
R = Bn   121
iii
BnO
O
OH
OBOM
OH
O
122
P
OBnO
BnO
P
OBn
OBn
O
BnO
O
OH
OBOM
O
O
123
P
OBnO
BnO
P
OBn
OBn
O
P
O
OBn
OBn
2
3 4 5
61
HO
O
OH
OH
O
O
124
P
ONaO
NaO
P
ONa
ONa
O
P
O
ONa
ONa
iv
vvi
 
Scheme 1.9.4.  Synthesis of D-Ins(3,5,6)P3 124.  i. Peptide 113, DPCP, Et3N, CH2Cl2, 53% yield (98% ee);  ii. a. 
BOMCl, Hünig’s base, THF;  b. (BnO)2PN(
i
Pr)2, dicyanoimidazole, CH2Cl2, then H2O2, 29% yield over 2 steps;  iii. NaH, 
BnOH, THF, 38% yield;  iv. DDQ, CH2Cl2/H2O, 83% yield;  v. (BnO)2PN(
i
Pr)2, dicyanoimidazole, CH2Cl2, then H2O2, 
53% yield;  vi. Pd(OH)2/C, H2, MeOH, then NaOH, 90% yield.
94 
Thus desymmetrisation of triol 11853 with peptide 113, gave the 3-position 
phosphate 119.  Regioselective protection of OH-1 as the BOM ether, followed 
by phosphitylation of the 5-position using phosphoramidite chemistry afforded 
the bisphosphate 120.  Transesterification of the 3-position phosphate, then 
PMB deprotection gave the diol 122.  Phosphorylation of the diol 122 furnished 
a single regioisomer of the trisphosphate 123, presumably due to less steric 
hinderance at the 6-position.  Global deprotection of 123 by hydrogenolysis 
provided D-Ins(3,5,6)P3 124.
94 
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Further to this work, Miller has reported the synthesis of phosphatidylinositols 
PI, PtdIns(3)P, PtdIns(3,5)P2 and their deoxygenated analogues.
95  A route to 
an analogue of PtdIns(5)P has also been reported.96  All of these syntheses 
depend on the catalytic asymmetric phosphorylation, which has been shown to 
be of great importance for the synthesis of inositol polyphosphates. 
 
1.10. Summary 
The biological importance of the inositol phosphates has been outlined, 
highlighting the essential role of InsP3 1 in Ca
2+ signalling.  The naturally 
occurring inositol polyphosphates and their analogues are essential biological 
tools for the study of Ca2+ signalling, therefore, robust synthetic methods are 
required for their synthesis.  These syntheses are challenging, but good 
methodology has been developed to deliver these enantiopure inositol 
compounds by optical resolutions, derivation from chiral pool materials and 
asymmetric desymmetrisations. 
In the following dissertation, two of these methods will be used in the synthesis 
of InsP3 and a number of its analogues as potential InsP3R-antagonists. 
  
  
 
2 Design of InsP3R-antagonists 
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2.  Structural requirements for InsP3R antagonists 
2.1. Introduction 
After the identification of D-myo-inositol 1,4,5-trisphosphate 1 as a key Ca2+-
releasing secondary messenger4 and the discovery of the InsP3Rs,
11 there has 
been a great deal of interest in elucidation of the specific activation mechanisms 
of the receptor.3, 10  Several groups have previously shown the global 
conformational changes of the homo-tetrameric receptor during activation and 
subsequent Ca2+-release by cryo-EM studies, however, the resolution was 
insufficient for mechanistic studies at the molecular level.13-17  Mikoshiba and 
co-workers have successfully crystallised two domains of the mouse type-1 
InsP3Rs; the suppressor domain (SD)
19 and the InsP3 binding domain.
18  The X-
ray crystal structure of the binding domain has provided a great deal of insight 
into the binding of InsP3, which has been proposed to occur via a “clam-shell” 
closing mechanism.97, 98  When InsP3 binds, it is thought that the two 
subdomains of the binding region are brought together, causing a 
conformational change that ultimately opens the channel to release Ca2+.  
However, at present, there is no crystal structure of the entire receptor, which 
would allow for more detailed study of the activation mechanism.  Attempts to 
obtain the crystal structure of the apo-form of the InsP3R binding domain have 
also been unsuccessful, hence it is difficult to identify the conformational 
change that is occurring. 
In the study of the InsP3Rs, antagonists will play a crucial role as biological tools 
for probing the receptor.  Such compounds will allow key steps of the receptor 
activation pathway to be arrested, so the more global downstream effects of 
receptor activation within the cell might be identified and studied.  These 
compounds will also be vital as probes for wider study of both InsP3 and Ca
2+ 
signalling pathways.   
The bifurcating nature of the InsP3 and Ca
2+ signalling cascade is such that 
inhibition of the upstream GPCR would not be useful for the study of Ca2+ 
signalling, as this would prevent formation of diacylglycerol (DAG) 3 as well as 
InsP3 1.  DAG is known to activate PKA, opening voltage-gates Ca
2+ 
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membranes, to release Ca2+ independently of the InsP3Rs.  Therefore, selective 
inhibition of the InsP3Rs (by novel antagonists) will allow for effects of InsP3-
induced Ca2+-release (IICR) to be studied independently from the DAG 
signalling pathways. 
 
2.2. Current known InsP3R antagonists 
Whilst there are a wide range of compounds that act as agonists of the InsP3Rs, 
there are far fewer InsP3R-antagonists.  The principal problem with the known 
antagonists is their lack of selectivity for the InsP3Rs versus other signalling 
cascades or Ca2+-channels. 
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Figure 2.2.1.  Structures of known InsP3R-antagonists: Heparin, Xestospongin C and 2-APB. 
Heparin, a high molecular weight non-membrane permeant polysulfonated 
polyanion, has potent antagonist activity against the InsP3Rs,
99 however, it also 
inhibits coupling between plasma-membrane receptors and G-proteins,100 
inhibits the InsP3 3-kinase
101 and stimulates the ryanodine receptors (RyRs).102  
The natural product Xestospongin C, isolated from the marine sponge 
Xestospongia, is a potent inhibitor of InsP3-mediated Ca
2+ release,103 however, 
it can inhibit nitric oxide synthase (NOS)104 and the RyRs;103 release Ca2+ from 
the intracellular stores;105, 106 and also is known to inhibit the sarcoplasmic / 
endoplasmic reticulum Ca2+ ATPase (SERCA) pumps.107  The anti-malarial 
chincona alkaloids, quinine and quinidine, inhibit InsP3-mediated Ca
2+ 
release108 but also can alter the glucose and insulin metabolism pathways by 
blocking ATP-sensitive K+ channels;109, 110 they have also been shown to inhibit 
subclasses of the cytochrome P450,111 making them wholly unsuitable as 
InsP3R antagonists.  2-Aminoethoxydiphenylborate (2-APB) is a membrane-
 Design of InsP3R antagonists 
51 
permeant compound, which inhibits InsP3-mediated Ca
2+ release by competing 
with InsP3 at the binding site.
112-114  However, 2-APB is not selective for the 
InsP3Rs and has been shown to inhibit sarcoplasmic / endoplasmic reticulum 
Ca2+ ATPases (SERCAs) that leads to depletion of Ca2+ from the intracellular 
stores;115 it acts as an activator of the transient receptor potential vanilloid 
cation channels (TRPV), types 1-3;116 and has also been shown to interact with 
multiple other cellular targets.  van Boom and co-workers reported that the 
racemic 5-position methylphosphonate analogue 126 of InsP3 showed weak 
activity as an inhibitor of the InsP3-mediated Ca
2+ release, however, the 
biological data was never published.117-119 
Cleary there is a need for better, selective antagonists of the InsP3Rs to 
facilitate study of the InsP3Rs and Ca
2+ signalling, without affecting other 
signalling cascades.  This lack of selective InsP3R-antagonist compounds is an 
ongoing research interest in the Conway group and represents one of the major 
research focuses of this dissertation. 
 
2.3. Current syntheses of inositol-based analogues of InsP3 
Most of the known InsP3R antagonists have little structural similarity to InsP3.  
Some are thought to bind to allosteric sites on the receptor, rather than in the 
InsP3 binding region identified by Mikoshiba.
18  In the search for selective 
compounds for the InsP3Rs, it is logical to synthesise compounds that have 
structural similarities to InsP3, as such compounds would be expected to bind at 
the same site as InsP3.  This approach has been employed in the Conway 
group for the synthesis of two series of InsP3 analogues, where single 
phosphate groups of InsP3 have been replaced by phosphate isosteres. 
 
2.3.1. Synthesis and evaluation of 4-position analogues of InsP3 
Bello et al. recently synthesised the first range of InsP3 analogues, in which the 
4-position phosphate group was replaced with lipophilic or extended-chain 
isosteric analogues (Figure 2.3.1.), with the aim of developing potential 
antagonists of the InsP3Rs.
49 
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Figure 2.3.1.  4-Position analogues of InsP3 synthesised as potential antagonists of InsP3Rs.
49 
It was thought that when InsP3 binds to the receptor, the two subdomains of the 
InsP3 binding region are brought closer together by the ligand in a “clam-shell” 
motion, causing a conformational change that leads to release of Ca2+.97  It was 
proposed that these 4-position analogues could act as competitive InsP3R-
antagonists by preventing interaction with the !-subdomain of the InsP3R 
(usually bound to 4-position phosphate), while still binding to the "-subdomain 
via the 1- and 5-position phosphate groups.  This decreased affinity for the !-
subdomain was expected to prevent the closure of the “clam-shell” and the 
subsequent conformational change, hence not leading to release of Ca2+. 
The biological evaluation of these compounds showed that the they did not bind 
the receptor.  The assays determined that the compounds did not evoke Ca2+ 
release themselves, nor prevent InsP3-induced Ca
2+-release (IICR).  One 
explanation for the lack of affinity was the lipophilic nature of the phosphate 
analogues at the 4-position, which may have prevented them entering the 
highly charged binding site of the receptor.  Alternatively, it is conceivable that 
the 4-position phosphate was crucial for binding and recognition at the InsP3R 
binding site, in such a way that any modification would prevent an analogue 
from docking. 
The initial hypothesis presented by Taylor et al., suggested that the “clam-shell” 
remained open until a molecule docked into the receptor site, at which point two 
subdomains together would be brought together as the “clam-shell” closed.97  
This hypothesis now appears to be incorrect, as the conformational change 
may be subtler.  Recent data obtained by Mikoshiba and co-workers has shown 
that there was only a small conformational change in the InsP3 binding region 
(IBR) on binding InsP3,
120 rather than the larger change originally proposed.  
These data indicated that the structures of the apo- and bound-forms of the 
isolated IBR were similar, rather than distinctly different, as would have been 
expected if a large conformational change occurred.  Hence, it has been 
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proposed that the two subdomains of the receptor may in fact remain in a 
partially closed state, even when in an inactive state. 
This new hypothesis and the assay data suggests that the 4-position phosphate 
group is crucial for binding and recognition, rather than receptor activation.  
Therefore, it appears that any alteration of this group removes the ability of the 
compound to bind to the InsP3Rs. 
 
2.3.2. Early synthesis and evaluation of 5-position analogues of InsP3 
To address the problems encountered with the 4-position analogues, the focus 
of Conway group research turned towards modification the 5-position of InsP3.  
New phosphate isosteres were selected, which possessed a single ionisable 
component, hence were expected to be able to bind in the charged IBR.  
Analogues bearing a methylphosphonate or sulfate group at the 5-position were 
chosen, as they were both mono-charged and could both be synthesised from a 
common precursor.  van Boom had previously reported that the racemic 
methylphosphonate showed InsP3R antagonism, however, no biological data 
has been published on this compound.118, 119  Whereas, the sulfate was a novel 
compound that was readily accessible and known to be a good isostere for the 
phosphate group.  Aslam proceeded to synthesise the enantiopure 5-position 
analogues 125 and 126, and their biological activity at the InsP3Rs was 
measured.121 
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Figure 2.3.2.  5-position analogues of InsP3 synthesised by Aslam.  Sulfate 125, methylphosphonate 126. 
The 5-position sulfate 125 and methylphosphonate 126 were tested for 
antagonist activity against the InsP3Rs in an L15 cell line in the presence of 
InsP3.  The normalised fractional loss plots for the two compounds are shown in 
Figures 2.3.3. and 2.3.4.   
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The sulfate analogue 125 (Figure 2.3.3.) was shown to be a weak agonist of the 
InsP3Rs, evoking an enhanced release of Ca
2+ in the presence of InsP3 
(potentiation) with respect to the control (shown in black).  At high 
concentrations (100 and 300 µM), 125 evoked Ca2+ release prior to treatment 
with InsP3, showing that 125 was an agonist of the InsP3Rs in its own right. 
 
HO
HO
O
O
OH
O
P
O
NaO
NaO
P
O
ONa
ONa
S
O
O
ONa
125  
Figure 2.3.3.  Fractional loss plots of Ca
2+
 in L15 cell lines when treated with 5-position sulfate analogue 125.  The 
lower horizontal bar indicates the time at which 125 was administered.  The smaller bar shows the time that InsP3 was 
applied to the cells. 
These results were in contrast with the work of van Boeckel, who synthesised 
the 1,4,5-tris sulfate,122 sulfamate, methylphosphonate and methylene 
carboxylate derivatives of InsP3, but found that none of these analogues had 
any affinity for the InsP3R.
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Figure 2.3.4. Fractional loss plots of Ca
2+
 in L15 cell lines when treated with 5-position methylphosphonate analogue 
126. The lower horizontal bar indicates the time at which 126 was administered.  The smaller bar shows the time that 
InsP3 was applied to the cells. 
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The methylphosphonate analogue 126 showed more promising activity against 
the InsP3Rs.  At a concentration of 126 at 30-100 µM and above, there was a 
small reduction in the InsP3-induced Ca
2+ release.  On increasing the 
concentration to 300 µM (shown in red) of 126, a 40% inhibition of InsP3-
induced Ca2+ release was observed (n=3), indicating that 126 is an antagonist 
of the InsP3Rs. 
 
2.4. New hypotheses for antagonist activity at the InsP3Rs 
The structural differences between the phosphate and methylphosphonate are 
minor, suggesting that an understanding of why one compound exhibits InsP3R 
agonist activity and one exhibits InsP3R-antagonist activity may provide some 
insight into the mechanism of InsP3R activation. 
There are two main differences between the phosphate 1, sulfate 125 and 
methylphosphonate 126 analogues, which could rationalise their different 
activities.  The first hypothesis is based on the varying pKa values of the two 5-
position substituents.  The second hypothesis is based on the different number 
of polar contacts that each 5-position substituent can make. 
 
2.4.1. Varying pKa values to rationalise activity 
When considering InsP3 and the two 5-position analogues, one significant 
difference between them is the pKa of the substituent on the 5-position.  
Approximate pKa values, based on isolated measurements of each substituent 
from literature values, are shown in Figure 2.4.1. 
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Figure 2.4.1.  Approximate pKa values for InsP3 and 5-position analogues 125 and 126.  Group of interest that pKa 
reflects is shown in blue. 
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The trend in pKa indicates that the borderline for agonist and antagonist activity 
may be around a pKa of 2.  The estimated pKa values for the analogues 125 
and 126 suggest that they will both be deprotonated at physiological pH.  
However, it might be possible for the local pH in the binding site to differ from 
physiological pH, due to the presence of concentrated sequences of basic or 
acidic amino acids, as is known for the serine proteases.  It is conceivable that, 
if the local pH in the binding site was around 2, the methylphosphonate 126 
may be protonated, whereas the sulfate 125 would still de deprotonated.  This 
could cause the two analogues to interact with the receptor in a different 
manner, with the protonated methylphosphonate unable to make the contacts 
required to initiate the conformational change that leads to Ca2+-release.  
However, such a low local pH seems unlikely; it is more probable that both 
analogues would share the same protonation state. 
Nevertheless, the border for InsP3 agonist / antagonist activity appears to be 
around a pKa of 2, with antagonism observed in the compound that had a higher 
pKa.  This hypothesis could be tested by the synthesis of structurally similar 5-
position analogues, with varying pKa values. 
 
2.4.2. Varying number of polar contacts to rationalise activity 
Another significant difference between InsP3 and the analogues 125 and 126 is 
the number of interactions with the receptor formed through polar contacts.  
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Figure 2.4.2.  Potential interactions of the bidentate and tridentate substituents on the 5-position of InsP3 with the InsP3 
binding site of the InsP3Rs. 
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The phosphate and sulfate moieties could be considered to be tridentate, 
whereas the methylphosphonate is only bidentate, due to the presence of the 
apolar methyl group.  The potential interactions are shown in Figure 2.4.2., 
when assuming that the compounds would bind to the receptor in the same 
location and orientation as InsP3. 
The reduced number of contacts in the bidentate ligands could be sufficient to 
prevent a conformational change in the receptor, by removing interactions with 
key residues.  Preventing this change could prevent Ca2+-release. 
Molecular docking studies, which were conducted in collaboration with 
Churchhill and Vasudevan, have shown that InsP3 1 and the 5-position 
methylphosphonate analogue 126 bind to the receptor in a very similar 
orientation,124 but 126 has fewer polar contacts with the receptor that InsP3, as 
expected.  The overlay of the modelling calculations is shown in Figure 2.4.3. 
As shown in Figure 2.4.3., 4-position phosphate groups of each molecule 
interact with the same residues on the !-subdomain of the receptor.  The 1- and 
5-position phosphate groups interact with residues on the "-subdomain.  The 1-
position phosphates both interact principally with Arg568, however, P-1 of the 
methylphosphonate 126 is shallower and more solvent exposed than P-1 of 
InsP3 1. 
 
Figure 2.4.3.  PyMol rendering of modelling study predicting docking conformations of InsP3 1 (shown in green) and 5-
position methylphosphonate analogue 126 (shown in pink) with the InsP3 binding domain of InsP3Rs (PDB code 1N4K).  
The key interactions of the 5-position groups with the receptor are shown in the corresponding molecule’s colour. 
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At the 5-position, the methylphosphonate (PCH3) shares some contacts with the 
phosphate (P-5) on InsP3, however, it is unable to interact with the deeper 
Lys508 residue at the bottom of the binding pocket.   
The lysine residue (Lys508), located at the bottom of the binding pocket, is 
attached to a helix on the !-subdomain, which is thought to shift on InsP3-
binding.  This movement could possibly initiate the conformational change, 
which leads to Ca2+-release.  Hence, as the methylphosphonate 126 cannot 
interact with this residue, this may rationalise the antagonist activity observed in 
the biological assays. 
 
2.4.3. Accuracy of the “clam-shell” mechanism 
These modelling studies cast doubt onto the current theory of the “clam-shell” 
mechanism for InsP3R activation.  The “clam-shell” hypothesis proposes that, 
on binding of InsP3 to the receptor site, the !- and "-subdomains move closer 
together (mediated by the ligand), causing the conformational change, which 
leads to opening of the Ca2+ channel.97  The modelling study shows that the 
methylphosphonate analogue binds in a similar mode to InsP3, thus would be 
expected to cause a similar conformational change on binding, and hence lead 
to a similar Ca2+-release.124  However, the Ca2+-flux assays have shown that 
126 reduces InsP3-induced Ca
2+-release therefore is an antagonist. 
The observations made in the modelling study suggest that the conformational 
change that leads to the release of Ca2+ does not arise from the two 
subdomains moving closer together.  The similar binding modes of 126 and 
InsP3 1 could indicate that the “clam-shell” is always in a partially closed state, 
and that ligand binding to the receptor does not alter this.120  Furthermore, it 
would appear that interactions of the 5-position substituent with residues 
towards the bottom of the binding site may be key to agonist / antagonist 
activity.  Interaction with these residues may be what causes the conformational 
change, which leads to Ca2+-release.  Therefore, the current working hypothesis 
is that reducing the number of potential polar contacts around the 5-position of 
InsP3 analogues may lead to further antagonist compounds. 
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2.5.  New analogues to test the antogonist hypotheses 
Through the work of Bello and Aslam,49, 121 the 5-position of InsP3 appears to be 
a key location for modification for the discovery of novel antagonists of the 
InsP3Rs.  A new series of 5-position analogues are proposed (Figure 2.5.1.), 
that would enable the two hypotheses for InsP3R-antagonism presented above 
to be tested. 
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Figure 2.5.1.  Proposed analogues with isosteric phosphate replacements at the 5-position. 
The sulfamate 127 and the methoxy phosphate ester 128 are structurally similar 
to the previous analogues, but have vastly different pKa values (sulfamate 127 
pKa 9; phosphate ester 128 pKa 1.3).  Both of these isosteres have the ability to 
make tridentate polar contacts.  The methylene carboxylate 129 is an isosteric 
replacement for the phosphate group, with a higher pKa (5) and only two points 
to make polar contacts form.  Finally, Ins(1,4)P2 130 lacks a substituent at the 
5-position, therefore will be used as a control compound. 
A summary for the predictions of the biological activity of the compounds, using 
each hypothesis, is shown below in Table 2.5.2. 
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Table 2.5.2.  Prediction of biological activity of 5-position analogues against InsP3Rs.  Compounds shown in blue are 
synthetic targets.  Entries shown in bold type have been confirmed experimentally. 
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2.6. Conclusions and project aims 
There is relatively little known about the structural motifs required for 
antagonists of the InsP3Rs.  Inositol-based compounds that have a phosphate 
replacement at the 4-position do not bind to the receptor, indicating that the 4-
position phosphate group is crucial.  Modification of the 5-position has shown 
mixed activity, with a methylphosphonate unit showing antagonist activity, 
whereas a sulfate unit is an agonist.  The mechanism of action of these 
compounds is unknown, but recent studies suggest that the “clam-shell” theory 
of receptor activation may be inaccurate.120, 124  These studies have shown that 
the key to agonist / antagonist activity could lie in either the pKa of the 5-position 
substituent or the number of polar contacts that it could form with the receptor.  
The synthesis of further similar compounds is required to test these hypotheses 
in order to gain further insight to InsP3R activation on a molecular level. 
The aim of the following project is to synthesise novel analogues that can be 
tested for biological activity against the InsP3Rs.  In the course of these 
syntheses, new routes will be explored, which can deliver enantiopure 
compounds in a more efficient manner to the current methodology.  Two 
different approaches will be attempted, with considerably different starting 
materials converging to similar final products.  Once synthesised, these 
compounds will be tested in a Ca2+-flux assay to ascertain their activity on the 
InsP3Rs. 
 
  
 
3 
Results and Discussion    
Ferrier-II rearrangement for inositol polyphosphate synthesis 
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3. Ferrier-II rearrangement for inositol synthesis 
3.1. Introduction and Aims 
3.1.1. New synthetic route to inositol polyphosphates 
When considering the synthesis of inositol polyphosphate derivatives, particular 
attention must be paid to the stereochemical configuration of the inositol ring.  
There are nine different isomers of inositol, however, these projects were 
specifically interested in the myo configuration; where all the hydroxyl groups 
are equatorial, except the 2-position, which is axial (Figure 3.1.1.).  This 
arrangement gives rise to a plane of symmetry in the molecule (between C-2 
and C-5), meaning the myo-inositol 4 is meso.  The myo configuration was 
desired, as the ultimate aim of the projects was to synthesise derivatives of 
myo-inositol 1,4,5-trisphosphate (InsP3) 1. 
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Figure 3.1.1.  Flat and 3-D representation of myo-inositol 4 ring configuration.  The dashed red lines indicate plane of 
symmetry present in the meso molecule between C-2 and C-5. 
There are two main strategies to obtain the correct core structure for the 
molecules; starting the synthesis from the parent myo-inositol itself (usually 
involving a resolution step), or by transformation to the myo ring configuration 
from another chiral pool source.  Both of these strategies have merits and 
pitfalls associated with them.  We chose to employ both of these methods, 
which will be discussed in separate chapters. 
The first method chosen was the construction of a myo-inositol ring by 
transformation from a chiral pool source.  This method was envisaged to 
provide us with a route to selectively and independently protect each hydroxyl 
group of the inositol ring in an orthogonal manner, thus allowing a number of 
derivatives to be easily synthesised from a common precursor.  There are 
several pre-existing methodologies in the literature for this strategy, such as ring 
closing metathesis (RCM),125-127 SmI2-mediated Pinacol couplings,
128-130 ring 
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closing ene reactions,131, 132 and the Ferrier rearrangement.62  The latter method 
was chosen, as this reaction could readily transform a glucopyranose skeleton 
into a myo-inositol ring in a single step (Figure 3.1.2.) and the chemistry for the 
construction of such precursors was well established in the literature. 
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Figure 3.1.2.  Outline of a generic Ferrier rearrangement of a glucopyranose skeleton to myo-inosose derivative.  
Numbering of R groups shows the positional fate of the protecting groups. 
Starting from a simple carbohydrate precursor, would allow for differentiation of 
the protecting groups on ultimately four (O-1, O-3, O-4 and O-5) out of six 
positions of the inositol ring (D-numbering).  This would leave a ketone (O-6) 
and a free hydroxyl group (O-2) that could be readily functionalised in an 
individual manner.  This would satisfy the requirement for orthogonality between 
most of the protecting groups, providing the protecting groups were orthogonal 
to each other. 
Other research groups (Prestwich,75, 133 Ikegami,84, 134 Potter,79 Ferrier,64 
Chapleur81 and Chung135) have previously studied the Ferrier rearrangement, 
however, each synthesis was targeted towards a specific molecule, with 
multiple sites protected with the same group.   
2
3 4 5
6
1
HO
O
OAr
OR2
R1O
OR4
Ar = Ph, 4-OMe-Ph
R4 = Ac, SiR3, Bz
R2 = Bn, PMB, Allyl, Bz
stereoselective reduction of 
ketone gives eq. or ax. OH 
or deoxygenation to give CH2
protection of OH-2 before 
reduction of ketone at C-6 of 
inositol - can use Bn, Bz, Allyl, 
SiR3, BOM, etc
R1 = TIPS, TBS, PMB, Allyl, Bn
Ferrier
rearrangement
OArO
OCH3
R2O
R1O
OR4
O
OCH3
R1O
HO
O
OAr
O
OCH3
HO
HO
O
OAr
O
OCH3
R1O
R2O
O
OAr
 
Figure 3.1.3.  Potential diversity of protecting groups around inosose ring, derived from a modified glucopyranose core. 
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We aimed to demonstrate that it would be possible to differentiate each position 
of the inositol ring in an independent fashion (Figure 3.1.3.), allowing for greater 
diversity of intermediates. 
 
3.1.2. Retrosynthetic analysis 
With a view to synthesis of 1-, 4- or 5-position analogues of InsP3, each of these 
positions would have to bear a different protecting group.  Therefore, the 
corresponding 6-, 3- and 2-positions of glucose would have to be protected 
individually.  The retrosynthetic steps working backwards from a Ferrier 
rearrangement product 131 are shown below (Scheme 3.1.4.). 
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Scheme 3.1.4.  Retrosynthetic scheme for synthesis of highly differentiated inosose 131.  Glucose derivatives 
numbered using conventional carbohydrate numbering.  Inosose 131 numbered using D-inositol numbering. 
The proposed synthesis of the inosose 131 would be achieved by Ferrier 
rearrangement of the enol 132, using a metal mediator such as PdCl2 or 
Hg(OAc)2.  The enol 132 would be derived from oxidation of the primary alcohol 
133 to the corresponding aldehdye, followed by base-induced enolisation.  The 
6-position primary alcohol 133 could be obtained by regioselective ring opening 
of acetal 134.  The acetal 134 could be constructed in two steps from diol 136 
by regioselective protection of either 2- or 3-positions, followed by alkylation of 
the remaining free hydroxyl group. The acetal diol 136 could be derived from 
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methyl-!-D-glucopyranoside 137 by treatment with an aryl aldehdye or aryl 
dimethyl acetal in the presence of a Lewis acid catalyst. 
 
 
3.2. Synthesis of Ferrier rearrangement precursor 
3.2.1. Synthesis of glucopyranose intermediate 145 
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Scheme 3.2.1.  Synthesis of glucopyranose intermediate 139 from !-D-glucopyranoside 137.  Reagents and conditions: 
i. anisaldehyde dimethyl acetal (1.1 eq), amberlyst-15, DMF, 80 ˚C, 200 mbar, 65% yield; ii. 
n
Bu2SnO (1.1 eq), TBABr 
(1 eq), BnBr (3 eq), MeCN, reflux, 18 h, 54% yield of 139 and 15% yield of 140. 
The initial step in the synthesis was the concurrent protection of the 4- and 6-
positions of methyl !-D-glucopyranoside 137 as the anisylidene acetal.  
Treatment of 137, using the method of Hirama and co-workers,136 with 
anisaldehyde dimethyl acetal and amberlyst-15 resin, under moderate vacuum 
(200 mbar) conditions, proceeded in 65% yield to afford diol 138.  This diol 138 
was then subjected to regioselective benzylation, protecting the 2-position over 
the 3-position as the benzyl ether, using stannylene acetal chemistry.  Using the 
one-pot procedure described by Gigg and co-workers,137 the 2-position was 
protected as the benzyl ether 139 with a selectivity of 2:1 (adjudged by isolated 
yields) over the 3-OBn regioisomer 140.  The regiochemical outcome of the 
reaction was confirmed by 2D NMR studies and an X-ray crystal structure of the 
desired regioisomer 139 (Figure 3.2.2.). 
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Figure 3.2.2.  VMD stick representation of X-ray crystal structure of desired regioisomer 139 from regioselective 
benzylation reaction.  Key: C, green; O, red; H, white. 
The level of selectivity observed was pleasing, as there is little difference 
between the O-2 or O-3 positions of the vicinal diol 138, which could restrict the 
formation of the stannylene acetal complex.  The proposed mechanism for this 
reaction (Figure 3.2.3.) involves the initial formation of a trigonal bipyrimidal 
stannylene acetal complex 141 between the glucopyranose 138 and the di-n-
butyl tin oxide, where the Sn–O bond to O-2 is longer than that to O-3.  This 
effectively places O-2 at one of the axial sites of the complex.  It is generally 
accepted that the longer bonds to the apical substituents are weaker, therefore 
it will be this bond that is more labile.138 
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Figure 3.2.3.  Mechanism of selective protection of diol 138 in polar solvents.  In non-polar solvents a tin-dimer complex 
forms, instead of coordination of the solvent. 
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When the stannylene acetal complex 141 reacts with benzyl bromide, the O-2 
atom reacts preferentially over the O-3 atom as it is slightly less sterically 
hindered, therefore more accessible for the bulky electrophile (O-2 is adjacent 
to the equatorial anomeric substituent, whereas O-3 is adjacent to the 
equatorial anisylidene acetal on O-4 and O-6).  The reactivity of the O-2 atom is 
also enhanced over the O-3 atom, as the apical Sn–O is longer than the 
equatorial one to O-3.  The difference in Sn–O bond lengths gives O-2 a more 
nucleophilic character, as the electrons are more diffuse in this bond (cf. 
shorter, equatorial Sn–O-3 bond) and therefore, are more accessible to react.  
This energy difference between the equatorial and apical Sn–O bonds is not 
large, hence the reaction is not entirely regioselective and a mixture of the two 
alcohols 139 and 140 are observed. 
 
3.2.2. Steps to formation of Ferrier rearrangement precursor 145 
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Scheme 3.2.4.  Formation of Ferrier rearrangement precursor 145.  Reagents and conditions:  i. Et3N (4 eq), TIPSOTf 
(1.5 eq), CH2Cl2, RT, 92% yield; ii. DIBAL-H (5 eq), CH2Cl2, RT, 88% yield; iii. Dess–Martin periodinane (1.5 eq), 
CH2Cl2, RT, 82% yield; iv. K2CO3 (5 eq), Ac2O (3 eq), DMAP (0.1 eq), MeCN, reflux, 65% yield.  
The remaining free secondary hydroxyl group at the 3-position of 139 was 
protected as the TIPS ether, affording the fully protected sugar 142 in excellent 
yield.  The next step was the regioselective opening of the anisylidene acetal 
142, allowing the 4- and 6-positions to be differentiated.  Literature methods 
prescribed the use of DIBAL-H139 or LiAlH4/AlCl3
140, 141 for this cleavage, 
allowing for the aromatic group to be placed on to the 4-position, revealing the 
primary alcohol at the 6-position.  Initial treatment of 142 with DIBAL-H yielded 
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the desired alcohol 143 in moderate yield (50-60%), with a significant amount of 
the 4,6-diol 146 observed. 
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Figure 3.2.5.  Undesired deprotection product diol 146 from side reaction with DIBAL-H. 
Modification of the workup procedure circumvented this problem.  Quenching 
the reaction at -10 ˚C with a mixture of water and sodium hydroxide, then 
maintaining this temperature until the aluminium salts had been removed, 
appeared to eliminate the side reaction.  This modified procedure afforded the 
alcohol 143 in high yield (88%). 
The primary alcohol 143 was oxidised to the corresponding aldehyde 144 using 
Dess-Martin periodinane.  The aldehdye was found to be stable to rapid silica 
gel column chromatography and indeed was shown to produce better results in 
the subsequent steps when purified, as opposed to being carried on in a crude 
form.  The aldehdye 144 was then converted to the enol acetate 145 by 
treatment with potassium carbonate and acetic anhydride, enolising the double 
bond and then trapping the enol as the acetate, providing the substrate 145 for 
the Ferrier rearrangement.  The reaction produced mixture of E and Z isomers, 
however, the Z-isomer of 145 was found to be the major isomer, which was 
exclusively isolated for subsequent reactions. 
 
 
3.3. Ferrier rearrangement reactions 
There are a number of different stoichiometric or catalytic metal mediators for 
the type-II Ferrier rearrangement that have been employed in the literature; 
such as HgCl2,
62 Hg(OAc)2,
63 Hg(OTf)2,
67 PdCl2.
84  Given that palladium is 
considerably less toxic than mercury and has been used in substoichiometric 
quantities, this was the first metal investigated for our Ferrier-II rearrangement.  
Treatment of the enol acetate 145 with palladium chloride (10-20 mol%) in a 
mixture of 1,4-dioxane and water (2:1) at 60 ˚C for 8-18 h, mirroring the 
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conditions reported by Takahasi,84 failed to complete the transformation.  
Further quantities of palladium were usually required before consumption of the 
starting material was observed.  Multiple products were observed from these 
reactions, not all of which could be separated by column chromatography.  
Mass spectrometry analysis of these fractions showed the correct mass for the 
expected inosose 147, however, a definite assignment by NMR was impossible 
due to the inseparable mixtures.  This result was not in accordance with 
Takahasi and co-workers,84 who found the isomers were separable.  However, 
we can ascribe the differences to the sterically bulky TIPS group at the 3-
position (not found in Takahasi’s molecule), which may interfere with the 
transition state. 
Stoichiometric mercury was next employed to effect the rearrangement.  
Following the method suggested by Ferrier,63 the enol acetate 145 was treated 
with Hg(OAc)2 (10 eq) in a mixture of acetone and water (2:1).  TLC analysis 
showed consumption of the starting material after 16 h.  Attempts to purify the 
crude material failed, as the material was thought to be breaking down on a 
silica gel column.  It was suspected that the presence of excess mercury salts 
may have been interfering with the column.   
The persistence of mercury salts in the crude Ferrier product appeared to be 
causing product degradation.  The aqueous workup had been conducted with 
ethyl acetate, which might have partially dissolved the mercury salts.  Changing 
the workup solvent to chloroform, as suggested by Prestwich,75 provided better 
results. 
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Scheme 3.3.1.  Type-II Ferrier rearrangement of enol acetate 145 to give inosose 147.  Reagents and conditions:  i. a. 
Hg(OAc)2 (10 eq), acetone:H2O (3:2), 15 min; b. NaCl(aq), 24 h, 35% yield. 
Therefore, a solution of the enol acetate 145 in acetone and water (2:1) was 
treated with Hg(OAc)2 (Scheme 3.3.1.).  After 1 h stirring, a solution of brine 
was added, turning the yellow mixture colourless (but slightly opaque) within 
5 min.  On stirring the mixture for a further 24 h, then extracting with chloroform, 
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the crude material was readily purified by column chromatography, affording the 
inosose 147 in 35% yield.  There were several less polar products observed by 
TLC analysis, which were shown to be complex mixtures of diastereoisomers 
(by 1H NMR).  Due to the mixtures, these isomeric products were not fully 
characterised. 
Crystallisation of the inosose 147 allowed for the relative stereochemistry of the 
ring to be confirmed by X-ray crystal structure (Figure 3.3.2.).  It can be seen 
that the 2-position hydroxyl group is orientated axial, which is required for the 
myo-configuration of the inositol ring.  The other substituents are orientated 
equatorial, as expected for the myo-configuration. 
 
Figure 3.3.2.  VMD stick representation of the X-ray crystal structure of inosose ring 147.  The relative stereochemistry 
of the 1-5 position oxygen atoms can be seen, with the 2-position hydroxyl group orientated in the axial position required 
for the myo-inositol ring.  Key: C, green; O, red; H, white; Si, gold.  Crystal structure data was deposited at the 
Cambridge Crystallographic Data Centre as supplementary publication number CCDC 718377. 
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3.3.1. Mechanistic rationale for stereochemistry of Ferrier rearrangement. 
The mechanism of the mercury-mediated type-II Ferrier rearrangements has 
been well studied in the literature.64, 70  The accepted mechanism, suggested by 
Machado and co-workers,71 is shown below (Figure 3.3.3.). 
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Figure 3.3.3.  Mechanism of the mercury-mediated type 2 Ferrier rearrangement.
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Oxymercuration of the vinylic double bond is presumed to install a hydroxyl 
group at the most substituted end of the alkene (directly attached to C-5 of the 
glucopyranose ring).  The mercury is thought to remain coordinated to the 
terminal end of the alkene.  Acid-promoted loss of methanol from the anomeric 
position leads to a !-keto aldehdye, with the coordinated mercury maintaining a 
pseudo chair transition state.  An intramolecular reorganisation of the complex 
forms the more stable chair intermediate, where the C-1 and C-2 carbons of the 
eventual inositol are placed next to each other.  Finally an intramolecular aldol 
reaction with loss of the mercury complex yields the expected inosose 147.  
The other possible diastereomeric products arise from alternate configurations 
of the final aldol reaction. 
The spectral data obtained for the inosose 147, along with the X-ray crystal 
structure confirm the configuration of the product is as would be predicted by 
the above mechanism. 
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3.4. Synthesis of InsP3 as proof of principle 
3.4.1. Synthetic steps to fully protected inositol 162 
For the synthesis of InsP3, there was no requirement to differentiate between 
the 2- and 6-positions of the inositol ring, therefore the ketone at the 6-position 
would be reduced, unmasking a diol 148 that could have these positions 
protected in a concurrent manner.   
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Scheme 3.4.1.  Reduction of the inosose 147, providing the myo-inositol ring 148.  Reagents and conditions: i. 
Me4NBH(OAc)3, AcOH, MeCN, -40 ˚C to RT, 18 h, 89% yield. 
Following the Ferrier rearrangement, the subsequent reduction of the 6-position 
ketone 147 to the myo-inositol 148 was achieved, in good yields, by treatment 
with tetramethylammonium triacetoxy borohydride.  The stereoselectivity of this 
reaction is thought to result from the reducing agent coordinating to the axial 2-
position hydroxyl group.  This mechanism leads to pseudo-intramolecular 
delivery of the hydride from the top face to the ketone, resulting in the equatorial 
6-position hydroxyl group of the diol 148.142, 143  There was only a single product 
148 observed from this reaction.  The assignment of the configuration of the 6-
position was based on 1H NMR coupling constants (Figure 3.4.2.) for the ring 
protons H-1, H-6 and H-5, which were 9.8 Hz (JH-1–H-6) and 9.3 Hz (JH-6–H-5).  
These values are indicative of axial-axial couplings (8.5-10.0 Hz), rather than 
axial-equatorial couplings (1.5-3.0 Hz) that would be observed if the reduction 
has occurred in the opposite sense. 
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Figure 3.4.2.  
1
H coupling for H-1, H-6 and H-5 in diol 148, demonstrating that, the hydroxyl group at the 6-position is 
equatorial. 
The diol 148 could not be isolated as a crystalline solid, however, the X-ray 
structure (Figure 3.4.13) of the fully protected inositol 162 showed that the 
reduction proceeded in the manner expected. 
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Protection of the 2- and 6-positions was required for the subsequent synthetic 
steps, and benzyl ethers were the obvious choice of protecting groups. 
However, it was know from previous work that the acetate group on the 1-
position is prone to migration under standard benzylation conditions; therefore, 
alternate conditions were sought.  Benzyl trichloroacetimidate in the presence 
of a Brønsted or Lewis acid was then considered as an alternative.144 
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Scheme 3.4.3.  Attempt to install benzyl groups on the 2 and 6-positions of diol 148 using trichloroacetimidate 
chemistry.  Reagents and conditions:  i. BnOCH(NH)CCl3 (4 eq), TfOH (cat.), cyclohexane, CH2Cl2, 6 h. 
Treatment of the diol 148 with fresh benzyl trichloroacetimidate and catalytic 
trifluoromethane sulfonic acid failed to effect the protection; instead the 
conditions resulted in the removal of the PMB group at the 5-position, affording 
the 2,5,6-triol 149.  Switching to a milder Lewis acid, triphenylcarbenium 
tetrafluoroborate, no reaction was observed even after prolonged reaction times 
(24 h) and greater catalyst loadings (0.05-0.25 eq).  In this case, the starting 
material 148 was returned intact. 
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Scheme 3.4.4.  Model study for installation of a benzyl group using trichloroacetimidate chemistry.  Reagents and 
conditions:  i. BnOCH(NH)CCl3 (4 eq), Lewis acid catalyst (0.1 eq), CH2Cl2, 96 h. 
In order to establish compatible conditions for this transformation, benzylation 
was attempted on a model system (Scheme 3.4.4.)  The mono-PMB alcohol 
150 was treated with benzyltrichloroacetimidate and a Lewis acid catalyst, 
under typical conditions for 96 h.  The acids chosen were triphenylcarbenium 
tetrafluoroborate and scandium triflate, with triflic acid being rejected as it was 
known to degrade the substrate.  In both reactions precipitates were observed, 
however, TLC analysis showed only the starting materials and breakdown of 
the benzyl trichloroacetimidate reagent.  At no point during the reaction was the 
desired product 151 observed.  It was decided not to pursue these conditions 
further, by using stronger Lewis acids, as it was suspected that these were 
likely to degrade the starting diol 150 in a similar manner to triflic acid. 
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The instability of the PMB group led us to investigate Dudley’s benzylation 
conditions,145 which involved the neutral salt 2-benzyloxy-1-methylpyridinium 
triflate (Dudley’s reagent) 154 in the presence of MgO.  Synthesis of the 
reagent was achieved in two steps, according to Dudley’s method.146 
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Scheme 3.4.5  Formation of Dudley’s reagent 154.  Reagents and conditions:  i. BnOH (1 eq), KOH (3.3 eq), 18-crown-
6 (0.05 eq), toluene, Dean and Stark, 1h, 100% yield;  ii. Me2OTf (1.05 eq), toluene, 0 ˚ C to RT, 97% yield. 
Nucleophilic substitution of 2-chloropyridine 152 by benzyl alcohol was 
achieved by heating a mixture of 2-chloropyridine 152, benzyl alcohol, 
potassium hydroxide and toluene, with the azeotropic removal of water via a 
Dean and Stark apparatus.146  This reaction provided 2-benzyloxypyridine 153 
in quantitative yield after chromatographic purification.  Subsequent treatment 
of the pyridine 153 with a cold solution of methyl triflate furnished Dudley’s 
reagent 154 as a colourless solid.  NMR assignment of the reagent 154 agreed 
with the literature values.145  The 13C NMR also displayed a large 1JC-F coupling 
of around 320 Hz, owing to the triflate salt. 
Several attempts at the benzylation reaction of diol 148 were attempted, as 
outlined in Scheme 3.4.6 and Table 3.4.7.  Entry 1 followed the optimised 
literature conditions, reacting the diol 148 and the pyridinium reagent 154 
(2.1 eq per OH) in the presence of an inorganic base (MgO, 2.1 eq per OH) in 
refluxing benzotrifluoride for 18 h.  These conditions yielded multiple inositol-
based products (adjudged by TLC and 1H NMR) in poor yields.  By 1H NMR it 
appeared that there was some incorporation of benzyl groups, however, there 
were no readily identifiable products. 
BnO
BnO
TIPSO
OAc
OBn
OPMB
HO
BnO
TIPSO
OAc
OH
OPMB
i
148 155
X
 
Scheme 3.4.6.  Attempts to install benzyl groups at the 2- and 6-positions of diol 148 using Dudley’s reagent.  Reagents 
and conditions:  i. see Table 3.4.7. 
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Entry 
Pyridinium 
salt 154 (eq) 
Base (eq) Solvent Conditions Outcome 
1 4.2 MgO (4.2) PhCF3 reflux, 85 ˚C, 18 h 
multiple 
products 
2 4.2 MgO (8) PhCF3 reflux, 85 ˚C, 48 h 
multiple 
products as 1 
3 4.2 2,6-lutidine (10) PhCF3 reflux, 85 ˚C, 8 h 
breakdown 
products 
Table 3.4.7.  Reaction conditions to install benzyl groups on diol 148 as outlined in Scheme 3.4.6. 
Suspecting that a small excess of triflic acid in solution (derived from partial 
hydrolysis of the reagent 154) may be causing migration of groups or 
breakdown of the products, a second experiment (entry 2) was conducted using 
a large excess of the inorganic base.  These conditions failed to improve the 
outcome of the reaction.  It was conjectured that the insolubility of the inorganic 
base in the solvent may be causing the problems, therefore a soluble amine 
base was considered as a substitute.  Under similar conditions as previous, 
except using 2,6-lutidine in lieu of MgO (entry 3), no identifiable products were 
isolated.  There were multiple products observed, as well as spots on the TLC 
plate, indicating that the reagent was breaking down, forming its pyridine 
precursor 153. 
Subsequent to this work, Miller has also reported these conditions to be 
ineffective for the installation of benzyl groups on inositol rings.96  These results 
suggest that the hydroxyl groups around the inositol ring are simply too 
hindered to be benzylated effectively with this reagent. 
A final attempt to install the benzyl groups onto the diol 148 was considered 
using the simple conditions of strong base and benzyl bromide.  The 
perbenzylation was conducted with a large excess of benzyl bromide (100 eq) 
as a component of the solvent mixture, ensuring that there was a rapid in situ 
quench of the alkoxide when the diol was deprotonated.  These conditions were 
intended to minimise the migration of the acetate group (Scheme 3.4.8). 
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Scheme 3.4.8.  Attempted perbenzylation of diol 148 using standard protecting conditions.  Reagents and conditions:  i. 
NaH (2.1 eq), BnBr (100 eq), THF, DMF, -10 ˚C, 2 h, 87% yield. 
The diol was dissolved in a mixture of THF/DMF and BnBr and cooled to -10 ˚C.  
Sodium hydride was then gradually added portionwise to the mixture.  After 2 h 
at -10 ˚C, an apparent single product was observed by TLC analysis, which was 
isolated by column chromatography.   
 
Figure 3.4.9.  
1
H NMR (300 MHz) of perbenzylation product 156 showing signs of migration.  The expanded regions 
indicate the presence of multiple PMB groups due to their complexity.  The signal in the region of 6.80-6.74 should be 
an apparent triplet (Ph ring protons), whereas the signal at 3.72 should be a singlet (OCH3 group). 
The mass of the product corresponded to the desired 2,6-bis benzylated 
material 156.  However, 1H NMR showed at least two signals in the PMB region 
(Figure 3.4.9), indicating that migration had once again occurred, affording 
unknown configuration(s) of the product 156.  It was concluded that this 
protocol was not feasible as a method to introduce the benzyl groups. 
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3.4.2. Alternate protecting group for the 2- and 6-positions 
It had become apparent through exhaustive investigation that it was very 
difficult to install benzyl groups onto the free hydroxyl positions of the diol 148.  
An alternative protecting group was therefore considered.  The requirements for 
such a group were stability to most protecting group manipulations and lability 
to hydrogenolysis.  It was decided to use the benzyloxymethyl (BOM) protecting 
group, as this group satisfied the criteria and could be installed using mild 
organic bases. 
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Scheme 3.4.10.  Construction of model compound 160 for studies on stability of BOM group.  Reagents and conditions:  
i. BOMCl (1.2 eq), Hünig’s base (2 eq), CH2Cl2, RT, 18 h, 53% yield of 158;  ii. TIPSOTf (1.2 eq), Et3N (3 eq), RT, 1 h, 
80% yield. 
To test the feasibility of the BOM group, a small range of studies were 
conducted, using a racemic trans-cyclohexane diol as a model compound 
(Scheme 3.4.10.)  The diol 157 was protected by treatment with BOMCl and 
Hünig’s base, forming the mono-substituted alcohol 158 in moderate yields and 
the bis substituted diol 159 as a major side product (16% yield).  The remaining 
free hydroxyl group of 158 was protected as the TIPS ether, as this was 
deemed to be the more labile functionality present on the actual synthetic route 
(on diol 148).   
The differentially protected compound 160 was then submitted to several 
deprotection protocols, to ascertain the stability of the BOM group (Scheme 
3.4.11.).  Treatment of 160 with TBAF solution in THF effected the removal of 
the TIPS group in near quantitative yields, without formation of any parent 
cyclohexane diol 157.  Similarly, on treatment of 160 with DDQ (the conditions 
required for removal of a PMB group, such as found on diol 148) no reaction 
was observed and the starting material 160 was returned in high yield without 
formation of side products.  These experiments demonstrated the required 
stability of the BOM group. 
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Scheme 3.4.11.  Deprotection studies of model compound 160, demonstrating the stability of BOM group.  Reagents 
and conditions:  i. TBAF (1 M in THF, 1.2 eq), THF, RT, 5 h, 98% yield;  ii. H-Cube hydrogenolysis, Pd/C cartridge, 
75 ˚C, 0.25 mM in MeOH, 1 mL/min, 74% yield;  iii. DDQ (2.2 eq), CH2Cl2/H2O (18:1), RT, 18 h, 160 recovered in 92% 
yield. 
Finally, to ensure that the BOM group could be removed, 160 was subjected to 
hydrogenolysis under Pd black catalysis.  This reaction was shown to proceed 
cleanly – although prolonged reaction times were required, possibly due to the 
relatively low solubility of 160 in the tBuOH and water mixture.  An alternative 
protocol was attempted using an H-Cube continuous flow reactor.  A solution of 
160 in methanol was passed through a heated Pd/C cartridge, affording the 
TIPS-protected alcohol 161 in good yields without the need for further 
purification beyond removal of the solvent.  These conditions showed that it 
would be possible to remove the BOM group by two different protocols, if 
required at a later stage. 
 
3.4.3. BOM protection of free hydroxyl groups of diol 148 
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Scheme 3.4.12.  Improved synthetic method for bis-BOM protection of diol 148.  Reagents and conditions: i. BOMCl 
(8 eq), Hünig’s base, 85 ˚C, 15 h, 82% yield. 
Optimisation revealed that high yields of the desired bis-BOM protected 
material 162 were obtained when the BOMCl was pre-treated with Hünig’s base 
for 2 h prior to the reaction with the diol 148.  Large amounts of insoluble salts 
were produced, during the pre-treatment, indicating the presence of excess acid 
in the reagent.  The salts were allowed to settle, before the BOMCl / Hünig’s 
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base mixture was carefully transferred via cannula to a solution of the diol 148 
in Hünig’s base, avoiding transfer of residual solids.  The mixture was then 
heated for 16 h at 85 ˚C – after which time TLC analysis indicated the presence 
of a single BOM-protected compound and some excess BOMCl.  On 
purification, this material was shown to be exclusively the bis-protected diol 
162.  On small-scale (230 mg) the yield was 74%, climbing to 82% when carried 
out on a multi-gram (4 g) scale. 
 
Figure 3.4.13.  VMD stick representation of X-ray crystal structure of bis-protected diol 162 (nksc14).  The BOM groups 
are located on the 2- and 6-positions.  Key: C, green; O, red; H, white; Si, gold. 
The bis-protected diol 162 was isolated as a crystalline solid, whose single 
crystal X-ray structure was solved (Figure 3.4.13.).  This structure confirmed 
both the substitution pattern of the ring, and the sense of the stereoselectivity of 
the earlier reduction of the inosose 147 to the inositol 148.  
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3.4.4. Deprotection steps to 1,4,5-triol 165 
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Scheme 3.4.14.  Sequential removal of protecting groups from fully protected inositol 162 to yield triol 165.  Reagents 
and conditions:  i.  LiOH (4.2 eq) , THF, MeOH, 15 min, RT, 97% yield;  ii. DDQ (2.2 eq), CH2Cl2/H2O (18:1), 10 min, 
RT, 95% yield;   iii. TBAF in THF, CH2Cl2, RT, 24 h, 90% yield. 
In order to synthesise InsP3 1, the protecting groups at the 1-, 4- and 5- 
positions had to be removed.  Removal of the acetate group from the 1-position 
was conducted first, in an effort to minimise any possible migration of the acyl 
group under other deprotection conditions.  Saponifiaction of 162 under basic 
conditions (LiOH in MeOH/THF/H2O, 8:3:2) afforded the 1-position alcohol 163 
in moderate yields.  Exclusion of water from the solvent system, still allowed 
adequate solubility of the reagents and furnished a near-quantitative yield of the 
1-position alcohol 163.  Two methods were evaluated for removal of the PMB 
group from the 5-position of 163 (see section 3.5.1.), before it was decided to 
use DDQ in wet CH2Cl2.  This reaction initially afforded the 1,5-diol 164 in low to 
moderate yields with a mild acidic workup (saturated ammonium chloride 
solution).  When the reaction was quenched with aqueous sodium hydrogen 
carbonate, the yields were near quantitative, owing to easier purification due to 
effective removal of the quinone by-products in the aqueous phase as opposed 
to by column chromatography.  The remaining TIPS group on the 4-position of 
diol 164 was removed smoothly using TBAF solution in THF and CH2Cl2, 
affording the known 1,4,5-triol 165.84  The data obtained for the triol 165 were in 
good agreement with the literature values.  Attaining the triol 165 represented a 
formal synthesis of InsP3 1. 
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3.4.5. Total synthesis of InsP3 
With the triol 165 in hand, the final steps to synthesise InsP3 1 were carried out.  
In order to install benzyl-protected phosphate groups onto the 1-, 4- and 5- 
positions of the triol 165, 1H-tetrazole-catalysed phosphoramidite chemistry was 
employed, using the methods developed by Johns147 and Fraser-Reid.148  The 
bis-benzyl phosphoramidite 165 was prepared in two steps from phosphorus 
trichloride (Scheme 3.4.15.) according to the method of Bannwarth.149 
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Scheme 3.4.15.  Generation of phosphoramidite 168 from PCl3.  Reagents and conditions:  i. a. pyridine (1 eq), BnOH 
(1 eq), Et2O, -78 ˚C;  b. N,N-diisopropylamine, -10 ˚C to RT, 75% yield;  ii. 1H-tetrazole (0.43 M in MeCN, 0.4 eq), 
BnOH (1 eq), CH2Cl2, 81% yield. 
Treatment of phosphorus trichloride with pyridine and benzyl alcohol under 
anhydrous conditions generated benzyloxy phosphorus dichloride 166, which 
was quenched by the addition of diisopropylamine prior to isolation, forming 
benzyloxy-bis(N,N-diisopropylamino) phosphine 167. To synthesise the 
bis(benzyloxy)-N,N-diisopropylamino phosphine 168, 167 was treated with 1H-
tetrazole and anhydrous benzyl alcohol, substituting one of the N-
diisopropylamine units for a benzyloxy group.  This material 168 was stable to 
rapid chromatography to remove impurities, such as tris(benzyloxy) phosphine 
that was generated as a by-product.  Once generated, the amidite 168 was 
used immediately. 
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Scheme 3.4.16.  Phosphitylation of 1,4,5-triol 165 to generate fully protected InsP3 precursor 169.  Reagents and 
conditions:  i. a. (BnO)2PN(
i
Pr)2 (6 eq), 1H-tetrazole (0.43 M in MeCN, 6 eq), CH2Cl2, RT; b. 3-chloroperoxybenzoic acid 
(6 eq), -78 ˚C to RT, 93% yield. 
The 1,4,5-triol 165 was phosphitylated by addition to a mixture of the amidite 
168 and 1H-tetrazole (Scheme 3.4.16.).  After stirring overnight, a single 
product was observed by TLC analysis, which was presumed to be the 
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intermediate phosphinate (P(III) species).  Oxidation of this newly formed 
intermediate with 3-chloroperoxybenzoic acid, generated the benzyl-protected 
trisphosphate 169 (now P(V) species).  The mechanistic explanation for this 
reaction is shown in Scheme 3.4.17. 
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Scheme 3.4.17.  General mechanism for the 1H-catalysed phosphitylation of alcohols using bis(benzyloxy)-N,N-
diisopropylamino phosphine 168. 
1H-Tetrazole acts as both an acid and a nucleophilic catalyst during the course 
of the phosphitylation reaction.  The mechanism of the reaction has been 
postulated through kinetic studies of the phosphitylation of simple alcohols.150, 
151  The phosphoramidite 168 is protonated by one molecule of 1H-tetrazole, 
while that molecule is simultaneously protonated by a second molecule of 1H-
tetrazole, generating a tetrazolide anion.  The tetrazolide anion attacks the 
phosphoramidite complex 170 at the phosphorus atom, which is now !+ due to 
high polarisation of the former P–N bond, extruding diisopropylamine and 
forming tetrazolide intermediate 171.  Tetrazolide 171 is the reactive 
intermediate that effects phosphitylation of the alcohol 172 (shown in blue), 
yielding phosphite 173.  The phosphite 173 can be susceptible to aerobic 
oxidation, therefore is not usually isolated, but instead is treated with an oxidant 
such as 3-chloroperoxybenzoic acid, forming the corresponding stable 
phosphate 174. 
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Scheme 3.4.18.  Global deprotection of protected trisphosphate 169, affording InsP3 1.  Reagents and conditions:  i. H2 
(g), 
t
BuOH/H2O (6:1), Pd black (20 eq), NaHCO3 (6 eq), RT, 95% yield. 
With the fully protected trisphosphate 169 in hand, the final step to InsP3 1 was 
global deprotection by palladium black-catalysed hydrogenolysis in the 
presence of sodium hydrogen carbonate, affording InsP3 as its presumed 
hexasodium salt (Scheme 3.4.18.).  InsP3 1 was isolated as its sodium salt, as it 
was easier to handle compared to the free acid.  The data obtained were in 
good agreement with the literature values, however, the optical rotation values 
were found to vary quite dramatically with pH, presumably owing to various 
sodiated states of the molecule in solution. 
InsP3 1 was synthesised in 14 linear steps, with an overall yield of 2.5%.  The 
biological activity of the synthetic InsP3 was assayed against natural InsP3 in a 
Ca2+-flux assay to ascertain whether the synthetic route had produced authentic 
material.  These results are discussed in Chapter 5.2. 
 
 
3.5. Synthesis of InsP3 analogues 
In light of previous work within the research group, it was decided to tailor the 
synthetic route for the synthesis of 4- and 5-position analogues of InsP3.  The 
corresponding phosphate group would be replaced by a bioisosteric moiety, in 
an attempt to modulate the biological activity of the compound. 
 
3.5.1. Model studies for selective removal of protecting groups 
Whilst the order of protecting group removal in the InsP3 route shown previously 
lends itself to the synthesis of 4-position analogues, it is unsuitable for 5-
position analogues, therefore an alternative order of protecting group removal 
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was considered.  A model system was employed to ascertain whether the PMB 
and TIPS groups on the alcohol 175 were orthogonal to each other, and 
therefore could be removed in either order. 
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Scheme 3.5.1.  Synthesis of model system 175 to ascertain orthogonality between TIPS and PMB protecting groups.  
Reagents and conditions:  i. NaH (1.3 eq), TBAI (0.2 eq), PMBCl (1.5 eq), THF, DMF, RT, 16 h, 56% yield;  ii. TIPSOTf 
(1.2 eq), Et3N (3 eq), CH2Cl2, RT, 18 h, 72% yield. 
Cyclohexane diol 157 was selectively deprotonated by dropwise addition of the 
diol to a stirred suspension of sodium hydride in THF, causing the mono sodium 
alkoxide to precipitate.  The alkoxide was treated with PMBCl, TBAI and DMF 
(for solubility) providing the mono PMB-protected alcohol 150 in moderate 
yields.  Protection of the remaining free hydroxyl group of 150 as the TIPS ether 
proceeded in high yields, furnishing the orthogonally protected diol 175. 
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Scheme 3.5.2.  Orthogonal deprotection of model system 175.  Reagents and conditions:  i. TBAF (1 M in THF, 1.2 eq), 
THF, RT, 24 h, 78% yield;  ii. DDQ (2.2 eq), CH2Cl2/H2O (18:1), RT, 10 min, 70% yield. 
Orthogonal deprotection conditions were established to selectively remove 
either protecting group (Scheme 3.5.2.).  The TIPS group was removed 
smoothly using TBAF in THF, providing the parent alcohol 150 in good yield.  
There were no detectable side products, indicating that the PMB group 
remained intact under the conditions.  Selective removal of the PMB group 
required more careful choice of conditions.  Initial attempts to remove the PMB 
group under oxidative deprotection conditions using ceric ammonium nitrate 
(CAN) proved unsuccessful, resulting in rapid removal of both protecting groups 
to give the parent diol 157.  A similar result was obtained when CAN was used 
under buffered conditions (pH 8.3 – tris, borate, EDTA buffer).  A switch to less 
acidic deprotection conditions, using DDQ provided the mono TIPS-protected 
alcohol 161 in reasonable yields, without removal of the TIPS group.  The DDQ 
conditions were therefore selected for the synthetic route. 
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3.5.2. Steps to 5-position analogue precursor 
The common intermediate used in the synthesis of all of these routes (to InsP3 
and derivatives) was the 1-position alcohol 163.  With the successful model 
studies showing that the TIPS group could be removed in the presence of the 
PMB group, this reaction was attempted on the alcohol 163, in contrast to the 
InsP3 route where the PMB group is removed first.  Several sets of conditions 
were attempted before a reliable set was obtained, as outlined in Scheme 3.5.3. 
and Table 3.5.4. 
BOMO
BnO
OH
OH
OBOM
OPMB
BOMO
BnO
TIPSO
OH
OBOM
OPMB
i
163 176  
Scheme 3.5.3.  Removal of TIPS group from alcohol 163 to provide 1,4-diol 176.  Reagents and conditions:  i. See 
Table 3.5.4. for conditions. 
Entry 
Fluoride 
source 
eq Solvent Conditions Outcome 
1 HF.py 100-300 THF RT, 24 h 
extensive breakdown 
products 
2 HF.py 5-1405 pyridine RT, 7 days 
74% yield of 176 after 
increasing HF.py 
3 TBAF 10 CH2Cl2 
RT, 24 h 
4 cycles to complete  
56% yield after 
multiple reactions 
4 TBAF 20 THF 
TBAF (20 eq), RT, 
18 h 
clean product, 89% 
yield of 176 
Table 3.5.4.  Conditions for removal of TIPS group from alcohol 163 in Scheme 3.5.3. 
Treatment of the alcohol 163 with HF.py complex in THF (entry 1) resulted in 
extensive breakdown of the products and starting materials, producing a 
complex mixture.  Under milder conditions, using HF.py complex in pyridine 
(entry 2), the reaction was very slow, but did not show degradation of the 
alcohol 163.  A large excess of HF.py (1400 eq) and long reaction times (7 
days) were required before the reaction was adjudged complete by TLC 
analysis. On purification, the isolated yield of the 176 in pyridine was 74%, 
however, prolonged reaction times were required.  These observations were 
consistent with the work of Miller, who used similar large excesses of HF.py for 
the removal of TBS groups adjacent to protected phosphates on an inositol 
skeleton.152   
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TBAF was then considered as an alternative source of fluoride.  Treatment of a 
CH2Cl2 solution of alcohol 163 with TBAF in THF (entry 3) required several 
attempts to complete the reaction.  After stirring overnight, it was difficult to 
judge the outcome by TLC analysis, as the alcohol 163 and the product 176 
had similar Rf values.  The reaction was worked up and purified to establish its 
outcome.  The main product was the unreacted starting material 163.  Only 
30% of the product mixture was found to be 176.  The unreacted material was 
resubmitted to the reaction conditions a further three times to react the bulk of 
the starting material 163 – resulting in an overall yield of 56% of 176 over 4 
iterations of the reaction. 
Switching solvent from CH2Cl2 to THF improved the reaction.  Treatment of a 
solution of 163 in THF with TBAF in THF (20 eq) (entry 4), showed complete 
consumption of the starting material after 18 h.  Only a single product was 
observed, affording the 1,4-diol 176 after purification in excellent yield.  The 
marked difference in the reactivity by changing from CH2Cl2 to THF could be 
ascribed to the differing solubility of the starting material and product in these 
two solvents. 
 
3.5.3. Synthesis of 5-position alcohol 178 
With the 1,4-diol 176 in hand, benzyl protected phosphate groups were installed 
on the two free hydroxyl groups.  Treatment of the diol 176 with bis(benzyloxy) 
phosphoramidite 168 and 1H-tetrazole, followed by oxidation with 3-
chloroperoxybenozic acid (Scheme 3.5.5.),147, 148 afforded the bisphosphate 177 
in excellent yield (89%) after careful chromatography.   
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Scheme 3.5.5.  Synthetic steps to 5-position alcohol 178.  Reagents and conditions:  i. a. (BnO)2PN(
i
Pr)2 (5 eq), 1H-
tetrazole (0.43 M in MeCN, 5 eq), CH2Cl2, RT, 19 h;  b. mCPBA (5 eq), -78 ˚C to RT, 2 h, 89% yield over 2 steps;  ii. 
CAN (3.5 eq), MeCN/H2O (4:1), RT, 40 min, 75% yield. 
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The remaining step to the synthesis of the alcohol 178, the precursor for the 5-
position analogues, was deprotection of the PMB group.  From previous 
precedent in the group, it was elected to use oxidative deprotection conditions 
of CAN in an acetonitrile/water mixture as the solvent.  TLC analysis of the 
initial reaction of the bisphosphate 177 with CAN (2.2 eq) showed that the 
reaction had arrested after 10 min (no change between 10 and 20 min).  A 
further aliquot of CAN (1 eq) was added, completing the reaction within another 
10 min of stirring.  On workup and purification a poor yield (44%) of the alcohol 
178 was obtained.  Repeating the reaction with a greater amount of CAN from 
the outset (3.5 eq), showed complete consumption of the starting material after 
40 min, without the need to add further CAN.  The improved conditions yielded 
the 5-position alcohol 178 in 75% yield, which is reasonable for these 
deprotection conditions. 
 
3.5.4. Synthesis of 5-methylphosphate ester analogue 128 of InsP3 
The first bioisosteric replacement considered for the 5-position phosphate was 
the methylphosphate ester.  This group occupies very similar chemical space 
when compared with the free phosphate, however, it reduces the number of 
charged contacts that could be made to the receptor.  It was envisaged that this 
compound could still bind to the InsP3Rs with a similar mode to InsP3, but might 
remove key interactions with the receptor, thus preventing Ca2+ release and 
ultimately creating an InsP3R antagonist.  Installation of the group was achieved 
using phosphoramidite chemistry, similar to that used to install the benzyl 
protected phosphate groups. 
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Scheme 3.5.6.  Synthesis of benzyloxy-methoxy phosphoramidite 179.  Reagents and conditions:  i. 1H-tetrazole 
(0.43 M in MeCN, 0.4 eq), MeOH (1 eq), CH2Cl2, RT, 4 h, 67% yield. 
The benzyloxymethoxy phosphoramidite 179, was synthesised from the stock 
benzyloxy-N,N-diisopropylamino phosphine 167 by treatment with 1H-tetrazole 
and anhydrous methanol (Scheme 3.5.6.) in the analogous manner to the 
synthesis of bis(benzyloxy) phosphoramidite 168.  Rapid chromatographic 
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purification of the sensitive material afforded the amidite 179 in 67% yield.  
Once synthesised, 179 was used immediately to prevent aerial oxidation.  This 
synthetic method was in contrast to that of Safrany153 or Caruthers,154 who 
synthesised the amidite 179 from methoxy dichlorophosphine.  Our method, 
however, was more flexible to allow for the synthesis of several 
phosphoramidites from a common precursor 167 in a divergent approach, 
rather than a convergent approach, which required each amidite to be 
individually synthesised from phosphorus trichloride. 
The 5-position alcohol 178 was treated with a mixture of the amidite 179 and 
1H-tetrazole, followed by oxidation with mCPBA, affording the trisphosphate 
180 as a 1:1 mixture of inseparable diastereoisomers (Scheme 3.5.7.).  The 
diastereoisomers arise from the new stereogenic phosphorus atom at the O-5 
position of the ring. 
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Scheme 3.5.7.  Final steps to 5-position analogue 128.  Reagents and conditions:  i. a. (BnO)(CH3O)PN(
i
Pr)2 (3 eq), 
1H-tetrazole (0.43 M in MeCN, 3 eq), CH2Cl2, RT, 19 h;  b. mCPBA (4 eq), -78 ˚C to RT, 92% yield over 2 steps;  ii. 
H2 (g), Pd black (20 eq), NaHCO3 (5 eq), 
t
BuOH/H2O (10:1), RT, 25 h, 51% yield. 
There are two possible attack conformations of the alcohol 178 on the 
phosphoramidite 179.  As a 1:1 mixture of diastereoisomers was produced, 
there appears to be no preferred attack conformation.  On oxidation from P(III) 
to P(V), the conformation of the newly formed phosphate group is fixed.  The 
assignment of the diastereoisomers was confirmed by 2D NMR studies, 
showing that there were two structurally similar compounds present in the 
product mixture.  It was not perceived to be a problem that the diastereoisomers 
could not be separated, as after the global deprotection step, the P atom is no 
longer stereogenic. 
The final step was the global deprotection of the protected trisphosphate 180, 
by palladium black-catalysed hydrogenolysis, affording the trisphosphate 
analogue 128 in 51% yield (Scheme 3.5.7.).  Sodium hydrogen carbonate was 
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present to enable isolation of the product 128 as its presumed pentasodium 
salt.  The yield was eroded as the material was resubmitted to the 
hydrogenolysis conditions, as deprotection was shown to be incomplete by 1H 
and 31P NMR after the initial reaction period (6.5 h).  As these compounds were 
not readily separable, the entire mixture was resubmitted for a further 16 h, after 
which time only the deprotected product 128 was observed. 
Once full analysis had been conducted on the compound, its biological activity 
was assessed in a Ca2+-flux assay, as outlined in Chapters 5.3.1 and 6.2. 
 
3.5.5. Synthesis of 5-Methylphosphonate analogue 126 
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Figure 3.5.8.  Racemic and enantiopure 5-methylphosphonate analogues of InsP3. 
The racemic 5-methyl phosphonate analogue of InsP3 126 has been previously 
reported to be an InsP3R-antagonist by van Boom and co-workers,
117-119 
however, no biological data were subsequently published to corroborate their 
claims.  More recently our group had produced preliminary data, suggesting 
that the enantiopure D-myo-inositol-1,4-bisphosphate-5-methylphosphonate 126 
did act as a weak antagonist of the InsP3Rs, with up to 40% inhibition of InsP3-
induced Ca2+ release at 300 µM.  Our renewed interest in this compound made 
it a logical choice as a synthetic target, in order to generate further material for 
biological study.  Thus, the synthesis of the analogue was approached from 
material derived from the Ferrier rearrangement route, as opposed to 
alternative means, which are discussed in Chapter 4.3.4. 
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Figure 3.5.9.  Reagents for the installation of methylphosphonate units onto alcohol substrates. 
The installation of the methylphosphonate unit onto the 5-position alcohol 178 
would be achieved using phosphorus(V) chemistry, as opposed to phosphorus 
(III) chemistry, which had been used for all previous phosphate groups.  
Previous work had shown that a simple phosphonylating agent, methyl 
phosphonic dichloride 181, was effective to install the methylphosphonate on a 
model substrate, however, these conditions did not translate onto an inositol 
polyphosphate substrate.121  The imidazole 182 and HOBT 183 derivatives of 
methylphosphonic dichloride had also been shown to be unreactive towards 
installing the methylphosphonate unit on a model substrate.121  To this end it 
had been shown that the methylphosphonylating agent was required to be 
highly activated.  We turned to the trifluoromethyl-HOBT derivative 186, which 
had been used by van Boom and co-workers in their original work.117 
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Scheme 3.5.10.  Synthesis of activated methylphosphonylating reagent 186.  Reagents and conditions:  i. H2NNH2.H2O 
(3 eq), EtOH, reflux, 22 h, 74% yield;  ii. methylphosphonic dichloride (1 eq), pyridine (2 eq), 1,4-dioxane, 3 Å molecular 
sieves, RT, 2 h, assumed 100% yield of 0.2 M stock solution. 
This reagent 186 was synthesised in two steps from commercially available 4-
chloro-3-nitro-benzotrifluoride 184 (Scheme 3.5.10.).  Nucleophilic aromatic 
substitution of the benzotrifluoride 184 with hydrazine hydrate, followed by 
subsequent in situ ring closure, afforded the 6-trifluoromethyl HOBT derivative 
185 in good yields.155  It was noted that this material produced better results in 
the subsequent step if it had been freshly recrystallised from diethyl ether.  The 
methylphosphonylating reagent 186 was then synthesised by treatment of the 
HOBT derivative 185 with methylphosphonic dichloride 181 in the presence of 
pyridine (to remove excess acid).  Schlenk filtration of the resulting mixture 
Results and Discussion – Ferrier Rearrangement 
92 
under argon afforded the reagent as a 0.2 M stock solution in 1,4-dioxane.  It 
should be noted that this reaction was extremely moisture sensitive; the HOBT 
derivative 185 required vacuum drying over P2O5 for 24 h prior to reaction; 1,4-
dioxane was freshly distilled from sodium and benzophenone; molecular sieves 
were placed in the reaction to remove any ingress of water; and the entire 
reaction was conducted under an argon atmosphere.  In the course of 
optimising the anhydrous conditions it was observed that the reagent was very 
susceptible to hydrolysis, forming methylphosphonic acid.  The purity of the 
reagent was assessed by 31P NMR of the stock solution in the presence of a D6-
benzene capillary to provide a lock signal (Figure 3.5.11.).  The !P 48.5, agrees 
closely with the literature value of !P 47.6 (using a CD3CN capillary).
117 
 
Figure 3.5.11.  
31
P NMR (101 MHz) of stock solution of methylphosphonate reagent 186. 
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Scheme 3.5.12.  Installation of the protected methylphosphonate unit onto alcohol 178.  Reagents and conditions: i. a. 
Methylphosphonylating reagent 186 (0.2 M in dioxane, 1.2 eq), pyridine, RT, 20 min;  b. BnOH (4.0 eq), RT, 3 h, 32% 
yield over 2 steps. 
The protected methylphosphonate unit was installed onto the alcohol 178 in two 
steps, conducted in a single pot (Scheme 3.5.12.)  The alcohol 178 was 
dissolved in pyridine, then treated with the activated phosphonylating agent 186 
for 20 min, forming the transient intermediate 187.  Anhydrous benzyl alcohol 
was then added, performing an in situ quench of the intermediate 187 by 
substituting the remaining 6-CF3 HOBT moiety for a benzyloxy group, affording 
the fully protected analogue 188. After extensive purification, the trisphosphate 
188 was isolated as a 10:1 mixture of inseparable diastereoisomers in low yield 
(32%).  A considerable amount of highly polar material was observed during 
purification, suggesting that some of the intermediate 187 had been quenched 
with water, forming the highly polar phosphate 189 (Figure 3.5.13.).  This 
material remained on the baseline during chromatography, only moving in a 
highly polar flush of the column (10-20% MeOH in EtOAc). 
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Figure 3.5.13.  Possible side product 189 formed during installation of methylphosphonate unit on alcohol 178.  This 
product arises from hydrolysis of the intermediate 187. 
The diastereoisomeric mixture of 188 is due to the stereogenic P atom on O-5.  
The ratio of diastereoisomers suggests that there is a preferred conformation of 
attack of the alcohol 178 on the methylphosphonylating reagent 186, which 
fixes the ratio of diastereoisomers.  The subsequent quench only substitutes 
one ligand on the phosphorus atom, hence cannot control the 
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diastereoselectivity of the reaction.  It is conceivable that there is a preferred 
attack conformation, as OH-5 is highly sterically encumbered, due to being 
flanked by a benzyloxymethyl group on O-6 and a benzyl-protected phosphate 
group on O-4. 
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Scheme 3.5.14.  Global deprotection step to reveal the enantiopure 5-methylphosphonate analogue 126.  Reagents 
and conditions:  i. H2 (g), Pd black (20-30 eq), NaHCO3 (5 eq), 
t
BuOH/H2O (10:1), RT, 10 h 97% yield. 
The final step to unmask the free enantiopure methylphosphonate analogue 
126 was global deprotection by hydrogenolysis (Scheme 3.5.14.).  After 10 h 
under the aforementioned conditions, a further quantity of palladium (10 eq) 
was added and the reaction was run for a further 5 h.  On workup and 
lypholisation, the product was found to be the desired compound 126, however, 
there was also a discrete methylphosphonate-containing impurity present.  
Owing to lack of other signals in both the 1H and 31P NMR spectra, it is 
suspected that this impurity may be methylphosphonic acid.  The 1H (!H 0.98, d, 
J 15.6) and 31P (!P 21.6) chemical shifts correspond closely with the literature 
values: (!H 1.09, d, J 15.7) and (!P 21.4) respectively.
156, 157 
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Figure 3.5.15.  Overlay of 
1
H and 
31
P NMR spectra of 5-position methylphosphonate analogue 126.  The trace in red is 
material derived from the Ferrier rearrangement; the trace in black is material derived from myo-inositol (vide supra). 
Overlay of the spectra with the authentic material, derived from myo-inositol, 
showed that that the correct material 126 was present as the major constituent 
of the product (Figure 3.5.15.).  Further analysis by high-resolution mass 
spectrometry confirmed that the material was indeed correct.  Owing to the 
impurity, this material was not tested in a biological system.  It is suspected that 
resynthesis of this precursor, followed by hydrogenolysis (without the addition of 
further palladium) would yield pure material.  However, this analogue 126 was 
also being generated via an alternate route, which proved to be a more viable 
method.  
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3.6. Towards the synthesis of 4-position analogues of InsP3 
Having successfully synthesised two 5-position analogues, we investigated 
whether the common intermediate 162 could be used for the synthesis of 4-
position InsP3 analogues.   
The order of protecting group removal for the InsP3 synthesis naturally lent itself 
to the synthesis of 4-position analogues.  Sequential removal of the acetate 
(from O-1) and the PMB (from O-5) groups from the fully protected intermediate 
162 afforded the 1,5- alcohol 164. 
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Scheme 3.6.1.  Phosphitylation of 1,5-diol 164 to provide protected bisphosphate 190.  Reagents and conditions: i. a. 
(BnO)2PN(
i
Pr)2 (5 eq), 1H-tetrazole (5 eq), CH2Cl2, RT, 20 h;  b. mCPBA (5 eq), -78 ˚C to RT, 4 h, 67% yield over 
2 steps. 
This diol 164 was phosphitylated using the 1H-tetrazole-catalysed 
phosphoramidite chemistry described previously (vide infra), furnishing the 1,5-
bisphopsphate 190 in moderate yield after extensive purification (Scheme 
3.6.1.).  The presence of the apolar TIPS group complicated purification of the 
bisphosphate 190, as it ran close to the phosphonate by-products. 
 
3.6.1. Attempted synthesis of 4-position alcohol 191 
A free hydroxyl group was required at the 4-position, in order to append the 
phosphate analogues onto the molecule.  Previous work within the research 
group had suggested that it was possible to remove a TIPS group in the 
presence of multiple phosphate groups, however, we were unable to remove 
the TIPS group from 190.  Various deprotection conditions were attempted 
(Scheme 3.6.2.), as outlined in Table 3.6.3. 
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Scheme 3.6.2.  Attempted deprotection of bisphosphate 190 to provide the free 4-position alcohol 191.  Reagents and 
conditions:  see Table 3.6.3. for details. 
Entry Conditions 
Temperature 
and time 
Solvent Outcome 
1 
TBAF in THF 
(1.0 M, 1 + 0.5 eq) 
RT, 6 h THF 
4 mg of 191 isolated from 
column (on 75 mg-scale 
reaction) 
2 
TBAF in THF 
(1.0 M, 10 eq) 
RT, 1 h THF 
New spots seen on TLC – 
minimal recovery from column 
3 
TBAF in THF  
(1.0 M, 10 eq) 
RT, 18 h CH2Cl2 
New spots seen on TLC – 
minimal recovery from column 
4 
TBAF in THF (1.0 M, 
1.5 eq), AcOH (1.5 eq) 
RT, 24 h THF No reaction observed 
5 
TBAF.3H2O (3 eq), 
AcOH (4 eq) 
RT, 18 h THF No reaction observed 
6 HF.py (100 eq) RT, 24 h THF 
Slow to form products.  MS 
indicated removal of BOM 
groups – TIPS intact 
7 
1% HCl in EtOH  
(10 eq) 
RT, 18 h 
then 85 ˚C, 3 h 
EtOH BnOH recovered 
8 
1% HCl in EtOH  
(10 eq) 
60 ˚C, 30 min 
80 ˚C, 45 min 
EtOH 
Starting material consumed, 
multiple products observed 
Table 3.6.3.  Conditions attempted for deprotection of bisphosphate 190 in Scheme 3.6.2. 
Treatment of the bisphosphate 190 with TBAF under normal conditions (entries 
1-3) afforded mixtures of highly polar materials, from which a very small quantity 
of the product 191 could be isolated in the presence of 1.5 eq of TBAF.  Under 
buffered TBAF-conditions, (entries 4-5) no reaction was observed and the 
starting materials were returned.  The use of alternate deprotection conditions 
was also unsuccessful.  Using HF.py complex in THF (entry 6) resulted in 
removal of the BOM groups, whereas treatment with acidic ethanol (entries 7-8) 
resulted in breakdown of the starting materials. 
It is suspected that the proximity of the 5-position phosphate group was 
hindering the deprotection of the TIPS group at the 4-position, due to either 
steric effects, or interaction with fluoride.  Future synthesis of 4-position 
analogues would require removal of the TIPS group prior to the phosphitylation 
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step, or the use of an alternate protecting group at the 4-position, such as an 
allyl ether. 
 
 
3.7. Summary 
A novel route to D-myo-inositol 1,4,5-trisphosphate (InsP3) 1 and two of its 5-
position analogues (126 and 128) has been developed, using a Ferrier-II 
rearrangement as the key-inositol ring forming reaction.  The stereoselectivity of 
this rearrangement and the subsequent reduction was confirmed by NMR and 
X-ray crystallography. 
The common enantiopure intermediate 163 has been shown to be a point of 
divergence, which allowed for the synthesis of InsP3 and 4- or 5-position 
analogues of InsP3.  Further synthetic studies will allow the synthesis of a wider 
range of analogues at both positions.  These analogues will be used as 
molecular probes for further detailed study of the behaviour of the InsP3Rs. 
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Figure 3.7.1.  Structure of InsP3 and 5-position-modified analogues, synthesised via a Ferrier-II rearrangement. 
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4. Inositol analogues derived from optical resolution 
4.1. Introduction and aims 
Having obtained encouraging results from the biological evaluation of our first 5-
position analogues of InsP3, we sought to develop a complimentary synthetic 
route to the Ferrier rearrangement methodology.  Building on the 
diastereoisomeric resolution methodology of Holmes, we planned to synthesise 
another series of 5-position InsP3 analogues, which would allow for the 
evaluation of more isosteric replacements of the phosphate group as potential 
InsP3R-antagonists. 
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Figure 4.1.1.  Proposed synthesis of 5-position-modified analogues of InsP3 from enantiopure intermediate 65. 
 
4.1.1. Synthesis of InsP3 analogues via a diastereoisomeric resolution 
There are three main strategies for construction of inositol polyphosphate 
molecules (Chapter 1.5.1.).  In the previous chapter, the strategy of construction 
of the inositol ring from chiral pool sources was demonstrated; this chapter will 
discuss syntheses commencing from the parent myo-inositol core.  This route 
holds the advantage that the stereochemistry of the inositol ring is already 
predetermined to the correct configuration.  However, as myo-inositol is a meso 
molecule, with a plane of symmetry between the C-2 and C-5 positions, a 
desymmetrisation and/or resolution step is required to synthesise non-racemic 
inositol polyphosphate derivatives.  There is pre-existing methodology in the 
literature for obtaining enantiopure inositol intermediates, which we planned to 
exploit to this end. 
Ozaki,27 Potter,30 Ley33 and Holmes40, 41, 158 have all employed various optical 
resolution methods to obtain enantiopure inositol intermediates from racemic 
materials.  We elected to follow the chemistry published by the Holmes group, 
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as this would provide us with a useful synthetic intermediate, where it was 
possible to differentiate between the 1-, 4- and 5-positions of myo-inositol. 
The synthetic targets we hoped to obtain via this chemistry were further 5-
position analogues (complementary to the those compounds 126 and 128 
generated via the Ferrier rearrangement route) and some 1- or 1,5-position 
modified analogues of InsP3.  These targets were of interest to us, on the basis 
of earlier biological results and literature precedent,117, 118 which indicated that 
the 5-position was amenable to modification to generate weak antagonists of 
the InsP3Rs. 
 
4.2. Synthesis of enantiopure alcohol 65 from myo-inositol 
The enantiopure intermediate 65 was synthesised in seven steps from the 
commercially available myo-inositol employing the elegant chemistry developed 
by Holmes and co-workers.  Their methodology extended the work of Billington 
and co-workers, using the inositol orthoformate 49 first reported by Kishi,38 to 
ultimately obtain an enantiopure intermediate 65 after a diastereomeric 
resolution.  This route has been optimised for large-scale synthesis of the 
intermediates.  For the work outlined in this chapter, the route to the 
intermediate 65 was commenced on 40-50 g scale of myo-inositol 4. 
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Scheme 4.2.1.  Synthetic steps to obtain racemic triol 64.  Reagents and conditions: i. CH(OEt)3 (5 eq), 4-TsOH.H2O 
(0.4 eq), DMF, 105 ˚C, 96 h, 71% yield;  ii. NaH (1.05 eq), PMBCl (1.10 eq), DMF, -10 ˚C to RT, 19 h, 78% yield;  iii. 
NaH (3.5 eq), BnBr (2.5 eq), DMF, -10 ˚C to RT, 19 h, 99% yield;  iv. DIBAL-H (1.0 M, 2.5 eq), CH2Cl2, 0 ˚C to RT, 20 h, 
96% yield;  v. NaH (1.8 eq), AllBr (2.5 eq), DMF, -10 ˚C to RT, 18 h, 92 % yield;  vi. HCl(conc), MeOH, reflux, 18 h, 39% 
yield. 
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The adamantane-like orthoformate 49 was synthesised by treatment of myo-
inositol with triethylorthoformate and toluene sulfonic acid monohydrate in DMF.  
These conditions were more amenable and consistent to large scale isolation of 
the orthoformate, compared to Kishi’s original conditions,38 which used DMSO 
as a solvent.  Owing to the symmetry and configuration of the molecule, the 1-, 
3- and 5-positions of myo-inositol are now regioselectively protected by the 
orthoformate, providing one equatorial (OH-2) and two axial (OH-4 and OH-6) 
hydroxyl groups for elaboration.  The orthoformate 49 is then desymmetrised in 
a racemic fashion, by regioselective alkylation of the axial OH-4 hydroxyl group.  
Careful treatment of the orthoformate 49 with a slight excess of sodium hydride 
(1.05 eq) effects deprotonation of one of the axial hydroxyl groups.  The protons 
of the axial hydroxyl groups are most acidic, therefore, will become the 
thermodynamic alkoxide species at equilibrium, even if the initial deprotonation 
occurs at the equatorial hydroxyl group.  Once a single deprotonation occurs, 
the sodium cation forms a presumed chelate bridge between the alkoxide and 
the remaining axial hydroxyl group (Figure 4.2.2.).39  
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Figure 4.2.2.   Formation of the presumed intermediate 192 with sodium chelate bridge, leading to selective alkylation 
of the axial position of the orthoformate.
39
  This regioselectivity only applies to the use of sodium hydride in DMF, other 
solvents and counterions may lead to a different outcome. 
Studies on the regioselectivity of this reaction by Billington and co-workers 
showed that a change in solvent or counterion size alters the outcome of the 
reaction, presumably by preventing formation of the sodium-chelate species 
192.39  The alkoxide intermediate 192 is then quenched by the addition of an 
electrophile (PMBCl), forming the mono-axially-alkylated diol 60.  Only a small 
excess of the electrophile is used (1.1 eq) in order to retard formation of bis-
alkylated by-products, however, if formed these by-products can be readily 
separated by column chromatography.  As the orthoformate 49 is a meso 
molecule, when a single axial position is alkylated, the plane of symmetry is 
broken, therefore there are two possible outcomes – alkylation on OH-4 or OH-
6.  There is no stereocontrol of this reaction, so a racemic mixture of 60 is 
Results and Discussion – Resolution Chemistry 
102 
produced.  The diol 60 is then subjected to perbenzylation with excess sodium 
hydride and benzyl bromide, protecting the remaining free hydroxyl groups as 
the benzyl ethers, affording the fully protected orthoformate 61. 
The next step is to differentiate the 5-position, by regioselective opening of the 
orthoformate 61.  The fully protected orthoformate 61 was opened by treatment 
with excess DIBAL-H, affording the 5-position alcohol 62 with excellent 
selectivity.  Previous studies by Holmes and co-workers have rationalised the 
selectivity of this reaction by studies of the cleavage of the tris-benzyl protected 
orthoformate 110 with DIBAL-H and DIBAL-D and other Lewis acids (Scheme 
4.2.3.).42, 43, 158 
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Scheme 4.2.3.  DIBAL-D mediated cleavage of orthoformate 110, opening the cage to afford a free hydroxyl group at 
the 5-position of the ring.  It is unclear whether the reduction from 195 to 196 is intra- or intermolecular.
158  
It is thought that coordination of DIBAL-D to the least hindered 5-position 
oxygen atom of the orthoformate 110 leads to cleavage of the orthoformate 
moiety 193, generating the oxacarbenium species 194.  Stress on the inositol 
ring is may be relieved by ring flipping from the chair to the boat conformation 
195.  Reduction of the oxacarbenium species, affords the 1,3-acetal 196 in very 
high selectivity, however, it has not been determined whether the delivery of the 
deuterium is intra- or intermolecular. 
Protection of the 5-position alcohol 62 as the allyl ether by treatment with 
excess sodium hydride and allyl bromide proceeded in high yields, affording the 
fully protected acetal 63.  The acetal and the PMB group were then removed by 
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acidic methanolysis, affording the racemic triol 64 in a moderate 39% yield (due 
to chromatographic losses).   
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Scheme 4.2.4.  Formation of the chiral 1-(S)-(-)-camphor dimethylacetal auxiliary 198.  Reagents and conditions:  i. K-
10 Montmorillonite clay, CH(OMe)3 (4 eq), hexane, RT, 72 h, 72% yield.  Product was shown to be composed of 77% 
198 and 23% starting material 197 as judged by 
1
H NMR spectroscopy. 
This racemic triol 64 was resolved by protection of the vicinal 3,4-diol using the 
camphor acetal method first described by Bruzik.44  The chiral camphor 
auxiliary, 1-(S)-(-)-camphor dimethylacetal 198, was prepared by stirring a 
solution of 1-(S)-camphor in hexane with acidic K-10 Montmorillonite clay at RT 
(Scheme 4.2.4.).  This reaction afforded a mixture of the desired acetal 198 
(77%) and the unreacted camphor starting material 197 (23%), adjudged by 1H 
NMR integration of the methyl protons. 
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Scheme 4.2.5.  Diastereomeric resolution of racemic triol 64, affording mixture of four possible diastereoisomers 65, 
199, 200 and 201.  The desired isomer 65 is indicated in the dashed box.  Reagents and conditions:  i. 1-(S)-(-)-
Camphor dimethylacetal 198 (3 eq), 4-TsOH.H2O (0.05 eq), CH2Cl2, reflux, 14 h, 20% yield of 65. 
This mixture, which contained camphor acetal 198, was reacted directly with the 
triol 64 in the presence of toluene sulfonic acid monohydrate under reflux 
conditions (Scheme 4.2.5.)  The reaction was adjudged to be complete after 
14 h by TLC analysis, as the starting material 64 could not longer be observed.  
Workup of the reaction furnished a mixture of four diastereoisomers as shown in 
Scheme 4.2.5.  These diastereoisomers arise from the triol 64 precursor being 
racemic. 
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Exhaustive diastereomeric resolution by silica gel chromatography allowed for 
isolation of the more polar diastereoisomer 65.  A mixture of the other three 
faster-running, less polar, diastereoisomers (199, 200 and 201) was found to be 
inseparable under the column conditions, which was consistent with the results 
published by Holmes and co-workers.41  The large loss of material, due to 
removal of the undesired diastereoisomers, led to a 20% isolated yield of the 
desired enantiomerically pure alcohol 65.  The observed specific optical rotation 
of 65 (
  
! 
"[ ]
D
20  -11.8) compared favourably with the literature value (
  
! 
"[ ]
D
20
-11.7).41 
 
4.3. Synthesis of 5-position modified analogues 
4.3.1. Synthesis of enantiopure 5-position alcohol 204 
With a view to the synthesis of a second series of 5-position analogues of InsP3, 
the 5-position alcohol 204 was synthesised from the enantiopure intermediate 
65 (Scheme 4.3.1.)  Removal of the camphor auxiliary from alcohol 65 was 
achieved by acidic methanolysis in good yield, affording the enantioenriched 
1,3,4-triol (-)-64.  The appropriate data for the enantiomer (-)-64 were in good 
agreement with the racemate (±)-64.   
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Scheme 4.3.1.  Synthesis of 5-position alcohol 204 from enantiopure intermediate 65.  Reagents and conditions:  i. 
AcCl (0.6 eq), MeOH, CH2Cl2, RT, 18 h, 83% yield;  ii. 
n
Bu2SnO (1.1 eq), TBABr (1.0 eq), BnBr (3 eq), MeCN, reflux, 
20 h, 79% yield;  iii. a. (BnO)2PN(
i
Pr)2 (2.8 eq), 1H-tetrazole (0.43 M in MeCN, 2.8 eq), CH2Cl2, RT, 16 h;  b. mCPBA 
(2.8 eq), -78 ˚C to RT, 2 h, 81% yield over 2 steps;  vi. PdCl2 (1.25 eq), RT, 2.5 h, 84% yield. 
Results and Discussion – Resolution Chemistry 
105 
The 3-position of vicinal 3,4-diol moiety was then regioselectively protected as 
the benzyl ether 202 using one-pot stannylene acetal method described by 
Gigg and co-workers.137 Determination of the regioselectivity ratio from the 
reaction was difficult, as the 1H NMR spectrum of the crude mixture of isomers 
had no clearly separated signals from which the ratio could be deconvoluted. 
After purification, the ratio of the isolated isomers was 9:2 in favour the 3-OBn 
isomer 202 (79% yield) over the 4-OBn isomer 205 (18% yield).  The 
regiochemistry of the two products was established by 2D NMR studies. 
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Figure 4.3.2.  Proposed intermediate 206 to rationalise the selectivity of the regioselective benzylation of the 3,4-vicinal 
diol (-)-64 in polar solvents. 
In polar solvents the intermediate stannylene acetal complex 206 is thought to 
form.  This complex exists where the Sn atom is penta-coordinated (Figure 
4.3.2.).138  The vicinal oxygen atoms at the C-3 and C-4 positions of the inositol 
(-)-64 are differentiated;  the O-3 atom lies at the apical position of the complex, 
whereas the O-4 atom occupies one of the equatorial positions.  In this 
configuration of the complex, the apical Sn–O bond is longer than the equatorial 
one.  When reacted with benzyl bromide, the O-3 atom reacts preferentially 
over the O-4 atom, as O-3 is more accessible to a bulky electrophile than O-4 
(O-3 is adjacent to an axial 2-position alcohol, compared to O-4, which is 
adjacent equatorial allyl ether so more sterically encumbered).  The O-3 atom is 
also more reactive, given that the apical Sn–O is longer than the equatorial one, 
thus giving O-3 a more nucleophilic character than O-4, due to the more diffuse 
electrons in the apical bond.  Therefore, the reaction provided a mixture of the 
3-OBn 202 (79% yield) and the 4-OBn 205 (18% yield) isomers. 
The requirement for 5-position InsP3 analogues is for phosphate groups on the 
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1- and 4-positions, thus benzyl protected phosphate groups were installed 
utilising the 1H-tetrazole-catalysed method described by Johns147 and Fraser-
Reid.148  The diol 202 was phosphitylated by addition to a mixture of 
bis(benzyloxy)-N,N-diisopropylamino phosphine 168 and 1H-tetrazole 
solution (in MeCN).  After 18 h a single product was observed, presumed to 
be the phosphinate intermediate.  This intermediate was oxidised, affording 
the bisphosphate 203 in good yields after careful column chromatography to 
remove phosphonate by-products. 
The bisphosphate 203 was, unexpectedly, isolated as a crystalline solid, 
whose structure was elucidated by single crystal X-ray crystallography (Figure 
4.3.3.).  This data confirmed the expected structure of the bisphosphate and 
the regioselectivity of the previous benzylation reaction. 
  
Figure 4.3.3. VMD stick representation of X-ray crystal structure of bisphosphate 203.  Key: C, green; O, red; H, white; 
P, orange. 
In order to obtain the 5-position alcohol 204 necessary for the synthesis of the 
InsP3 analogues, the allyl group had to be removed from the 5-position.   
Whilst there are many methods in the literature for removal of the allyl group, 
there are few that are compatible with protected phosphate groups.  Some of 
these conditions had been previously attempted in the group on similar 
substrates (Wilkinson’s catalyst and Pd(PPh3)4), however, with only moderate 
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levels of success.  Recent work in the group had shown that PdCl2 could 
remove allyl groups in the presence of phosphate groups in good yields.  In 
this instance, the PdCl2 acts as both the isomerising agent and the acid 
source for cleavage of the vinyl ether intermediate.  Thus, treatment of the fully 
protected bisphosphate 203 with a small excess of palladium dichloride 
(1.25 eq) showed complete consumption of the starting material after 2 h 
(Scheme 4.3.1.).  The method of Knight was found to be useful in the 
purification of the compound, by removal of excess palladium residues using 
an oxidative workup procedure.159  This oxidative workup afforded the crude 
alcohol 204 in reasonable purity and, after a simple chromatographic 
separation, the pure alcohol 204 was obtained in 81-84% yield.   
With the purified 5-position alcohol 204 in hand, a series of analogues was 
generated by appending phosphate mimics onto the free hydroxyl group. 
 
4.3.2. Synthesis of methylene carboxylate analogue 129 
A close bioisosteric replacement for the phosphate group is the methylene 
carboxylate group, which removes one of the hydrogen bond donors but 
maintains the other and a hydrogen bond acceptor.123, 160, 161  At physiological 
pH the methylene carboxylate would bear a single negative charge, rather than 
the double negative charge of the phosphate group.  It has been previously 
shown that substitution of all three phosphate positions of InsP3 with methylene 
carboxylate groups removes all biological activity.123  However, on substitution 
of the 3-position of Ins(1,3,4,5)P4 with such a group, the biological activity is 
retained.160, 161  It was hypothesised that substitution of the 5-position of InsP3 
with the methylene carboxylate group would still maintain affinity for the 
receptor, but might show altered activity.  The reduced the number of potential 
polar bonding interactions with the receptor (in an analogous manner to the 
methylphosphonate analogue 126) could prevent interaction with key residues, 
which causes the conformational change that leads to Ca2+-release.  Therefore, 
129 was anticipated to be an InsP3R antagonist. 
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There are two main synthetic approaches to the methylene carboxylate group.  
A free hydroxyl group can be alkylated with chloroacetic acid or a bromoacetate 
and a strong base, however, harsh conditions are required to effect this reaction 
on an inositol substrate.123  Alternatively, an allyl group can be oxidatively 
cleaved to reveal the methylene carboxylate group.162  The latter method was 
chosen, as this could be achieved using the bisphosphate intermediate 203.  In 
addition, it was considered that the use of strong bases in the presence of the 
protected phosphate groups could lead to phosphate group migration or 
transesterification with the bromoacetates. 
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Scheme 4.3.4.  Synthesis of 5-position carboxymethyl analogue 129.  Reagents and conditions: i. RuCl3 (0.02 eq), 
NaIO4 (4.1 eq), CCl4, MeCN, H2O, RT, 8 h, 44% yield;  ii. H2 (g), Pd black (20 eq), NaHCO3 (5 eq), 
t
BuOH/H2O (6:1), RT, 
14 h 98% yield. 
The 5-O-allyl bisphosphate 203 was treated with catalytic ruthenium(III) 
trichloride and sodium periodate in a biphasic mixture of carbon tetrachloride, 
acetonitrile and water (Scheme 4.3.4.).162  After an oxidative workup with 
hydrogen peroxide solution (to remove ruthenium by-products) and careful 
chromatography, the highly polar protected methylene carboxylate analogue 
207 was obtained in a 44% yield.  Global deprotection of 207 by 
hydrogenolysis, in the presence of sodium hydrogen carbonate, afforded the 
final methylene carboxylate analogue 129 in 98% yield, as the presumed 
pentasodium salt. 
 
4.3.3. Synthesis of 5-position sulfamate analogue 127 
The sulfamate group is a classical bioisosteric replacement for the phosphate 
group, being very similar in both size and electronic configuration.  The key 
difference however, is in the hydrogen bonding, where the sulfamate has two 
acceptors and one donor, compared with one acceptor and two donors in the 
phosphate group.  We envisaged that this substitution may alter the binding 
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properties or interactions with the InsP3Rs, hence modulating the biological 
activity.  Previous work by van Boeckel and co-workers showed that substitution 
of all three phosphate positions of InsP3 as sulfonamides removed all affinity for 
the receptor,123 however, as with our other analogues, we believed a single 
substitution could maintain affinity, while altering the biological activity. 
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Scheme 4.3.5.  Formation of sulfamoyl chloride 209.  Reagents and conditions: i. HCOOH (1.05 eq), CH2Cl2, 0 ˚C to 
RT, 6 h, presumed 100% yield of 2.5 M stock solution of  209.
163 
The sulfamylating agent, sulfamoyl chloride 209, was synthesised freshly for the 
reaction by the acid-mediated decomposition of chlorosulfonyl isocyanate 
(Scheme 4.3.5.).163  The 2.5 M stock solution generated was maintained at 
-20 ˚C, and could be stored for several weeks. 
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Figure 4.3.6.  5-position alcohol 178. 
Previously, the synthesis of the sulfamate analogue had been attempted on the 
5-position alcohol 178, derived from the Ferrier rearrangement.  Under the 
standard sulfamylating conditions164 (sulfamoyl chloride, K2CO3 and DMF) 
migration of the phosphate groups was observed when installation of the 
sulfamate was attempted, affording a mixture of assumed sulfamylated 
products.  Okada and co-workers had shown that sulfamylation of hydroxyl 
groups could be achieved in the absence of a base, using N,N-
dimethylacetamide (DMA) as the solvent.165  Therefore, the 5-position alcohol 
204 was treated with excess sulfamoyl chloride 209 in DMA, affording the 
protected 5-position sulfonamide 210 analogue in good (80%) yield (Scheme 
4.3.7.), without any sign of phosphate migration. 
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Scheme 4.3.7.  Synthesis of 5-position sulfonamide 127.  Reagents and conditions:  i. Sulfamoyl chloride (2.5 M in 
CH2Cl2, 2 eq), DMA, 0˚C, 6 h, 80% yield;  ii. H2 (g), Pd black (20 eq), NaHCO3 (4 eq), 
t
BuOH/H2O (6:1), RT, 14 h, 80% 
yield. 
Subsequent global deprotection of 210 by hydrogenolysis (Scheme 4.3.7.) in 
the presence of sodium hydrogen carbonate afforded the 5-position 
sulfonamide 127 in reasonable 80% yield, as the presumed tetrasodium salt. 
The low and high-resolution mass spectra indicated the correct mass for 127.  
However, the 31P NMR spectrum of the analogue 127 showed only a single 
resonance, suggesting that one of the phosphate groups had been removed 
during the hydrogenolysis.  As this did not correlate with the other analytical 
data obtained, some 2D NMR experiments were conducted to rationalise the 
single 31P resonance. 
In order to interpret the heteronuclear correlations, assignment of the 1H NMR 
spectrum of 127 was required.  This assignment was achieved by analysis of 
the 2D COSY (1H-1H coupling) spectrum shown in Figure 4.3.8.  
   
Figure 4.3.8.  
1
H-
1
H NMR correlation spectrum (COSY) of sulfamate analogue 127 (at 500 MHz).  The dashed red 
boxes indicate the correlation to other protons within the molecule. 
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The H-2 proton was assigned on the premise of the two small axial-equatorial 
couplings (J 2.7 and 2.4 Hz), which it experiences by coupling to H-1 and H-3.  
The H-3 proton was distinguished from H-1, as it was only coupled to two other 
spin systems (hence dd).  The H-1 proton’s signal was further complicated by 
coupling to phosphorus, hence was formally a ddd, however, the signal was 
overlapped by H-6.  The rest of the assignment was made in a logical order by 
coupling correlation, using H-2 and H-3 as the start/end point for going around 
the inositol ring. 
The heteronuclear multibond coherence (HMBC) experiment shows long-range 
couplings of 2JHP, 
3
JHP and 
4
JHP between the 
1H and 31P nuclei.  The 2D 
spectrum obtained (Figure 4.3.8.) showed crosspeaks from !P 4.22 to !H 4.12-
4.02 and !H 4.52-4.37 corresponding to H-1 and H-4 respectively.  These 
protons are too remote from each other to be coupled to the same phosphorus 
atom, therefore, it can be deduced that there are two different phosphorus 
atoms in the molecule.   
  
Figure 4.3.9.  
1
H-
31
P heteronuclear multibond coherence (HMBC) spectrum of sulfate analogue 127 (500 MHz 
1
H 
channel, 202 MHz 
31
P channel).  The two crosspeak regions indicate long range couplings to H-1, H-6 and H-4, H-5 – 
proving that the single peak in the 
31
P NMR spectrum is composed of two independent, but overlapping, signals arising 
from two different phosphorus atoms. 
The HMBC experiment has shown that the two phosphate groups must be 
intact, but have identical resonance frequencies despite being in different 
environments.  This is a very unusual situation, as the signals for the 1- and 4-
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position phosphate groups are typically several ppm apart in the other 
analogues in this series. 
In a final effort to support the evidence from the HMBC experiment, the NMR 
sample of 127 (made up in D2O) was spiked with d6-DMSO.  The 
31P NMR was 
recorded once again, this time revealing a marginal splitting of the signal 
(Figure 4.3.10.).  This experiment helped to show that the signals for the two 
phosphate groups are indeed coincident. 
 
Figure 4.3.10.  
31
P NMR (121 MHz) of 127 in mixed D2O/D6-DMSO solvent system.  Note the marginal splitting of the 
signal indicating that there are two separate phosphorus environments present in the molecule.  
 
4.3.4. Synthesis of methylphosphonate analogue 126 
Following earlier reports by van Boom and co-workers117 and promising 
preliminary biological results within our group,121 we were keen to synthesise 
further quantities of the 5-position methyl phosphonate analogue 126.  This 
synthesis would complement the alternate synthesis discussed previously in 
Chapter 3.5.5., where the compound was derived from D-glucose. 
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Figure 4.3.10.  Methylphosphonylating agent 186, used to install a protected methylphosphonate unit onto a free 
hydroxyl group.117 
We chose to synthesise the methylphosphonate analogue 126 using the same 
phosphorus(V) chemistry as previously described (Chapter 3.5.5.). The 
protected methylphosphonate unit was installed on the 5-position alcohol 204 in 
a two-step, one-pot reaction (Scheme 4.3.11.).   
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Scheme 4.3.11.  Formation of protected methylphosphonate analogue 212.  Reagents and conditions: i. a. 186 (0.2 M 
in dioxane, 2 eq), pyridine, 3 Å molecular sieves, RT, 10 min;  b. BnOH (4 eq), RT, 90 min, 36% yield over 2 steps. 
A solution of the alcohol 204 in pyridine was treated with the phosphonylating 
reagent 186 for 10 min, forming the presumed transient intermediate 211.  The  
intermediate 211 was then quenched in situ by the addition of anhydrous benzyl 
alcohol, substituting the remaining 6-CF3 HOBT unit for a benzyl ether affording 
the fully protected analogue 212.  After rigorous purification, the phosphonate 
212 was isolated as a 2:1 mixture of inseparable diastereoisomers (determined 
by 1H NMR integration of the methyl protons) in low yield (36%).  As with the 
previous synthesis, a quantity of highly polar material was observed during 
purification, suggesting that some of the intermediate 211 may have been 
quenched with water, thus contributing to the low yield.  A similar yield was 
obtained for an identical reaction in the absence of molecular sieves. 
The diastereoisomeric mixture arises from the new stereogenic phosphorus 
centre, located on O-5.  The ratio of the isomers (2:1) is considerably lower in 
contrast to the previous experiment (10:1), when appending the 
methylphosphonate onto the 6-O-BOM alcohol 178.  Although the selectivity is 
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lower, the ratio suggests that there is still a preferred conformation of attack of 
the alcohol 204 on the methylphosphonylating reagent 186, which fixes the ratio 
of diastereoisomers.  The difference could be attributed to steric hindrance of 
the flanking 6-position protecting groups.  The diastereoselectivity is high in the 
presence of the more bulky BOM group, but lower in the presence of a benzyl 
group.   
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Scheme 4.3.12.  Deprotection of 212 to afford 5-position methylphosphonate analogue 126.  Reagents and conditions:  
i. H2 (g), Pd black (20 eq), NaHCO3 (5 eq), 
t
BuOH/H2O (6:1), RT, 12 h, 93% yield. 
The final step to reveal the enantiopure methylphosphonate analogue 126 was 
global deprotection of 212 by hydrogenolysis in the presence of sodium 
hydrogen carbonate, affording 126 in 93% yield.  The 1H NMR spectrum of 126 
showed a doublet for the methyl group, attributed to 2JHP coupling of the methyl 
protons to the phosphorus atom. 
Overlay of the 1H and 31P NMR spectra (Figure 4.3.13.) of the 
methylphosphonate analogue 126, obtained via the two different synthetic 
routes, showed good correlation.  The major difference was due to the 
methylphosphonate-containing impurity present in the sample derived from the 
Ferrier rearrangement, thought to be methylphosphonic acid.  Overall it can be 
concluded that both synthetic routes are viable methods to synthesise this 
methylphosphonate analogue 126. 
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Figure 4.3.13.  Overlay of 
1
H and 
31
P NMR spectra of 5-position methylphosphonate analogue 126.  The trace in red is 
material derived from the Ferrier rearrangement, as discussed in Chapter 3.5.5.; the trace in black is material derived 
from myo-inositol, described above.  
 
4.3.5. Synthesis of Ins(1,4)P2 130 
We were interested in the synthesis of several control compounds against 
which the activity of our analogues could be measured.  One such compound is 
Ins(1,4)P2 130, where the phosphate group is absent from the 5-position 
(compared to InsP3).  This compound would allow us to ascertain the effect is 
substitution on the 5-position. 
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Scheme 4.3.14.  Global deprotection to afford Ins(1,4)P2 130.  Reagents and conditions:  i. H2 (g), Pd black (20 eq), 
NaHCO3 (4 eq), 
t
BuOH/H2O (6:1), RT, 12 h, 88% yield. 
Thus, Ins(1,4)P2 130 was obtained by global deprotection of the intermediate 5-
position alcohol 204 by hydrogenolysis in the presence of sodium hydrogen 
carbonate (Scheme 4.3.14), affording 130 in 88% yield, as the presumed 
tetrasodium salt.  The data obtained matched closely with the literature 
values.36, 166 
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4.3.6. Towards the synthesis of 5-position ketone 214 
The final analogue that was proposed, was simply oxidation of the 5-position 
hydroxyl group of 204, to furnish the inosose 214.  This modification would 
allow an interesting comparison with Ins(1,4)P2 130, to determine whether 
changing the 5-position from a hydrogen bond donor to an acceptor had an 
effect on InsP3Rs-mediated Ca
2+ release, possibly by altering or preventing the 
structural changes that open the Ca2+ channels.  Such oxidations of inositol to 
inosose have been previously attempted by Frost and co-workers,167 using a 
Swern oxidation to transform 3,4,5,6-tetra-O-benzyl-myo-inositol 1-O-
dibenzylphosphate into the corresponding 2-position inosose. 
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Scheme 4.3.15.  Steps towards synthesis of 5-position inosose 214.  Reagents and conditions:  i. Dess Martin 
periodinane (2.5 eq), CH2Cl2, RT, 2 h, 69% yield.  Proposed step:  ii. H2 (g), Pd black, NaHCO3, 
t
BuOH/H2O, RT. 
With the presence of multiple phosphate groups in 5-position alcohol 204, it was 
decided to attempt an alternate oxidation using Dess Martin periodinane, as 
there was no base present (cf. Swern conditions), which could potentially cause 
phosphate migration.  Thus, alcohol 204 was treated with Dess Martin 
periodinane to afford the corresponding inosose 213 in moderate (69%) yield 
(Scheme 4.3.15.).  The reaction required two portions of the oxidant (1.25 eq + 
1.25 eq) to complete the reaction.  However, after purification, 213 was not 
deemed sufficiently pure to deprotect to afford the inosose 214.  Future re-
synthesis of the protected inosose 213 will provide the material required to 
submit to global deprotection, affording the desired analogue 214 for biological 
testing. 
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4.4. Steps towards the synthesis of 1,5-position modified 
 analogues of InsP3 
The methylphosphonate 126 is the first reported example of an inositol-based 
antagonist of the InsP3Rs, however, it has low affinity for the receptor, exhibiting 
only a 40% inhibition of InsP3-induced Ca
2+ release (IICR) at 300 µM.  We 
sought to improve the affinity of the compound 126 by modification of the 1-
position phosphate (Figure 4.4.1.), which is thought to be largely solvent 
exposed when docked in the InsP3 binding site of the InsP3Rs. 
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Figure 4.4.1.  Proposed 1-position modified analogue of methylphosphonate analogue 215. 
Nagano and co-workers have previously shown that modification of the 1-
position phosphate can increase affinity for the InsP3Rs, when a large 
hydrophobic moiety (such as fluorescein or malachite green) is tagged to the 
phosphate group via an amino propanol linker.168, 169  Following the promising 
biological results obtained for the 5-position methylphosphonate 126 as a partial 
antagonist (see Chapter 5.3.3.), we aimed to improve its activity by modification 
of the 1-position in a similar manner to that of Nagano’s InsP3 analogues.  
Therefore, we aimed to independently modify both the 1- and 5- positions of 
InsP3. 
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Figure 4.4.2.  Advanced enantiopure synthetic intermediates 65 and 162. 
There were two advanced synthetic intermediates to choose from as potential 
starting materials for this route; 162 derived from the Ferrier rearrangement and 
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65 derived from myo-inositol (Figure 4.4.2.).  The alcohol 65 was chosen, as its 
arrangement of protecting groups would most easily accommodate modification 
of the 4-, 1- and 5-positions in that order.  Ultimately, 65 allowed for a later 
stage modification of the 1-position, without the requirement to deprotect and 
then reprotect (as would be required with the acetate group on the 1-position of 
162). 
 
4.4.1. Synthesis of enantiopure 1-position alcohol intermediate 220 
Therefore, using the enantiopure alcohol 65 (from the diastereomeric 
resolution), the 1-position hydroxyl group was protected as the PMB ether 216 
by treatment with sodium hydride and PMBCl in THF (Scheme 4.4.3.).45  The 
addition of DMF after formation of the alkoxide was required to aid solubility.  
On purification, 216 was isolated in 84% yield.  Cleavage of the chiral camphor 
auxiliary by acidic methanolysis, afforded the 3,4-vicinal diol 217 in high (93%) 
yield.45   
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Scheme 4.4.3.  Synthesis of enantiopure 1-position alcohol 220.  Reagents and conditions:  i. NaH (1.5 eq), PMBCl 
(1.5 eq), THF, DMF, -10 ˚C to RT, 20 h, 84% yield; 
 
ii. AcCl (0.6 eq), CH2Cl2, MeOH, -10 ˚C to RT, 4 h, 93% yield;
  
iii. 
n
Bu2SnO (1.1 eq), TBABr (1.0 eq), BnBr (4.8 eq), MeCN, reflux, 21 h, 68% yield;  iv. a. (BnO)2PN(
i
Pr)2 (3 eq), 1H-
tetrazole (0.43 M in MeCN, 3 eq), CH2Cl2, RT, 18 h;  b. mCPBA (3 eq), -78 ˚C to RT, 2 h, 86% yield over 2 steps;  v. 
CAN (3.5 eq), MeCN, H2O, RT, 30 min, 80% yield. 
The vicinal 3- and 4-positions of 217 were then differentiated by regioselective 
benzylation using one-pot stannylene acetal method described by Gigg and co-
workers.45, 137  This reaction afforded the 3-OBn alcohol 218 in reasonable yield 
(68%) and selectivity over the 4-OBn alcohol (18% yield), after repeated 
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purification.45  The configuration of the product was determined by 2D NMR 
studies and later confirmed by X-ray crystal structure of a more advanced 
intermediate 220.  The selectivity of the reaction could be rationalised in a 
similar manner to the previous regioselective benzylation of the 1,3,4-triol (-)-64 
(Figure 4.3.2.).  This alcohol 218 could be used as a good platform for the 
synthesis of 1-position analogues, however, this project was concerned with 
manipulation of the 1- and 5-positions. 
Phosphitylation of the remaining free hydroxyl group of 218 was achieved by 
treatment of the alcohol 218 with a mixture of bis(benzyloxy)-N,N-
diisopropylamino phosphine 168 and 1H-tetrazole solution (in MeCN) 
(Scheme 4.4.3.).  Subsequent oxidation of the presumed P(III) phosphinate 
intermediate afforded the protected phosphate 219 in high yield (86%), after 
purification to remove phosphonate by-products.  Finally, the PMB group was 
removed from the 1-position by oxidative deprotection, using ceric ammonium 
nitrate, furnishing the 1-position alcohol 220 as a crystalline solid in 80% 
yield.  The structure of alcohol 220 was confirmed by solving the single crystal 
X-ray structure (Figure 4.4.4.), which also confirmed the regioselectivity of the 
previous benzylation step on O-3. 
 
Figure 4.4.4. VMD stick representation of X-ray crystal structure of phosphate 220.  Key: C, green; O, red; H, white; P, 
orange. 
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4.4.2. Installation of tagged phosphate group to 1-position of alcohol 220 
In order to attach a range of 1-position substituents, we wanted to use an 
amino-propanol linker between the phosphate group on the 1-position and the 
hydrophobic moiety.  This type of linker has been used previously by 
Prestwich133, 170-172 for the synthesis of photoaffinity labels and bioaffinity 
matrices and by Nagano168, 169  for the synthesis of 1-position analogues of 
InsP3.  This group is installed using the general phosphoramidite chemistry 
methods described by Johns147 and Fraser-Reid.148 
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Scheme 4.4.5.  Synthesis of phosphoramidite 223, used to install the tagged phosphate group onto alcohol 220.  
Reagents and conditions: i.  Benzyl chloroformate (1.0 eq), NaHCO3 (1.5 eq), H2O, RT, 18 h, 43% yield;  ii. 
phosphoramidite 167 (1.0 eq), 1H-tetrazole (0.4 eq), alcohol 222 (1.0 eq), RT, 6 h, 65% yield.
170
 
The amidite 223 was prepared in two steps from 3-amino propanol 221 
(Scheme 4.4.5.).  CBz protection of the amine portion of 221 was achieved by 
treatment of 221 with benzylchloroformate under phase transfer conditions, 
affording the alcohol 222 in moderate yield (43%).  The alcohol 222 was then 
appended onto benzyloxy-bis(N,N-diisopropylamino) phosphine 167 via a 1H-
tetrazole-catalysed substitution reaction, affording the phosphoramidite 223 in 
65% yield. 
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Scheme 4.4.6.  Phosphitylation of alcohol 220 with protected tagged phosphate group.  Reagents and conditions:  i. a. 
223 (2.5 eq), 1H-tetrazole (0.43 M in MeCN, 2.5 eq), CH2Cl2, RT, 4 h;  b. mCPBA (3 eq), -78 ˚C to RT, 1 h, 78% yield 
over 2 steps; 
The tagged phosphate was attached to the 1-position alcohol 220 in two steps 
(Scheme 4.4.6).  The alcohol 220 was treated with a solution of the 
phosphoramidite 223 and 1H-tetrazole (in MeCN), forming a presumed transient 
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phosphinate intermediate.  The presumed P(III) intermediate was then oxidised 
to the corresponding phosphate, affording the bisphosphate 224 in good (78%) 
yield, as a 2:1 mixture of diastereoisomers after extensive purification. 
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Figure 4.4.7.  Phosphoramidite by-products 225 and 226 from phosphitylation reaction. 
The purification of the bisphosphate 224 was complicated by the presence of 
two phosphonate by-products (Figure 4.4.7.), which coeluted with the product 
224.  These by-products could be removed by running slow, non-polar solvent 
gradients through the column. 
 
4.4.3. Deprotection of allyl group from bisphosphate 224 
In order to install the methylphosphonate unit onto the molecule, the allyl group 
had to be removed from the 5-position of 224.  Previous work within the group 
had shown Wilkinson’s catalyst was an ineffective reagent for allyl group 
removal in the presence of phosphate groups, as it regularly produced low and 
inconsistent yields.  Previous work in the group had also shown that Kusama’s 
deprotection conditions (Pd(PPh3)4 in acetic acid)
173  had been effective in the 
presence of phosphate groups. Therefore, the deallylation of bisphosphate 224 
was attempted by treatment of a solution of 224 in glacial acetic acid with 
palladium tetrakis (0.5 eq) (Scheme 4.4.8.).  Two further aliquots of Pd(PPh3)4 
(0.5 eq, 0.1 eq) were required before the reaction adjudged complete by the 
absence of the CH proton of the allyl ether in a crude 1H NMR spectrum. 
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Scheme 4.4.8.  Attempted deprotection of allyl group from 5-position of bisphosphate 224.  Reagents and conditions: i. 
Pd(PPh3)4 (1.1 eq), AcOH, RT; 227 was not isolated. 
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Purification of the alcohol 227 proved difficult, as there was large contamination 
from triphenylphosphine oxide (from the tetrakis reagent).  Multiple attempts to 
remove this impurity by column chromatography, by adsorption onto activated 
charcoal and trituration from non-polar solvent all proved unsuccessful.   
The reaction was repeated, starting with lower loadings of Pd(PPh3)4.  However, 
it was determined that a stoichiometric amount was required to complete the 
deallylation reaction.  This result led to similar purification issues, as the 
triphenylphosphine proved impossible to separate from the alcohol.  
 
4.4.4. Future steps to 1,5-analogue 215 
At the time of writing this synthetic route was incomplete, due to difficulties with 
the allyl deprotection step shown above.  Subsequent work on the series of 5-
position analogues has indicated that palladium dichloride may effect this 
deprotection in a much cleaner manner than Pd(PPh3)4, however, we have not 
yet attempted this.  We are therefore encouraged that we will be able to 
proceed to complete this synthesis.  The following scheme (Scheme 4.4.9.) 
outlines the proposed steps, which will be conducted to complete the synthesis 
of the 1,5-analogue 215.  This route will also be able to accommodate other 5-
position analogues, which we have identified as potential InsP3R-antagonists. 
Allyl deprotection of the bisphosphate 224 with palladium dichloride in methanol 
will furnish the 5-position alcohol 227.  Installation of the methyl phosphonate 
unit (or another phosphate bioisostere identified through the screening of the 5-
position analogues) via the activated methylphosphonylating reagent 186 would 
furnish the fully protected trisphosphate 228.  Global deprotection of 228 by 
hydrogenolysis in the presence of sodium hydrogen carbonate would afford 229 
as the tetrasodium salt, with a free pendant amine group on the 1-position 
phosphate.  Finally, the hydrophobic moiety would be installed by reaction of 
the amine 229 with the N-hydroxy succinimide ester derivative of the 
hydrophobic group, providing the final 1,5-bisphosphate analogue 215. 
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Scheme 4.4.9.  Proposed future steps to complete synthesis of 1,5-analogue 215.  Proposed reagents and conditions: 
i. PdCl2, MeOH, RT;  ii. a. 186, pyridine;  b. BnOH;  iii. Pd black, H2, NaHCO3, 
t
BuOH/H2O;  iv. NHS ester, 
triethylammonium bicarbonate buffer. 
The hydrophobic moieties we intend to use are based on extended, planar 
aromatic systems such as a naphthyl ester or larger, which are known to 
enhance affinity of the ligands for the InsP3 binding site. 
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4.5. Summary and conclusions 
A novel route has been devised and characterised for the synthesis of a series 
of novel 5-position analogues of InsP3, using the enantiopure alcohol 
intermediate 65 (derived from myo-inositol) described by Holmes and co-
workers.  These analogues bear bioisosteric replacements for the phosphate 
group in the form of either a carboxymethyl group; or sulfamate group; or 
methylphosphonate (Figure 4.5.1.). 
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Figure 4.5.1.  5-position-modified analogues of InsP3 synthesised via diastereoisomeric resolution. 
Based on the initial biological results obtained for the methylphosphonate 
analogue 126, steps have been taken towards an improved analogue.  This 
analogue will be modified at the 1-position to enhance affinity for the InsP3Rs.  
A route has been devised and partially executed for the synthesis of this 1,5-
position-modified analogue 215.  The advanced intermediate 224 has now been 
obtained on 0.5 g scale and will be used in the completion of this series.  
Recent results obtained from the 5-position series have provided 
encouragement that we will be able to solve the current problems and proceed 
to complete the synthesis of analogue 215. 
The 1,5-route will provide the intermediate alcohol 227, which will enable us to 
synthesise a series of analogues that have the same 5-position modifications as 
our previous series.  We will also be able to append a range of hydrophobic 
moieties onto each analogue in the final step, allowing for a wide range of 
compounds to be produced for biological evaluation.  
Both the 5-position and the proposed 1,5-position analogues will allow further 
investigation into the mechanisms of InsP3R activation.  These molecules will 
be excellent tools for the study of these receptors, allowing us further insight 
into the mechanism of Ca2+ release via the InsP3Rs at a molecular level. 
  
 
5 Biological Results and Analysis 
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5. Biological evaluation of inositol analogues 
5.1. Ca2+-flux assay details  
The biological activities of the previously described inositol analogues were 
evaluated by our collaborator Dr Geert Bultynck (KU, Leuven).  Using Ca2+-flux 
assays, Bultynck and co-workers have been able to determine whether our 
compounds behave as agonists or antagonists of the InsP3Rs.  This 
collaboration has given us valuable insight into the activity of our compounds, 
allowing us to develop basic structural activity relationship (SAR) data for 
antagonist activity at the InsP3Rs.  The details of the assay will be outlined 
below, followed by the biological data for each of the six compounds that were 
synthesised. 
 
5.1.1. Ca2+-flux assays 
A major consideration when testing the inositol polyphosphate compounds is 
their highly-polar nature.  InsP3 1 is released within the cell by the 
phospholipase-C-catalysed hydrolysis of the membrane bound PtdIns(4,5)P2 2, 
hence, InsP3 1 never traverses the cell membrane.  Therefore, methods to 
introduce them into the cells for testing must be considered.  In order to get the 
compounds into the cells, either the phosphate groups need to be protected 
with cell membrane permeant esters (similar to the work of Tsien47 and 
Conway29), or the cell membranes must be permeabilised.  Due to the complex 
nature of the synthesis of the membrane permeant groups, the cells used in 
these assays were permeabilised, allowing free passage of the compounds 
across the membrane. 
The assays were run in one of three different cell lines, all based on mouse 
fibroblast cells.  2MEFwt cells are immortalised wild-type mouse embryonic 
fibroblast cells; they express “normal” levels of InsP3R-1 and InsP3-3.  L-15 cells 
are mouse L-fibroblast cells, which stably over express InsP3R-1 by 8-10 fold, 
compared to the endogenous InsP3R-1 levels.  In L-15 cells, the ratio of InsP3R-
1 to InsP3R-3 is at least 3:1.  Lvec cells are transfected with an empty vector, 
hence only contain endogenous levels of InsP3R-1 and InsP3-3 in a 1:3 ratio. 
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5.1.2. General procedure for Ca2+-flux assay 
The assays were conducted by following the procedures reported by Kasri and 
co-workers.174  Each experiment was carried out in duplicate to account for 
variation in individual wells.  Permeabilised cells are loaded with 45Ca2+, and 
then the intracellular Ca2+-pumps on the ER are inhibited.  After a set period, 
the cells are challenged with the compound of interest, followed by InsP3 
several minutes later.  Release of Ca2+ is measured by scintillation counts of 
45Ca2+ and then plotted as % fraction loss.  The detailed procedure is outlined in 
the experimental section. 
 
5.1.3. Normalisation of results 
The calcium ionophore, A23187 230 (Figure 5.1.1.),175, 176 is used as a control 
compound to estimate the potential maximum releasable quantity of Ca2+ from 
the ER stores.  A23187 230 forms pores in the cell membranes, which are Ca2+ 
permeable.  Hence, a run with 230 allows for the total releasable content of 
Ca2+ from the ER stores to be measured at a given time. 
N
H
OHO
N
O
O O O
NH
230  
Figure 5.1.1.  Structure of the calcium ionophore A23187 230. 
Therefore, the results obtained from the assays are usually normalised to the 
A23187-releasable Ca2+ (i.e. fractional loss at that time), reflecting the actual 
Ca2+-mobilising / inhibiting potential of our compounds.  
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5.2. Evaluation of synthetic InsP3 1 
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Figure 5.2.1. Fractional Ca
2+
-loss plot for synthetic InsP3 1 in Lvec cells at varying concentrations.  The black bar shows 
when the compound was applied.  Results are shown ± SE and were obtained from duplicate values.
177 
The synthetic InsP3 1, which was obtained from the Ferrier route as a proof of 
principle compound, was evaluated alongside commercial InsP3 from Sigma 
Aldrich in order to confirm its expected biological activity.177  1 was tested for 
InsP3-induced Ca
2+-release (IICR) in Lvec cells over a range of concentrations 
and showed a dose-dependant Ca2+-release, even as low as [1] of 0.3 µM 
(Figure 5.2.1.).  The data obtained from the flux experiments were normalised 
to the maximum amount of releasable Ca2+ (relative to A23187) allowing the 
dose-response curves to be drawn (Figure 5.2.2.). 
 
Figure 5.2.2. Dose-response curve for synthetic and commercial InsP3 1 against the InsP3Rs in Lvec cells.  The curves 
are fitted using a sigmoidal model in Kalidegraph.  EC50 values are calculated based on the maximum releasable Ca
2+
 
by the calcium ionophore A23187.
177
 
Biological Results 
130 
The EC50 value obtained from the dose-response curve showed that the 
synthetic InsP3 1 (EC50 = 2.71 µM) had a similar potency in stimulating Ca
2+-
release as commercial InsP3 (EC50 = 4.10 µM) obtained by extraction.  Similar 
results were obtained when the experiments were repeated in an L15 cell line, 
(EC50 of 1 = 0.67 µM; EC50 of commercial InsP3 = 0.91 µM).  In these 
experiments, the EC50 values were lower, owing to a greater excess of the 
receptors in the cells.  The values obtained were in good agreement with the 
previously reported data of Kasri and co-workers.174 
The small difference in EC50 values between the synthetic and commercial 
InsP3 samples could be ascribed to purity.  The synthetic InsP3 was shown to 
be the only component of the sample by 1H and 31P NMR, whereas, the 
commercial InsP3 is obtained as a natural extract and therefore may have some 
contamination from the extraction process. 
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5.3. Evaluation of 5-position analogues of InsP3 
The 5-position analogues from the two synthetic routes were evaluated in Ca2+-
flux assays over a range of concentrations.  These assays allowed for the 
determination of agonist or antagonist activity.  Individual assay conditions are 
outlined in each section.  Some of the compounds were only tested at high 
concentrations, as prior work had indicated that large doses of the compounds 
were required to effect a response. 
 
5.3.1. Methyl phosphate ester 128 (nk404) 
The methyl phosphate ester 128 was shown to invoke Ca2+ release in the 
presence of a low concentration of InsP3 (less than 50% of EC50), with the 
maximum release observed by a [128] of 30 µM (shown in dark blue, Figure 
5.3.1.). 
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Figure 5.3.1.  Fractional Ca
2+
-loss plot for methyl phosphate ester analogue 128 in 2MEFwt cells at varying 
concentrations.  The red bar represents time over which mixtures of 128 and InsP3 (2 µM) were applied to the cells.  
The black bar shows when InsP3 was applied.  Results are shown ± SE and were obtained from duplicate values. 
On further dosing of InsP3 at 9 min, there was no further release of Ca
2+, 
indicating that the stores had already been depleted by the initial release rather 
than a large IICR inhibition.  These data showed that 128 was a full agonist of 
the InsP3Rs.  The data obtained from the flux experiments were normalised to 
the maximum amount of releasable Ca2+ from the cells by A23187, allowing the 
dose-response curves to be drawn (Figure 5.3.2.). 
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Figure 5.3.2.  Dose response curve for activity of methyl phosphate ester analogue 128 and InsP3 1 against the 
InsP3Rs in 2MEFwt cells.  The curves are fitted using a sigmoidal model in Kalidegraph.  EC50 values are calculated 
based on the maximum releasable Ca
2+
 by the calcium ionophore A23187. 
The dose response curves show that 128 (EC50 = 9.7 µM) was approximately 
half as potent as commercial InsP3 (EC50 = 5.2 µM) at releasing Ca
2+ from the 
intracellular stores on the ER. 
It was speculated that, these results could be due to the ester 128 behaving as 
a prodrug, releasing InsP3 1 through hydrolysis of the methoxy phosphate ester 
moiety to a phosphate group.  A crude stability study was conducted to confirm 
this, by dissolving 128 in D2O and measuring the 
1H and 31P NMR spectra.  The 
solution was left at room temperature and the spectra were re-recorded after 
60 h.  After the time course, the doublet of the methoxy group was clearly 
observed in the 1H spectrum and the 31P NMR showed only the same 3 peaks 
as the initial spectrum.  There were no major changes to the spectra, and no 
breakdown products were observed.  Whilst this experiment was not 
quantitative, it showed that 128 was not susceptible to hydrolysis or migration in 
water, suggesting that 128 is not acting as a prodrug. 
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5.3.2. Methylene carboxylate 129 (nk440) 
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The methylene carboxylate analogue 129 experiments were run in the presence 
of InsP3, rather than pre-incubating the cells with the compound, then 
challenging with InsP3.  This revised protocol appears to produce more 
consistent results that has made inhibition of IICR easier to measure. 
  
Figure 5.3.3.  Fractional Ca
2+
-loss plots for carboxymethyl analogue 129 in L15 cells at 300 µM and 600 µM.  The 
horizontal bar indicates the time over which the compounds were applied to the cells.  Results are shown ± SE and 
were obtained from duplicate values. 
The fractional loss plots (Figure 5.3.3.) show that 129 does not invoke Ca2+-
release on its own, even at higher concentrations.  When 129 was dosed with a 
sub-EC50 quantity of InsP3 (0.4 µM), it showed strong inhibition of IICR; at 
600 µM of 129, this was almost complete inhibition, as shown in Figure 5.3.4. 
  
Figure 5.3.4.  Plots of concentration dependant inhibition of IICR by methylene carboxylate analogue 129. 
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These results for the carboxymethyl analogue 129 confirm that it is an 
antagonist of the InsP3Rs, by inhibiting IICR.  Further experiments will be 
conducted on this compound. 
In these runs of experiments there appeared to be a ‘vehicle effect’, where 
water appeared to invoke a Ca2+-efflux.  This efflux is most likely due to osmotic 
diffusion or leeching of intracellular Ca2+ through the permeabilised membranes.  
It is noteworthy that when the cells are treated with 129, this efflux stops, 
indicating that 129 is preventing any background IICR from occurring. 
 
5.3.3. Methylphosphonate 126 (nk444) 
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Figure 5.3.5.  Fractional Ca
2+
-loss plot for methylphosphonate analogue 126 in L15 cells (shown in cyan @300 µM and 
pink @600 µM).  The top horizontal bar represents time over which 126 was applied to the cells.  The lower horizontal 
bar shows when InsP3 was applied.  Results are shown ± SE and were obtained from duplicate values. 
The newly synthesised batch of methylphosphonate analogue 126 showed 
slightly different activity to the previous material synthesised by Aslam.  At 
300 µM of 126, a small Ca2+ release was observed when dosing the compound, 
but on addition of InsP3, IICR was clearly inhibited, as previously observed. 
On increasing the dose to 600 µM of 126, a large release of Ca2+ was observed 
during initial dosing.  When InsP3 was added to the 600 µM run, there was 
significant inhibition of IICR, however, this may have been due to depletion of 
the Ca2+ stores during the initial efflux.  The results at 300 µM still suggest that 
126 is an antagonist of the InsP3Rs by inhibiting IICR, however, the large 
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release of Ca2+ at 600 µM suggests that 126 could also be a partial agonist at 
higher concentrations.  The alternative interpretation for the Ca2+ blip is that the 
initial loss of Ca2+ may be due to a vehicle effect of the water solution in which 
126 is administered.  This phenomenon has been observed previously when 
testing these compounds, therefore these results should be interpreted with 
caution.   
Therefore, 126 shows mixed activity against the InsP3Rs, at this time.  Further 
experiments at 300-600 µM are required to confirm the antagonist activity.  New 
assay protocols have been developed by Bultynck and co-workers, which 
appear to suppress any vehicle effects.  126 will be re-screened under these 
new conditions to clarify the previous results. 
 
5.3.4. Sulfamate 127 (nk443) 
The sulfamate 127 was a key compound in the series of analogues, as it had 
been predicted to be both an agonist and an antagonist by the two different 
hypotheses.  The outcome of this assay would be critical in determining which 
hypothesis was correct. 
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Figure 5.3.6.  Fractional Ca
2+
-loss plot for sulfamate analogue 127 in L15 cells (shown in dark blue).  The top horizontal 
bar represents time over which 127 was applied to the cells.  The lower horizontal bar shows when InsP3 was applied.  
Results are shown ± SE and were obtained from duplicate values. 
The sulfamate analogue 127 invoked release of Ca2+ without InsP3 (from 4 to 
8 min), showing that it was an agonist of the InsP3Rs.  Importantly, in contrast to 
the methylphosphonate 126, on addition of InsP3 to the efflux medium, 127 
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potentiated IICR, rather than inhibited it.  This result suggests that the pKa 
hypothesis was perhaps incorrect, as the sulfamate group was estimated to 
have a pKa of 9 and hence was predicted to be an antagonist.  However, this 
result does support the bidentate / tridentate theory, which predicted that the 
sulfamate would be an agonist as it had three points from which it could make 
polar contacts with the receptor. 
 
5.3.5. Ins(1,4)P2 130 (nk441) 
Ins(1,4)P2 130 could be considered a control compound, as it does not bear a 
substituent on the 5-position of the inositol ring. 
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Figure 5.3.7.  Fractional Ca
2+
-loss plot for synthetic Ins(1,4)P2 130 in L15 cells (shown in green).  The top horizontal bar 
represents time over which 130 was applied to the cells.  The lower horizontal bar shows when InsP3 was applied.  
Results are shown ± SE and were obtained from duplicate values. 
When administered, 130 appears to invoke a small release of Ca2+ itself, as 
shown by the small bump between 4 and 8 min (Figure 5.3.7.), however, this 
may have been a vehicle-effect artefact.  130 then potentiates IICR when InsP3 
is added to the experiment.  This result is consistent with the literature, showing 
that 130 is a partial agonist of the InsP3Rs, but with considerably less potency 
than InsP3.
166 
These data suggest that the just 1- and 4-position phosphates are sufficient to 
bind to the receptor to evoke opening of the Ca2+ channel, without any 
substituent at the 5-position.  However, the response is considerably lower than 
when a phosphate group is present at the 5-position (as in InsP3). 
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5.4.  Prediction of InsP3R-1 antagonists 
The compounds synthesised through the course of this project have allowed for 
the testing of the two hypotheses discussed in Chapter 2.4.  It was proposed 
that InsP3R-1 antagonist activity could arise from the pKa of the 5-position 
substituent being higher than ~2, or from substituents that only had two points 
from which to make polar contacts with the receptor.  The results are 
summarised in Table 5.4.1. 
Compound 
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9 tridentate agonist 
Table 5.4.1.  Summary of biological activity of 5-position-modified analogues of InsP3 at the InsP3Rs. 
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5.4.1. pKa Hypothesis 
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Figure 5.4.2.  pKa predictions for 5-position analogues.  The dashed line indicates the hypothesised division for agonist 
/ antagonist activity. 
Through the early evaluation of the 5-position sulfate and methylphosphonate, it 
was hypothesised that a 5-position substituent with a pKa higher than 2 may be 
an InsP3R-antagonist.  Two of the predictions based on this assumption were 
shown to be correct; ester 128 was an agonist and methylene carboxylate 129 
was an antagonist.  However, this hypothesis incorrectly predicted the 
sulfamate 127 as an antagonist, where it was actually shown to be a relatively 
potent agonist.   
The opposite activity of the sulfamate 127 suggests the pKa hypothesis to be 
incorrect.  Further compounds that have pKa values between 2 and 9 should be 
synthesised (if possible) to confirm this, however, it appears unlikely that the 
pKa is a controlling factor in the activity against the InsP3Rs. 
 
5.4.2. Polar contacts hypothesis 
The second hypothesis for antagonist activity was based on the number of polar 
contacts that could be made from the 5-position substituent.  Using this 
hypothesis, all of the biological outcomes were correctly identified. 
The tridentate ligands (such as phosphate, phosphate ester, sulfamate, sulfate) 
all show agonist properties, as they are of similar size and can probably form 
similar networks of polar contacts similar to InsP3.  The bidentate ligands 
(methylphosphonate and carboxymethyl) both show antagonist activity, possibly 
through disrupting the network of polar contacts required to initiate the 
conformational change that opens the Ca2+-channel.  Equally, the bidentate 
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ligands could form an entirely different set of polar contacts, which again could 
prevent opening of the Ca2+-channel. 
Future synthesis should focus on more bidentate, and possibly monodentate 
analogues.  These compounds appear to bind to the InsP3R, but, for reasons 
currently unknown, do not lead to Ca2+-release.  Co-crystallisation of the 
analogues with the InsP3R would allow for elucidation of the antagonist-
mechanisms. 
 
 
5.5. Summary and conclusions 
The biological evaluation of the range of 5-position analogues of InsP3 has 
given an insight into the behaviour of the InsP3Rs at the molecular level.  At this 
early stage, the methyl phosphate ester 128 and sulfamate 127 have shown 
agonist activity, invoking IICR in the absence of InsP3.  Re-synthesis and testing 
of the new batch of methylphosphonate 126 has confirmed the earlier results, 
showing that 126 is an antagonist at high concentrations, by inhibiting IICR.  A 
new antagonist, the methylene carboxylate analogue 129, has been identified 
and shown to inhibit IICR over a range of concentrations  These compounds 
represent the first report of inositol-based InsP3R-antagonists. 
Two hypotheses for InsP3R-antagonist activity were proposed.  The testing of 
the compounds has indicated that pKa is not an important factor for antagonism.  
Whereas, the number of polar contact points that an inositol compound can 
make at its 5-position substituent appears to be a key factor for antagonist 
activity.  
These new InsP3 analogues could be used as biological tools to further probe 
the InsP3R-activation and Ca
2+ release mechanisms.  Future studies of these 
systems are expected to involve co-crystallisation of the analogues with the 
binding domain (or the entire receptor) of the InsP3R-1.  If these crystallisations 
are successful, the X-ray crystal structures of the bound ligands could give an 
insight into the interactions required to initiate or prevent Ca2+ release at a 
molecular level. 
  
 
6 Experimental Section 
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6. Experimental Section 
6.1. General Experimental Protocols 
1H NMR spectra were recorded on Bruker DPX250 (250 MHz); Bruker Avance 
300 (300 MHz); Bruker Avance 400 (400 MHz); Bruker Avance II 400 
(400 MHz); Bruker DRX500 (500 MHz); Bruker Avance 500 (500 MHz); or 
Bruker Avance III 500 (500 MHz) using deuterochloroform (unless indicated 
otherwise) as a reference for internal deuterium lock.  The chemical shift data 
for each signal are given as !H in units of parts per million (ppm) relative to 
tetramethylsilane (TMS) where ! (TMS) = 0.00 ppm.  Each spectrum is 
corrected to the appropriate solvent reference; ! (CDCl3) = 7.26 ppm.  The 
multiplicity of each signal is indicated by: s (singlet); br s (broad singlet); d 
(doublet); t (triplet); q (quartet); dd (doublet of doublets); ddd (doublet of doublet 
of doublets); dddd (doublet of doublet of doublet of doublets); ddt (doublet of 
doublet of triplets); sp (septet); or m (multiplet).  The number of protons (n) for a 
given resonance signal is indicated by nH.  Coupling constants (J) are quoted in 
Hz and are recorded to the nearest 0.1 Hz. Identical proton coupling constants 
(J) are averaged in each spectrum and reported to the nearest 0.1 Hz.  The 
coupling constants are determined by analysis using Bruker TopSpin software.  
13C NMR spectra were recorded on Bruker Avance 300 (75 MHz); Bruker 
Avance II 400 (100 MHz); or Bruker Avance III 500 (125 MHz) spectrometers 
using the PENDANT or DEPT Q pulse sequences with broadband proton 
decoupling and internal deuterium lock.  The chemical shift data for each signal 
are given as ! in units of parts per million (ppm) relative to tetramethylsilane 
(TMS) where !C (TMS) = 0.00 ppm. Each spectrum is corrected to the 
appropriate solvent reference; ! (CDCl3) = 77.0 ppm. Where appropriate, 
coupling constants (J) are quoted in Hz and are recorded to the nearest 0.1 Hz. 
1H and 
13C spectra were assigned using 2D NMR experiments including COSY, 
HSQC, HMBC and DEPT Q.   
31P NMR spectra were recorded on Bruker Avance II 400 (162 MHz) or Bruker 
DRX500 (202 MHz) spectrometers using broadband proton decoupling pulse 
sequences and deuterium internal lock.  The chemical shift data for each signal 
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are given as !P in units of parts per million (ppm) relative to 85% phosphoric 
acid as an external reference.   
19F NMR spectra were recorded on a Bruker Avance II 400 (282 MHz) using a 
broadband proton decoupling pulse sequence and deuterium internal lock.  The 
chemical shift data for each signal are given as !F in units of parts per million 
(ppm).  Where appropriate, coupling constants (J) are quoted in Hz and are 
recorded to the nearest 0.1 Hz. 
Mass spectra were acquired on a VG platform spectrometer.  For electron 
impact spectra, the instrument was operating at 70 eV.  Chemical ionisation 
spectra were obtained using isobutane as the ionising gas.  Electrospray 
ionisation spectra were obtained on Micromass LCT; Micromass LCT Premier; 
and Bruker MicroTOF spectrometers, operating in positive or negative mode, 
from solutions of methanol, acetonitrile or water.  m/z values are reported in 
Daltons and followed by their percentage abundance in parentheses. 
Melting points were determined from recrystallised samples using an 
Electrothermal 9100 melting point apparatus or Kofler hot stage microscope 
and are uncorrected.  The solvent(s) from which the sample was crystallised is 
given in parentheses. 
Infrared Specta were obtained either as: a thin film on sodium chloride discs; b 
potassium bromide disc; c nujol mull as indicated in parentheses.  The spectra 
were recorded on Perkin Elmer GX FT-IR or Bruker Tensor 27 spectrometers. 
Absorption maxima are reported in wavenumbers (cm-1). 
Specific Optical Rotations were measured using Perkin Elmer Model 241 and 
341 polarimeters, in cells with a path length of 1 dm.  The light source was 
maintained at 589 nm.  The concentration (c) is expressed in g/100 mL 
(equivalent to g/0.1 dm3).  Specific rotations are denoted 
  
! 
"[ ]
D
T
 and are given in 
implied units of 10-1 deg cm2 g-1 (T = ambient temperature in ˚C). 
Analytical thin layer chromatography (TLC) was carried out on Merck silica 
gel 60 F254 aluminum-supported thin layer chromatography sheets.  
Visualisation was by absorption of UV light ("max 254 or 365 nm), or thermal 
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development after dipping in one of: a ethanolic solution of phosphomolybdic 
acid (PMA); b aqueous solution of potassium permanganate, potassium 
carbonate and sodium hydroxide; c ethanolic solution of 4-anisaldehyde, 
sulfuric acid and acetic acid. 
Flash Column chromatography was carried out on Apollo Scientific Ltd silica 
gel 40-63 micron or Merck silica gel 60 (240-400 mesh), eluting with solvents as 
supplied, under a positive pressure of compressed air (unless otherwise stated). 
Continuous flow hydrogenation reactions were conducted on a ThalesNano 
H-Cube Continuous-Flow Hydrogenation Reactor from solutions of methanol 
(0.25 mM) using a 30mm 10% Pd/C catalyst cartridge. 
Anhydrous solvents were obtained under the following conditions: dry 
acetonitrile was distilled from calcium hydride in a recycling still; dry N,N-
dimethylformamide was purchased from SigmaAldrich UK in a SureSealTM 
bottle and used without further purification or was distilled under reduced 
pressure from activated 4 Å molecular sieves and stored over 4 Å molecular 
sieves under an N2 atmosphere; dry dimethyl sulfoxide was pre-dried over 
activated alumina, then distilled from calcium hydride and stored over activated 
4 Å molecular sieves under an N2 atmosphere; anhydrous 1,4-dioxane was 
distilled from sodium and benzophenone in a recycling still and stored over 
activated 3 Å molecular sieves under an Ar atmosphere.  Anhydrous 
dichloromethane, diethyl ether, toluene, hexane and tetrahydrofuran were 
obtained using a MBRAUN GmbH MB SPS-800 solvent purification system, 
where solvent was dried by passage through filter columns and dispensed 
under an atmosphere of N2 or Ar gas. 
Chemicals were purchased from Acros UK, Sigma Aldrich UK, Alfa Aesar UK, 
Fisher UK, Fluka UK, Fluorochem, Merck or TCI-Europe.  All solvents and 
reagents were purified, when necessary, by standard techniques.178  Where 
appropriate and if not stated otherwise, all non aqueous reactions were 
performed in a flame-dried flask under an inert atmosphere of nitrogen or argon, 
using a double vacuum manifold with the inert gas passing through a bed of 
activated 4 Å molecular sieves and self indicating silica gel.   
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In vacuo refers to the use of a rotary evaporator attached to a diaphragm 
pump.  Brine refers to a saturated aqueous solution of sodium chloride.  
Rochelle’s Salt refers to a saturated aqueous solution of potassium sodium 
tartrate tetrahydrate.  Hexane refers to a mixture of hexane isomers and 
petroleum ether to the fraction boiling between 40-60 ˚C. 
Millipore Frit refers to a Millipore Millex-GP Filter Unit (model SLGP033RS), 
which has a 33 mm filter membrane (polyethersulfone) with a pore size of 
0.22 µm.  The solution is passed through the frit under pressure from a syringe. 
Lypholisation refers to the removal of water by using a Christ Alpha 2-4 LD-2 
Freeze Drier attached to a rotary-vane oil pump.  The water solution is frozen 
with liquid nitrogen, then attached to the freeze drier, which removes the water 
by sublimation under high vacuum (>0.1 mbar). 
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6.2. Ca2+-flux assays 
The Ca2+ assays were conducted by our collaborator, Dr Geert Bultynck, at the 
Katholieke Universiteit in Leuven, Belgium.  The experiments were carried out 
in at least duplicate to account for variation in individual wells. 
 
6.2.1. Cell lines 
Three cell lines, all based on mouse fibroblast cells, were used in the biological 
evaluation. L-15 cells are mouse L-fibroblast cells, which stably overexpress 
InsP3R-1 by 8-10 fold, compared to endogenous levels.  The ratio of InsP3R-1 
to InsP3R-3 is at least 3:1 in the L-15 cell line.  Lvec cells are transfected with 
an empty vector, hence only contain endogenous levels of InsP3R-1 and InsP3-
3 in a 1:3 ratio.  2MEFwt cells are immortalised wild-type mouse embryonic 
fibroblast cells; expressing “normal” levels of InsP3R-1 and InsP3-3. 
 
6.2.2. General procedure for Ca2+-flux assay 
i. Cells (2MEFwt, L15 or Lvec) are seeded into the bottom of wells, forming 
a confluent monolayer.  The culture is allowed to grow for 6-8 days prior 
to the flux experiments. 
ii. Cells are incubated with saponin, which permeabilises the cell 
membranes, allowing the free passage of Ca2+ and the inositol 
analogues across the membrane. 
iii. The non-mitochondrial Ca2+ stores are then loaded with free Ca2+, 
containing 45Ca2+. 
iv. Cells are washed twice with a medium containing thapsigargin, which 
inhibits the ER Ca2+ pumps, ensuring that any release of Ca2+ that is 
observed is a result of inositol-induced Ca2+-release (IICR). 
v. The run is commenced, then the efflux medium is replaced every 2 min 
over the duration of the run. 
vi. After a set period (indicated on the fractional loss plots), the cells are 
challenged with the compound of interest for several minutes. 
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vii. InsP3 is applied to the cells later in the experiment, to induce IICR. 
viii. At the end of the run, the Ca2+ stores are emptied by treatment with 2% 
sodium dodecyl sulfate (SDS) to allow the entire remaining Ca2+ content 
to be measured. 
ix. 45Ca2+ efflux from the ER membranes over each 2 min period is 
measured in a scintillation counter. 
x. Ca2+ release is plotted as % fractional loss: 
  
! 
amount of Ca2+ released in 2 min
total Ca2+ store content at timepoint
"100 
xi. The results are normailised to the potential maximum releasable quantity 
of Ca2+ by the calcium ionophore, A23187 230. 
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6.3. Experimental procedures 
6.3.1.  (+)-Methyl 4,6-O-anisylidene-!-D-glucopyranoside 138 
4
3
2 1
O5
7
O
6
O
OCH3
HO
HO
8
9
10
11
H3CO
12  
A mixture of methyl !-D-glucopyranoside 137 (26.0 g, 134 mmol, 1 eq), 
anisaldehyde dimethylacetal (26.8 g, 25.1 mL, 147 mmol, 1.1 eq) and 
amberlyst-15 resin (1.30 g) was suspended in N,N-dimethylformamide (65 mL).  
The mixture was heated to 80 °C under 200 mbar vacuum for 48 h.  After this 
time, TLC analysis showed consumption of the starting material.  The hot 
mixture was filtered through a pad of Celite and the residue was washed with 
N,N-dimethylformamide (100 mL).  The filtrate was concentrated in vacuo, 
providing a thick colourless paste, which was taken up in CHCl3 (200 mL) and 
water (5 mL).  The solids were isolated by filtration, affording a colourless solid, 
which was recrystallised from ethyl acetate yielding methyl 4,6-O-anisylidene-!-
D-glucopyranoside 138 (27.1 g, 65%) as fine colourless needles: Rf 0.32 (ethyl 
acetate); 
  
! 
"[ ]
D
20
 +104.8 (c 1.00 in CHCl3) [lit.
179 
  
! 
"[ ]
D
20
 +104.7 (c 0.7 in CHCl3)]; mp 
193-195 °C (from ethyl acetate) [lit.179 mp 195 °C]; !max (KBr disc)/cm
-1 3373 (s), 
2939 (s), 2868 (s), 1615 (s), 1588 (m), 1518 (s), 1459 (s), 1423 (s), 1304 (s), 
1036 (s), 931 (s), 890 (m) and 809 (s); 1H NMR (300 MHz; CDCl3) " 7.45-7.40 
(2H, m, H-9,9’ Ar), 6.91-6.88 (2H, m, H-10,10’ Ar), 5.49 (1H, s, H-7), 4.79 (1H, 
d, J 4.0, H-1), 4.30-4.26 (1H, m, H-5), 3.92 (1H, ddd, J 9.5, 9.2, 1.5, H-3), 3.80 
(3H, s, OCH3 H-12), 3.84-3.76 (1H, m, CHeq-6), 3.73 (1H, dd, J 10.3, 10.1, 
CHax-6), 3.63 (1H, ddd, J 9.3, 9.2, 4.0, H-2), 3.47 (1H, dd, J 9.5, 9.2, H-4), 3.46 
(3H, s, OCH3), 2.88 (1H, d, J 1.5, OH-3) and 2.39 (1H, d, J 9.3, OH-2); 
13C NMR 
(100 MHz; CDCl3) " 160.3 (C-11 Ar), 129.5 (C-8 Ar), 127.6 (CH-9,9’ Ar), 113.7 
(CH-10,10’ Ar), 101.9 (CH-7), 99.9 (CH-1), 80.9 (CH-5), 72.9 (CH-3), 71.8 (CH-
2), 68.9 (CH2 C-6), 62.4 (CH-4), 55.6 (OCH3 C-12) and 55.3 (OCH3); HRMS m/z 
(ES+) [Found: (M+Na)+ 335.1101, C15H20O7Na requires M
+, 335.1107]; m/z 
(ES+) 335 ([M+Na]+, 100%); Anal. Calcd. for C15H20O7: C, 57.69; H, 6.45. 
Found: C, 57.95, H, 6.37.  The data are in good agreement with the literature 
values.179, 180 
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6.3.2.  (+)-Methyl 2-O-benzyl-4,6-O-anisylidene-!-D-glucopyranoside 139
   and (+)-methyl 3-O-benzyl-4,6-O-anisylidene-!-D   
  glucopyranoside 140 
4
3
2 1
O5
7
O
6
O
OCH3
HO
O
8
9
10
11
H3CO
12
13
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A mixture of (+)-methyl 4,6-O-anisylidene-!-D-glucopyranoside 138 (15.0 g, 
48.0 mmol, 1 eq), di-n-butyl tin oxide (13.2 g, 52.8 mmol, 1.1 eq), 
tetrabutylammonium bromide (15.5 g, 52.8 mmol, 1 eq) and benzyl bromide 
(24.6 g, 17.2 mL, 144.1 mmol, 3 eq) was suspended in acetonitrile (400 mL).  
The suspension was heated under reflux, with azeotropic removal of water via a 
Soxhlet thimble filled with activated 3 Å molecular sieves, for 18 h.  After this 
time, TLC analysis indicated consumption of the starting material.  The mixture 
was cooled to RT and the volatile components were removed in vacuo 
providing a colourless residue, which was partitioned between water (250 mL) 
and ethyl acetate (250 mL).  The layers were separated and the aqueous layer 
was re-extracted with ethyl acetate (3 ! 250 mL).  The combined organic 
phases were washed with brine (200 mL), dried over magnesium sulfate, 
filtered and concentrated in vacuo affording a colourless solid.  Purification of 
the solid by silica gel chromatography, eluting with hexane, ethyl acetate and 
triethylamine (70:29:1, 65:34:1, 60:39:1), yielded (+)-methyl 2-O-benzyl-4,6-O-
anisylidene-!-D-glucopyranoside 139 (10.39 g, 54%) as a colourless crystalline 
solid: Rf 0.45 (hexane/ethyl acetate 50:50); 
  
! 
"[ ]
D
20
 +32.0 (c 1.00 in CHCl3) [lit.
181 
  
! 
"[ ]
D
20
 +31.9 (c 1.30 in CHCl3)]; mp 136-138 °C (from ethyl acetate) [lit.
181 mp 
135-136.5 °C]; "max (KBr disc) /cm
-1 3475 (s), 2919 (w), 1613 (s), 1518 (s), 1365 
(m), 1250 (s), 1089 (s), 1040 (s) and 990 (s); 1H NMR (400 MHz; CDCl3) " 7.45-
7.29 (7H, m, Ar H), 6.92-6.86 (2H, m, H-10,10’ Ar), 5.48 (1H, s, H-7), 4.80 (1H, 
d, J 12.2, CHAHB H-13), 4.71 (1H, d, J 12.2, CHAHB H-13’), 4.62 (1H, d, J 3.6, 
H-1), 4.25 (1H, dd, J 10.1, 4.7, Heq-6), 4.15 (1H, ddd, J 9.0, 9.0, 1.4, H-3), 3.84-
3.77 (1H, m, H-5), 3.80 (3H, s, OCH3 H-12), 3.69 (1H, dd, J 10.2, 10.1, Hax-6), 
3.51-3.45 (2H, m, H-2 and H-4), 3.38 (3H, s, OCH3) and 2.66 (1H, d, J 1.4, OH-
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3); 13C NMR (100 MHz; CDCl3) ! 160.2 (C-11 Ar), 138.0 (C-14 Ph), 129.7 (C-8 
Ar), 128.6 (Ph), 128.2 (Ph), 127.7 (CH-9,9’ Ar), 113.7 (CH-10,10’ Ar), 101.9 
(CH-7), 98.7 (CH-1), 81.3 (CH), 79.6 (CH), 73.4 (CH2Ph), 70.3 (CH-3), 69.0 
(CH2-6), 62.0 (CH-5), 55.4 (Ar OCH3 H-12) and 55.3 (OCH3); HRMS m/z (ES
+) 
[Found: (M+Na)+ 425.1570. C22H26O7Na
+ requires M+, 425.1576]; m/z (ES+) 425 
([M+Na]+, 100%); Anal. Calcd. for C22H26O7: C, 65.66; H, 6.51.  Found: C, 
65.96; H, 6.80.  
4
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Further elution provided (+)-methyl 3-O-benzyl-4,6-O-anisylidene-"-D-
glucopyranoside 140 (2.80 g, 15%) as a colourless amorphous solid: Rf 0.29 
(hexane/ethyl acetate 50:50); 
  
! 
"[ ]
D
20
 +76.6 (c 1.00 in CHCl3) [lit.
181 
  
! 
"[ ]
D
20
+76.2 (c 
1.70 in CHCl3)]; mp 177-178 °C (from ethyl acetate) [lit.
181 176-178 °C]; !max 
(KBr disc) /cm-1 3449 (s), 1618 (m), 1517 (m), 1370 (m), 1252 (m), 1076 (s); 1H 
NMR (400 MHz; CDCl3) ! 7.45-7.27 (7H, m, Ar H), 6.94-6.89 (2H, m, H-10,10’ 
Ar), 5.54 (1H, s, H-7), 4.96 (1H, d, J 11.6, CHAHB H-13), 4.82 (1H, d, J 3.8, H-
1), 4.79 (1H, d, J 11.6, CHAHB H-13’), 4.29 (1H, dd, J 9.6, 4.5, Heq-6), 3.87-3.71 
(7H, m, Ar OCH3 H-12, H-2, H-3, H-4 and H-5) 3.64 (1H, dd, J 9.6, 9.2, Hax-6), 
3.46 (3H, s, OCH3) and 2.33 (1H, d, J 7.4, OH-2); 
13C NMR (100 MHz; CDCl3) ! 
160.0 (C-11 Ar), 138.5 (C-14 Ph), 129.9 (C-8 Ar), 128.4 (Ph), 128.0 (Ph), 127.7 
(C Ph), 127.4 (CH-9,9’ Ar), 113.6 (CH-10,10’ Ar), 101.3 (C-7), 99.9 (CH-1), 81.9 
(CH), 78.9 (CH), 74.8 (CH2Ph C-13), 72.4 (CH), 69.0 (CH2 C-6), 62.6 (CH), 55.4 
(Ar OCH3 C-12) and 55.3 (OCH3); HRMS m/z (ES
+) [Found: (M+Na)+ 425.1582. 
C22H26O7Na requires M
+, 425.1576]; m/z (ES+) 425 ([M+Na]+, 100%); Anal. 
Calcd. For C22H26O7: C, 65.66; H, 6.51. Found: C, 65.82; H, 6.45.  The data are 
in good agreement with the literature values.181, 182 
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6.3.3.  (-)-Methyl 2-O-benzyl-3-O-triisopropylsilyl-4,6-O-anisylidene-!-D-
  glucopyranoside 142 
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To a solution of (+)-methyl-2-O-benzyl-4,6-O-anisylidene-!-D-glucopyranoside 
139 (17.6 g, 43.8 mmol, 1 eq) in CH2Cl2 (300 mL) was added a mixture of 
triethylamine (17.7 g, 24.4 mL, 175.0 mmol, 4 eq) and triisopropyl 
trifluoromethyl sulfonate (20.1 g, 17.7 mL, 65.6 mmol, 1.5 eq), via a pressure 
equalised dropping funnel, over a period of 20 min.  The solution was stirred for 
2.5 h at RT, turning from colourless to pale orange, after which time TLC 
analysis indicated consumption of the starting material. The reaction was 
quenched by the addition of aqueous saturated sodium bicarbonate solution 
(200 mL).  The layers were separated and the aqueous phase was extracted 
with CH2Cl2 (2 ! 300 mL).  The combined organic phases were washed with 
brine (200 mL), dried over magnesium sulfate, filtered and concentrated in 
vacuo providing an orange oil.  Purification by silica gel chromatography, eluting 
with hexane and diethyl ether (90:10), provided (-)-methyl 2-O-benzyl-3-O-
triisopropylsilyl-4,6-O-anisylidene-!-D-glucopyranoside 142 (22.5 g, 92%) as a 
colourless oil: Rf 0.25 (hexane/diethyl ether 80:20); 
  
! 
"[ ]
D
20
 -13.5 (c 0.97 in 
CHCl3); "max (KBr disc) /cm
-1 2942 (s), 2865 (s), 1616 (m), 1518 (s), 1375 (m), 
1303 (m), 1250 (s), 1054 (s), 992 (s) and 831 (s); 1H NMR (400 MHz; CDCl3) " 
7.41-7.28 (7H, m, Ar H), 6.89-6.87 (2H, m, H-10,10’ Ar), 5.40 (1H, s, H-7), 4.84 
(1H, d, J 12.3, CHAHB H-13), 4.60 (1H, d, J 12.3, CHAHB H-13’), 4.47 (1H, d, J 
3.7, H-1), 4.26 (1H, dd, J 8.9, 8.9, H-3), 4.20 (1H, dd, J 10.1, J 4.7, Heq-6), 3.81 
(3H, s, Ar OCH3 H-12), 3.81-3.78 (1H, m, H-5), 3.66 (1H, dd, J 10.2, 10.1, Hax-
6), 3.42-3.36 (2H, m, H-2 and H-4), 3.33 (3H, s, OCH3), 1.13-1.04 (3H, m, CH 
TIPS) and 1.04-0.99 (18H, m, CH3 TIPS); 
13C NMR (100 MHz; CDCl3) " 160.1 
(C-11 Ar), 138.5 (C-14 Ph), 129.9 (C-8 Ar), 128.4 (Ph), 128.2 (Ph), 127.9 (C 
Ph), 127.7 (CH-9,9’ Ar), 113.4 (CH-10,10’ Ar), 102.1 (CH-7), 99.3 (CH-1), 82.7 
(CH), 80.8 (CH), 73.8 (CH2Ph C-13), 71.8 (CH), 69.1 (CH2-6), 62.6 (CH), 55.3 
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(2 ! OCH3), 18.2 (CH3 TIPS) and 12.8 (CH TIPS); HRMS m/z (ES
+) [Found: 
(M+Na)+ 581.2919.  C31H46O7SiNa requires M
+, 581.2911]; m/z (ES+) 581 
([M+Na]+, 100%); Anal. Calcd. For C31H46O7Si: C, 66.63; H, 8.30. Found: C, 
66.36; H, 8.65. 
 
6.3.4.  (+)-Methyl 2-O-benzyl-4-O-(4-methoxybenzyl)-3-O-  
  triisopropylsilyl-!-D-glucopyranoside 143 
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To a solution of (-)-methyl 2-O-benzyl-3-O-triisopropylsilyl-4,6-O-anisylidene-!-
D-glucopyranoside 142 (22.5 g, 40.2 mmol, 1 eq) dissolved in CH2Cl2 (400 mL) 
at RT was added a solution of DIBAL-H in hexanes (1.0 M, 201 mL, 201 mmol, 
5 eq) dropwise, via a pressure equalised dropping funnel, over a period of 
30 min.  The colourless solution was stirred for an additional 40 min at RT, after 
which time TLC analysis indicated consumption of the starting material.  The 
solution was cooled to -10 °C and the reaction was quenched by the sequential, 
dropwise, addition of water (8.04 mL), aqueous sodium hydroxide solution (15% 
w/v, 8.04 mL) and a further portion of water (20 mL).  CAUTION: This 
quenching procedure led to the rapid evolution of hydrogen gas.  A viscous 
colourless gel formed, which was stirred for 30 min at 0 °C then filtered through 
a pad of Celite.  The residue was washed with cold CH2Cl2 (3 ! 500 mL); the 
resulting filtrates were combined and concentrated in vacuo to provide a pale 
yellow oil.  Purification of the oil by silica gel chromatography, eluting with 
hexane and diethyl ether (40:60), yielded (+)-methyl 2-O-benzyl-4-O-(4-
methoxybenzyl)-3-O-triisopropylsilyl-!-D-glucopyranoside 143 (19.82 g, 88%) as 
a thick colourless oil: Rf 0.35 (hexane/diethyl ether 30:70); 
  
! 
"[ ]
D
20
 +64.6 (c 1.56 in 
CHCl3); "max (thin film)/cm
-1 3458 (m), 2942 (s), 2865 (s), 1613 (m), 115 (s), 
1464 (m), 1250 (s), 1158 (m), 1104 (s); 1H NMR (400 MHz; CDCl3) " 7.40-7.24 
(7H, m, Ar H), 6.91-6.86 (2H, m, H-12,12’ Ar), 4.85 (1H, d, J 10.7, CHAHB H-9), 
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4.65 (1H, d, J 11.8, CHA’HB’ H-7), 4.56 (1H, d, J 10.7, CHAHB H-9’), 4.54 (1H, d, 
J 3.4, H-1), 4.52 (1H, d, J 11.8, CHA’HB’ H-7’), 4.22 (1H, dd, J 9.1, 8.9, H-3), 
3.81 (3H, s, Ar OCH3 H-14), 3.76-3.56 (3H, m, H-5, Heq-6, Hax-6), 3.41 (1H, dd, 
J 9.9, 8.9, H-4), 3.33 (1H, dd, J 9.1, 3.4, H-2), 3.21 (3H, s, OCH3), 1.68-1.64 
(1H, m, OH-6) and 1.20-1.05 (21H, m, TIPS); 13C NMR (100 MHz; CDCl3) ! 
159.2 (C-13 Ar), 138.5 (C-8 Ph), 130.7 (C-10 Ar), 129.3 (CH-11,11’ Ar), 128.2 
(CH Ph), 128.0 (CH Ph), 127.7 (C Ph), 113.8 (CH-12,12’ Ar), 97.6 (CH-1), 81.3 
(CH-2), 78.9 (CH-4), 74.4 (CH-3), 74.3 (CH2 C-7), 72.6 (CH2 C-9), 70.4 (CH-5), 
62.0 (CH2 C-6), 55.2 (Ar OCH3 C-14), 54.9 (OCH3), 18.3 (CH3 TIPS) and 13.6 
(CH TIPS); HRMS m/z (ES+)  [Found: (M+Na)+ 583.3071. C31H48O7SiNa 
requires M+, 583.3067]; m/z (ES
+) 583 ([M+Na]+, 100%); Anal. Calcd. For 
C31H48O7Si: C, 66.39; H, 8.63. Found: C, 66.62; H, 8.71. 
 
6.3.5.  Methyl 2-O-benzyl-4-O-(4-methoxybenzyl)-3-O-triisopropylsilyl-"-
  D-glucohexadialdo-1,5-pyranoside 144 
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To a solution of (+)-methyl 2-O-benzyl-4-O-(4-methoxybenzyl)-3-O-
triisopropylsilyl-"-D-glucopyranoside 143 (19.8 g, 35.3 mmol, 1 eq) in CH2Cl2 
(300 mL) was treated with Dess Martin periodinane (22.5 g, 53.0 mmol, 1.5 eq), 
in a single portion.  The resulting suspension was stirred at RT for 1.5 h, after 
which time TLC analysis indicated consumption of the starting material.  The 
suspension was diluted with diethyl ether (200 mL) and aqueous saturated 
sodium bicarbonate solution (200 mL), then sodium thiosulfate (135 g) was 
added.  The biphasic mixture was stirred vigorously for 30 min until two clear 
layers were observed.  The layers were separated and the aqueous phase was 
re-extracted with diethyl ether (2 ! 400 mL).  The combined organic phases 
were then washed with aqueous saturated sodium bicarbonate solution 
(300 mL) and water (400 mL), dried over magnesium sulfate, filtered and 
concentrated in vacuo providing a pale yellow oil.  Purification of the oil by silica 
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gel chromatography, eluting with hexane and diethyl ether (40:60), yielded 
methyl 2-O-benzyl-4-O-(4-methoxybenzyl)-3-O-triisopropylsilyl-!-D-
glucohexadialdo-1,5-pyranoside 144 (16.26 g, 82%) as a colourless oil: Rf 0.47 
(hexane/ethyl acetate 50:50); !max (thin film) /cm
-1 2943 (s), 2865 (s), 1742 (m), 
1613 (m), 1515 (s), 1464 (m), 1250 (s), 1051 (s); 1H NMR (400 MHz; CDCl3) ! 
9.59 (1H, d, J 0.6, CHO H-6), 7.40-7.21 (7H, m, Ar H), 6.90-6.86 (2H, m, H-
12,12’ Ar), 4.82 (1H, d, J 10.8, CHAHB H-9), 4.67 (1H, d, J 11.9, CHA’HB’ H-7), 
4.64 (1H, d, J 3.3, H-1), 4.52 (1H, d, J 11.9, CHA’HB’ H-7’), 4.51 (1H, d, J 10.8, 
CHAHB H-9’), 4.28 (1H, dd, J 8.8, 8.0, H-3), 4.16 (1H, dd, J 9.9, 0.6, H-5), 3.81 
(3H, s, Ar OCH3 H-14), 3.49 (1H, dd, J 9.9, 8.0, H-4), 3.33 (1H, dd, J 8.8, 3.3, 
H-2), 3.24 (3H, s, OCH3) and 1.18-1.02 (21H, m, TIPS); 
13C NMR (100 MHz; 
CDCl3) ! 198.0 (CHO C-6), 159.4 (C-13 Ar), 138.3 (C-8 Ph), 129.7 (C-10 Ar), 
129.5 (CH-11,11’ Ar), 128.3 (CH Ph), 128.0 (CH Ph), 127.8 (C Ph), 113.8 (CH-
12,12’ Ar), 97.9 (CH-1), 82.3 (CH), 79.1 (CH), 74.9 (CH), 74.3 (CH2 C-7), 74.0 
(CH), 72.8 (CH2 C-9), 55.6 (Ar OCH3 C-14), 55.3 (OCH3), 18.3 (CH3 TIPS) and 
13.4 (CH TIPS); HRMS m/z (ES+) [Found: (M+Na)+ 581.2902. C31H46O7SiNa 
requires M+, 581.2911]; m/z (ES+) 581 ([M+Na]+, 100%). This material was used 
immediately in the next step. 
 
6.3.6.  (-)-Methyl 6-O-acetyl-2-O-benzyl-4-O-(4-methoxybenzyl)-3-O-
  triisopropylsilyl-"-D-glucohex-5-enopyranoside 145 
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To a solution of methyl 2-O-benzyl-4-O-(4-methoxybenzyl)-3-O-triisopropylsilyl-
"-D-glucohexadialdo-1,5-pyranoside 144 (16.3 g, 29.1 mmol, 1 eq) in 
acetonitrile (300 mL) was added acetic anhydride (8.9 g, 6.4 mL, 87.3 mmol, 
3 eq), potassium carbonate (20.1 g, 145.5 mmol, 5 eq) and DMAP (355 mg, 
2.9 mmol, 0.1 eq).  The stirred suspension was heated to 90 °C for 1 h, after 
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which time TLC analysis showed consumption of starting material.  The mixture 
was cooled to RT and the volatile components were removed in vacuo 
providing a yellow residue.  This residue was partitioned between water 
(400 mL) and CH2Cl2 (400 mL).  The layers were separated and the aqueous 
layer was re-extracted with CH2Cl2 (3 ! 400 mL).  The combined organic layers 
were washed with brine (400 mL), dried over magnesium sulfate, filtered and 
concentrated in vacuo to give a light brown oil.  Purification of this oil by silica 
gel chromatography, eluting with hexane and diethyl ether (75:25), provided (-)-
methyl 6-O-acetyl-2-O-benzyl-4-O-(4-methoxybenzyl)-3-O-triisopropylsilyl-!-D-
glucohex-5-enopyranoside 145 (11.42 g, 65%) as a colourless oil: Rf 0.18 
(hexane/diethyl ether 75:25); 
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D
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 -8.64 (c 1.32 in CHCl3); "max (thin film) /cm
-1 
3444 (w), 3128 (w), 2943 (s), 2866 (s), 1760 (s), 1709 (w), 1614 (m), 1515 (s), 
1465 (m), 1302 (w), 1251 (s), 1218 (s), 1161 (s), 1096 (s), 1070 (s), 1040 (s), 
990 (s), 930 (m), 883 (m), 822 (m), 737 (m), 681 (m) and 655 (w); 1H NMR 
(400 MHz; CDCl3) " 7.43-7.28 (7H, m, Ar H), 7.08 (1H, d, J 1.5, CHOAc H-6), 
6.92-6.88 (2H, m, H-12,12’ Ar), 4.78 (1H, d, J 12.0, CHAHB H-7), 4.68 (1H, d, J 
3.0, H-1), 4.64 (1H, d, J 10.9, CHA’HB’ H-9), 4.61 (1H, d, J 12.0, CHAHB H-7’), 
4.58 (1H, d, J 10.9, CHA’HB’ H-9’), 4.19 (1H, dd, J 8.0, 7.1, H-3), 3.83 (3H, s, Ar 
OCH3 H-14), 3.76 (1H, dd, J 7.1, 1.5, H-4), 3.46 (1H, dd, J 8.0, 3.0, H-2), 3.41 
(3H, s, CH3 H-16), 2.17 (3H, s, OCH3) and 1.10-1.03 (21 H, m, TIPS); 
13C NMR 
(100 MHz; CDCl3) " 167.4 (C=O C-15), 159.2 (C-13 Ar), 138.4 (C-8 Ph), 135.1 
(C-5), 129.9 (C-10 Ar), 129.4 (CH-11,11’ Ar), 128.3 (CH Ph), 128.1 (CH Ph), 
127.8 (C Ph), 123.1 (CHOAc C-6), 113.7 (CH-12,12’ Ar), 100.0 (CH-1), 80.2 
(CH-2), 78.5 (CH-4), 73.4 (CH-3), 73.3 (CH2 C-7), 72.6 (CH2 C-9), 56.3 (OCH3), 
55.3 (Ar OCH3 C-14), 20.6 (CH3 C-16), 18.2 (CH3 TIPS) and 12.9 (CH TIPS); 
HRMS m/z (ES+) [Found: (M+Na)+ 623.3018.  C33H48O8SiNa requires M
+, 
623.3016]; m/z (ES+) 623 ([M+Na]+, 100%); Anal. Calcd. for C33H48O8Si: C, 
65.97; H, 8.05.  Found: C, 65.88; H, 8.45. 
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6.3.7.  (-)-3-O-Benzyl-2-hydroxy-5-O-(4-methoxybenzyl)-4-O- 
  triisopropylsilyl-6-oxocyclohexyl acetate 147 
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To a solution of (-)-methyl 6-O-acetyl-2-O-benzyl-4-O-(4-methoxybenzyl)-3-O-
triisopropylsilyl-!-D-gluco-hex-5-enopyranoside 145 (11.4 g, 19.0 mmol, 1 eq) in 
acetone (400 mL) and water (260 mL) was added mercuric acetate (30.3 g, 
95.1 mmol, 5 eq) in a single portion.  The cloudy solution immediately turned to 
a thick yellow suspension.  The suspension was stirred for 3 h at RT, after 
which time TLC analysis indicated consumption of the starting material.  The 
suspension was diluted with brine (130 mL), turning the suspension to a slightly 
cloudy colourless solution after 15 min.  The mixture was then stirred for an 
additional 24 h.  The mixture was diluted with water (200 mL) and extracted with 
CHCl3 (400 mL).  The aqueous phase was re-extracted with a further portion of 
CHCl3 (400 mL).  The combined organic layers were washed with brine 
(200 mL), dried over magnesium sulfate, filtered and concentrated in vacuo to 
give a thick colourless oil.  Purification of the oil by silica gel chromatography, 
eluting with hexane and diethyl ether (75:25, 70:30, 60:40, 0:100), yielded a 
colourless solid.  Crystallisation from hexane and diethyl ether yielded (-)-3-O-
benzyl-2-hydroxy-5-O-(4-methoxybenzyl)-4-O-triisopropylsilyl-6-oxocyclohexyl 
acetate 147 (3.85 g, 35%) as colourless needles: Rf 0.51 (hexane/ethyl acetate 
50:50); 
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-28.9 (c 3.02 in CHCl3);  mp 102-103 °C (from hexane/diethyl 
ether); !max (thin film) /cm
-1 3490 (s), 2943 (s), 2866 (s), 1756 (s), 1737 (s), 
1611 (m), 1514 (m), 1467 (m), 1367 (m), 1242 (s), 1145 (s), 1094 (m), 1073 
(m), 1027 (m) and 885 (m); 1H NMR (400 MHz; CDCl3) " 7.41-7.32 (7H, m, Ar 
H), 6.90-6.86 (2H, m, H-14,14’ Ar), 5.28-5.25 (1H, m, H-1), 4.79 (1H, d, J 9.7, 
CHAHB H-11), 4.78 (1H, d, J 11.8, CHA’HB’ H-9), 4.68 (1H, d, J 11.8, CHA’HB’ H-
9), 4.40 (1H, d, J 9.7, CHAHB H-11’), 4.33 (1H, dd, J 4.2, 2.7, H-2), 4.28 (1H, dd, 
J 8.8, 8.6, H-4), 4.00 (1H, dd, J 8.8, 1.0, H-5), 3.83 (3H, s, OCH3 H-16), 3.78 
(1H, dd, J 8.6, 2.7, H-3), 2.45 (1H, s, OH-2), 2.26 (3H, s, CH3 H-8) and 1.14-
1.01 (21 H, m, TIPS); 13C NMR (100 MHz; CDCl3) " 198.3 (C=O C-6), 169.6 
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(C=O C-7), 159.2 (C-15 Ar), 137.4 (C-10 Ph), 130.0, 129.6 (C-12 Ar), 128.6, 
128.1, 127.8 (CH-13,13’ Ar), 113.5 (CH-14,14’ Ar), 83.7 (CH-5), 80.9 (CH-3), 
74.9 (CH-4), 74.9 (CH-1), 72.9 (CH2 C-9), 72.7 (CH2 C-11), 68.6 (CH-2), 55.3 
(OCH3 C-16), 20.6 (CH3 C-8), 18.2 (CH3 TIPS) and 13.0 (CH TIPS); HRMS m/z 
(ES+) [Found: (M+Na)+ 609.2859.  C32H46O8SiNa requires M
+, 609.2860]; m/z 
(ES+) 609 ([M+Na]+, 100%);  Anal. Calcd. for C32H46O8Si: C, 65.50; H, 7.90.  
Found: C, 65.32; H, 8.29. 
 
6.3.8.  (+)-D-1-O-Acetyl-3-O-benzyl-5-O-(4-methoxybenzyl)-4-O- 
  triisopropylsilyl-myo-inositol 148 
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A solution of acetic acid (36.5 mL) and acetonitrile (36.5 mL) was cooled to 
-40 °C and to this solution was added tetra-N-methylammonium 
triacetoxyborohydride (8.6 g, 32.8 mmol, 5 eq).  To the resulting slurry was 
added a solution of (-)-3-O-benzyl-2-hydroxy-5-O-(4-methoxybenzyl)-4-O-
triisopropylsilyl-6-oxocyclohexyl acetate 147 (3.85 g, 6.6 mmol, 1 eq) in 
acetonitrile (23.9 mL) via cannula and the mixture stirred for 10 min at -40 °C.  
The mixture was then allowed to warm to RT and was stirred for a further 18 h, 
by which time a clear solution had formed.  The reaction was quenched by the 
addition of an aqueous saturated solution of Rochelle’s Salt solution (100 mL).  
The resulting emulsion was stirred vigorously for 1 h and then diluted with 
CH2Cl2 (250 mL).  The layers were separated and the aqueous phase was re-
extracted with CH2Cl2 (2 ! 250 mL).  The combined organic phases were 
washed with brine (200 mL), dried over magnesium sulfate, filtered and 
concentrated in vacuo providing a brown oil.  The excess AcOH was then 
removed by azeotropic distillation with cyclohexane (3 ! 100 mL), resulting in a 
brown gum. Purification of the gum by silica gel chromatography, eluting with 
hexane and diethyl ether (50:50, 40:60, 0:100), yielded (+)-D-1-O-acetyl-3-O-
benzyl-5-O-(4-methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 148 (3.42 g, 
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89%) as a colourless oil: Rf 0.39 (hexane/ethyl acetate 50:50); 
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 +17.1 (c 
1.00 in CHCl3); !max (thin film) /cm
-1 3449 (m), 3012 (m), 2945 (m), 2867 (w), 
1735 (m), 1612 (w), 1514 (m), 1215 (s), 768 (s); 1H NMR (400 MHz; CDCl3) ! 
7.39-7.26 (7H, m, Ar CH), 6.90-6.89 (2H, m, H-14,14’ Ar), 4.87 (1H, d, J 11.4, 
CHAHB H-11), 4.75 (1H, dd, J 9.8, 2.2, H-1), 4.70 (1H, d, J 11.4, CHAHB H-11’), 
4.61-4.55 (2H, m, CH2 H-9,9’), 4.31-4.28 (1H, m, H-2), 4.15 (1H, dd, J 8.9, 8.8, 
H-4), 4.05 (1H, ddd, J 9.8, 9.3, 3.1, H-6), 3.80 (3H, s, Ar OCH3 H-16), 3.41 (1H, 
dd, J 8.9, 2.8, H-3), 3.26 (1H, dd, J 9.3, 8.8, H-5), 2.28 (1H, s, OH-2), 2.14 (3H, 
s, COCH3 H-8), 1.64 (1H, d, J 3.1, OH-6) and 1.16-1.03 (21H, m, TIPS); 
13C 
NMR (100 MHz; CDCl3) ! 170.9 (C=O C-7), 159.2 (C-15 Ar), 137.6, 131.0, 
129.2 (CH-13,13’ Ar), 128.5 (CH Ph), 128.0 (CH Ph), 127.6 (CH Ph), 114.0 
(CH-14,14’ Ar), 84.2 (CH-5), 81.4 (CH-3), 74.9 (CH2 C-9), 73.5 (CH-4), 73.2 
(CH-1), 71.7 (CH2 C-11), 70.3 (CH-6), 66.5 (CH-2), 55.3 (OCH3 C-16), 21.1 
(CH3 C-8), 18.2 (CH3 TIPS) and 13.5 (CH TIPS); HRMS m/z (ES
+) [Found: 
(M+Na)+ 611.3012. C32H48O8SiNa requires M
+, 611.3016]; m/z (ES+) 611 
([M+Na]+, 100%); Anal. Calcd. for C32H48O8Si: C, 65.28; H, 8.22. Found: C, 
64.99; H, 8.17. 
 
6.3.9.  (-)-D-1-O-Acetyl-3-O-benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-
  methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 162 
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A mixture of benzyloxymethyl chloride (7.3 g, 6.5 mL, 46.5 mmol, 8 eq) and 
Hünig’s base (20 mL) was stirred for 1 h at RT, forming a light brown 
precipitate.  The precipitate was allowed to settle, then the solution was 
carefully decanted from the mixture via cannula into a solution of (+)-D-1-O-
acetyl-3-O-benzyl-5-O-(4-methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 148 
(3.42 g, 5.8 mmol, 1 eq) in Hünig’s base (40 mL).  The resulting solution was 
heated to 85 °C for 15 h, then allowed to cool to RT.  TLC analysis of the 
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mixture indicated consumption of the starting material.  The volatile components 
were removed in vacuo and the resulting brown residue was partitioned 
between water (250 mL) and ethyl acetate (250 mL).  The layers were 
separated and the aqueous phase re-extracted with ethyl acetate (2 ! 250 mL).  
The combined organic layers were washed with brine (250 mL) dried over 
magnesium sulfate, filtered and concentrated in vacuo affording a brown oil.  
Purification of the oil by silica gel chromatography, eluting with hexane and 
diethyl ether (100:0, 98:2, 96:4, 94:6, 92:8, 80:20), furnished (-)-D-1-O-acetyl-3-
O-benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-methoxybenzyl)-4-O-
triisopropylsilyl-myo-inositol 162 (3.94 g, 82%) as a colourless gum, which 
solidified on standing to waxy solid: Rf 0.46 (hexane/diethyl ether 50:50); 
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-40.7 (c 0.75 in CHCl3); "max (KBr disc) /cm
-1 3415 (m), 2944 (s), 2866 (s), 
1741 (s) 1615 (m), 1514 (s), 1458 (m), 1366 (m), 1247 (s), 1119 (s), 1039 (s), 
739 (s) and 699 (m); 1H NMR (400 MHz; CDCl3) ! 7.25-7.15 (17H, m, Ar H), 
6.77-6.73 (2H, m, H-17,17’ Ar), 4.87 (1H, d, J 6.7, OCHAHBO H-20), 4.81-4.65 
(8H, m, H-1 and 7 ! CHAHB protons), 4.59 (1H, d, J 12.3, CHA’HB’ H-21), 4.50 
(1H, d, J 12.3, CHA’’HB’’ H-10), 4.39 (1H, d, J 12.3, CHA’HB’ H-21’), 4.38 (1H, d, J 
11.1, CHA’’’HB’’’ H-12), 4.31 (1H, dd, J 2.1, 2.1, H-2), 4.23 (1H, dd, J 9.3, 9.0, H-
4), 4.14 (1H, dd, J 9.3, 9.2, H-6), 3.71 (3H, s, Ar OCH3 H-19), 3.29 (1H, dd, J 
9.2, 9.0, H-5), 3.27 (1H, dd, J 9.3, 2.1, H-3), 1.72 (3H, s, CH3 H-8) and 0.96-
0.90 (21H, m, TIPS); 13C NMR (100 MHz; CDCl3) # 170.7 (C=O C-7), 158.7 (C-
18 Ar), 138.0 (C-22 Ph), 137.8 (C-11 Ph), 137.6 (C-13 Ph), 131.2 (C-15 Ar), 
128.4, 128.3 (CH-16,16’ Ar), 128.3, 128.2, 127.6, 127.5, 127.5, 127.4, 127.4, 
113.5 (CH-16,16’ Ar), 96.2 (OCH2O C-20), 95.0 (OCH2O C-9), 84.7 (CH-5), 
81.0 (CH-3), 77.2 (CH-6), 75.1 (CH2 C-14), 73.8 (CH-4), 72.9 (CH-1), 72.0 (CH-
2), 71.9 (CH2 C-12), 69.7 (CH2 C-21), 69.2 (CH2 C-10), 55.3 (Ar OCH3 C-19), 
21.0 (CH3 C-8), 18.2 (CH3 TIPS) and 13.5 (CH TIPS); HRMS m/z (ES
+) [Found: 
(M+Na)+ 851.4155. C48H64O10SiNa requires M
+, 851.4166]; m/z (ES+) 851 
([M+Na]+, 100%); Anal. Calcd. for C48H64O10Si: C, 69.53; H, 7.78 Found: C, 
69.41; H, 7.91. 
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6.3.10. (-)-D-3-O-Benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-  
  methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 163 
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In an open flask, (-)-D-1-O-acetyl-3-O-benzyl-2,6-bis-O-benzyloxymethyl-5-O-
(4-methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 162 (3.48 g, 4.2 mmol, 
1.0 eq) was dissolved in methanol (90 mL) and tetrahydrofuran (30 mL).  To this 
solution was added lithium hydroxide (422 mg, 17.6 mmol, 4.2 eq) in a single 
portion.  The mixture was stirred vigorously at RT for 15 min, after which time 
TLC analysis indicated consumption of the starting material.  The reaction was 
quenched by the addition of saturated aqueous ammonium chloride solution 
(20 mL) and the volatile components were removed in vacuo.  The resulting 
residue was partitioned between water (150 mL) and CH2Cl2 (150 mL).  The 
layers were separated and the aqueous layer was re-extracted with CH2Cl2 (3 ! 
100 mL).  The combined organic phases were washed with brine (100 mL), 
dried over magnesium sulfate, filtered and concentrated in vacuo, furnishing a 
colourless oil.  Purification of the oil by silica gel chromatography, eluting with 
hexane and diethyl ether (70:30), afforded (-)-D-3-O-benzyl-2,6-bis-O-
benzyloxymethyl-5-O-(4-methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 163 
(3.19 g, 97%) as a colourless oil, which solidified on standing to give a waxy 
solid: Rf 0.37 (hexane/diethyl ether 50:50); 
  
! 
"[ ]
D
20
 -17.9 (c 1.47 in CHCl3); "max 
(thin film) /cm-1 3449 (m), 2942 (s), 2863 (s), 1617 (w), 1514 (s), 1464 (s), 1382 
(w), 1245 (s), 1164 (s), 1133 (s), 1069 (s), 1030 (s), 885 (w), 824 (m), 749 (m) 
and 699 (m); 1H NMR (500 MHz; CDCl3) ! 7.32-7.25 (15H, m, Ar H), 7.24-7.22 
(2H, m, H-14,14’ Ar), 6.86-6.83 (2H, m, H-15,15’ Ar), 4.92 (1H, d, J 6.8, 
OCHAHBO H-7), 4.83 (1H, d, J 6.6, OCHA’HB’O H-18), 4.79 (1H, d, J 6.6, 
OCHA’HB’O H-18’), 4.78 (1H, d, J 10.9, OCHA’’HB’’ H-12), 4.77 (1H, d, J 6.8, 
OCHAHBO H-7’), 4.74 (1H, d, J 10.9, OCHA’’HB’’ H-12’), 4.73 (1H, d, J 11.9, 
CHA’’’HB’’’ H-19), 4.72 (1H, d, J 12.0, CHA’’’’HB’’’’ H-8), 4.70 (1H, d, J 11.5, 
CHA’’’’’HB’’’’’ H-10), 4.58 (1H, d, J 12.0, CHA’’’’HB’’’’ H-8’), 4.53 (1H, d, J 11.9, 
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CHA’’’HB’’’ H-19’), 4.49 (1H, d, J 11.5, CHA’’’’’HB’’’’’ H-10’), 4.27 (1H, dd, J 8.9, 8.6, 
H-4), 4.36 (1H, dd, J 2.5, 2.3, H-2), 3.88 (1H, d, J 4.8, OH-1, ex. in D2O), 3.86 
(1H, dd, J 9.1, 8.9, H-6), 3.80 (3H, s, OCH3 H-17), 3.53 (1H, ddd, J 9.1, 4.8, 2.5, 
H-1), 3.33 (1H, dd, J 8.9, 8.6, H-5), 3.31 (1H, dd, J 8.9, 2.3, H-3) and 1.09-0.99 
(21H, m, TIPS); 13C NMR (100 MHz; CDCl3) ! 158.8 (C-16 Ar), 137.9 (C-11 
Ph), 137.8 (C-9 Ph), 137.3 (C-20 Ph), 131.4 (C-13 Ar), 128.6, 128.5 (CH-14,14’ 
Ar), 128.3, 128.1, 128.0, 127.8, 127.6, 127.6, 127.5, 113.5 (CH-15,15’ Ar), 96.5 
(OCH2O C-18), 95.5 (OCH2O C-7), 83.8 (CH-6), 83.7 (CH-5), 80.9 (CH-3), 74.8 
(OCH2 C-12), 74.7 (CH-2), 73.7 (CH-4), 71.9 (CH2 C-10), 71.2 (CH-1), 70.1 
(CH2 C-19), 69.5 (CH2 C-8), 55.3 (OCH3 C-17), 18.3 (CH3 TIPS) and 13.4 (CH 
TIPS);  HRMS m/z (ES+) [Found: (M+Na)+ 809.4079.  C46H62O9SiNa requires 
M+, 809.4061]; m/z (ES+) 809 ([M+Na]+, 100%); Anal. Calcd. For C46H62O9Si: C, 
70.20; H, 7.94. Found: C, 70.21; H, 7.74. 
 
6.3.11. (+)-D-3-O-Benzyl-2,6-bis-O-benzyloxymethyl-4-O-triisopropylsilyl-
  myo-inositol 164 
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To a solution of (-)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-
methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 163 (1.23 g, 1.6 mmol, 1.0 eq) 
in CH2Cl2 (60.0 mL) and water (3.3 mL) was added 2,3-dichloro-5,6-
dicyanobenzoquinone (780 mg, 3.4 mmol, 2.2 eq) in a single portion, turning 
the mixture dark green.  After 10 min stirring at RT, the colour changed to 
orange/yellow and TLC analysis indicated consumption of the starting material.  
The solution was diluted with aqueous saturated sodium hydrogen carbonate 
solution (40 mL) and CH2Cl2 (80 mL), forming a dark biphasic mixture.  The 
biphasic mixture was filtered through a pad of Celite and the layers were 
subsequently separated.  The aqueous phase was re-extracted with CH2Cl2 
(3 ! 80 mL).  The combined organic phases were washed with aqueous 
saturated sodium hydrogen carbonate solution (100 mL) and brine (100 mL), 
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dried over magnesium sulfate, filtered and concentrated in vacuo affording a 
pale brown oil.  Purification of the oil by silica gel chromatography, eluting with 
hexane and diethyl ether (60:40), furnished (+)-D-3-O-benzyl-2,6-bis-O-
benzyloxymethyl-4-O-triisopropylsilyl-myo-inositol 164 (993 mg, 95%) as a 
colourless oil: Rf 0.21 (hexane/diethyl ether 50:50); 
  
! 
"[ ]
D
20
 +3.60 (c 2.45 in 
CHCl3); !max (thin film) /cm
-1 3439 (s), 3065 (m), 3032 (m), 2493 (s), 2866 (s), 
1719 (m), 1497 (m), 1455 (s), 1368 (s), 1273 (m), 1025 (s), 884 (s), 826 (s), 737 
(s) and 698 (s); 1H NMR (400 MHz; CDCl3) ! 7.30-7.17 (15H, m, Ar H), 4.89 
(1H, d, J 10.4, OCHAHBO H-12), 4.87 (1H, d, J 10.4, OCHAHBO H-12’), 4.85 
(1H, d, J 6.6, OCHA’HB’O H-7), 4.68 (1H, d, J 6.6, OCHA’HB’O H-7’), 4.65 (1H, d, 
J 11.9, OCHA’’HB’’ H-8), 4.62 (2H, s, OCH2Ph H-13,13’), 4.59 (1H, d, J 11.6, 
CHA’’’HB’’’ H-10), 4.51 (1H, d, J 11.9, OCHA’’HB’’ H-8’), 4.49 (1H, d, J 11.6, 
CHA’’’HB’’’ H-10’), 4.10 (1H, dd, J 2.3, 2.3, H-2), 4.06 (1H, dd, J 9.3, 8.9, H-4), 
3.60 (1H, dd, J 9.2, 9.0, H-6), 3.47 (1H, d, J 5.6, OH-1), 3.44-3.38 (1H, m, H-1), 
3.32 (1H, ddd, J 9.0, 8.9, 2.0, H-5), 3.19 (1H, dd, J 9.3, 2.3, H-3), 3.01 (1H, d, J 
2.0, OH-5) and 1.11-0.95 (21H, m, TIPS); 13C NMR (100 MHz; CDCl3) ! 138.0 
(C-14 Ph), 137.6 (C-9 Ph), 137.0 (C-11 Ph), 128.5, 128.4, 128.2, 128.1, 128.0, 
127.9, 127.7, 127.6, 127.6, 96.5 (OCH2O C-12), 95.9 (OCH2O C-7), 84.1 (CH-
6), 80.3 (CH-3), 76.3 (CH-2), 75.5 (CH-5), 74.3 (CH-4), 72.2 (CH2 C-10), 70.9 
(CH-1), 70.4 (CH2 C-13), 69.8 (CH2 C-8), 18.3 (CH3 TIPS) and 13.0 (CH TIPS); 
HRMS m/z (ES+) [Found: (M+Na)+ 689.3475.  C38H54O8SiNa requires M
+, 
689.3486]; m/z (ES+) 689 ([M+Na]+, 100%); Anal. Calcd. For C38H54O8Si: C, 
68.44; H, 8.16. Found: C, 68.02; H, 8.30. 
 
6.3.12. (+)-D-3-O-Benzyl-2,6-bis-O-benzyloxymethyl-myo-inositol 165 
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To a solution of (+)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-4-O-
triisopropylsilyl-myo-inositol 164 (947 mg, 1.4 mmol, 1 eq) in CH2Cl2 (30 mL) 
was added a solution of tetrabutylammonium fluoride in tetrahydrofuran (1.0 M, 
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14.2 mL, 10 eq).  The solution was stirred at RT for 24 h, after which time TLC 
analysis indicated consumption of the starting material.  The reaction was 
quenched by the addition of saturated aqueous sodium hydrogen carbonate 
solution (50 mL) and the layers were separated.  The aqueous phase was re-
extracted with CH2Cl2 (4 ! 50 mL).  The combined organic phases were washed 
with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in 
vacuo, providing a brown oil.  Purification of this oil by silica gel 
chromatography, eluting with hexane and ethyl acetate (40:60), provided (+)-D-
3-O-benzyl-2,6-bis-O-benzyloxymethyl-myo-inositol 165 (655 mg, 90%) as a 
colourless solid: Rf 0.26 (hexane/ethyl acetate 65:35); 
  
! 
"[ ]
D
20
 +27.3 (c 0.11 in 
CHCl3) [lit.
84 
  
! 
"[ ]
D
24
 +26.8 (c 0.45 in CHCl3)]; mp 113-114 °C (from ethyl acetate) 
[lit.84 112 °C]; "max (thin film) /cm
-1 3438 (s), 2899 (m), 1498 (w), 1454 (m), 1378 
(m), 1171 (s), 1129 (s), 1105 (s), 1065 (s), 1020 (s), 942 (m), 737 (s) and 698 
(s); 1H NMR (500 MHz; CDCl3) ! 7.37-7.28 (15H, m, Ar H), 5.00 (1H, d, J 6.8, 
OCHAHBO H-7), 4.98 (1H, d, J 7.0, OCHA’HB’O H-12), 4.92 (1H, d, J 7.0, 
OCHA’HB’O H-12’), 4.82 (1H, d, J 6.8, OCHAHBO H-7’), 4.74 (1H, d, J 11.7, 
CHA’’HB’’ H-13), 4.73 (1H, d, J 12.0, CHA’’’HB’’’ H-8), 4.72 (1H, d, J 11.9, 
CHA’’’’HB’’’’ H-10), 4.69 (1H, d, J 11.7, CHA’’HB’’ H-13), 4.64 (1H, d, J 12.0, 
CHA’’’HB’’’Ph H-8’), 4.62 (1H, d, J 11.9, CHA’’’’HB’’’’ H-10’), 4.25 (1H, dd, J 2.4, 2.3, 
H-2), 3.99 (1H, dd, J 9.7, 9.3, H-4), 3.65 (1H, dd, J 9.2, 9.1, H-6), 3.66-3.62 (1H, 
m, OH-5), 3.54 (1H, d, J 5.6, OH-1), 3.51-3.48 (1H, m, H-1), 3.43 (1H, dd, J 9.3, 
9.1, H-5), 3.32 (1H, dd, J 9.7, 2.4, H-3) and 2.71 (1H, br s, OH-4); 13C NMR 
(100 MHz; CDCl3) ! 137.6 (C-9 Ph), 137.5 (C-11 Ph), 136.8 (C-14 Ph), 128.6, 
128.6, 128.5, 128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 96.6 (OCH2O C-12), 
96.0 (OCH2O C-7), 84.6 (CH-6), 78.9 (CH-3), 76.0 (CH-2), 74.0 (CH-5), 72.4 
(CH-4), 72.2 (CH2 C-10), 71.0 (CH-1), 70.5 (CH2 C-13) and 70.0 (CH2 C-8); 
HRMS m/z (ES+) [Found: (M+Na)+ 533.2159. C29H34O8SiNa requires M
+, 
533.2151]; m/z (ES+) 533 ([M+Na]+, 100%). The data are in good agreement 
with the literature values.84 
 
Experimental Section 
163 
6.3.13. (-)-D-3-O-Benzyl-2,6-bis-O-benzyloxymethyl-myo-inositol 1,4,5-
  tris(dibenzyl phosphate) 169 
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To a solution of bis(benzyloxy)-N,N-bisisopropylamine phosphine (2.30 g, 
6.7 mmol, 6 eq) in CH2Cl2 (100 mL) was added a solution of 1H-tetrazole in 
acetonitrile (0.43 M, 15.5 mL, 6.7 mmol, 6 eq).  The mixture was stirred at RT 
for 20 min, before a solution of (+)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-
myo-inositol 165 (566 mg, 0.04 mmol, 1 eq) in CH2Cl2 (50 mL) was added 
dropwise via a pressure equalised dropping funnel over a period of 1 h.  The 
resulting solution was stirred overnight at RT, after which time TLC analysis 
indicated the consumption of the starting material.  The solution was cooled to 
-78 °C and 3-chloroperoxybenzoic acid (1.49 g, 6.65 mmol, 6 eq) was added in 
a single portion.  The mixture was allowed to warm to RT and stirred for a 
further 3 h, after which TLC indicated consumption of the intermediate.  The 
reaction was quenched by the addition of aqueous sodium sulfite solution (10% 
w/v, 100 mL).  The layers were separated and the aqueous phase was re-
extracted with CH2Cl2 (3 ! 100 mL).  The combined organic layers were washed 
with brine (100 mL), dried over magnesium sulfate, filtered and concentrated in 
vacuo, providing a light brown oil.  Purification of the oil by silica gel 
chromatography, eluting with hexane and ethyl acetate (50:50), provided (-)-D-
3-O-benzyl-2,6-bis-O-benzyloxymethyl-myo-inositol 1,4,5-tris(dibenzyl 
phosphate) 169 (1.32 g, 93%) as a colourless oil: Rf 0.13 (hexane/ethyl acetate 
50:50); 
  
! 
"[ ]
D
20
 -18.1 (c 1.00 in CHCl3) [lit.
84 
  
! 
"[ ]
D
24
 -17.6 (c 0.85 in CHCl3)]; "max 
(thin film)/ cm-1 3065 (w), 3032 (w), 2894 (w), 2359 (m), 1498 (m), 1455 (w), 
1378 (m), 1283 (s), 1215 (m), 1122 (m), 1036 (s), 1024 (s), 880 (m), 733 (s) and 
696 (s); 1H NMR (500 MHz; CDCl3) ! 7.31-7.15 (43H, m, Ar H), 7.11-7.08 (2H, 
m, Ar H), 5.13-4.94 (11H, m, 5 ! CH2Ph and H-4), 4.91 (1H, d, J 6.9, CHAHB H-
7), 4.88 (1H, d, J 6.9, CHA’HB’ H-12), 4.86 (1H, d, J 8.3, CHAHBPh), 4.85 (1H, d, 
J 6.9, CHAHB H-7’), 4.83 (1H, d, J 8.3, CHAHBPh), 4.81 (1H, d, J 6.9, CHA’HB’ H-
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12’), 4.71 (1H, d, J 12.2, CHA’’HB’’ H-13), 4.64 (2H, s, CH2 H-8,8’), 4.53 (1H, d, J 
12.2, CHAHB H-13’), 4.51 (1H, dd, J 2.1, 2.1, H-2), 4.49 (2H, s, CH2, H-10,10’), 
4.42 (1H, ddd, J 9.6, 9.5, 9.4, H-5), 4.30 (1H, dd, J 9.8, 9.6, H-6), 4.14 (1H, ddd, 
J 9.8, 8.3, 2.1, H-1) and 3.37 (1H, dd, J 9.9, 2.1); 13C NMR (125 MHz; CDCl3) ! 
138.1 (C-14 Ph), 137.8 (C-9 Ph), 137.0 (C-11 Ph), 136.18, 136.1, 136.0, 135.8, 
135.63, 135.6, 128.6, 128.4, 128.36, 128.32, 128.3, 128.28, 128.23, 128.2, 
128.1, 128.0, 127.97, 127.95, 127.9, 127.8, 127.77, 127.7, 127.68, 127.6, 
127.4, 127.3, 96.6 (OCH2O C-12), 95.5 (OCH2O C-7), 79.0 (m, CH-5), 77.5 (m, 
CH-4), 76.8 (CH-3), 76.4 (d, J 5.5, CH-1), 74.9 (d, J 5.9, CH-6), 72.6 (CH-2), 
72.0 (CH2 C-10), 70.3 (CH2 C-13), 69.7 (CH2 C-8), 69.65 (d, J 6.2, CH2), 69.6 
(d, J 5.3, CH2), 69.4 (d, J 5.5, CH2), 69.39 (d, J 5.0, CH2), 69.36 (d, J 6.1, CH2), 
and 69.1 (d, J 5.2, CH2); 
31P NMR (202 MHz; CDCl3) ! -0.97, -1.08 and -1.51; 
isotope distribution m/z (ES+) [Found: 1313.3637 (100), 1314.3665 (79), 
1315.3696 (32), 1316.3725 (8), 1317.3748 (2). C71H73O17P3Na requires M
+, 
1313.3953 (100), 1314.3986 (78), 1315.4020 (34), 1316.4053 (10), 1317.4087 
(3)]; m/z (ES+) 1313 ([M+Na]+, 100%). The data are in good agreement with the 
literature values.84 
 
6.3.14. (-)-D-myo-Inositol 1,4,5-trisphosphate hexakis sodium salt 1 
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To a solution of (-)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-myo-inositol 1,4,5-
tris(dibenzyl phosphate) 169 (120 mg, 93 µmol, 1 eq) in a mixture t-butanol 
(6 mL) and water (1 mL) were added palladium black (198 mg, 1.86 mmol, 
20 eq) and sodium hydrogen carbonate (47 mg, 558 µmol, 6 eq).  The mixture 
was placed under vacuum and the atmosphere was replaced first with nitrogen 
gas and then with hydrogen gas.  The suspension was then vigorously stirred 
under an atmosphere of hydrogen for 16 h.  The mixture was filtered through a 
pad of Celite and the residue was washed with diethyl ether (2 ! 5 mL); the 
organic filtrates were discarded.  The palladium residue was washed with water 
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(6 ! 10 mL), and the combined aqueous filtrates were lypholised, providing (-)-
D-myo-inositol 1,4,5-trisphosphate hexakis sodium salt 1 (40.5 mg, 95%) as a 
colourless solid: 
  
! 
"[ ]
D
25
 -19.2 (c 0.25 in H2O, pH ~9) [lit.
183   
! 
"[ ]
D
24
 -20 (c 0.05 in 
H2O, pH 9)]; 
1H NMR (500 MHz; D2O) ! 4.28-4.22 (1H, m, H-2), 4.10-4.02 (1H, 
m, H-4), 3.85-3.73 (3H, m, H-1, H-5 and H-6) and 3.59 (1H, dd, J 9.8, 2.7, H-3); 
13C NMR (125 MHz; D2O) ! 77.0 (m, CH-5), 74.9 (m, CH-4), 74.4 (d, J 5.3, CH-
6), 72.3 (d, J 7.3, CH-1), 71.6 (CH-3) and 70. 5 (CH-2); 31P NMR (202 MHz; 
D2O) ! 4.89, 4.79 and 3.13; HRMS m/z (ES
+) [Found: (M-Na+2H)+ 530.8791. 
C6H11O15P3Na5 requires M
+, 530.8794]; m/z (ES-) 485 ([M-3Na+2H]-, 12%), 463 
(40), 441 (63), 419 (52) and 339 (73).  The data are in agreement with the 
literature values.84  It should be noted that there is a large variation in the 
  
! 
"[ ]
D
T
 
values quoted for InsP3 (-3.2 to -30) in the literature. 
  
! 
"[ ]
D
26
 -3.2 (c 0.26 in H2O)
84 
  
! 
"[ ]
D
24
 -20 (c 0.05 in H2O, pH 9)
183 
  
! 
"[ ]
D
24
 -24 (c 0.5 in H2O, pH 9.3)
184 
  
! 
"[ ]
D
25
 -27 (H2O, pH 9)
185 
  
! 
"[ ]
D
24
 -30 (c 0.80 in H2O, pH 8.5)
186 
  
! 
"[ ]
D
25
 -30 (c 1.0 in H2O, pH 10)
187 
  
! 
"[ ]
D
25
 -30 (c 0.5 in H2O, pH 9.5)
188 
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6.3.15. (-)-D-3-O-Benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-  
  methoxybenzyl)-myo-inositol 176 
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To a solution of (-)-D-1-O-acetyl-3-O-benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-
methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 163 (234 mg, 0.3 mmol, 1 eq) 
in THF (5 mL) was added a solution of tetrabutylammonium fluoride in THF 
(1.0 M, 6.0 mL, 6.0 mmol, 20 eq).  The solution was stirred at RT for 18 h, after 
which time TLC analysis showed consumption of the starting material.  The 
reaction solution was diluted with water (20 mL), then extracted with diethyl 
ether (30 mL).  The aqueous phase was re-extracted with CH2Cl2 (2 ! 30 mL). 
The combined organic phases were washed with brine (20 mL), dried over 
magnesium sulfate, filtered and concentrated in vacuo, providing a colourless 
solid.  Purification of this solid by silica gel chromatography, eluting with hexane 
and ethyl acetate (70:30, 50:50), provided (-)-D-3-O-benzyl-2,6-bis-O-
benzyloxymethyl-5-O-(4-methoxybenzyl)-myo-inositol 176 (167 mg, 89%) as a 
colourless solid: Rf 0.13 (hexane/ethyl acetate 70:30); 
  
! 
"[ ]
D
20
 -16.9 (c 0.54 in 
CHCl3);  mp 105-106 °C (from hexane/ethyl acetate); "max (KBr disc) /cm
-1 
3465 (s), 2892 (w), 1611 (m), 1514 (s), 1498 (m), 1454 (m), 1370 (m), 1251 (s), 
1175 (s), 1065 (s), 1029 (s), 818 (w), 735 (s), 700 (m) and 586 (w); 1H NMR 
(400 MHz; CDCl3) ! 7.37-7.27 (17H, m, Ar H), 6.92-6.88 (2H, m, H-15,15’ Ar), 
5.00 (1H, d, J 6.8, OCHAHBO H-7), 5.00 (1H, d, J 6.7, OCHA’HB’O H-18), 4.93 
(1H, d, J 6.7, OCHA’HB’O H-18’), 4.87-4.59 (9H, m, 4.5 ! CHAHB), 4.30 (1H, dd, 
J 2.4, 2.3, H-2), 4.11 (1H, ddd, J 9.7, 9.3, 1.9, H-4), 3.86 (1H, dd, J 9.6, 9.3, H-
6), 3.83 (3H, s, OCH3 H-17), 3.80 (1H, d, J 4.8, OH-1, ex. in D2O), 3.51 (1H, 
ddd, J 9.6, 4.8, 2.4, H-1), 3.38 (1H, dd, J 9.3, 9.3, H-5), 3.32 (1H, dd, J 9.7, 2.3, 
H-3) and 2.55 (1H, d, J 1.9 OH-4, ex. in D2O); 
13C NMR (100 MHz; CDCl3) ! 
159.2 (C-16 Ar), 137.7 (C-11 Ph), 137.6 (C-9 Ph), 137.3 (C-20 Ph), 130.9 (C-13 
Ph), 129.5 (CH-14,14’ Ar), 128.6, 128.5, 128.4, 128.0, 127.96, 127.9, 127.7, 
113.9 (CH-15,15’ Ar), 96.7 (OCH2O C-18), 95.7 (OCH2O C-7), 82.9 (CH-6), 
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82.4 (CH-5), 79.2 (CH-3), 75.2 (CH-2), 75.0 (CH2 C-12), 73.0 (CH-4), 72.1 (CH2 
C-10), 71.5 (CH-1), 70.2 (CH2 C-19), 69.7 (CH2 C-8) and 55.3 (OCH3 C-17); 
HRMS m/z (ES+) [Found: (M+Na)+ 653.2723.  C37H42O9Na requires M
+, 
653.2727]; m/z (ES+) 653 ([M+Na]+, 100%); Anal. Calcd. for C37H42O9: C, 70.46; 
H, 6.71. Found: C, 70.58; H, 6.62. 
 
6.3.16. (-)-D-3-O-Benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-  
  methoxybenzyl)-myo-inositol 1,4-bis(dibenzyl phosphate) 177 
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To a solution of bis(benzyloxy)-N,N-bisisopropylamine phosphine (455 mg, 
1.32 mmol, 5 eq) in CH2Cl2 (10 mL) was added a solution of 1H-tetrazole in 
acetonitrile (0.43 M, 3.10 mL, 1.32 mmol, 5 eq).  The solution was stirred for 
15 min, turning opaque.  To this solution was added a solution of (-)-D-3-O-
benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-methoxybenzyl)-myo-inositol 176 
(166 mg, 0.26 mmol, 1 eq) in CH2Cl2 (10 mL) dropwise via a pressure equalised 
dropping funnel over 1 h.  The resulting solution was stirred for 18 h at RT, after 
which time TLC indicated consumption of the starting material.  The mixture 
was cooled to -78 ˚C and 3-chloroperoxybenzoic acid (228 mg, 1.32 mmol, 
5 eq) was added in a single portion.  The mixture was stirred at -78 ˚C for 
15 min, then allowed to warm to RT over 90 min, after which TLC indicated 
consumption of the intermediate.  The solution was diluted with aqueous 
sodium sulfite solution (10% w/v, 20 mL) and CH2Cl2 (20 mL) and the layers 
were separated.  The aqueous phase was re-extracted with CH2Cl2 (3 ! 20 mL).  
The combined organic layers were washed with saturated aqueous sodium 
bicarbonate solution (20 mL) and brine (20 mL), dried over magnesium sulfate, 
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filtered and concentrated in vacuo, providing a colourless oil.  Purification of this 
oil by silica gel chromatography, eluting with hexane and ethyl acetate (80:20, 
70:30, 60:40, 50:50), provided (-)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-5-O-
(4-methoxybenzyl)-myo-inositol 1,4-bis(dibenzyl phosphate) 177 (263 mg, 89%) 
as a colourless solid: Rf 0.24 (hexane/ethyl acetate 60:40); 
  
! 
"[ ]
D
20
 -8.2 (c 0.67 in 
CHCl3); mp 59-61 ˚C (from diethyl ether); !max (KBr disc) /cm
-1 3063 (w), 3034 
(w), 2959 (w), 2892 (w), 1612 (w), 1513 (s), 1498 (m), 1455 (m), 1372 (m), 1259 
(s), 1163 (m), 1116 (m), 1025 (s), 824 (w), 735 (s), 696 (s) and 513 (m); 1H 
NMR (500 MHz; CDCl3) ! 7.32-7.16 (33H, m, Ar H), 7.13-7.06 (4H, m, Ar H), 
6.76-6.73 (2H, m, H-19,19’), 5.02 (2H, dd, J 7.8, 3.1, CH2Ph), 4.99-4.96 (3H, m, 
1.5 " CHAHBPh), 4.95-4.78 (9H, m, 4.5 " CHAHBPh), 4.70 (1H, d, J 10.3, CHAHB 
H-16’), 4.66 (1H, d, J 12.1, CHA’HB’ H-23), 4.61 (2H, s, CH2 H-10,10’), 4.55 (1H, 
d, J 11.5, CHA’’HB’’ H-12), 4.53 (1H, d, J 12.1, CHA’HB’ H-23’), 4.48-4.46 (1H, m, 
H-2), 4.47 (1H, d, J 11.5, CHA’’HB’’ H-12’), 4.24 (1H, dd, J 9.9, 9.3, H-6), 4.18 
(1H, ddd, J 9.9, 8.1, 2.1, H-1), 3.75 (3H, s, OCH3 H-21), 3.46 (1H, dd, J 9.3, 9.1, 
H-5) and 3.36 (1H, dd, J 9.9, 2.1, H-3); 13C NMR (100 MHz; CDCl3) ! 159.0 (C-
20 Ar), 138.0 (C-24 Ph), 137.8 (C-11 Ph), 137.2 (C-13 Ph), 136.2 (d, J 8.3), 
136.1 (d, J 8.3), 135.7 (d, J 7.2), 130.3 (C-17 Ar), 129.2 (CH-18,18’ Ar), 128.6, 
128.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.9, 127.7, 127.5, 127.4, 113.6 
(CH-19,19’ Ar), 96.2 (OCH2O C-22), 95.3 (OCH2O C-9), 81.2 (CH-5), 79.5 (d, J 
7.0, CH-4), 77.6 (CH-3), 77.2 (d, J 5.5, CH-1), 76.0 (d, J 6.5, CH-6), 74.7 (CH2 
C-16), 72.8 (CH-2), 72.0 (CH2 C-12), 70.2 (CH2 C-23), 69.7 (CH2 C-10), 69.6 (d, 
J 5.3, CH2Ph), 69.4 (d, J 5.2, CH2Ph), 69.2 (d, J 5.3, CH2Ph), 69.1 (d, J 5.2, 
CH2Ph), and 55.2 (OCH3 C-21); 
31P NMR (162 MHz; CDCl3) ! -0.86 (P-1) and -
1.41 (P-4); isotope distribution m/z (ES+) [Found: (M+Na)+ 1173.3645 (100), 
1174.3678 (72), 1175.3709 (27), 1176.3727 (6.4), 1177.3731 (1). 
C65H68O15P2Na requires M
+, 1173.3926 (100), 1174.3959 (72), 1175.3992 (28), 
1176.4026 (8), 1177.4060 (2)]; m/z (ES+) 1173 ([M+Na]+, 100%); Anal. Calcd. 
For C65H68O15P2: C, 67.82; H, 5.95. Found: C, 67.51; H, 5.89. 
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6.3.17. (+)-D-3-O-Benzyl-2,6-bis-O-benzyloxymethyl-myo-inositol 1,4-
  bis(dibenzyl phosphate) 178 
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To a solution of (-)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-5-O-(4-
methoxybenzyl)-myo-inositol 1,4-bis(dibenzyl phosphate) 177 (262 mg, 
0.2 mmol, 1 eq) in a mixture of acetonitrile (12 mL) and water (3 mL) was added 
ceric ammonium nitrate (437 mg, 0.8 mmol, 3.5 eq) in a single portion, turning 
the solution orange.  The mixture was stirred for 40 min, after which time TLC 
showed consumption of the starting material.  The volatile components were 
removed in vacuo and the resulting residue was reconstituted with water 
(20 mL) and ethyl acetate (20 mL).  The layers were separated and the 
aqueous phase was re-extracted with ethyl acetate (3 ! 20 mL).  The combined 
organic layers were washed with brine (20 mL), dried over magnesium sulfate, 
filtered and concentrated in vacuo affording a colourless oil.  Purification of the 
oil by silica gel chromatography, eluting with hexane and ethyl acetate (60:40, 
55:45, 50:50, 40:60), provided (+)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-
myo-inositol 1,4-bis(dibenzyl phosphate) 178 (178 mg, 75%) as a colourless 
waxy solid.  A small portion was recrystallised from diethyl ether, affording a 
colourless microcrystalline solid: Rf 0.16 (hexane/ethyl acetate 60:40); 
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D
20
 +24.0 (c 0.6 in CHCl3); mp 88-89 ˚C (from diethyl ether); "max (KBr 
disc) /cm-1 3283 (m), 3035 (w), 2894 (m), 1498 (m), 1456 (s), 1381 (m), 1267 
(s), 1164 (w), 1024 (s), 899 (m), 764 (s), 696 (s), 603 (w) and 500 (m); 1H NMR 
(400 MHz; CDCl3) ! 7.33-7.17 (35H, m, Ar H), 5.09-4.95 (8H, m, 4 ! CHAHBPh), 
4.92 (1H, d, J 6.8, CHAHB H-16), 4.87 (1H, d, J 7.1, CHA’HB’ H-9), 4.85 (1H, d, J 
7.1, CHA’HB’ H-9’), 4.82 (1H, d, J 6.8, CHAHB H-16’), 4.75 (1H, ddd, J 9.5, 9.1, 
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9.0, H-4), 4.73 (1H, d J 11.8, CHA’’HB’’ H-17), 4.62 (2H, s, CH2 H-10,10’), 4.61 
(1H, d, J 11.8, CHA’’HB’’ H-17’), 4.58 (1H, d, J 11.7, CHA’’’HB’’’ H-12), 4.53 (1H, d, 
J 2.0, OH-5), 4.46-4.43 (1H, m, H-2), 4.44 (1H, d, J 11.7, CHA’’’HB’’’ H-12’), 4.25 
(1H, ddd, J 9.5, 9.2, 2.1, H-1), 4.03 (1H, dd, J 9.2, 9.1, H-6), 3.62 (1H, ddd, J 
9.1, 9.0, 2.0, H-5) and 3.39 (1H, dd, J 9.5, 2.1, H-3); 13C NMR (100 MHz; 
CDCl3) ! 137.8 (C-11 Ph), 137.4 (C-18 Ph), 137.3 (C-12 Ph), 136.0 (d, J 7.5), 
135.9 (d, J 7.8), 135.7 (d, J 7.5), 135.66 (d, J 7.2), 128.6, 128.5, 128.45, 128.4, 
128.35, 128.3, 128.0, 127.98, 127.9, 127.8, 127.79, 127.7, 127.67, 127.5, 96.2 
(OCH2O C-16), 95.3 (OCH2O C-9), 80.4 (d, J 6.0, CH-4), 79.5 (d, J 5.6, CH-6), 
77.3 (d, J 5.2, CH-3), 76.9 (d, J 5.8, CH-1), 73.6 (CH-5), 73.0 (CH-2), 72.2 (CH2 
C-12), 70.2 (CH2 C-17), 69.7 (CH2 C-10), 69.54 (d, J 4.9, CH2Ph), 69.5 (d, J 
5.1, CH2Ph), 69.45 (d, J 5.2, CH2Ph) and 69.4 (d, J 5.3, CH2Ph); 
31P NMR 
(162 MHz; CDCl3) ! -0.16 and -1.06; isotope distribution m/z (ES
+) [Found: 
(M+Na)+ 1053.3103 (100), 1054.3133 (60), 1055.3164 (19), 1056.3182 (5). 
C57H60O14P2Na requires M
+, 1053.3351 (100), 1054.3384 (63), 1055.3417 (22), 
1056.3451 (6), 1057.3485 (1)]; m/z (ES+) 1053 ([M+Na]+, 100%). 
 
6.3.18. Benzyl methyl (N,N-diisopropylamino)phosphoramidite 179 
P
OCH3
NiPr2
BnO  
To a solution of benzyl bis-(N,N-diisopropylamino)phosphoramidite 167 (5.00 g, 
14.8 mmol, 1 eq) in CH2Cl2 (100 mL) was added a solution of 1H-tetrazole in 
acetonitrile (0.43 M, 13.7 mL, 5.9 mmol, 0.4 eq), turing the mixture cloudy over 
10 min stirring.  A solution of anhydrous methanol (474 mg, 600 µL, 14.8 mmol, 
1 eq) in CH2Cl2 (100 mL) was then added dropwise via a pressure equalised 
dropping funnel over 1 h at RT.  The resulting solution was stirred for a further 
3 h, after which TLC indicated consumption of the starting material.  The solvent 
was removed in vacuo, providing a sticky off-white solid.  Purification of the 
material by silica gel chromatography, eluting with petroleum ether, ethyl 
acetate and triethylamine (85:10:5), afforded benzyl methyl (N,N-
diisopropylamino)phosphoramidite 179 (3.13 g, 67%) as a colourless oil: Rf 0.71 
(hexane/ethyl acetate 80:20); 1H NMR (400 MHz; CDCl3) ! 7.41-7.26 (5H, m, Ar 
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H), 4.80 (1H, dd, J 12.6, 8.0, CHAHB), 4.71 (1H, dd, J 12.6, 8.5, CHAHB), 3.73-
3.63 (2H, m, CH(CH3)2), 3.47 (3H, d, J 13.1, OCH3) and 1.23 (12H, dd, J 6.9, 
4.2 CH(CH3)2); 
31P NMR (162 MHz; CDCl3) ! -148.50.  The data are in good 
agreement with the literature values.153 
 
6.3.19. (-)-D-3-O-Benzyl-5-O-(benzyl methylphophono)-2,6-bis-O- 
  benzyloxymethyl-myo-inositol 1,4-bis(dibenzyl phosphate) 180 
P
O
O
H3CO
16
17
18
2
3
4
5
6
1
O
9
O
O O
O
19
O
P
O
O
O
PO O
O
14
15
14'
15'
7'
8'
7
8
O
12
13
O
10
11
20
21
 
To a solution of benzyl methyl (N,N-diisopropylamino)phosphoramidite 179 
(77 mg, 0.24 mmol, 3 eq) in CH2Cl2 (5 mL) was added a solution of 1H-tetrazole 
in acetonitrile (0.43 M, 570 µL, 0.24 mmol, 3 eq).  The solution was stirred for 
10 min, then a solution of (+)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-myo-
inositol 1,4-bis(dibenzyl phosphate) 178 (84 mg, 81 µmol, 1 eq) in CH2Cl2 
(5 mL) was added dropwise via a pressure equalised dropping funnel over 
30 min.  The resulting mixture was stirred for 18 h, after which time TLC showed 
consumption of the starting material.  The mixture was cooled to -78 ˚C, then 3-
chloroperoxybenzoic acid (56 mg, 0.33 mmol, 4 eq) was added in a single 
portion.  The mixture was stirred for 15 min at -78 ˚C, then allowed to warm to 
RT over 1 h.  TLC analysis of the reaction mixture indicated consumption of the 
intermediate.  The reaction was quenched by the addition of aqueous sodium 
sulfite solution (10% w/v, 20 mL) and CH2Cl2 (20 mL), then the layers were 
separated.  The aqueous phase was re-extracted with CH2Cl2 (3 ! 20 mL), then 
the combined organic phases were washed with saturated aqueous sodium 
bicarbonate solution (20 mL) and brine (20 mL), dried over magnesium sulfate, 
filtered and concentrated in vacuo, providing a colourless oil.  Purification of the 
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oil by silica gel chromatography, eluting with hexane and ethyl acetate (65:35, 
60:40, 50:50, 40:60, 0:100), provided (-)-D-3-O-benzyl-5-O-(benzyl 
methylphophono)-2,6-bis-O-benzyloxymethyl-myo-inositol 1,4-bis(dibenzyl 
phosphate) 180 (91 mg, 92%) as a colourless oil containing a 1:1 mixture of 
diastereoisomers (adjudged by 1H NMR): Rf 0.30 (hexane/ethyl acetate 30:70); 
  
! 
"[ ]
D
20
 -16.9 (c 0.51 in CHCl3); !max (KBr disc) /cm
-1 3449 (m), 3033 (w), 2955 
(w), 1497 (m), 1456 (m), 1381 (m), 1278 (s), 1215 (m), 1025 (s), 882 (m), 738 
(s), 697 (s), 602 (m) and 499 (m); 1H NMR (400 MHz; CDCl3) ! 7.34-7.18 (38H, 
m, Ar H), 7.15-7.09 (2H, m, Ar H), 5.21-4.80 (15.5H, m), 4.73 (0.5H, d, J 12.1, 
CHAHB H-20 diastereoisomer 1), 4.67-4.65 (2H, m, CH2 H-10,10’), 4.66 (0.5H, 
d, J 12.0, CHAHB H-20’ diastereoisomer 2), 4.56 (0.5H, d, J 12.1, CHAHB H-20’ 
diastereoisomer 1), 4.53-4.51 (1H, m, H-2), 4.50-4.48 (2H, m, CH2 H-12,12’), 
4.47-4.36 (1H, m, H-5), 4.30 (0.5H, dd, J 9.5, 9.5, H-6 diastereoisomer 1), 4.29 
(0.5H, dd, J 9.6, 9.6, H-6 diastereoisomer 2), 4.18-4.12 (1H, m, H-1), 3.66 
(1.5H, d, J 4.9, OCH3 H-16 diastereoisomer 1), 3.63 (1.5H, d, J 4.9, OCH3 H-16 
diastereoisomer 2) and 3.38 (1H, dd, J 9.9, 2.0, H-3); 13C NMR (100 MHz; 
CDCl3) ! 138.1 (C-21 Ph), 137.8 (C-11 Ph), 137.0 (C-13 Ph), 136.2 (d, J 7.7), 
136.18 (d, J 4.4), 136.15 (d, J 7.8), 136.1 (d, J 7.3), 136.0 (d, J 7.2), 135.64 (d, 
J 7.1), 135.6 (d, J 7.5), 128.6, 128.5, 128.45, 128.4, 128.3, 128.26, 128.2, 
128.1, 128.08, 128.0, 127.9, 127.86, 127.83, 127.8, 127.7, 127.69, 127.5, 
127.4, 96.6 (OCH2O C-19 diastereoisomer 1), 96.5 (OCH2O C-19 
diastereoisomer 2), 95.5 (OCH2O C-9), 79.0 (m, CH-5), 77.5 (m, CH-4), 76.8 
(CH-3), 76.4 (m, CH-1), 75.1 (m, CH-6), 72.6 (d, J 3.7, CH-2), 72.0 (CH2 C-12), 
70.5 (CH2 C-20 diastereoisomer 1), 70.4 (CH2 C-20 diastereoisomer 2), 69.9 
(CH2 C-10), 69.7 (d, J 5.9, CH2Ph), 69.67 (d, J 4.5, CH2Ph), 69.5 (d, J 4.8, 
CH2Ph), 69.4 (d, J 4.8, CH2Ph), 69.2 (d, J 5.1, CH2Ph), 54.8 (d, J 6.3, OCH3 
C-16 diastereoisomer 1) and 54.5 (d, J 5.4, OCH3 C-16 diastereoisomer 2); 
31P 
NMR (162 MHz; CDCl3) ! -0.07, -0.12, -1.09, -1.11, -1.64 and -1.73; m/z (ES
+) 
1237 ([M+Na]+, 100%); Anal. Calcd. For C65H69O17P3: C, 64.25; H, 5.72. Found: 
C, 63.91; H, 5.83. 
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6.3.20. D-5-O-(Methyl phosphate)-myo-inositol 1,4-O-bisphosphate  
  pentakis sodium salt 128 
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To a solution of (-)-D-3-O-benzyl-5-O-(benzyl methylphophono)-2,6-O-
bisbenzyloxymethyl-myo-inositol 1,4-bis(dibenzyl phosphate) 180 (80 mg, 
66 µmol, 1 eq) in t-butanol (6.7 mL) and water (0.7 mL) was added palladium 
black (140 mg, 1.32 mmol, 20 eq) and aqueous sodium bicarbonate solution 
(0.5 M, 660 µL, 0.33 mmol, 5 eq).  The flask was evacuated and the 
atmosphere purged with hydrogen gas three times, then the heterogeneous 
mixture was stirred vigorously under an atmosphere of hydrogen for 6.5 h.  The 
mixture was filtered through a pad of Celite and the residue was washed with 
water (2 mL).  This filtrate was lypholised, providing a colourless solid 
(31.8 mg), shown to be incomplete deprotected material.  The remaining dark 
palladium residue was washed with ethyl acetate (2 ! 4 mL), discarding the 
organic layer, and water (5 ! 10 mL).  The aqueous filtrate was then lypholised, 
providing a fine solid (> 0.1 mg).  The initial product (31.8 mg) was resubmitted 
to hydrogenolysis under the above conditions for a further 16 h.  The 
heterogeneous mixture was filtered through a pad of Celite and the residue was 
washed with ethyl acetate (2 ! 4 mL).  The organic filtrates were discarded and 
the remaining residue was washed with water (5 ! 10 mL).  The filtrate was 
passed through a Millipore frit then lypholised, affording D-5-O-(methyl 
phosphate)-myo-inositol 1,4-O-bisphosphate pentakis sodium salt 128 
(18.2 mg, 51%) as a light brown solid: 
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 -7.2 (c 0.50 in H2O); "max (KBr disc) 
/cm-1 3423 (s), 1655 (m), 1457 (s), 1230 (w), 1089 (m), 974 (m), 881 (w), 866 
(w) and 556 (br w); 1H NMR (400 MHz; CDCl3) ! 4.13 (1H, br s, H-2), 4.13-4.06 
(1H, m, H-4), 3.88-3.77 (3H, m, H-1, H-5 and H-6), 3.61 (1H, dd, J 9.7, 2.5, H-3) 
and 3.54 (3H, d, J 10.8, OCH3 H-7); 
13C NMR (125 MHz; CDCl3) ! 79.1 (CH-5), 
74.7 (CH-4), 74.0 (d, J 4.9, CH-6), 71.5 (2C by HSQC, CH-1 and CH-3), 70.8 
(CH-2) and 53.4 (d, J 5.8, OCH3); 
31P NMR (162 MHz; CDCl3) ! 4.16 (P-4), 3.71 
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(P-1) and 1.60 (P-5); HRMS m/z (ES-) [Found: (M-2Na+H)- 498.9170. 
C7H13O15P3Na3 requires M
-, 498.9166]; m/z (ES-) 499 ([M-2Na+H]-, 6%), 477 
([M-3Na+2H]-, 17), 455 ([M-4Na+3H]-, 18), 433 ([M-5Na+4H]-, 19), 375 (18) and 
353 (100).  
 
6.3.21. (-)-D-2-O-Benzyl-2,6-bis-O-benzyloxymethyl-5-(benzyl  
  methylphosphonate)-myo-inositol 1,4-O-bis(dibenzyl phosphate)
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To a stirred solution of (+)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-myo-inositol 
1,4-bis(dibenzyl phosphate) 178 (67.2 mg, 65 µmol, 1.0 eq) in anhydrous 
pyridine (180 µL) was added a solution of bis(1-[6-trifluoromethyl]benzotriazolyl) 
methylphosphonate in dioxane (0.2 M, 395 µL, 79 µmol, 1.2 eq).  The solution 
was stirred for 20 min at RT.  Anhydrous benzyl alcohol (28.2 mg, 27 µL, 
0.26 mmol, 4.0 eq) was then added in a single portion and the mixture stirred 
for a further 3 h, after which time the reaction was adjudged complete by TLC 
analysis.  The reaction was quenched by the addition of triethylammonium 
bicarbonate buffer solution (1 M, 1 mL), causing effervescence.  The resulting 
mixture was diluted with CH2Cl2 (20 mL) and saturated sodium bicarbonate 
solution (30 mL) and the layers were separated.  The organic phase was 
washed with water (10 mL), triethylammonium bicarbonate buffer solution (1 M, 
6 mL) and a further portion of water (10 mL).  The organic phase was then dried 
over magnesium sulfate, filtered and concentrated in vacuo, affording a light 
colourless oil.  Repeated purification of the oil by silica gel chromatography, 
eluting with hexane and ethyl acetate (50:50, 45:55, 0:100), afforded (-)-D-2-O-
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benzyl-2,6-bis-O-benzyloxymethyl-5-(benzyl methylphosphonate)-myo-inositol 
1,4-O-bis(dibenzylphosphate) 188 (25.2 mg, 32%) as a colourless waxy solid, 
composed of a 10:1 mixture of diastereoisomers (ds1:ds2, adjudged by 1H 
NMR): 
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-15.0 (c 0.60 in CHCl3); !max (KBr disc) /cm
-1 3448 (w), 3033 (w), 
2954 (w), 2360 (w), 1607 (w), 1498 (m), 1456 (s), 1380 (m), 1313 (m), 1273 (s), 
1215 (m), 1119 (m), 1024 (s), 925 (m), 736 (s), 697 (s), 601 (w) and 498 (m); 1H 
NMR (500 MHz; CDCl3) ! 7.31-7.13 (40H, m, Ar H), 5.21 (1H, dd, J 11.9, 7.4, 
CHAHB H-17), 5.13 (1H, dd, J 11.8, 6.7, CHAHBPh), 5.07-4.95 (7H, m, 3 " 
CHAHB and CHAHB H-17’), 4.92-4.81 (5H, m, H-4, CH2 H-9,9’, CH2 H-19,19’ and 
CHA’HB’ H-7’), 4.70 (1H, d, J 12.1, CHA’’HB’’ H-20), 4.64 (2H, s, CH2 H-10,10’), 
4.55 (1H, d, J 12.1, CHA’’HB’’ H-20’), 4.53-4.45 (4H, m, H-2, H-5 and CHAHB H-
12,12’), 4.29 (1H, dd, J 9.9, 9.7, H-6), 4.15 (1H, ddd, J 9.9, 8.3, 2.0, H-1), 3.38 
(1H, dd, J 9.9, 2.1, H-3 diastereoisomer 1), 3.31 (1H, dd, J 10.0, 2.0, H-3 
diastereoisomer 2), 1.57 (3H, d, J 18.2, CH3 H-16 diastereoisomer 1) and 1.49 
(3H, d, J 18.0, CH3 H-16 diastereoisomer 1); 
13C NMR (125 MHz; CDCl3) ! 
138.0 (C-21 Ph diastereoisomer 1), 137.95 (C-21 Ph diastereoisomer 2), 137.7 
(C-11 Ph), 137.0 (C-13 Ph), 136.6 (d, J 6.7, C-18 Ph), 136.1 (d, J 6.4), 136.0 (d, 
J 7.3), 135.6 (d, J 7.1), 135.57 (d, J 7.4), 128.6, 128.5, 128.4, 128.37, 128.33, 
128.3, 128.24, 128.2, 128.18, 128.1, 128.0, 127.9, 127.8, 127.79, 127.77, 
127.73, 127.7, 127.64, 127.6, 127.4, 127.38, 96.7 (OCH2O C-19 
diastereoisomer 2), 96.3 (OCH2O C-19 diastereoisomer 1), 95.5 (OCH2O C-9), 
77.50-77.46 (m, CH-4), 76.7 (CH-3 from HSQC), 76.6 (d, J 5.8, CH-1), 75.90-
75.77 (m, CH-5), 74.5 (d, J 6.4, CH-6), 72.9 (CH-2 diastereoisomer 1), 72.6 
(CH-2 diastereoisomer 2), 72.2 (CH2 C-12 diastereoisomer 1), 72.1 (CH2 C-12 
minor), 70.6 (CH2 C-20 diastereoisomer 2), 70.3 (CH2 C-20 diastereoisomer 1), 
69.7 (CH2 C-10), 69.6 (d, J 5.4, 2 " CH2Ph), 69.4 (d, J 5.0, CH2Ph), 69.2 (d, J 
5.3, CH2 C-7), 67.7 (d, J 5.9, CH2 C-17 diastereoisomer 2), 67.3 (d, J 5.7, CH2 
C-17 diastereoisomer 1), 12.5 (d, J 145.4, CH3 C-16 diastereoisomer 2) and 
12.1 (d, J 146.8, CH3 C-16 diastereoisomer 1); 
31P NMR (202 MHz; CDCl3) ! 
34.77 (P-5 major), 33.06 (P-5 diastereoisomer 2), 0.16 (diastereoisomer 2), 
0.11 (diastereoisomer 1), -0.20 (diastereoisomer 1) and -0.40 (diastereoisomer 
2); isotope distribution m/z (ES+) [Found: (M+Na)+ 1221.3624 (100), 1222.3666 
(71), 1223.3719 (25) and 1224.3752 (5). C65H69O16P3Na requires M
+, 
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1221.3691 (100), 1222.3724 (72), 1223.3757 (29), 1224.3791 (8), 1225.3825 
(2) and 1226.3834 (0)]; m/z (ES+) 1221 ([M+Na]+, 100%). 
 
6.3.22. (-)-D-5-(Methylphosphonate)-myo-inositol 1,4-bisphosphate  
  pentakis sodium salt 126 (from 188) 
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To a solution of (-)-D-2-O-benzyl-2,6-bis-O-benzyloxymethyl-5-(benzyl 
methylphosphonate)-myo-inositol 1,4-O-bis(dibenzylphosphate) 188 (25.2 mg, 
21 µmol, 1 eq) in a mixture of t-butanol (1.8 mL) and water (0.3 mL) under Ar 
was added sodium bicarbonate (8.8 mg, 0.11 mmol, 5 eq) and palladium black 
(44.7 mg, 0.42 mmol, 20 eq).  The flask was evacuated and the atmosphere 
was purged with hydrogen gas.  The heterogeneous mixture was vigorously 
stirred under a hydrogen atmosphere for 10 h.  After this time, a further quantity 
of palladium black (22.3 mg, 0.210 mmol, 10 eq) was added and the mixture 
stirred for a further 5 h.  The mixture was filtered through a pad of Celite and the 
residue was washed with diethyl ether (2 ! 5 mL); the filtrates were discarded.  
The palladium residues were then washed with water (4 ! 5 mL).  The aqueous 
filtrates were passed through a Millipore frit and lypholised to furnish impure (-)-
D-5-(methylphosphonate)-myo-inositol 1,4-bisphosphate pentakis sodium salt 
126 (10.8 mg, 97%) as a light brown solid: 1H NMR (250 MHz; D2O) ! 4.15 (1H, 
dd, J 2.7, 2.2, H-2), 4.12-4.03 (1H, m, H-4), 3.92-3.71 (3H, m, H-5, H-1 and H-
6), 3.62 (1H, dd, J 9.6, 2.7, H-3) and 1.33 (3H, d, J 16.9, CH3 H-7); 
31P NMR 
(101 MHz; D2O) ! 29.68 (P-5), 5.22 and 4.94; HRMS m/z (ES
-) [Found: (M-H)- 
482.9214. C7H13O14P3Na3 requires M
-, 482.9217]; m/z (ES-) 483 ([M-2Na+H]-, 
3), 461 ([M-3Na+2H]-, 12), 439 ([M-4Na+3H]-, 14), 417 ([M-5Na+4H]-, 18), 359 
(25), 337 (100) and 259 (13).  The data are consistent with the previous sample 
derived from an alternative substrate (212), however, NMR showed a 
methylphosphonate containing impurity shown to be present in this sample, 
thought to be methylphosphonic acid. 
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6.3.23. (-)-D-3-O-Benzyl-2,6-bis-O-benzyloxymethyl-4-O-triisopropylsilyl-
  myo-inositol 1,5 bis(dibenzyl phosphate) 190 
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To a solution of bis(benzyloxy)-N,N-diisopropylamino phosphine (663 mg, 
1.9 mmol, 5 eq) in CH2Cl2 (15 mL) was added a solution of 1H-tetrazole in 
acetonitrile (0.43 M, 4.5 mL, 1.9 mmol, 5 eq).  The mixture was stirred for 
15 min at RT, becoming slightly cloudy.  A solution of (+)-D-3-O-benzyl-2,6-bis-
O-benzyloxymethyl-4-O-triisopropylsilyl-myo-inositol 164 (256 mg, 0.4 mmol, 
1 eq) in CH2Cl2 (15 mL) was added dropwise over 1.5 h via a pressure 
equalised dropping funnel.  The resulting solution was stirred for 18 h at RT, 
after which time TLC analysis indicated the consumption of the starting material.  
The solution was cooled to -78 °C and 3-chloroperoxybenzoic acid (430 mg, 
1.92 mmol, 5 eq) was added in a single portion.  The mixture was stirred for 
30 min at -78 ˚C, then was warmed to RT and stirred for a further 3 h, after 
which time TLC analysis indicated consumption of the intermediate.  The 
reaction was quenched by the addition of aqueous sodium sulfite solution (10% 
w/v, 25 mL).  The layers were separated and the aqueous phase was re-
extracted with CH2Cl2 (3 ! 25 mL).  The combined organic layers were washed 
with water (25 mL) and brine (25 mL), dried over magnesium sulfate, filtered 
and concentrated in vacuo, providing a colourless oil.  Purification of the oil by 
silica gel chromatography, eluting with hexane and ethyl acetate (90:10, 85:15, 
80:20, 75:25, 60:40), afforded (-)-D-3-O-benzyl-2,6-bis-O-benzyloxymethyl-4-O-
triisopropylsilyl-myo-inositol 1,5 bis(dibenzyl phosphate) 190 (301 mg, 67%) as 
a colourless oil: Rf 0.12 (hexane/ethyl acetate 90:10); 
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-16.3 (c 0.41 in 
CHCl3);  "max (KBr disc) /cm
-1 3423 (m), 3034 (m), 2944 (m), 285 (m), 1719 (s), 
1498 (m), 1456 (m), 1383 (m), 1266 (s), 1216 (s), 1116 (m), 1020 (s), 885 (m), 
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820 (w), 737 (s), 697 (s), 604 (w) and 600 (w);  1H NMR (500 MHz; CDCl3) ! 
7.34-7.22 (35H, m, Ar H), 5.05-4.96 (8H, m, 4 ! CH2Ph), 4.93 (2H, s, OCH2O H-
12,12’), 4.92 (1H, d, J 6.9, OCHAHBO H-7), 4.86 (1H, d, J 6.9, OCHAHBO H-7’), 
4.78 (1H, d, J 12.0, CHA’HB’ H-13), 4.71 (1H, d, J 12.3, CHA’’HB’’ H-8), 4.64 (1H, 
d, J 12.3, CHA’’HB’’ H-8’), 4.61 (1H, d, J 12.0, CHA’HB’ H-13’), 4.59 (1H, d, J 11.1, 
CHA’’’HB’’’ H-10), 4.55-4.53 (1H, m, H-2), 4.35-4.26 (5H, m, H-1, H-4, H-5, H-6 
and CHA’’’HB’’’ H-10’), 3.23 (1H, dd, J 7.9, 1.7, H-3), 1.21-1.03 (3H, m, CH TIPS) 
and 1.00-0.94 (18H, m, CH3 TIPS); 
13C NMR (125 MHz; CDCl3) ! 138.2 (C-14 
Ph), 137.9 (C-9 Ph), 137.4 (C-11 Ph), 136.1 (d, J 7.2, C-15 Ph), 136.0 (d, J 7.8, 
C-15’ Ph), 135.8 (2C, d, J 7.2, C-18 and C-18’), 128.6, 128.52, 128.5, 128.48, 
128.34, 128.3, 128.27, 128.1, 128.07, 128.0, 127.8, 127.5, 127.4, 96.6 (OCH2O 
C-12), 95.2 (OCH2O C-7), 81.4 (d, J 6.1, CH-4), 79.9 (CH-3), 76.6 (d, J 5.5, CH-
5), 75.5 (d, J 6.5, CH-6), 72.2 (d, J 4.3, CH-1), 72.0 (CH-2), 71.7 (CH2 C-10), 
70.5 (CH2 C-13), 69.6 (CH2 C-8), 69.5 (d, J 5.4, CH2Ph), 69.4 (d, J 5.5, CH2Ph), 
69.37 (d, J 5.6, CH2Ph), 69.2 (d, J 5.5, CH2Ph), 18.2 (CH3 TIPS), 18.1 (CH3 
TIPS) and 13.3 (CH TIPS); 31P NMR (202 MHz; CDCl3) ! -1.17 and -1.36; m/z 
(ES+) 1209 ([M+Na]+, 100%); Anal. Calcd. for C66H80O14P2Si: C, 66.76; H, 6.79. 
Found: C, 66.51; H, 6.99. 
 
6.3.24  (±)-trans-2-(4-methoxybenzyloxy)cyclohexanol 150 
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To a stirred suspension of sodium hydride (4.5 g, 112.0 mmol, 1.3 eq) in 
tetrahydrofuran (100 mL) was added a solution of (±)-trans-cyclohexane-1-2-
diol (10.0 g, 86.1 mmol, 1 eq) in tetrahydrofuran (200 mL) dropwise via a 
pressure equalised dropping funnel over 1 h.  The resulting white suspension 
was stirred for 1 h further, then TBAI (6.4 g, 17.2 mmol, 0.2 eq) and 4-
(methoxy)benzyl chloride (20.2 g, 17.5 mL, 129.0 mmol, 1.5 eq) were added in 
single portions.  The suspension was stirred at RT for 16 h, then N,N-
dimethylformamide (5 mL) was added, causing the remaining solids to dissolve.  
The solution was stirred at RT for a further 18 h.  The solvent was removed in 
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vacuo providing a yellow oil which was partitioned between water (400 mL) and 
CH2Cl2 (400 mL).  The layers were separated and the aqueous phase was 
extracted with CH2Cl2 (200 mL).  The combined organic phases were dried over 
magnesium sulfate, filtered and concentrated in vacuo to give a pale yellow oil.  
Purification of the oil by silica gel chromatography, eluting with hexane and 
diethyl ether (80:20), provided 2-(4-methoxybenzyloxy)cyclohexanol 150 
(11.48 g, 56%) as a colourless oil:  Rf 0.16 (petroleum ether/diethyl ether 
50:50); !max (thin film) /cm
-1 3439 (m), 2934 (s), 2861 (m), 1612 (s), 1514 (s), 
1452 (m), 1248 (s); 1H NMR (400 MHz; CDCl3) ! 7.34-7.29 (2H, m, H-9,9’ Ar), 
6.95-6.90 (2H, m, H-10,10’ Ar), 4.67 (1H, d, J 11.2, CHAHB H-7), 4.44 (1H, d, J 
11.2, CHAHB H-7’), 3.84 (3H, s, OCH3 H-12), 3.55-3.45 (1H, m, H-2), 3.25-3.15 
(1H, m, H-1), 2.75 (1H, d, J 1.4, OH-1 ex. in D2O), 2.22-2.13 (1H, m, Hax-3), 
2.09-1.97 (1H, m, Hax-6), 1.82-1.68 (2H, m, Heq-3,6) and 1.37-1.18 (4H, m, CH2-
4,5); HRMS m/z (ES+) [Found: (M+Na)+ 259.1308.  C14H20O3Na requires M
+, 
259.1310]; m/z (ES+) 259 ([M+Na]+, 100%).  The data are in good agreement 
with the literature values.189 
 
Method 2: Deprotection 
A solution of (±)-triisopropyl(2-(4-methoxybenzyloxy)cyclohexyloxy)silane 175 
(400 mg, 1.0 mmol, 1 eq) in tetrahydrofuran (5 mL) was treated with a solution 
of tetrabutylammonium fluoride in tetrahydrofuran (1.0 M, 1.2 mL, 1.2 mmol, 
1.2 eq) at RT.  The resulting pale yellow solution was stirred for 24 h at RT.  
The solution was diluted with CH2Cl2 (10 mL) and the reaction was quenched 
by the addition of aqueous saturated sodium bicarbonate solution (10 mL).  The 
tetrahydrofuran was removed in vacuo and the resulting mixture was extracted 
with CH2Cl2 (2 " 40 mL).  The combined organic phases were dried over 
magnesium sulfate, filtered and concentrated in vacuo, providing a brown oil.  
Purification of the oil by silica gel chromatography, eluting with hexane and 
diethyl ether (80:20), yielded (±)-trans-2-(4-methoxybenzyloxy)cyclohexyloxy) 
150 (187 mg, 78%) as a colourless oil:  Rf 0.26 (hexane/diethyl ether 50:50); 
1H 
NMR (400 MHz, CDCl3) ! 7.33-7.28 (2H, m, H-9,9’ Ar), 6.94-6.89 (2H, m, H-
10,10’ Ar), 4.65 (1H, d, J 11.2, CHAHB H-7), 4.42 (1H, d, J 11.2, CHAHB H-7’), 
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3.82 (3H, s, OCH3 H-12), 3.53-3.45 (1H, m, H-2), 3.22-3.15 (1H, m, H-1), 2.73 
(1H, d, J 1.4, OH-1 ex. in D2O), 2.19-2.13 (1H, m, Hax-3), 2.06-1.99 (1H, m, Hax-
6), 1.80-1.67 (2H, m, Heq-3,6) and 1.34-1.18 (4H, m, CH2-4,5).  The data are 
comparable to the previous synthesis and the literature values.189 
 
6.3.25. (±)-trans-2-(benzyloxymethoxy)cyclohexanol 158 
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A solution of (±)-trans-cyclohexane-1,2-diol (10.0 g, 86.1 mmol, 1 eq) in CH2Cl2 
(300 mL) was cooled to -10 ˚C, then treated with Hünig’s base (22.3 g, 30.0 mL, 
172 mmol, 2 eq) and freshly distilled benzyloxymethyl chloride (27.0 g, 23.9 mL, 
103 mmol, 1.2 eq).  The solution was allowed to warm to RT over 90 min, and 
stirred for 18 h at RT.  The solution was diluted with CH2Cl2 (250 mL) then 
washed with water (400 mL).  The organic phase was dried over magnesium 
sulfate, filtered and concentrated in vacuo providing an orange oil.  Purification 
of the oil by silica gel chromatography, eluting with hexane and diethyl ether 
(100:0, 98:2, 96:4, 90:10, 0:100), provided (±)-trans-2-
(benzyloxymethoxy)cyclohexanol 158 (10.84 g, 53%) as a colourless oil:  Rf 
0.04 (hexane/diethyl ether 80:20);  !max (thin film) /cm
-1 3445 (m), 2935 (s), 
2862 (s), 1497 (w), 1453 (s), 1380 (m); 1H NMR (400 MHz; CDCl3) ! 7.41-7.30 
(5H, m, Ar H), 4.92 (1H, d, J 7.1, CHAHBO H-7), 4.90 (1H, d, J 7.1, CHAHBO H-
7’), 4.74 (1H, d, J 11.1, CHA’HB’ H-8), 4.65 (1H, d, J 11.1, CHA’HB’ H-8’), 3.51-
3.43 (1H, m, H-2), 3.42 (1H, d, J 1.6, OH-1 ex. in D2O), 3.36-3.30 (1H, m, H-1), 
2.13-2.02 (2H, m, Hax-3,6), 1.76-1.67 (2H, m, Heq-3,6) and 1.38-1.22 (4H, m, 
CH2-4,5);  
13C NMR (100 MHz; CDCl3) ! 137.3 (C-9 Ph), 128.5 (CH Ph), 128.0 
(CH Ph), 127.9 (C-12 Ph), 94.7 (OCH2O C-7), 84.6 (CH-2), 73.8 (CH-1), 70.0 
(CH2 C-8), 32.7 (CH2 C-3), 31.0 (CH2 C-6), 24.3 (CH2 C-4) and 23.9 (CH2 C-5);  
HRMS m/z (ES+) [Found: (M+Na)+ 259.1310.  C14H20O3Na requires M
+, 
259.1310]; m/z (ES+) 259 ([M+Na]+, 100%). 
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Method 2: Deprotection 
A solution of (trans-2-(benzyloxymethoxy)cyclohexyloxy)triisopropylsilane 160 
(400 mg, 1.0 mmol, 1 eq) in tetrahydrofuran (5 mL) was treated with a solution 
of tetrabutylammonium fluoride in tetrahydrofuran (1.0 M, 1.2 mL, 1.2 mmol, 
1.2 eq) at RT.  The resulting yellow solution was stirred for 5 h at RT.  The 
reaction was quenched by the addition of aqueous saturated sodium 
bicarbonate solution (5 mL).  The tetrahydrofuran was removed in vacuo and 
the resulting mixture was extracted with CH2Cl2 (3 ! 5 mL).  The combined 
organic phases were dried over magnesium sulfate, filtered and concentrated in 
vacuo, providing a yellow oil.  Purification of the oil by silica gel 
chromatography, eluting with petroleum ether and diethyl ether (60:40), yielded 
(±)-trans-2-(benzyloxymethoxy)cyclohexanol 158 (237 mg, 98%) as a colourless 
oil:  Rf 0.26 (hexane/diethyl ether 50:50); 
1H NMR (400 MHz; CDCl3) ! 7.38-
7.28 (5H, m, Ar H), 4.90 (1H, d, J 7.0, CHAHBO H-7), 4.88 (1H, d, J 7.0, 
CHAHBO H-7’), 4.72 (1H, d, J 11.7, CHA’HB’ H-8), 4.63 (1H, d, J 11.7, CHA’HB’ H-
8’), 3.50-3.42 (2H, m, CH-2 and OH overlap), 3.35-3.27 (1H, m, H-1), 2.11-2.01 
(2H, m, Hax-3,6), 1.75-1.66 (2H, m, Heq-3,6) and 1.36-1.20 (4H, m, CH2-4,5).  
The data are in agreement with the previous synthesised material above. 
 
6.3.26. (±)-trans-Triisopropyl(2-(4-methoxybenzyloxy)cyclohexyloxy)silane
   175 
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To a solution of 2-(4-methoxybenzyloxy)cyclohexanol 150 (3.2 g, 13.6 mmol, 
1 eq) in CH2Cl2 (180 mL) was added triethylamine (4.1 g, 5.7 mL, 40.9 mmol, 
3 eq) and TIPSOTf (5.0 g, 4.4 mL, 16.4 mmol, 1.2 eq) successively in single 
portions.  The colourless solution was stirred at RT for 18 h, turning orange.  
The solution was diluted with CH2Cl2 (150 mL) then washed with saturated 
aqueous sodium hydrogen carbonate solution (100 mL).  The layers were 
separated and the aqueous phase was re-extracted with CH2Cl2 (150 mL).  The 
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combined organic phases were dried over magnesium sulfate, filtered and 
concentrated in vacuo providing a brown oil.  Purification of the oil by silica gel 
chromatography, eluting with petroleum ether and diethyl ether (98:2), furnished 
(±)-trans-triisopropyl(2-(4-methoxybenzyloxy)cyclohexyloxy)silane 175 (3.82 g, 
72%) as a colourless oil: Rf 0.74 (petroleum ether/diethyl ether 50:50); !max (thin 
film) /cm-1 2950 (s), 2865 (s), 1613 (m), 1513 (s), 1464 (m), 1113 (s), 1057 (s); 
1H NMR (300 MHz; CDCl3) ! 7.22-7.17 (2H, m, H-9,9’ Ar), 6.81-6.76 (2H, m, H-
10,10’ Ar), 4.48 (1H, d, J 11.6, CHAHB H-7), 4.42 (1H, d, J 11.6, CHAHB H-7’), 
3.77-3.71 (1H, m, H-2), 3.73 (3H, s, OCH3), 3.26-3.19 (1H, m, H-1), 1.85-1.72 
(2H, m, Hax-3,6), 1.64-1.46 (2H, m, Heq-3,6), 1.44-1.31 (2H, m, Hax-4,5), 1.27-
1.14 (2H, m, Heq-4,5) and 0.99-0.95 (21H, m, TIPS); 
13C NMR (100 MHz; 
CDCl3) ! 158.9 (C-11 Ar), 131.5 (C-8 Ar), 129.1 (CH-9,9’ Ar), 113.6 (CH-10,10’ 
Ar), 79.6 (CH-2), 71.8 (CH -1), 70.8 (CH2 C-7), 55.3 (OCH3 C-12), 31.8 (CH2 C-
3), 27.5 (CH2 C-6), 22.1 (CH2 C-4), 21.8 (CH2 C-5), 18.1 (CH3 TIPS), 12.5 (CH 
TIPS); HRMS m/z (ES+) [Found: (M+NH4)
+ 410.3081.  C23H44O3SiN requires 
M+, 410.3085]; m/z (ES+) 410 ([M+NH4]
+, 23%), 393 (10), 271 (10) and 121 
(100); Anal. Calcd. for C23H40O3Si: C, 70.35; H, 10.27.  Found: C: 70.55, H, 
10.68. 
 
6.3.27. (±)-trans-(2-(Benzyloxymethoxy)cyclohexyloxy)triisopropylsilane
  160 
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To a solution of (±)-2-(benzyloxymethoxy)cyclohexanol 158 (3.0 g, 12.7 mmol, 
1 eq) in CH2Cl2 (150 mL) was added triethylamine (3.9 g, 5.3 mL, 38.1 mmol, 
3 eq) and TIPSOTf (4.7 g, 4.1 mL, 15.2 mmol, 1.2 eq) successively in single 
portions.  The colourless solution was stirred at RT for 1 h, turning light orange.  
The solution was diluted with CH2Cl2 (200 mL) then washed with saturated 
aqueous sodium hydrogen carbonate solution (200 mL).  The layers were 
separated, then the aqueous phase was re-extracted with CH2Cl2 (200 mL).  
The combined organic phases were dried over magnesium sulfate, filtered and 
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concentrated in vacuo providing a light brown oil.  Purification of the oil by silica 
gel chromatography, eluting with petroleum ether and diethyl ether (98:2), 
yielded (±)-trans-(2-(benzyloxymethoxy)cyclohexyloxy)triisopropylsilane 160 
(3.97 g, 80%) as a colourless oil: Rf 0.76 (hexane/diethyl ether 50:50); !max (thin 
film) /cm-1 2941 (s), 2865 (s), 1463 (m), 1381 (w), 1111 (s), 1027 (s); 1H NMR 
(400 MHz; CDCl3) ! 7.39-7.35 (4H, m, Ar H), 7.34-7.28 (1H, m, H-12 Ph), 4.90 
(1H, d, J 6.8, OCHAHBO H-7), 4.86 (1H, d, J 6.8, OCHAHBO H-7’), 4.69 (1H, d, J 
11.7, CHA’HB’ H-8), 4.59 (1H, d, J 11.7, CHA’HB’ H-8’), 3.87-3.76 (1H, m, H-2), 
3.58-3.52 (1H, m, H-1), 2.04-1.94 (1H, m, Hax-3), 1.93-1.85 (1H, m, Hax-6), 1.73-
1.59 (2H, m, Heq-3,6), 1.52-1.40 (2H, m, Hax-4,5), 1.39-1.22 (2H, m, Heq-4,5) 
and 1.13-1.03 (21H, m, TIPS); 13C NMR (100 MHz; CDCl3) ! 138.1 (C-9 Ph), 
128.4 (CH Ph), 127.9 (CH Ph), 127.6 (C-12 Ph), 94.6 (OCH2O C-7), 79.6 (CH-
2), 72.8 (CH-1), 69.3 (CH2 C-8), 32.5 (CH2 C-3), 29.3 (CH2 C-6), 22.7 (CH2 C-
4), 22.3 (CH2 C-5), 18.1 (CH3 TIPS) and 12.6 (CH TIPS); HRMS m/z (ES
+) 
[Found (M+H)+ 393.2819.  C23H41O3Si requires M
+, 393.2819]; m/z (ES+) 415 
([M+Na]+, 100%); Anal. Calcd. for C23H40O3Si: C, 70.35; H, 10.27.  Found: C, 
70.29; H, 10.30. 
 
6.3.28. (±)-trans-2-(Triisopropylsilyloxy)cyclohexanol 161 
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To a solution of (±)-trans-triisopropyl(2-(4-methoxybenzyloxy) 
cyclohexyloxy)silane 175 (420 mg, 1.1 mmol, 1 eq) in CH2Cl2 (6 mL) and water 
(0.35 mL) (18:1) was added DDQ (534 mg, 2.4 mmol, 2.2 eq) in a single 
portion, turning the solution dark green.  The mixture was stirred at RT for 
10 min, turning orange.  TLC analysis showed consumption of the starting 
material.  The reaction was quenched by the addition of aqueous saturated 
ammonium chloride solution (10 mL).  The mixture was extracted with CH2Cl2 
(3 " 25 mL).  The combined organic fractions were washed with brine (25 mL) 
and water (25 mL), dried over magnesium sulfate, filtered and concentrated in 
vacuo providing a brown oil.  Purification of the oil by silica gel chromatography, 
eluting with hexane and diethyl ether (95:5), yielded (±)-trans-2-
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(triisopropylsilyloxy)cyclohexanol 161 (204 mg, 70%) as a colourless oil: 1H 
NMR (400 MHz; CDCl3) ! 3.55-3.46 (1H, m, H-2), 3.41-3.33 (1H, m, H-1), 2.60 
(1H, br s, OH-2), 2.03-1.87 (2H, m, Hax-3,6), 1.73-1.65 (2H, m, Heq-3,6), 1.38-
1.19 (4H, m, CH2-4,5) and 1.12-1.03 (21H, m, TIPS); 
13C NMR (100 MHz; 
CDCl3) ! 77.3 (CH-2), 75.6 (CH-1), 33.5 (CH2 C-3), 31.5 (CH2 C-6), 24.4 (CH2 
C-5), 23.9 (CH2 C-4), 18.1 (CH3 TIPS) and 12.6 (CH TIPS); HRMS m/z (ES
+) 
[Found: (M+Na)+ 295.2070. C15H32O2SiNa requires M
+, 295.2069]; m/z (ES+) 
295 ([M+Na]+, 100%); Anal. Calcd. for C15H32O2Si: C, 66.11; H, 11.84.  Found: 
C, 65.88; H, 11.85. 
 
Method 2: from (±)-trans-(2-(benzyloxymethoxy)cyclohexyloxy)triisopropylsilane 
160 
A solution of (±)-trans-(2-(benzyloxymethoxy)cyclohexyloxy)triisopropylsilane 
160 (100 mg, 0.25 mmol, 1 eq) in methanol (10 mL) was passed through an H-
Cube continuous flow hydrogenation reactor under the following conditions: Full 
H2 Mode; 10% Pd/C cartridge; atmospheric pressure; 75 ˚C heating; 0.25 mM 
solution; and 1 mL/min flow rate.  The eluant was collected and TLC analysis 
indicated complete consumption of the starting material.  The solvent was 
concentrated in vacuo, affording (±)-trans-2-(triisopropylsilyloxy)cyclohexanol 
161 (50.5 mg, 74%) as a colourless oil without the requirement for purification; 
Rf 0.42 (hexane/diethyl ether 75:25); 
1H NMR (400 MHz; CDCl3) ! 3.54-3.47 
(1H, m, H-2), 3.42-3.33 (1H, m, H-1), 2.60 (1H, br s, OH-2), 2.02-1.90 (2H, m, 
Hax-3,6), 1.72-1.64 (2H, m, Heq-3,6), 1.38-1.16 (4H, m, CH2-4,5) and 1.15-1.03 
(21H, m, TIPS).  The data were in agreement with the previous sample obtained 
by deprotection of 175. 
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6.3.29. D-myo-inositol 1,3,5-orthoformate 49 
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To a solution of myo-inositol 4 (40.0 g, 222 mmol, 1 eq) in N,N-
dimethylformamide (160 mL) was added triethylorthoformate (165.0 g, 185 mL, 
1.11 mol, 5 eq) and 4-toluene sulfonic acid monohydrate (16.9 g, 89 mmol, 
0.4 eq).  The mixture was heated to 105 ˚C for 96 h, then allowed to cool to RT.  
TLC analysis indicated consumption of the starting material.  The solution was 
neutralised by the addition of solid sodium hydrogen carbonate (ca. 20 g) until 
effervescence ceased.  The volatile components were removed in vacuo 
furnishing a yellow paste, which was taken up in methanol (600 mL) and 
shaken vigorously.  The mixture was cooled to -20 ˚C for 4 h, then filtered to 
removed excess sodium hydrogen carbonate and sodium tosylate by-products.  
The filtrate was concentrated in vacuo affording a golden brown oil.  The oil was 
taken up in methanol (100 mL) and cooled to -20 ˚C for 2 days.  A colourless 
crystalline solid was observed, which was isolated by filtration.  The solid was 
washed with chloroform (50 mL) and air dried to provide D-myo-inositol 1,3,5-
orthoformate 49 (15.0 g) as a colourless crystalline solid.  The remaining filtrate 
was concentrated in vacuo affording a yellow paste.  Purification of this paste 
by silica gel chromatography, eluting with dichloromethane and methanol 
(95:5), provided D-myo-inositol 1,3,5-orthoformate 49 (15.0 g) as a colourless 
crystalline solid.  The combined materials provided D-myo-inositol 1,3,5-
orthoformate 49 (30.0 g, 71%): Rf 0.39 (ethyl acetate/acetonitrile 80:20); mp 
254-258 ˚C dec. (from ethyl acetate) [lit.38 300-302 ˚C sealed tube];  1H NMR 
(300 MHz; D6-DMSO) !  5.48 (1H, br s, OH-2), 5.48-5.46 (2H, m, 2 ! axial OH), 
5.31 (1H, d, J 6.2, CH H-7), 4.31-4.23 (2H, m, H-1 and H-3), 4.09-4.04 (1H, m, 
H-5), 4.03-3.98 (1H, m, H-2) and 3.97-3.92 (2H, m, H-4 and H-6);  13C NMR 
(75 MHz; d6-DMSO) ! 102.2 (CH-7), 74.7 (CH-1 and CH-3), 69.6 (CH-5), 67.8 
(CH-4 and CH-6) and 58.9 (C-2);  m/z (ES+) 213 ([M+Na]+, 100%).  These data 
are in good agreement with the literature values.38 
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6.3.30. (±)-D-4-O-(4-methoxybenzyl)-myo-inositol 1,3,5-orthoformate 60  
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To a solution of D-myo-inositol 1,3,5-orthoformate 49 (25.0 g, 132 mmol, 1 eq) 
in N,N-dimethylformamide (250 mL) cooled to -10 ˚C, was added sodium 
hydride (5.5 g, 138 mmol, 1.05 eq) as a 60% dispersion in mineral oil, in 
portions over 70 min.  The resultant slurry was allowed to warm to RT and 
stirred for 3 h.  The slurry was then re-cooled to -10 ˚C before 4-methoxybenzyl 
chloride (22.7 g, 19.6 mL, 145 mmol, 1.1 eq) was added dropwise over 30 min 
via a pressure equalised dropping funnel.  The reaction mixture was allowed to 
warm to RT and stirred for 18 h, after which time TLC analysis indicated 
consumption of the starting material.  The reaction was quenched by the careful 
addition of water (10 mL) and the volatile components were removed in vacuo 
providing a brown oil.  The oil was partitioned between ethyl acetate (250 mL) 
and water (200 mL) and the layers separated.  The aqueous phase was re-
extracted with ethyl acetate (3 ! 100 mL).  The combined organic layers were 
washed with brine (200 mL), dried over magnesium sulfate, filtered and 
concentrated in vacuo affording a light brown oil.  Purification of the oil by silica 
gel chromatography, eluting with petroleum ether and ethyl acetate (80:20, 
70:30, 60:40, 50:50, 30:70), provided (±)-D-4-O-(4-methoxybenzyl)-myo-inositol 
1,3,5-orthoformate 60 (32.0 g, 78%) as a colourless solid: Rf 0.18 (hexane/ethyl 
acetate 50:50); mp 99-100 ˚C (from ethyl acetate);  1H NMR (400 MHz; CDCl3) 
! 7.27-7.24 (2H, m, H-10,10’) and 6.95-6.91 (2H, m, H-11,11’) 5.46 (1H, d, J 
1.3, CH H-7), 4.64 (1H, d, J 11.3, CHAHB H-8), 4.60 (1H, d, J 11.3, CHAHB H-8’), 
4.50-4.41 (2H, m, H-4 and H-6), 4.29-4.25 (1H, m, H-5), 4.25-4.21 (2H, m, H-1 
and H-3), 4.12-4.07 (1H, m, H-2), 3.84 (3H, s, OCH3 H-13), 3.80 (1H, d, J 10.3, 
OH-6) and 3.29 (1H, d, J 11.8, OH-2); 13C NMR (100 MHz; CDCl3) ! 160.0 (C-
12 Ar), 129.9 (CH C-10,10’ Ar), 127.9 (C-9 Ar), 114.3 (CH C-11,11’ Ar), 102.7 
(CH-7), 74.7 (CH-6), 73.7 (CH-4), 72.7 (CH2 C-8), 67.9 (CH-1), 67.2 (CH-3), 
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60.6 (CH-2) and 55.3 (OCH3 C-13); m/z (ES
+) 333 ([M+Na]+, 100%).  These 
data are in good agreement with the literature values.41 
 
6.3.31. (±)-D-2,6-Bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3,5-
  orthoformate 61 
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A 60% dispersion of sodium hydride (11.3 g, 282 mmol, 3.5 eq) in mineral oil 
was washed with hexane (2 ! 50 mL) and dried in vacuo.  The flask was cooled 
to -10 ˚C and the sodium hydride was suspended in N,N-dimethylformamide 
(100 mL).  To this suspension was gradually added a solution of  (±)-D-4-O-(4-
methoxybenzyl)-myo-inositol 1,3,5-orthoformate 60 (25.0 g, 80.6 mmol, 1 eq) in 
N,N-dimethylformamide (100 mL) via a pressure equalised dropping funnel, 
maintaining the internal temperature below -5 ˚C.  The mixture was stirred for 
30 min, then benzyl bromide (34.5 g, 24.0 mL, 20.2 mmol, 2.5 eq) was added in 
a single portion.  The mixture was stirred for 18 h, warming to RT, forming a 
thick yellow slurry.  TLC analysis indicated consumption of the starting material.  
The volatile components were removed in vacuo affording a thick brown slurry.  
The slurry was reconstituted with water (200 mL) and ethyl acetate (200 mL) 
and the layers were separated.  The aqueous phase was re-extracted with ethyl 
acetate (3 ! 100 mL) and the combined organic phases were washed with brine 
(200 mL), dried over magnesium sulfate, filtered and concentrated in vacuo 
providing a yellow oil.  Purification of the oil by silica gel chromatography, 
eluting with petroleum ether and ethyl acetate (80:20, 70:30), provided (±)-D-
2,6-bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3,5-orthoformate 61 
(39.0 g, 99%) as a colourless oil: Rf 0.58 (hexane/ethyl acetate 50:50); 
1H NMR 
(400 MHz; CDCl3) ! 7.45-7.22 (10H, m, Ar H), 7.17-7.13 (2H, m, H-12 and H-
12’), 6.86-6.83 (2H, m, H-13 and H-13’), 5.56 (1H, d, J 1.3, CH H-7), 4.67 (2H, 
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s, CH2 H-8 and H-8’), 4.64 (1H, d, J 11.5, CHAHBPh H-16), 4.57 (1H, d, J 11.2, 
CHA’HB’ H-10), 4.50 (1H, d, J 11.5, CHAHBPh H-16’), 4.45-4.44 (1H, m, H-5), 
4.44 (1H, d, J 11.2, CHA’HB’ H-10’), 4.38-4.33 (2H, m, H-4 and H-6), 4.33-4.29 
(2H, m, H-1 and H-3), 4.07 (1H, dd, J 3.1, 1.6, H-2) and 3.83 (3H, s, OCH3 H-
15); 13C NMR (100 MHz; CDCl3) ! 159.4 (C-14 Ar), 137.9 (C-17 Ph), 137.6 (C-9 
Ph), 129.7 (C-11 Ar), 129.3 (CH-12,12’ Ar), 128.5, 128.4, 128.1, 127.9, 127.7, 
113.8 (CH-13,13’ Ar), 103.3 (CH C-7), 74.1 (CH-6), 73.8 (CH-4), 71.6 (CH2 C-
8), 71.6 (CH2 C-16), 71.3 (CH2 C-10), 70.7 (CH-1), 70.6 (CH-3), 68.2 (CH-5), 
67.4 (CH-2) and 55.3 (OCH3 C-15); m/z (ES
+) 513 ([M+Na]+, 100%).  These 
data are in agreement with the literature values.41 
 
6.3.32. (±)-D-2,6-Bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3-O-
  methylene 62 
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A solution of DIBAL-H in hexane (1.0 M, 199 mL, 199 mmol, 2.5 eq) was added 
dropwise over 90 min to a solution of (±)-D-2,6-bis-O-benzyl-4-O-(4-
methoxybenzyl)-myo-inositol 1,3,5-orthoformate 61 (39.0 g, 79.4 mmol, 1 eq) in 
CH2Cl2 (300 mL), maintaining the temperature below 0 ˚C.  The mixture was 
allowed to warm to RT and stirred for 18 h, after which time TLC analysis 
indicated consumption of the starting material.  The colourless solution was 
cooled to 0 ˚C, then water (8 mL) was added dropwise causing rapid 
effervescence.  A solution of sodium hydroxide (15% w/v, 8 mL) was then 
added dropwise, forming a colourless gel.  A further quantity of water (20 mL) 
was added, and the mixture was allowed to warm to RT, forming a colourless 
suspension.  The suspension was stirred for 30 min and filtered through a pad 
of Celite.  The residue was washed with CH2Cl2 (4 ! 250 mL), and the 
combined filtrates were concentrated in vacuo, providing (±)-D-2,6-bis-O-benzyl-
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4-O-(4-methoxybenzyl)-myo-inositol 1,3-O-methylene 62 (37.4 g, 96%), without 
further purification, as a colourless oil: Rf 0.24 (hexane/ethyl acetate 70:30);  
1H 
NMR (400 MHz; CDCl3) ! 7.42-7.31 (10H, m, Ar H), 7.27-7.23 (2H, m, H-
12,12’), 6.91-6.88 (2H, m, H-13,13’), 5.62 (1H, d, J 4.9, CHAHB H-7), 4.72 (1H, 
d, J 11.9, CHA’HB’Ph H-16), 4.72 (1H, d, J 4.9, CHAHB H-7’), 4.66 (2H, s, CH2 H-
8,8’), 4.65 (1H, d, J 11.6, CHA’’HB’’ H-10), 4.62 (1H, d, J 11.9, CHA’HB’Ph H-16’), 
4.56 (1H, d, J 11.6, CHA’’HB’’ H-10’), 4.51-4.46 (2H, m, H-1 and H-3), 4.34 (1H, 
dd, J 1.4, 1.4, H-2), 4.09-4.05 (2H, m, H-4 and H-6), 4.04-3.99 (1H, m, H-5), 
3.85 (3H, s, OCH3 H-15)  and 3.07 (1H, d, J 10.3, OH-5);  
13C NMR (100 MHz; 
CDCl3) ! 159.3 (C-14 Ar), 138.0 (C-17 Ph), 137.7 (C-9 Ph), 130.0 (C-11 Ar), 
129.3 (CH-12,12’ Ar), 128.5, 128.4, 127.9, 127.8, 127.6, 113.8 (CH-13,13’ Ar), 
85.7 (CH2 C-7), 81.2 (CH-6), 80.8 (CH-4), 72.8 (CH-1), 72.7 (CH-3), 72.1 (CH2 
C-16), 71.8 (CH2 C-10), 70.8 (CH2 C-8), 70.3 (CH-2), 69.5 (CH-5) and 55.3 
(OCH3 C-15); m/z (ES
+) 515 ([M+Na]+, 100%).  These data are in good 
agreement with the literature values.41 
 
6.3.33. (±)-D-5-O-Allyl-2,6-bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-
  inositol 1,3-O-methylene 63 
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Sodium hydride (60% dispersion in mineral oil, 5.5 g, 137 mmol, 1.8 eq) was 
washed with hexane (2 ! 50 mL) then dried in vacuo.  The flask was cooled to 
-10 ˚C and the sodium hydride was suspended in N,N-dimethylformamide 
(100 mL).  To this suspension was gradually added a solution of (±)-D-2,6-bis-
O-benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3-O-methylene 62 (37.4 g, 
75.9 mmol, 1 eq) in N,N-dimethylformamide (150 mL), maintaining the 
temperature below -5 ˚C, forming a pale orange slurry.  The slurry was stirred 
for 30 min, then allyl bromide (34.5 g, 24.0 mL, 20.2 mmol, 2.5 eq) was added 
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in three portions.  The mixture was allowed to warm to RT, and was stirred for 
16 h, after which time TLC analysis indicated consumption of the starting 
material.  The volatile components were removed in vacuo, affording an orange 
oil, which was partitioned between ethyl acetate (250 mL) and water (250 mL).  
The layers were separated, then the aqueous phase was re-extracted with ethyl 
acetate (3 ! 150 mL).  The combined organic phases were washed with brine 
(200 mL), dried over magnesium sulfate, filtered and concentrated in vacuo to 
afford an orange oil.  Purification by silica gel chromatography, eluting with 
hexane and ethyl acetate (80:20, 70:30), provided (±)-D-5-O-allyl-2,6-bis-O-
benzyl-4-O-(4-methoxybenzyl)-myo-inositol 1,3-O-methylene 63 (37.2 g, 92%) 
as a colourless oil: Rf 0.41 (hexane/ethyl acetate 70:30);  
1H NMR (400 MHz; 
CDCl3) ! 7.42-7.26 (12H, m, Ar H), 6.91-6.88 (2H, m, H-18,18’), 5.91 (1H, dddd, 
J 17.2, 10.5, 5.6, 5.6, CH H-13), 5.26 (1H, dddd, J 17.2, 1.7, 1.6, 1.6, CHXHY H-
14), 5.21 (1H, d, J 5.6, CHAHB H-7), 5.19 (1H, dddd J 10.5, 1.7, 1.5, 1.5, CHXHY 
H-14’), 4.85 (1H, d, J 5.6, CHAHB H-7’), 4.68 (1H, d, J 11.6, CHA’HB’Ph H-10), 
4.67 (2H, s, CH2Ph, H-8,8’), 4.62 (1H, d, J 11.4, CHA’’HB’’ H-15), 4.62 (1H, d, J 
11.6, CHA’HB’ H-10’), 4.55 (1H, d, J 11.4, CHA’’HB’’ H-15’), 4.29-4.26 (2H, m, H-1 
and H-3), 4.16 (2H, ddd, J 5.6, 1.6, 1.5, CH2 H-12,12’), 3.93-3.90 (2H, m, H-4 
and H-6), 3.85 (1H, dd, J 2.0, 2.0, H-2), 3.83 (3H, s, OCH3 H-20) and 3.55 (1H, 
dd, J 5.7, 5.7, H-5); 13C NMR (100 MHz; CDCl3) ! 159.4 (C-16 Ar), 137.8 (C-9 
Ph), 137.7 (C-11 Ph), 135.0 (CH C-13), 129.8 (C-16 Ar), 129.5 (CH C-17,17’) 
128.5, 128.5, 127.9, 127.9, 127.8, 117.0 (CH2 C-14), 113.9 (CH C-18,18’), 85.5 
(CH2 C-7), 82.0 (CH-6), 81.7 (CH-4), 72.6 (CH2 C-12), 72.1 (CH-1), 72.0 (CH-
3), 71.8 (CH2 C-10), 71.5 (CH2 C-15), 71.0 (CH2 C-8), 70.3 (CH-2) and 55.3 
(OCH3 C-20); m/z (ES
+) 555 ([M+Na]+, 100%).  These data are in agreement 
with the literature values.41 
 
6.3.34. (±)-D-5-O-Allyl-2,6-bis-O-benzyl-myo-inositol 64 
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To a solution of (±)-D-5-O-allyl-2,6-bis-O-benzyl-4-O-(4-methoxybenzyl)-myo-
inositol 63 (37.2 g, 70 mmol, 1 eq) in methanol (150 mL) was added 
concentrated hydrochloric acid (50 mL).  The mixture was heated under reflux 
for 18 h, after which TLC analysis indicated consumption of the starting 
material.  The mixture was cooled to 5 ˚C, and the reaction was quenched by 
the gradual addition of solid sodium bicarbonate until an apparent pH of 7 was 
attained.  The mixture was stirred for a further 2 h, while warming to RT.  The 
excess sodium bicarbonate was removed by filtration and the filtrate was 
concentrated in vacuo providing a beige solid, which was adsorbed onto silica 
gel.  Purification of the solid by silica gel chromatography, eluting with hexane 
and ethyl acetate (50:50, 0:100), provided (±)-D-5-O-allyl-2,6-bis-O-benzyl-myo-
inositol 64 (10.9 g, 39%) as a colourless solid: Rf 0.47 (ethyl acetate); mp 115-
116 ˚C (from ethyl acetate) [lit.41 111-112 ˚C]; 1H NMR (500 MHz; CDCl3) ! 
7.41-7.31 (10H, m, Ar H), 5.99 (1H, dddd, J 17.2, 10.5, 5.8, 5.6, CH H-10), 5.32 
(1H, dddd, J 17.2, 1.5, 1.5, 1.5, CHXHY H-11), 5.21 (1H, dddd, J 10.5, 1.5, 1.3, 
1.3, CHXHY H-11’), 4.93 (1H, d, J 11.2, CHAHB H-12), 4.85 (1H, d, J 11.5, 
CHA’HB’ H-7), 4.80 (1H, d, J 11.5, CHA’HB’ H-7’), 4.77 (1H, d, J 11.2, CHAHB H-
12’), 4.40 (1H, dddd, J 12.5, 5.6, 1.5, 1.3, CHA’’HB’’ H-9), 4.34 (1H, dddd, J 12.5, 
5.8, 1.5, 1.3, CHA’’HB’’ H-9’), 4.02 (1H, dd, J 2.9, 2.8, H-2), 3.82 (1H, ddd, J 9.7, 
9.3, 2.4, H-4), 3.74 (1H, dd, J 9.6, 9.4, H-6), 3.58 (1H, ddd, J 9.6, 5.1, 2.8, H-1), 
3.47 (1H, ddd, J 9.7, 7.1, 2.9, H-3), 3.23 (1H, dd, J 9.4, 9.3, H-5), 2.78 (1H, d, J 
2.4, OH-4), 2.54 (1H, d, J 7.1, OH-3) and 2.42 (1H, d, J 5.1, OH-1); 13C NMR 
(125 MHz; CDCl3) ! 138.5 (C-13 Ph), 138.4 (C-8 Ph), 135.0 (CH C-10), 128.6, 
128.5, 128.1, 128.0, 127.9, 127.8, 117.2 (CH2 C-11), 82.7 (CH-5), 81.7 (CH-6), 
78.9 (CH-2), 75.5 (CH2 C-12), 75.3 (CH2 C-7), 74.1 (CH-4), 74.0 (CH2 C-9), 
72.7 (CH-1) and 72.4 (CH-3); m/z (ES+) 423 ([M+Na]+, 100%).  The data are in 
agreement with the literature values.41 
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6.3.35. 1-(S)-(-)-Camphor dimethylacetal  198 
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To a solution of 1-(S)-(-)-camphor (30.0 g, 197 mmol, 1 eq) in hexane (300 mL) 
was added K-10 montmorillonite clay (54.0 g) and trimethylorthoformate 
(83.7 g, 60.7 mL, 788 mmol, 4 eq).  The suspension was stirred rapidly for 
3 days, then filtered though a pad of Celite.  The residue was washed with 
hexane (4 ! 100 mL) and the combined filtrates were concentrated in vacuo 
providing 1-(S)-(-)-camphor dimethylacetal 198 (36.5 g, 72%) as a colourless 
oil.  Analysis by 1H NMR showed the material was 77% pure.  1H NMR 
(400 MHz; CDCl3) ! 3.22 (3H, s, OCH3), 3.16 (3H, s, OCH3), 2.22-2.16 (1H, m, 
camphor ring), 1.78-1.64 (3H, m, camphor ring), 1.46-1.19 (2H, m, camphor 
ring), 1.15 (1H, d, J 12.9, Hax-3), 0.97 (3H, s, CH3 on C-7), 0.91 (3H, s, CH3 on 
C-1) and 0.85 (3H, s, CH3 on C-7).  The data are in good agreement with the 
literature values.190 
 
6.3.36. (-)-D-5-O-Allyl-2,6-bis-O-benzyl-3-O-endo,4-O-exo-(L-1’,7’,7’- 
  trimethylbicyclo[2.2.1]hept-2’-ylidene)-myo-inositol 65 
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To a solution of (±)-D-5-O-allyl-2,6-bis-O-benzyl-myo-inositol 64 (10.9 g, 
27.3 mmol, 1 eq) in CH2Cl2 (100 mL) was added 1(S)-(-)-camphor 
dimethylacetal  198 (77%, 21.1 g, 81.8 mmol, 3 eq) and 4-TsOH·H2O (262 mg, 
1.4 mmol, 0.05 eq).  The solution was heated under reflux for 14 h, then 
allowed to cool to RT, after which time TLC analysis indicated consumption of 
the starting material.  The solvent was removed in vacuo, providing a colourless 
oil.   Purification of the oil by silica gel chromatography, eluting with petroleum 
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ether and ethyl acetate (95:5, 94:6, 93:7, 92:8; 90:10, 88:12, 80:20, 70:30, 
50:50), provided (-)-D-5-O-allyl-2,6-bis-O-benzyl-3-O-endo,4-O-exo-(L-1’,7’,7’-
trimethylbicyclo[2.2.1] hept-2’-ylidene)-myo-inositol 65 (2.97 g, 20%) as a 
colourless oil: Rf 0.51 (hexane/ethyl acetate, 70:30);  
  
! 
"[ ]
D
20
 -11.8 (c 4.30 in 
CHCl3) [lit.
41 
  
! 
"[ ]
D
20
 -11.7 (c 1.3 in CHCl3)]; 
1H NMR (500 MHz; CDCl3) ! 7.42-
7.26 (10H, m, Ar H), 5.96 (1H, dddd, J 17.2, 10.5, 5.6, 5.4, H-10), 5.32 (1H, 
dddd, J 17.2, 1.6, 1.6, 1.5, CHXHY H-11), 5.17 (1H, dddd, J 10.5, 1.6, 1.4, 1.4, 
CHXHY H-11’), 5.01 (1H, d, J 11.6, CHAHB, H-7), 4.93 (1H, d, J 11.0, CHA’HB’ H-
12), 4.78 (1H, d, J 11.0, CHA’HB’, H-12’), 4.69 (1H, d, J 11.6, CHAHB, H-7’), 4.40 
(1H, dddd, J 12.9, 5.4, 1.5, 1.4, CHA’’HB’’ H-9), 4.21 (1H, dd, J 3.1, 2.2, H-2), 
4.20 (1H, dddd, J 12.9, 5.6, 1.6, 1.4, CHA’’HB’’ H-9’), 3.97 (1H, dd, J 9.8, 9.5, H-
4), 3.67 (1H, ddd, J 8.7, 8.2, 3.1, H-1), 3.60 (1H, dd, J 8.7, 8.6, H-6), 3.52 (1H, 
dd, J 9.5, 8.6, H-5), 3.30 (1H, dd, J 9.8, 2.2, H-3), 2.46 (1H, d, J 8.2, OH-1), 
2.15 (1H, ddd, J 13.5, 4.1, 3.5, Heq-3’ camphor ring), 1.91 (1H, ddd, J 12.8, 9.2, 
3.6, Heq-6’ camphor ring), 1.77-1.69 (2H, m, H-4’ and H eq-5’ camphor ring), 1.47 
(1H, d, J 13.5, Hax-3’ camphor ring), 1.44-1.38 (1H, m, Hax-6’ camphor ring), 
1.25-1.19 (1H, m, Hax-5’ camphor ring), 1.03 (3H, s, 1 ! CH3 on C-7’), 0.87 (3H, 
s, CH3 on C-1’) and 0.86 (3H, s, 1 ! CH3 on C-7’); 
13C NMR (125 MHz; CDCl3) ! 
138.8 (C-13 Ph), 138.0 (C-8 Ph), 135.2 (CH C-10), 128.4, 128.3, 128.2, 128.0, 
127.8, 127.77, 127.6, 120.4 (C-2’ camphor ring), 116.6 (CH2 C-11), 83.9 (CH-
6), 80.8 (CH-5), 77.3 (CH-4), 76.7 (CH-3), 76.0 (CH2 C-12), 74.2 (CH2 C-6), 
74.1 (CH-2), 73.5 (CH-1), 71.7 (CH2 C-9), 52.9 (C-1’ camphor ring), 48.2 (C-7’ 
camphor bridge), 46.1 (C-3’ camphor ring), 44.9 (C-4’ camphor ring), 28.9 (C-6’ 
camphor ring), 26.7 (C-5’ camphor ring), 20.3 (CH3 on C-7’ camphor bridge), 
20.1 (CH3 on C-7’ camphor bridge) and 9.7 (CH3 on C-1’ camphor ring); m/z 
557 ([M+Na]+, 100%).  The data are in good agreement with the literature 
values.41 
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6.3.37. (-)-D-5-O-Allyl-2,6-bis-O-benzyl-myo-inositol (-)-64 
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To a solution of (-)-D-5-O-allyl-2,6-bis-O-benzyl-3-O-endo-4-O-exo-(L-1’,7’,7’-
trimethylbicyclo[2.2.1]hept-2’-ylidene)-myo-inositol 65 (2.50 g, 4.7 mmol, 1 eq) 
in CH2Cl2 (20 mL) and methanol (12 mL) was added acetyl chloride (220 mg, 
200 µL, 2.80 mmol, 0.6 eq) dropwise.  The mixture was stirred for 18 h at RT 
after which time TLC analysis indicated consumption of the starting material.  
The reaction was quenched by the careful addition of triethylamine (1 mL) and 
stirred for 20 min at RT.  The solvent was the removed in vacuo, affording a 
yellow oil, which was adsorbed onto silica gel.  Purification of the material by 
silica gel chromatography, eluting with chloroform and methanol (98:2), afforded  
a colourless solid.  Crystallisation of the solid from diethyl ether afforded (-)-D-5-
O-allyl-2,6-bis-O-benzyl-myo-inositol 64 (1.56 g, 83%) as a microcrystalline 
solid: Rf 0.20 (chloroform/methanol 98:2); 
  
! 
"[ ]
D
20
 -22.5 (c 1.00 in CHCl3); mp 110-
111 ˚C (from diethyl ether); !max (KBr disc) cm
-1 3388 (s), 3065 (w), 3031 (w), 
2922 (m), 1646 (w), 1497 (w), 1454 (m), 1359 (m), 1151 (m), 1131 (m), 1054 
(s), 928 (m), 697 (m) and 620 (m); 1H NMR (400 MHz; CDCl3) ! 7.41-7.29 (10H, 
m, Ar H), 5.98 (1H, dddd, J 17.2, 10.5, 5.8, 5.6, H-10), 5.32 (1H, dddd, J 17.2, 
1.6, 1.5, 1.5, CHXHY H-11), 5.20 (1H, dddd, J 10.5, 1.6, 1.4, 1.3, CHXHY H-11’), 
4.93 (1H, d, J 11.1, CHAHB H-12), 4.89 (1H, d, J 11.6, CHA’HB’ H-7), 4.79 (1H, d, 
J 11.6, CHA’HB’ H-7’), 4.76 (1H, d, J 11.1, CHAHB H-12’), 4.39 (1H, dddd, J 12.5, 
5.6, 1.5, 1.4, CHA’’HB’’ H-9), 4.33 (1H, dddd, J 12.5, 5.8, 1.5, 1.3, CHA’’HB’’ H-9’), 
4.00 (1H, dd, J 2.8, 2.7, H-2), 3.81 (1H, dd, J 9.6, 9.4, H-4), 3.74 (1H, dd, J 9.6, 
9.4, H-6), 3.57 (1H, ddd, J 9.6, 5.2, 2.7, H-1), 3.45 (1H, ddd, J 9.6, 6.8, 2.8, H-
3), 3.22 (1H, dd, J 9.4, 9.4, H-5), 2.88 (1H, d, J 1.4, OH-4), 2.62 (1H, d, J 6.8, 
OH-3) and 2.45 (1H, d, J 5.2, OH-1); HRMS m/z (ES+) [Found: (M+Na)+ 
423.1771. C23H28O6Na requires M
+
, 423.1778]; m/z (ES
+) 459 
[(M+MeCN+NH4)
+, 100%).  The appropriate data are in good agreement with 
the literature values for the racemic compound.41 
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6.3.38. (-)-D-5-O-Allyl-2,3,6-tris-O-benzyl-myo-inositol 202 
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To a solution of (-)-D-5-O-allyl-2,6-O-bis-benzyl-myo-inositol (-)-64 (1.40 g, 
3.50 mmol, 1 eq) in acetonitrile (50 mL) was added di-n-butyl tin oxide (0.96 g, 
3.85 mmol, 1.1 eq), TBABr (1.13 g, 3.50 mmol, 1 eq) and benzyl bromide 
(1.79 g, 1.25 mL, 10.5 mmol, 3 eq).  The mixture was heated under reflux for 
20 h, with azeotropic removal of water via a Soxhlet apparatus filled with 
activated 3 Å molecular sieves.  After this time TLC analysis indicated 
consumption of the starting material.  The solvent was concentrated in vacuo, 
affording a thick yellow oil, which was partitioned between water (60 mL) and 
ethyl acetate (60 mL).  The layers were separated and the aqueous phase was 
re-extracted with ethyl acetate (2 ! 60 mL).  The combined organic phases were 
treated with saturated aqueous sodium bicarbonate solution (60 mL), 
precipitating the residual tin salts as a fine colourless suspension.  The mixture 
was filtered through a pad of Celite and the layers were separated again.  The 
organic phase was washed with brine (60 mL), dried over magnesium sulfate, 
filtered and concentrated in vacuo providing a light brown oil.  Purification of the 
oil by silica gel chromatography, eluting with petroleum ether and ethyl acetate 
(85:15, 80:20), afforded (-)-D-5-O-allyl-2,3,6-tris-O-benzyl-myo-inositol 202 
(1.35 g, 79%) as a colourless oil: Rf 0.59 (petroleum ether/ethyl acetate 50:50), 
  
! 
"[ ]
D
24
 -3.5 (c 1.15 in CHCl3); "max (KBr disc) /cm
-1 3424 (s), 3088 (w), 3030 (m), 
2891 (m), 1644 (w), 1496 (m), 1454 (s), 1360 (s), 1244 (m), 1211 (s), 1152 (s), 
1067 (s), 1025 (m), 930 (w), 815 (s), 701 (s) and 606 (w); 1H NMR (500 MHz; 
CDCl3) ! 7.40-7.28 (15H, m, Ar H), 5.99 (1H, dddd, J 17.2, 10.5, 5.8, 5.7, CH-
12), 5.31 (1H, dddd, J 17.2, 1.5, 1.5, 1.4, CHXHY H-13), 5.18 (1H, dddd, J 10.5, 
1.5, 1.4, 1.3, CHXHY H-13’), 4.93 (1H, d, J 11.6, CHAHB H-7), 4.91 (1H, d, J 
11.1, CHA’HB’ H-14), 4.77 (1H, d, J 11.1, CHA’HB’ H-14’), 4.72 (1H, d, J 11.6, 
CHAHB H-7’), 4.70 (1H, d, J 11.7, CHA’’HB’’ H-9), 4.61 (1H, d, J 11.7, CHA’’HB’’ H-
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9’), 4.39 (1H, dddd, J 12.5, 5.8, 1.5, 1.4, CHA’’’HB’’’ H-11), 4.35 (1H, dddd, J 12.5, 
5.7, 1.4, 1.3, CHA’’’HB’’ H-11’), 4.11 (1H, ddd, J 9.7, 9.4, 1.7, H-4), 4.07 (1H, dd, 
J 2.7, 2.5, H-2), 3.75 (1H, dd, J 9.5, 9.3, H-6), 3.49 (1H, ddd, J 9.5, 6.3, 2.7, H-
1), 3.28 (1H, dd, J 9.7, 2.5, H-3), 3.27 (1H, dd, J 9.4, 9.3, H-5), 2.56 (1H, d, J 
1.7, OH-4) and 2.29 (1H, d, J 6.3, OH-1); 13C NMR (125 MHz; CDCl3) ! 138.6 
(C-15 Ph), 138.5 (C-8 Ph), 137.8 (C-10 Ph), 135.2 (CH C-12), 128.6, 128.5, 
128.3, 128.1, 127.9, 127.8, 127.77, 127.75, 127.6, 116.9 (CH2 C-13), 82.9 (CH-
5), 81.8 (CH-6), 80.3 (CH-3), 76.1 (CH-2), 75.5 (CH2 C-14), 74.7 (CH2 C-7), 
74.1 (CH2 C-11), 73.0 (CH-4), 72.5 (CH2 C-9) and 72.49 (CH-1); HRMS m/z 
(ES+) [Found: (M+Na)+ 513.2244. C30H34O6Na requires M
+, 513.2248]; m/z 
(ES+) 549 ([M+MeCN+NH4]
+, 100%); Anal. Calcd. For C30H34O6: C, 73.45; H, 
6.99. Found: C, 73.39; H, 7.05. 
 
6.3.39. Bis(benzyloxy)-N,N-diisopropylamino phosphine 168 
P
N
OBnBnO  
To a solution of benzyloxy-bis(N,N-bisisopropylamino) phosphine 167 (5.0 g, 
14.8 mmol, 1 eq) in CH2Cl2 (100 mL) was added a solution of 1H-tetrazole in 
acetonitrile (0.43 M, 13.7 mL, 5.9 mmol, 0.4 eq).  To this solution was added a 
solution of anhydrous benzyl alcohol (1.60 g, 14.8 mmol, 1 eq) in CH2Cl2 
(50 mL) dropwise via a pressure equalised dropping funnel over 2  h.  The 
mixture was stirred at RT for a further 5 h, after which time TLC analysis 
showed consumption of the phosphine starting material.  The volatile 
components were removed in vacuo, furnishing a cloudy yellow oil.  Purification 
of the oil by silica gel chromatography, eluting with hexane, ethyl acetate and 
triethylamine (85:10:5), provided bis(benzyloxy)-N,N-diisopropylamino 
phosphine 168 (4.15 g, 81%) as a colourless oil:  Rf 0.64 (hexane/ethyl acetate 
80:20); 1H NMR (400 MHz; CDCl3) ! 7.39-7.25 (10H, m, Ar H), 4.83 (2H, dd, J 
12.6, 8.1, CHAHB), 4.75 (2H, dd, J 12.6, 8.6, CHAHB), 3.78-3.67 (2H, m, 
CH(CH3)2) and 1.23 (12H, d, J 6.8 CH(CH3)2);  
31P NMR (162 MHz; CDCl3) 
! 147.7.  These data are in agreement with the literature values.147, 149 
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6.3.40. (-)-D-5-O-Allyl-2,3,6-tris-O-benzyl-myo-inositol 1,4-O-  
  bis(dibenzyl phosphate) 203 
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To a solution of bis(benzyloxy)-N,N-diisopropylamino phosphine (2.35 g, 
6.8 mmol, 2.8 eq) in CH2Cl2 (50 mL) was added a solution of 1H-tetrazole in 
acetonitrile (0.43 M, 15.1 mL, 6.8 mmol, 2.8 eq), turning the mixture cloudy after 
15 min stirring.  A solution of (-)-D-5-O-allyl-2,3,6-O-tris-benzyl-myo-inositol 202 
(1.20 g, 2.5 mmol, 1 eq) in CH2Cl2 (50 mL) was added dropwise over 30 min via 
a pressure equalised dropping funnel.  The resulting solution stirred for 16 h at 
RT, forming a colourless precipitate.  TLC analysis of the mixture showed 
consumption of the starting material.  The mixture was cooled to -78 ˚C and 3-
chloroperoxybenzoic acid (1.18 g, 6.8 mmol, 2.8 eq) was added in a single 
portion.  The mixture stirred for 20 min at -78 ˚C then was allowed to warm to 
RT over 90 min, after which TLC analysis indicated consumption of the 
intermediate.  The solution was diluted with CH2Cl2 (100 mL) and the reaction 
was quenched by addition of aqueous sodium sulfite solution (10% w/v, 
100 mL).  The layers were separated and the aqueous phase was re-extracted 
with CH2Cl2 (2 ! 100 mL).  The combined organic layers were washed with 
aqueous saturated sodium bicarbonate solution (100 mL) and brine (100 mL), 
dried over magnesium sulfate, filtered and concentrated in vacuo affording a 
colourless oil, which solidified on standing.  Purification of the solid, eluting with 
petroleum ether and ethyl acetate (70:30, 50:50), furnished a colourless solid.  
Crystallisation of the solid from diethyl ether, afforded (-)-D-5-O-allyl-2,3,6-tris-
O-benzyl-myo-inositol 1,4-O-bis(dibenzyl phosphate) 203 (2.00 g, 81%) as 
colourless needles: Rf 0.42 (petroleum ether/ethyl acetate 50:50); 
  
! 
"[ ]
D
24
 -0.9 (c 
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0.86 in CHCl3); mp 90-91 ˚C (from diethyl ether); !max (KBr disc) /cm
-1 3032 (w), 
2930 (w), 1498 (m) 1455 (m), 1357 (m), 1264 (s), 1215 (w), 1024 (s), 999 (s), 
966 (m), 745 (s), 696 (s), 603 (w) and 500 (w); 1H NMR (500 MHz; CDCl3) ! 
7.35-7.15 (35H, m, Ar H), 5.85 (1H, dddd, J 17.2, 10.6, 5.7, 5.6, CH-16), 5.15 
(1H, dddd, J 17.2, 1.6, 1.6, 1.5, CHXHY H-17), 5.03 (1H, dddd, J 10.6, 1.5, 1.5, 
1.4, CHXHY H-17’), 5.00-4.84 (9H, m, H-4 and 4 " CHAHBPh), 7.43 (1H, d, J 
11.4, CHAHB H-9), 4.81 (1H, d, J 10.7, CHA’HB’ H-18), 4.74 (1H, d, J 10.7, 
CHA’HB’ H-18’), 4.67 (1H, d, J 11.4, CHAHB H-9’), 4.52 (2H, s, CH2 H-11,11’), 
4.33-4.25 (3H, m, H-2 and CH2 H-15,15’), 4.22 (1H, ddd, J 9.8, 7.7, 2.5, H-1), 
4.03 (1H, dd, J 9.8, 8.5, H-6) and 3.39-3.34 (2H, m, H-3 and H-5); 13C NMR 
(125 MHz; CDCl3) ! 138.3 (C-10 Ph), 138.2 (C-19 Ph), 137.4 (C-12 Ph), 136.2 
(d, J 7.5), 136.18 (d, J 7.4), 135.7 (d, J 7.6), 135.65 (d, J 7.8), 134.8 (CH-16), 
128.54, 28.5, 128.49, 128.4, 138.34, 138.32, 138.31, 128.2, 128.17, 128.1, 
128.05, 127.8, 127.78, 127.72, 127.7, 127.66, 127.6, 127.54, 127.5, 127.4, 
116.8 (CH2 C-17), 80.9 (CH-5), 79.7 (d, J 7.2, CH-6), 79.4 (d, J 7.3, CH-4), 78.5 
(d, J 2.6, CH-3), 78.1 (d, J 6.3, CH-1), 75.5 (CH2 C-18), 75.4 (CH2 C-2), 75.1 
(CH2 C-9), 74.4 (CH2 C-15), 72.3 (CH2 C-11), 69.4 (d, J 5.5, CH2Ph), 69.24 (d, J 
5.7, CH2Ph), 69.2 (d, J 5.6, CH2Ph) and 69.0 (d, J 5.1, CH2Ph); 
31P NMR (202 
MHz; CDCl3) ! -0.28 and -0.36; isotope distribution m/z (ES
+) [Found: (M+Na)+ 
1033.3271 (100), 1034.3310 (64), 1035.3340 (20), 1036.3353 (5). 
C58H60O12P2Na requires M
+, 1033.3452 (100), 1034.3486 (64), 1035.3519 (23), 
1036.3553 (6)]; m/z (ES+) 1070 ([M+MeCN+NH4]
+, 100%); Anal. Calcd. For 
C58H60O12P2: C, 68.90; H, 5.98. Found: C, 68.99; H, 5.93. 
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6.3.41. (-)-D-2,3,6-Tris-O-benzyl-myo-inositol 1,4-O-bis(dibenzyl  
  phosphate) 204  
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Six reactions were performed in parallel (total scale 1.20 g), then combined 
after workup for purification.  To a stirred solution of (-)-D-5-O-allyl-2,3,6-tris-O-
benzyl-myo-inositol 1,4-O-bis(dibenzyl phosphate) 203 (200 mg, 0.20 mmol, 
1 eq) in methanol (8 mL) was added palladium dichloride (44 mg, 0.25 mmol, 
1.25 eq) in a single portion.  The heterogeneous mixture was vigorously stirred 
for 2.5 h at RT, after which time TLC analysis indicated consumption of the 
starting material.  The solvent was removed in vacuo and the resulting dark 
residue was partitioned between CH2Cl2 (25 mL) and hydrogen peroxide 
solution (15% v/v, 25 mL), stirring for 15 min until effervescence subsided.  The 
layers were separated and the aqueous phase was re-extracted with CH2Cl2 
(2 ! 30 mL).  The organic phases from all six experiments were combined, 
washed with water (100 mL) and brine (100 mL), dried over magnesium sulfate, 
filtered and concentrated in vacuo, affording a pale yellow oil that solidified to a 
waxy solid on standing.  Purification of the solid by silica gel chromatography, 
eluting with petroleum ether and ethyl acetate (50:50, 0:100), afforded a 
colourless solid.  Crystallisation of the solid from diethyl ether furnished (-)-D-
2,3,6-tris-O-benzyl-myo-inositol 1,4-O-bis(dibenzyl phosphate) 204 (970 mg, 
84%) as a microcrystalline colourless solid: Rf 0.30 (petroleum ether/ethyl 
acetate 50:50); 
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"[ ]
D
24
 -7.2 (c 1.10 in CHCl3); mp 103-104 ˚C (from diethyl ether); 
"max (KBr disc) /cm
-1 3362 (m), 3032 (m), 2889 (m), 1497 (m), 1456 (s), 1382 
(m), 1266 (s), 1217 (m), 1011 (s), 886 (m), 734 (s), 696 (s), 622 (w); 1H NMR 
(500 MHz; CDCl3) ! 7.39-7.35 (2H, m, Ar H), 7.34-7.21 (29H, m, Ar H), 7.20-
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7.17 (4H, m, Ar H), 5.05-5.00 (3H, m, 1.5 ! CHAHBPh), 5.00-4.90 (6H, m, 
CHAHB H-15 and 2.5 ! CHAHBPh), 4.81 (1H, d, J 11.6, CHA’HB’ H-9), 4.77-4.69 
(3H, m, H-4, CHAHB H-15’ and CHA’HB’ H-9’), 4.51 (1H, d, J 11.5, CHA’’HB’’ H-
11), 4.44 (1H, d, J 11.5, CHA’’HB’’ H-11’), 4.34 (1H, dd, J 2.5, 2.5, H-2), 4.26 (1H, 
d, J 2.5, ex. in D2O, OH-5), 4.23 (1H, ddd, J 9.8, 7.8, 2.5, H-1), 3.98 (1H, dd, J 
9.8, 9.1, H-6), 3.71 (1H, ddd, J 9.1, 8.9, 2.5, H-5) and 3.38 (1H, dd, J 9.7, 2.5, 
H-3); 13C NMR (125 MHz; CDCl3) ! 138.5 (C-16 Ph), 138.3 (C-10 Ph), 137.4 (C-
12 Ph), 135.7 (d, J 7.5), 135.66 (d, J 7.3), 135.6 (d, J 7.4), 135.56 (d, J 7.7), 
128.53, 128.5, 128.49, 128.33, 128.3, 128.22, 128.2, 128.0, 127.82, 127.8, 
127.72, 127.7, 127.6, 127.5, 127.47, 81.0 (d, J 5.9, CH-4), 79.6 (d, J 7.4, CH-6), 
78.0 (d, J 6.2, CH-3), 77.7 (d, J 5.9, CH-1), 75.7 (CH-2), 75.4 (CH2 C-15), 75.1, 
(CH2 C-9), 74.8 (CH-5), 72.5 (CH2 C-11), 69.73 (d, J 5.8, CH2Ph), 69.7 (d, J 5.6, 
CH2Ph), 69.4 (d, J 5.6, CH2Ph) and 69.3 (d, J 5.5, CH2Ph); 
31P NMR (202 MHz; 
CDCl3) ! 1.61 (P-4) and -0.46 (P-1); HRMS m/z (ES
+) [Found: (M+Na)+ 
993.3162. C55H56O12P2 requires M
+, 993.3139]; m/z (ES+) 1029 
([M+MeCN+NH4]
+, 100%); Anal. Calcd. For C55H56O12P2: C, 68.03; H, 5.81. 
Found: C, 68.13; H, 5.73. 
 
6.3.42. 1-Hydroxy-6-(trifluoromethyl)benzotriazole 185 
N
NN
HO
F3C  
To a solution of 4-chloro-3-nitrobenzotrifluoride (25.0 g, 16.5 mL, 111 mmol, 
1 eq) in absolute ethanol (34 mL) was added hydrazine hydrate (16.7 g, 
16.2 mL, 333 mmol, 3 eq), turning the solution dark brown.  The mixture was 
heated under reflux for 22 h, forming a thick paste, which turned from dark red 
to yellow.  The volatile components were removed in vacuo affording a thick 
yellow paste.  The mixture was partitioned between diethyl ether (500 mL) and 
water (500 mL) and the layers were separated.  The ether layer was extracted 
with aqueous sodium carbonate solution (10% w/v, 500 mL).  The two aqueous 
fractions were carefully acidified to pH 1 with concentrated hydrochloric acid, 
precipitating the product as an off white solid.  The solid was isolated by 
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filtration, washed with water (3 ! 100 mL), air dried for 30 min then crystallised 
from diethyl ether affording 1-hydroxy-6-(trifluoromethyl)benzotriazole 185 
(16.47 g, 74%) as an off white crystalline solid: 1H NMR (400 MHz; D6-acetone) 
! 12.90 (1H, br s, OH), 8.22 (1H, d, J 8.8, H-4), 8.18 (1H, s, H-7) and 7.74 (1H, 
dd, J 8.8, 0.9, H-5).  The data were in agreement with the literature values.155 
 
6.3.43. Bis(1-[6-trifluoromethyl]benzotriazolyl)methylphosphonate 186 
N
N
N
O
F3C
P
O
H3C
2  
To a solution of 1-hydroxy-6-(trifluoromethyl)benzotriazole 185 (2.0 g, 10 mmol, 
2 eq) in anhydrous dioxane (15 mL) were added activated 3 Å molecular sieves 
and pyridine (790 mg, 0.8 mL, 10 mmol, 2 eq).  A solution of methylphosphonic 
dichloride (665 mg, 5 mmol, 1 eq) in dioxane (10 mL) was added dropwise over 
10 min via a pressure equalized dropping funnel, turning the mixture cloudy.  
The resulting suspension was stirred for 90 min at RT before the solids were 
removed by Schlenk filtration under a positive pressure of Ar gas, affording a 
colourless stock solution of bis(1-[6-trifluoromethyl]benzotriazolyl) 
methylphosphonate 186 (0.20 M in dioxane): 31P NMR (101 MHz; C6D6) ! 48.5 
[lit.117 ! 47.6 (CD3CN)]. 
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6.3.44. (-)-D-2,3,6-Tris-O-benzyl-5-(benzyl methylphosphonate)-myo- 
  inositol 1,4-O-bis(dibenzyl phosphate) 212  
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To a stirred solution of (-)-D-2,3,6-tris-O-benzyl-myo-inositol 1,4-O-bis(dibenzyl 
phosphate) 204 (180 mg, 0.19 mmol, 1 eq) in pyridine (600 µL) was added 
activated 3 Å molecular sieves.  A solution of bis(1-[6-
trifluoromethyl]benzotriazolyl) methylphosphonate 186 in dioxane (0.2 M, 
1.85 mL, 0.37 mmol, 2 eq) was added and the resulting mixture was stirred for 
10 min at RT.  Anhydrous benzyl alcohol (80 mg, 77 µL, 0.74 mmol, 4 eq) was 
added dropwise and the mixture stirred for a further 90 min, after which time 
TLC analysis indicated consumption of the starting material.  The reaction was 
quenched by the addition of triethylammonium bicarbonte buffer (1 M, 10 mL, 
pH 8.5) and CH2Cl2 (10 mL).  The layers were separated and the aqueous layer 
was re-extracted with CH2Cl2 (2 ! 10 mL).  The combined organic layers were 
washed with triethylammonium bicarbonate buffer (10 mL), water (10 mL) and 
brine (10 mL), dried over magnesium sulfate, filtered and concentrated in 
vacuo, affording a colourless oil.  Purification of the oil by silica gel 
chromatography, eluting with petroleum ether and ethyl acetate (40:60, 30:70, 
20:80, 0:100), afforded (-)-D-2,3,6-tris-O-benzyl-5-(benzyl methylphosphonate)-
myo-inositol 1,4-O-bis(dibenzyl phosphate) 212 (78 mg, 36%) as a colourless 
oil and 2:1 mixture of diastereoisomers (ds1:ds2, adjudged by 1H NMR): Rf 0.30 
(petroleum ether/ethyl acetate 30:70); 
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 -4.9 (c 0.48 in CHCl3); "max (KBr 
disc) /cm-1 3449 (w), 3033 (w), 2925 (w), 2361 (w), 2341 (w), 1636 (w), 1498 
(m), 1456 (m), 1378 (m), 1270 (s), 1015 (s), 919 (m), 736 (s) and 697 (s); 1H 
NMR (500 MHz; CDCl3) ! 7.43-6.99 (40H, m, Ar H), 5.11-4.80 (12H, m, 6 ! 
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CHAHB), 4.77 (1H, d, J 11.2, CHAHB H-18’), 4.69 (1H, d, J 11.4, CHA’HB’ H-9’ 
diastereoisomer 2), 4.69 (1H, d, J 11.4, CHA’HB’ H-9’ diastereoisomer 1), 4.60-
4.51 (2H, m, H-5 and CHA’’HB’’ H-11), 4.48 (1H, d, J 11.6, CHA’’HB’’ H-11’ 
diastereoisomer 1), 4.47 (1H, d, J 11.6, CHA’’HB’’ H-11’ diastereoisomer 2), 4.40 
(1H, ddd, J 9.6, 9.6, 9.5, diastereoisomer 2, H-5), 4.37-4.34 (1H, m, H-2), 4.30 
(1H, ddd, J 9.8, 7.5, 2.5, H-1 diastereoisomer 1), 4.26 (1H, ddd, J 9.8, 7.5, 2.5, 
H-1 diastereoisomer 2), 4.08 (1H, dd, J 9.8, 9.6, H-6), 3.44 (1H, dd, J 9.9, 2.2, 
H-3 diastereoisomer 1), 3.43 (1H, dd, J 9.8, 2.3, H-3 diastereoisomer 2), 1.49 
(3H, d, J 18.0, CH3 H-15 diastereoisomer 1) and 1.33 (3H, d, J 18.0, CH3 H-15 
diastereoisomer 2); 13C NMR (125 MHz; CDCl3) ! 138.3 (C-10 Ph), 138.1 (C-19 
Ph diastereoisomer 1), 137.7 (C-19 Ph diastereoisomer 2), 137.3 (C-12 Ph), 
136.7 (d, J 6.8, diastereoisomer 2), 136.6 (d, J 6.4, diastereoisomer 1), 136.1 
(d, J 7.8), 136.0 (d, J 7.5), 135.53 (d, J 7.2), 135.5 (d, J 7.2), 135.46 (d, J 6.7), 
128.6, 128.54, 128.5, 128.4, 128.3, 128.24, 128.2, 128.12, 128.1, 128.0, 
127.93, 127.9, 127.84, 127.8, 127.76, 127.74, 127.7, 127.62, 127.6, 127.55, 
127.5, 127.4, 127.37, 127.2, 127.1, 78.0 (CH-4 diastereoisomer 2), 77.97 (CH-4 
major), 77.84 (CH-3), 77.8 (CH-6), 77.74 (d, J 6.7, CH-1), 76.5 (CH-5 
diastereoisomer 2), 75.8 (CH-5 diastereoisomer 1), 75.4 (CH-2 diastereoisomer 
1), 75.3 (CH2 C-9), 75.2 (CH-2 diastereoisomer 2), 74.6 (CH2 C-18 
diastereoisomer 2), 74.5 (CH2 C-18 diastereoisomer 1), 72.5 (CH2 C-11 
diastereoisomer 1), 72.4 (CH2 C-11 diastereoisomer 2), 69.6 (d, J 5.7, CH2Ph 
diastereoisomer 1), 69.55 (d, J 4.9, CH2Ph diastereoisomer 2), 69.5 (d, J 5.7, 
CH2Ph diastereoisomer 1), 69.4 (d, J 5.7, CH2Ph diastereoisomer 2), 69.36 (d, 
J 6.1, CH2Ph diastereoisomer 2), 69.3 (d, J 5.8, CH2Ph diastereoisomer 1), 69.2 
(d, J 5.5, CH2Ph diastereoisomer 1), 69.16 (d, J 5.8, CH2Ph diastereoisomer 2), 
67.3 (d, J 5.9, CH2Ph diastereoisomer 2), 67.0 (d, J 5.7, CH2Ph diastereoisomer 
1), 12.4 (d, J 145.7, CH3 C-15 diastereoisomer 2) and 12.2 (d, J 146.1, CH3 C-
15 diastereoisomer 1); 31P NMR (202 MHz; CDCl3) ! 33.10 (P-5 
diastereoisomer 1), 31.43 (P-5 diastereoisomer 2), -1.54 (diastereoisomer 2), 
-1.59 (diastereoisomer 1), -1.62 (diastereoisomer 1) and -1.84 (diastereoisomer 
2);  isotope distribution m/z (ES+) [Found: (M+Na)+ 1161.3456 (100), 1162.3456 
(68), 1163.3524 (22), 1164.3595 (4), 1165.3462 (1). C63H65O14P3Na requires 
M+, 1161.3479 (100), 1162.3513 (70), 1163.3546 (27), 1164.3580 (7), 
1165.3613 (2)];  m/z (ES+) 1197 ([M+MeCN+NH4]
+, 100%). 
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6.3.45. (-)-D-5-(Methylphosphonate)-myo-inositol 1,4-bisphosphate 
   pentakis sodium salt 126 
P
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To a solution of (-)-D-2,3,6-tris-O-benzyl-5-(benzyl methylphosphonate)-myo-
inositol 1,4-O-bis(dibenzyl phosphate) 212 (63 mg, 55 µmol, 1 eq) in a mixture 
of t-butanol (4.0 mL) and water (0.7 mL) under Ar was added sodium 
bicarbonate (23.2 mg, 276 µmol, 5 eq) and palladium black (118 mg, 
1.10 mmol, 20 eq).  The flask was evacuated and the atmosphere was purged 
with hydrogen gas.  The heterogeneous mixture was vigorously stirred under a 
hydrogen atmosphere for 12 h.  The mixture was filtered through a pad of Celite 
and the residue was washed with diethyl ether (3 ! 5 mL); the filtrates were 
discarded.  The palladium residues were then washed with water (6 ! 5 mL).  
The aqueous filtrates were passed through a Millipore frit and lypholised to 
furnish (-)-D-5-(methylphosphonate)-myo-inositol 1,4-bisphosphate pentakis 
sodium salt 126 (25.8 mg, 93%) as a colourless solid: 
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 -10.4 (c 0.63 in 
H2O); "max (KBr disc) /cm
-1 3410 (s), 1637 (m), 1377 (w), 1154 (s), 1123 (s) and 
1019 (s); 1H NMR (500 MHz; D2O) ! 4.17 (1H, dd, J 2.8, 2.7, H-2), 4.11 (1H, 
ddd, J 9.2, 8.7, 8.1, H-4), 3.90-3.83 (2H, m, H-1 and H-5), 3.78 (1H, dd, J 9.5, 
9.5, H-6), 3.64 (1H, dd, J 9.2, 2.8, H-3) and 1.34 (3H, d, J 16.9, CH3 H-7); 
13C 
NMR (125 MHz; D2O) ! 77.6 (dd, J 6.6, 6.6, CH-5), 74.8 (dd, J 4.3, 4.3, CH-4), 
74.0 (d, J 5.2, CH-1), 71.6 (CH-3), 71.3 (d, J 4.7, CH-6), 70.8 (CH-2) and 12.9 
(d, J 138.3, CH3 C-7); 
31P NMR (202 MHz; D2O) ! 28.6 (P-5), 4.1 and 3.8; 
HRMS m/z (ES-) [Found: (M-2Na+H)- 482.9215. C7H13O14P3Na3 requires M
-, 
482.9217]; m/z (ES-) 483 ([M-2Na+H]-, 5), 461 ([M-3Na+2H]-, 23), 439 ([M-
4Na+3H]-, 19), 417 ([M-5Na+4H]-, 24), 359 (41), 337 (100) and 259 (13). 
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6.3.46. (+)-D-2,3,6-Tris-O-benzyl-5-O-(carboxymethyl)-myo-inositol 1,4-O-
  bis(dibenzyl phosphate) 207 
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To a solution of (-)-D-5-O-allyl-2,3,6-tris-O-benzyl-myo-inositol 1,4-O-
bis(dibenzyl phosphate) 203 (250 mg, 0.25 mmol, 1.0 eq) in a biphasic mixture 
of carbon tetrachloride (2 mL), acetonitrile (2 mL) and water (3 mL) was added 
sodium periodate (217 mg, 1.04 mmol, 4.1 eq) and ruthenium trichloride (1 mg, 
5.0 µmol, 0.02 eq).  The dark mixture was stirred for 8 h at RT, after which time 
TLC analysis indicated consumption of the starting material.  The volatile 
components were removed in vacuo, and the resulting aqueous phase was 
partitioned between CH2Cl2 (30 mL) and hydrogen peroxide solution (15% v/v, 
30 mL).  The mixture was stirred vigorously for 30 min, then passed through a 
pad of Celite.  The dark residue was washed with CH2Cl2 (30 mL) and water 
(30 mL).  The filtrate layers were separated and the aqueous phase was re-
extracted with CH2Cl2 (2 ! 50 mL).  The combined organic phases were washed 
with hydrogen peroxide solution (15% v/v, 20 mL) by vigorously stirring for 
20 min.  The mixture was passed through a fresh pad of Celite and the layers 
were separated.  The organic phase was washed with brine (50 mL), dried over 
magnesium sulfate, filtered and concentrated in vacuo, affording a purple/brown 
oil that was adsorbed onto silica gel.  Purification of the material by silica gel 
chromatography, eluting with ethyl acetate and acetic acid (100:0, 99:1), 
provided (+)-D-2,3,6-tris-O-benzyl-5-O-(carboxymethyl)-myo-inositol 1,4-O-
bis(dibenzyl phosphate) 207 (114 mg, 44%) as a colourless viscous oil: 
  
! 
"[ ]
D
25
 
+7.1 (c 2.65 in CHCl3); "max (KBr disc) /cm
-1 3442 (m), 3064 (m), 3033 (m), 
2952 (m), 2921 (m), 1750 (s), 1635 (w), 1498 (s), 1455 (m), 1377 (m), 1263 (s), 
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1214 (w), 1169 (m), 1016 (s), 917 (w), 738 (s), 697 (s) and 601 (w); 1H NMR 
(500 MHz; CDCl3) ! 7.35-7.16 (35H, m, Ar H), 5.05-4.91 (8H, m, 4 ! CH2Ph), 
4.80 (1H, d, J 11.4, CHAHB H-9), 4.80 (1H, d, J 11.0, CHA’HB’ H-18), 4.75 (1H, 
ddd, J 9.7, 9.3, 9.2, H-4), 4.71 (1H, d, J 11.4, CHAHB H-9’), 4.64 (1H, d, J 11.0, 
CHA’HB’ H-18’), 4.52 (1H, d, J 14.7, CHA’’HB’’ H-15), 4.51 (1H, d, J 11.7, CHA’’’HB’’’ 
H-11), 4.45 (1H, d, J 11.7, CHA’’’HB’’’ H-11’), 4.35 (1H, dd, J 2.3, 2.2, H-2), 4.18 
(1H, ddd, J 9.4, 7.6, 2.3, H-1), 4.03 (1H, dd, J 9.4, 9.1, H-6), 4.02 (1H, d, J 14.7, 
CHA’’HB’’ H-15’), 3.32 (1H, dd, J 9.7, 2.2, H-3) and 3.20 (1H, dd, J 9.2, 9.1, H-5); 
13C NMR (125 MHz; CDCl3) ! 170.0 (C=O, C-16), 138.1 (C-10 Ph), 137.1 (C-12 
Ph), 137.0 (C-19 Ph), 135.5 (d, J 5.7), 135.4 (d, J 5.7), 135.39 (d, J 5.6), 135.2 
(d, J 6.6), 128.7, 128.65, 128.62, 128.6, 128.57, 128.5, 128.47, 128.43, 128.4, 
128.3, 128.1, 128.0, 127.95, 127.93, 127.9, 127.86, 127.7, 127.67, 127.6, 
127.58, 82.0 (CH-5), 79.5 (d, J 7.6, CH-6), 78.2 (d, J 5.9, CH-1), 77.9 (d, J 5.9, 
CH-4), 77.7 (d, J 4.8, CH-3), 75.5 (CH2 C-9), 75.4 (CH2 C-18), 75.3 (CH-2), 
72.6 (CH2 C-11), 71.6 (CH2 C-15), 70.1 (d, J 5.6, CH2Ph), 69.9 (d, J 5.3, 
CH2Ph), 69.7 (d, J 5.6, CH2Ph) and 69.5 (d, J 5.6, CH2Ph); 
31P NMR (202 MHz; 
CDCl3) ! -0.21 and -1.23; HRMS m/z (ES
+) [Found: (M+Na)+ 1051.3199. 
C57H58O14P2Na requires M
+, 1051.3194]; m/z (ES-) 1027 ([M-H]-, 100%). 
 
6.3.47. (+)-D-5-O-(Carboxymethyl)-myo-inositol 1,4-bisphosphate 
  pentakis sodium salt 129 
2
3
4
5
6
1
O
HO
HO O
OH
O
P
ONa
ONa
O
PO ONa
ONa
7
8
ONa
O
 
To a solution of (+)-D-2,3,6-tris-O-benzyl-5-O-(carboxymethyl)-myo-inositol 1,4-
O-bis(dibenzyl phosphate) 207 (114 mg, 0.11 mmol, 1 eq) in a mixture of t-
butanol (6 mL) and water (1 mL) under Ar was added sodium bicarbonate 
(46.5 mg, 0.55 mmol, 5 eq) and palladium black (236 mg, 2.22 mmol, 20 eq).  
The flask was evactuated and the atmosphere was purged with hydrogen gas.  
The heterogeneous mixture was stirred vigorously under a hydrogen 
atmosphere for 14 h, then vented.  The mixture was filtered through a pad of 
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Celite and the residue was washed with diethyl ether (2 ! 5 mL); the filtrates 
were discarded.  The palladium residue was then washed with water (6 ! 5 mL) 
to release the product.  The aqueous filtrates were passed through a Millipore 
frit and lypholised, affording (+)-D-5-O-(carboxymethyl)-myo-inositol 1,4-
bisphosphate pentakis sodium salt 129 (54.9 mg, 98%) as a colourless solid: 
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+2.7 (c 0.53 in H2O); "max (KBr disc) /cm
-1 3424 (s), 1609 (s), 1427 (m), 
1377 (m), 1095 (s), 974 (s), 850 (m), and 695 (s); 1H NMR (500 MHz; D2O) ! 
4.35 (1H, d, J 16.3, CHAHB H-7), 4.21-4.14 (2H, m, H-2 and H-4), 4.07 (1H, d, J 
16.3, CHAHB H-7’), 3.84 (1H, ddd, J 9.4, 6.7, 2.4, H-1), 3.81 (1H, dd, J 9.4, 9.3, 
H-6), 3.61 (1H, dd, J 9.7, 2.9, H-3) and 3.23 (1H, dd, J 9.3, 9.0, H-5); 13C NMR 
(125 MHz; D2O) ! 82.8 (d, J 6.2, CH-5), 76.0 (d, J 5.0, CH-4), 74.4 (d, J 5.2, 
CH-1), 71.6 (CH-3), 71.4 (CH2 C-7), 71.0 (d, J 6.0, CH-6) and 70.8 (CH-2); 
31P 
NMR (202 MHz; D2O) ! 4.23 and 3.60; HRMS m/z (ES
-) [Found: (M-Na)- 
484.9222. C8H11O14P2Na4 requires 484.9220]; m/z (ES
-) 441 ([M-3Na+2H]-, 2), 
419 ([M-4Na+3H]-, 9), 397 ([M-5Na+4H]-, 48) and 317 (100). 
 
6.3.48. Sulfamoyl chloride 209 
Cl S
O
O
NH2
 
To a solution of chlorosulfonyl isocyanate (4.95 g, 3.1 mL, 35.0 mmol, 1 eq) in 
CH2Cl2 (14 mL) cooled to 0 ˚C was added formic acid (1.70 g, 1.4 mL, 
36.8 mmol, 1.05 eq) in two portions, causing evolution of gas.  The mixture was 
stirred for 30 min under a slow stream of Ar, then warmed to RT and stirred for 
a further 5 h, affording a pale pink stock solution of sulfamoyl chloride 209 in 
CH2Cl2 (presumed 2.5 M).  The stock solution was used as was, without further 
purification. 
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6.3.49. (+)-D-2,3,6-Tris-O-benzyl-5-O-sulfamoyl-myo-inositol 1,4-O- 
  bis(dibenzyl phosphate) 210 
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To a stirred, cooled (0 ˚C) solution of (-)-D-2,3,6-tris-O-benzyl-myo-inositol 1,4-
O-bis(dibenzyl phosphate) 204 (100 mg, 0.103 mmol, 1 eq) in N,N-
dimethylacetamide (1 mL) was added a solution of sulfamoyl chloride in CH2Cl2 
(2.5 M, 83 µL, 0.206 mmol, 2 eq) in a single portion.  The mixture was stirred for 
6 h, after which time TLC analysis indicated consumption of the starting 
material.  The mixture was diluted with water (15 mL) and ethyl acetate (15 ml), 
then the layers were separated.  The aqueous phase was re-extracted with 
ethyl acetate (2 ! 15 mL).  The combined organic phases were washed with 
brine (15 mL), dried over magnesium sulfate, filtered and concentrated in 
vacuo, affording a pale yellow gum.  Purification of the gum, eluting with 
petroleum ether and ethyl acetate, afforded (+)-D-2,3,6-tris-O-benzyl-5-O-
sulfamoyl-myo-inositol 1,4-O-bis(dibenzyl phosphate) 210 (86 mg, 80%) as a 
colourless solid: 
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 +5.4 (c 0.55 in CHCl3); mp 124-126 ˚C (from CHCl3); "max 
(KBr disc) /cm-1 3064 (w), 1498 (m), 1456 (m), 1365 (s), 1259 (s), 1187 (s), 999 
(s), 882 (w), 789 (w), 746 (m), 697 (s), 626 (w), 602 (w) and 497 (w); 1H NMR 
(500 MHz; CDCl3) ! 7.45-7.42 (2H, m, CH-18,18’ Ph), 7.33-7.13 (33H, m, Ar H), 
5.93 (2H, s, NH2 H-15, ex. in D2O), 5.0-4.82 (10H, m, 4.5 ! CH2Ph and H-4), 
4.78 (1H, d, J 11.4, CHAHB H-9), 4.72 (1H, d, J 11.4, CHAHB H-9’), 4.63 (1H, dd, 
J 9.5, 9.3, H-5), 4.62 (1H, d, J 10.1, CHA’HB’ H-16’), 4.47 (1H, d, J 11.4, CHA’’HB’’ 
H-11), 4.42 (1H, d, J 11.4, CHA’’HB’’ H-11’), 4.39 (1H, dd, J 2.2, 2.0, H-2), 4.16 
(1H, ddd, J 9.7, 7.5, 2.2, H-1), 4.06 (1H, dd, J 9.7, 9.5, H-6) and 3.36 (1H, dd, J 
9.8, 2.0); 13C NMR (125 MHz; CDCl3) ! 138.1 (C-10 Ph), 137.5 (C-17 Ph), 
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137.0 (C-12 Ph), 135.5 (d, J 6.3, C-8 Ph, C-14 Ph and C-14’ Ph), 135.4 (d, J 
6.5, C-8’ Ph), 128.6 (CH-18,18’ Ph), 128.53, 128.5, 128.45, 128.34, 128.3, 
128.2, 127.9, 127.85, 127.8, 127.7, 127.66, 127.6, 82.1 (CH-5), 77.8 (CH-3), 
77.77 (CH-4), 77.6 (CH-1), 77.4 (CH-6), 75.7 (CH2 C-16), 75.3 (CH2 C-9), 75.0 
(CH-2), 72.6 (CH2 C-11), 70.0 (d, J 5.4, CH2Ph), 69.98 (d, J 5.4, CH2Ph), 69.6 
(d, J 5.6, CH2Ph) and 69.4 (d, J 5.5, CH2Ph); 
31P NMR (202 MHz; CDCl3) 
! -1.77 and -2.26; isotope distribution m/z (ES+) [Found: (M+Na)+ 1072.2841 
(100), 1073.2874 (60), 1074.2894 (21) and 1075.2584 (6). C55H57O14NP2SNa 
requires M+, 1072.2867 (100), 1073.2901 (62), 1074.2931 (26), 1075.2966 (8), 
1076.2893 (2) and 1077.2926 (0)]; m/z (ES-) 1048 ([M-H]-, 100%); Anal. Calcd. 
for C55H57O14NP2S: C, 62.91; H, 5.47; N, 1.33; S, 3.05. Found: C, 62.88; H, 
5.36; N, 1.28; S, 3.00. 
 
6.3.50. (-)-D-5-O-sulfamoyl-myo-inositol 1,4-O-bisphosphate tetrakis  
  sodium salt 127 
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To a solution of (+)-D-2,3,6-tris-O-benzyl-5-O-sulfamoyl-myo-inositol 1,4-O-
bis(dibenzylphosphate) 210 (86 mg, 82 µmol, 1 eq) in t-butanol (5.00 mL) and 
water (0.85 mL) under Ar was added sodium bicarbonate (27.4 mg, 327 µmol, 
4 eq) and palladium black (174 mg, 1.63 mmol, 20 eq).  The flask was 
evacuated, then purged with hydrogen gas (~12 L).  The heterogeneous 
mixture was stirred vigorously for 14 h under a hydrogen atmosphere before the 
flask was vented.  The mixture was filtered through a pad of Celite and the 
residue was washed with diethyl ether (3 ! 5 mL); the filtrates were discarded.  
The palladium residue was washed with water (6 ! 5 mL) to release the 
product.  The aqueous filtrates were passed through a Millipore frit and 
lypholised to furnish (-)-D-5-O-sulfamoyl-myo-inositol 1,4-O-
bis(dibenzylphosphate) tetrakis sodium salt 127 (33.2 mg, 80%) as a colourless 
solid: 
  
! 
"[ ]
D
25
 -1.1 (c 0.32 in H2O); "max (KBr disc) /cm
-1 3450 (s), 2920 (w), 1672 
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(s), 1355 (s), 1188 (m), 1130 (s), 1083 (s), 989 (s), 856 (w), 834 (w), 720 (w) 
and 607 (m); 1H NMR (500 MHz; D2O) ! 4.33 (1H, dd, J 9.5, 9.2, H-5), 4.26 
(1H, ddd, J 9.5, 9.2, 7.6, H-4), 4.14 (1H, dd J 2.7, 2.4, H-2), 3.93 (1H, dd, J 9.8, 
9.5, H-6), 3.93-3.88 (1H, m, H-1) and 3.68 (1H, dd, J 9.5, 2.7, H-3); 13C NMR 
(125 MHz; D2O) ! 84.8 (d, J 6.1, CH-5), 73.8 (d, J 5.3, CH-4), 73.7 (d, J 5.1, 
CH-1), 71.3 (CH-3), 70.8 (d, J 3.0, CH-2) and 70.3 (d, J 3.7, CH-6); 31P NMR 
(202 MHz; D2O) ! 4.22 (overlapping signals P-1 and P-4; HMBC shows 
correlation to H-1 and H-4); HRMS m/z (ES-) [Found: (M-H)- 505.8896. 
C6H10O14NP2SNa4 requires M
-, 505.8894], [Found: (M-Na)- 483.9077. 
C6H10O14NP2SNa3 requires M
-, 483.9074]; m/z (ES-) 484 ([M-Na]-, 8), 462 ([M-
2Na+H]-, 15), 440 ([M-3Na+2H]-, 11), 360 (28) and 339 (100). 
 
6.3.51. (+)-D-myo-Inositol 1,4-bisphosphate tetrakis sodium salt 130 
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To a solution (-)-D-2,3,6-tris-O-benzyl-myo-inositol 1,4-O-bis (dibenzyl 
phosphate) 204 (55 mg, 57 µmol, 1 eq) in a mixture of t-butanol (4 mL) and 
water (0.7 mL) were added sodium bicarbonate (19 mg, 0.23 mmol, 4 eq) and 
palladium black (121 mg, 1.14 mmol, 20 eq).  The flask was evacuated and the 
atmosphere was purged with hydrogen gas.  The heterogeneous mixture was 
stirred vigorously under a hydrogen atmosphere for 12 h, before the flask was 
vented.  The mixture was filtered through a pad of Celite and the residue was 
washed with diethyl ether (2 ! 5 mL); the filtrates were discarded.  The 
palladium residues were washed with water (6 ! 5 mL) to release the product.  
The combined aqueous filtrates were passed through a Millipore frit and 
lypholised, affording (+)-D-myo-inositol 1,4-bisphosphate tetrakis sodium salt 
130 (21.5 mg, 88%) as a colourless solid: 
  
! 
"[ ]
D
25
 +2.5 (c 0.47 in H2O); "max (KBr 
disc) /cm-1 3418 (s), 1647 (m) 1094 (s), 972 (s), 852 (m) and 542 (m); 1H NMR 
(500 MHz; D2O) ! 4.13 (1H, dd, J 2.8, 2.8, H-2), 4.04 (1H, ddd, J 9.5, 9.3, 7.5, 
H-4), 3.84 (1H, ddd, J 9.7, 8.5, 2.8, H-1), 3.73 (1H, dd, J 9.7, 9.4, H-6), 3.58 
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(1H, dd, J 9.5, 2.8, H-3) and 3.38 (1H, dd, J 9.4, 9.3, H-5); 13C NMR (125 MHz; 
D2O) ! 76.1 (d, J 5.1, CH-4), 74.3 (d, J 5.3, CH-1), 74.1 (d, J 3.1, CH-5), 72.1 
(d, J 3.7, CH-6), 71.3 (d, J 2.8, CH-2) and 71.0 (d, J 3.0, CH-3); 31P NMR (202 
MHz; D2O) ! 4.59 and 3.96; HRMS m/z (ES
-) [Found: (M-Na)- 404.9346. 
C6H10O12P2Na3 requires M
-, 404.9346]; m/z (ES-) 361 ([M-3Na+2H]-, 45), 339 
([M-4Na+3H]-, 86) and 259 (100).  The data are in good agreement with the 
literature values.36, 166 
 
6.3.52. D-2,3,6-Tris-O-benzyl-5-oxo-myo-inositol 1,4-O-bis(dibenzyl  
  phosphate) 213 
2
3
4
5
6
1
O
9
O
O
O
O
18
O
P
O
O
O
PO O
O
13
14
13'
14'
7'
8'
7
8
10
11
12
19
 
To a solution of (-)-D-2,3,6-tris-O-benzyl-myo-inositol 1,4-O-bis (dibenzyl 
phosphate) 204 (50 mg, 51 µmol, 1.00 eq) in CH2Cl2 (2 mL) was added Dess 
Martin periodinane (27 mg, 64 µmol, 1.25 eq) in a single portion.  The 
suspension was stirred for 1 h at RT.  A further portion of Dess Martin 
periodinane (27 mg, 64 µmol, 1.25 eq) was added, and the mixture stirred for 
another 1 h, after which time TLC indicated consumption of the starting 
material.  The reaction mixture was diluted with diethyl ether (2 mL) and 
saturated aqueous sodium bicarbonate solution (2 mL), then sodium thiosulfate 
(324 mg) was added and the mixture was stirred vigorously for 20 min, until two 
distinct layers were observed.  The layers were separated and the aqueous 
phase was re-extracted with diethyl ether (3 ! 10 mL).  The combined organic 
layers were sequentially washed with water (5 mL), saturated aqueous sodium 
bicarbonate solution (5 mL) and brine (5 mL), dried over magnesium sulfate, 
filtered and concentrated in vacuo to furnish a pale yellow oil.  Repeated 
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purification (! 3) of the oil, eluting with petroleum ether and ethyl acetate (70:30, 
50:50), afforded D-2,3,6-tris-O-benzyl-5-oxo-myo-inositol 1,4-O-bis(dibenzyl 
phosphate) 213 (34.2 mg, 69%) as a colourless gum: "max (thin film) /cm
-1 3063 
(w), 3031 (w), 1751 (s), 1497 (m), 1455 (m), 1283 (s), 1215 (w), 1141 (m), 1024 
(s), 1010 (m), 732 (s) and 696 (s); 1H NMR (400 MHz; CDCl3) ! 7.46-7.15 (35H, 
m, Ar H), 5.50 (1H, dd, J 10.3, 9.9, H-4), 5.29 (1H, dd, J 11.7, 7.0, CHAHBPh), 
5.25 (1H, dd, J 11.7, 6.6, CHAHBPh), 5.08-5.02 (2H, m, CH2Ph), 5.01-4.89 (7H, 
m, 3.5 ! CH2Ph), 4.80 (1H, d, J 11.4, CHAHBPh), 4.66 (1H, d, J 10.5, H-6), 4.54 
(2H, s, CH2Ph), 4.50 (1H, dd, J 3.0, 2.8, H-2), 4.48 (1H, d, J 10.8, CHAHBPh), 
4.37 (1H, ddd, J 10.5, 8.0, 3.0, H-1) and 3.58 (1H, dd, J 10.3, 2.8, H-3); 13C 
NMR (63 MHz; CDCl3) ! 198.2 (C=O C-5), 137.7 (C), 137.2 (C), 137.0 (C), 
135.9 (d, J 8.6, C), 135.8 (d, J 8.2, C), 135.5 (d, J 7.6, C), 135.49 (d, J 7.2, C), 
128.53, 128.5, 128.44, 128.4, 128.36, 128.3, 128.25, 128.0, 127.9, 127.8, 
127.6, 127.56, 80.9 (d, J 7.1, inositol ring CH), 80.5 (d, J 6.3, inositol ring CH), 
78.0 (d, J 5.7, inositol ring CH), 76.8 (d, J 5.8, inositol ring CH), 75.7 (CH2Ph), 
75.5 (CH-2), 73.8 (CH2Ph), 72.8 (CH2Ph), 69.7 (d, J 5.3, CH2Ph), 69.5 (d, J 5.7, 
CH2Ph), 69.4 (d, J 5.7, CH2Ph) and 69.2 (d, J 5.3, CH2Ph); 
31P NMR (101 MHz; 
CDCl3) ! -0.57 and -0.88; HRMS m/z (ES
+) [Found: (M+Na)+ 991.2947. 
C55H54O12P2Na requires M
+, 991.2983]; m/z (ES+) 1027 ([M+MeCN+NH4]
+, 
100). 
 
6.3.53. (-)-D-5-O-Allyl-2,6-bis-O-benzyl-1-O-(4-methoxybenzyl)-3-O-endo- 
  4-O-exo-(L-1’,7’,7’-trimethylbicyclo[2.2.1]hept-2’-ylidene)-myo-
  inositol 216 
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A suspension of sodium hydride (60% dispersion in mineral oil, 112 mg, 
2.8 mmol, 1.5 eq) was washed with hexane (2 ! 20 mL).  The solvent was 
removed via cannula, then the solid was dried in vacuo.  The sodium hydride 
was then suspended in tetrahydrofuran (20 mL) and cooled to -10 ˚C.  To the 
suspension was added a solution of (-)D-5-O-allyl-2,6-bis-O-benzyl-3-O-endo, 
4-O-exo-(L-1’,7’,7’-trimethylbicyclo[2.2.1]hept-2’-ylidene)-myo-inositol 65 
(1.00 g, 1.9 mmol, 1 eq) in tetrahydrofuran (20 mL) dropwise via cannula.  The 
mixture was stirred for 1 h, then allowed to warm to RT.  The mixture was re-
cooled to -10 ˚C, then 4-methoxybenzyl chloride (439 mg, 380 µL, 2.8 mmol, 
1.5 eq) and N,N-dimethylformamide (10 mL) were added.  The mixture was 
allowed to warm to RT and stirred for 18 h, after which time TLC analysis 
indicated consumption of the starting material.  The volatile components were 
removed in vacuo, and the resulting residue was partitioned between ethyl 
acetate (100 mL) and water (100 mL).  The layers were separated, and the 
aqueous phase was re-extracted with ethyl acetate (2 ! 100 mL).  The 
combined organic phases were washed with brine (100 mL), dried over 
magnesium sulfate, filtered and concentrated in vacuo, providing a brown oil.  
Purification of the oil by silica gel chromatography, eluting with hexane and 
ethyl acetate (98:2, 97:3, 96:4, 95:5), provided (-)-D-5-O-allyl-2,6-bis-O-benzyl-
1-O-(4-methoxybenzyl)-3-O-endo-4-O-exo-(L-1’,7’,7’-trimethylbicyclo[2.2.1]hept-
2’-ylidene)-myo-inositol 216 (1.03 g, 84%) as a colourless oil: 
  
! 
"[ ]
D
20
 -19.9 (c 1.30 
in CHCl3) [lit.
41 
  
! 
"[ ]
D
20
 -20.1 (c 2.6 in CHCl3)]; 
1H NMR (400 MHz; CDCl3) ! 7.46-
7.28 (10H, m, Ar H), 7.22-7.19 (2H, m, H-9,9’), 6.84-6.80 (2H, m, H-10,10’), 
5.97 (1H, dddd, J 17.2, 10.5, 5.6, 5.4, CH H-16), 5.32 (1H, dddd, J 17.2, 1.6, 
1.6, 1.5, CHXHY H-17), 5.17 (1H, dddd, J 10.5, 1.6, 1.5, 1.4, CHXHY H-17’), 4.90 
(1H, d, J 12.2, CHAHB H-13), 4.89 (1H, d, J 10.7, CHA’HB’ H-18), 4.83 (1H, d, J 
10.7, CHA’HB’ H-18’), 4.81 (1H, d, J 12.2, CHAHB H-13’), 4.52 (2H, s, CH2 H-
7,7’), 4.39 (1H, dddd, J 13.0, 5.4, 1.6, 1.5, CHA’’HB’’ H-15), 4.21 (1H, dddd, J 
13.0, 5.6, 1.5, 1.4, CHA’’HB’’ H-15’), 4.14 (1H, dd, J 2.6, 1.6, H-2), 4.02 (1H, dd, J 
9.8, 9.7, H-4), 3.86 (1H, dd, J 9.6, 8.7, H-6), 3.81 (3H, s, OCH3 H-12), 3.49 (1H, 
dd, J 9.7, 8.7, H-5), 3.45 (1H, dd, J 9.6, 2.6, H-1), 3.17 (1H, dd, J 9.8, J 1.6, H-
3), 2.13 (1H, ddd, J 13.5, 3.7, 3.7, Heq-3’ camphor ring), 1.93 (1H, ddd, J 12.7, 
9.5, 3.4, Heq-6’ camphor ring), 1.77-1.68 (2H, m, H-4’ and Heq-5’ camphor ring), 
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1.42 (1H, d, J 13.5, Hax-3’ camphor ring), 1.44-1.36 (1H, m, Hax-6’ camphor 
ring), 1.25-1.16 (1H, m, Hax-5’ camphor ring), 1.03 (3H, s, CH3 on C-7’), 0.87 
(3H, s, CH3 on C-1’) and 0.86 (3H, s, CH3 on C-7’); 
13C NMR (100 MHz; CDCl3) 
! 159.2 (C-11 Ar), 139.1 (C-19 Ph), 138.5 (C-14 Ph), 135.4 (CH C-16), 130.3 
(C-8 Ar), 129.5 (CH-9,9’ Ar), 128.3, 128.2, 128.16, 128.0, 127.5, 120.4 (C-2’ 
camphor ring), 116.4 (CH2 C-17), 113.7 (C-10,10’ Ar), 82.8 (CH-6), 81.8 (CH-5), 
80.8 (CH-1), 77.2 (CH-4), 76.7 (CH-3), 76.4 (CH2 C-18), 73.4 (CH2 C-13), 72.2 
(CH2 C-7), 71.7(CH2 C-15), 70.9 (CH-2), 55.3 (OCH3 C-12), 52.9 (C-1’ camphor 
ring), 48.2 (C-7’ camphor bridge), 46.2 (C-3’ camphor ring), 44.9 (C-4’ camphor 
ring), 29.0 (C-6’ camphor ring), 26.7 (C-6’ camphor ring), 20.3 (CH3 on C-7’ 
camphor bridge), 20.2 (CH3 on C-7’ camphor bridge) and 9.7 (CH3 on C-1’ 
camphor ring); m/z (ES+) 677 ([M+Na]+, 100%).  The data are in good 
agreement with the literature values.41 
 
6.3.54. (-)-D-5-O-Allyl-2,6-bis-O-benzyl-1-O-(4-methoxybenzyl)-myo- 
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To a solution of D-5-O-allyl-2,6-bis-O-benzyl-1-O-(4-methoxybenzyl)-3-O-endo, 
4-O-exo-(L-1’,7’,7’-trimethylbicyclo[2.2.1]hept-2’-ylidene)-myo-inositol 216 
(1.23 g, 1.9 mmol, 1 eq) in CH2Cl2 (18 mL) cooled to -10 ˚C, was added  
solution of acetyl chloride (89 mg, 80 µL, 1.1 mmol, 0.6 eq) in methanol 
(12 mL).  The mixture was allowed to warm to RT and stirred for 3.5 h, after 
which TLC indicated consumption of the starting material.  The reaction was 
quenched by the addition of triethylamine (1 mL), then the volatile components 
were removed in vacuo, affording a light oil.  Purification of the oil by silica gel 
chromatography, eluting with hexane and ethyl acetate (50:50), furnished a 
colourless gum.  Crystallisation of the gum from ethyl acetate provided D-5-O-
allyl-2,6-bis-O-benzyl-1-O-(4-methoxybenzyl)-myo-inositol 217 (913 mg, 93%) 
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as a microcrystalline solid: Rf 0.16 (hexane/ethyl acetate 60:40); 
  
! 
"[ ]
D
20
 -26.4 (c 
2.40 in CHCl3) [lit.
45 
  
! 
"[ ]
D
20
 -26.6 (c 1.0 in CHCl3)]; mp 122-123 ˚C (from ethyl 
acetate) [lit.45 125-126 ˚C]; 1H NMR (500 MHz; CDCl3) ! 7.38-7.28 (10H, m, Ar 
H), 7.28-7.25 (2H, m, H-9,9’), 6.89-6.85 (2H, m, H-10,10’), 5.97 (1H, dddd, J 
17.2, 10.5, 5.8, 5.6, CH-16), 5.29 (1H, dddd, J 17.2, 1.6, 1.5, 1.5, CHXHY H-17), 
5.18 (1H, dddd, J 10.5, 1.6, 1.4, 1.4, CHxHy H-17’), 5.06 (1H, d, J 11.6, CHAHB 
H-13), 4.92 (1H, d, J 10.7, CHA’HB’ H-18), 4.82 (1H, d, J 10.7, CHA’HB’ H-18’), 
4.68 (1H, d, J 11.6, CHAHB H-13’), 4.67 (1H, d, J 11.4, CHA’’HB’’ H-7), 4.63 (1H, 
d, J 11.4, CHA’’HB’’ H-7’), 4.42 (1H, dddd, J 12.5, 5.6, 1.5, 1.4, CHA’’’HB’’’ H-15), 
4.28 (1H, dddd, J 12.5, 5.8, 1.5, 1.4, CHA’’’HB’’’ H-15’), 3.99 (1H, dd, J 2.6, 2.6, 
H-2), 3.95 (1H, dd, J 9.8, 9.3, H-6), 3.82 (3H, s, OCH3 H-12), 3.80 (1H, dd, J 
10.0, 9.6, H-4),  3.44 (1H, dd, J 9.8, J 2.6, H-1), 3.40-3.35 (1H, m, H-3), 3.20 
(1H, dd, J 9.6, 9.3, H-5), 2.66 (1H, br s, OH-4) and 2.37 (1H, br s, OH-3); 13C 
NMR (125 MHz; CDCl3) ! 159.3 (C-11 Ar), 138.7 (C-19 Ph), 138.6 (C-14 Ph), 
135.1 (CH C-16), 130.3 (C-8 Ar), 129.3 (CH-9,9’ Ar), 128.4, 128.37, 128.1, 
127.8, 127.7, 127.6, 117.0 (CH2 C-17), 113.9 (CH-10,10’ Ar), 82.6 (CH-5), 81.4 
(CH-6), 80.9 (CH-1), 77.4 (CH-2), 75.7 (CH2 C-18), 74.9 (CH2 C-13), 74.2 (CH2 
C-17), 73.8 (CH-4), 72.9 (CH2 C-7), 72.1 (CH-3) and 55.3 (OCH3 C-12); m/z 
(ES+) 543 ([M+Na]+, 100%).  The data are in good agreement with the literature 
values.45 
 
6.3.55. (-)-D-5-O-Allyl-2,3,6-tris-O-benzyl-1-O-(4-methoxybenzyl)-myo-
  inositol 218 
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To a solution of (-)-D-5-O-allyl-2,6-tris-O-benzyl-1-O-(4-methoxybenzyl)-myo-
inositol 217 (912 mg, 1.8 mmol, 1.0 eq) in acetonitrile (90 mL) was added di-n-
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butyl tin oxide (480 mg, 1.9 mmol, 1.1 eq), TBABr (565 mg, 1.8 mmol, 1.0 eq) 
and benzyl bromide (1.44 g, 1.0 mL, 8.4 mmol, 4.8 eq).  The mixture was 
heated under reflux for 21 h with azeotropic removal of water via a Soxhlet 
apparatus filled with activated 3 Å molecular sieves, after which time TLC 
analysis showed consumption of the starting material.  The solvent was 
removed in vacuo, providing a colourless paste that was reconstituted with 
water (100 mL) and ethyl acetate (100 mL).  The layers were separated and the 
aqueous phase was re-extracted with ethyl acetate (2 ! 100 mL).  The 
combined organic phases were treated with saturated aqueous sodium 
bicarbonate solution (100 mL), causing precipitation of the tin salts as a 
colourless solid.  The precipitate was removed by filtration through a pad of 
Celite, and the filtrate layers were separated.  The organic phase was washed 
with brine (100 mL), dried over magnesium sulfate, filtered and concentrated in 
vacuo to afford a pale brown oil.  Purification of the oil by silica gel 
chromatography, eluting with petroleum ether and diethyl ether (70:30, 50:50), 
provided (-)-D-5-O-allyl-2,3,6-tris-O-benzyl-1-O-(4-methoxybenzyl)-myo-inositol 
218 (724 mg, 68%) as a colourless waxy solid: Rf 0.14 (petroleum ether/diethyl 
ether 70:30); 
  
! 
"[ ]
D
20
 -0.53 (c 3.40 in CHCl3) [lit.
45 
  
! 
"[ ]
D
20
 -0.6 (c 0.4 in CHCl3)]; 
1H 
NMR (500 MHz; CDCl3) ! 7.41-7.29 (15H, m, Ar H), 7.27-7.24 (2H, m, H-9,9’ 
Ar), 6.89-6.86 (2H, m, H-10,10’ Ar), 5.99 (1H, dddd, J 17.2, 10.5, 5.8, 5.7, CH-
18), 5.30 (1H, dddd, J 17.2, 1.6, 1.5, 1.5, CHxHY H-19), 5.18 (1H, dddd, J 10.5, 
1.6, 1.4, 1.4, CHXHY H-19’), 4.90 (1H, d, J 10.6, CHAHB H-20), 4.88 (1H, d, J 
12.0, CHA’HB’ H-13), 4.82 (1H, d, J 10.6, CHAHB H-20’), 4.80 (1H, d, J 12.0, 
CHA’HB’ H-13’), 4.61 (1H, d, J 11.3, CHA’’HB’’ H-7), 4.60 (1H, d, J 11.8, CHAHB H-
15), 4.57 (1H, d, J 11.3, CHAHB H-7’), 4.55 (1H, d, J 11.8, CHA’’’HB’’’ H-15’), 4.38 
(1H, dddd, J 12.6, 5.7, 1.5, 1.4, CHA’’’’HB’’’’ H-17), 4.34 (1H, dddd, J 12.6, 5.8, 
1.5, 1.4, CHA’’’’HB’’’’ H-17’), 4.12 (1H, dd, J 9.8, 9.4, H-4), 4.01 (1H, dd, J 2.1, 2.1, 
H-2), 3.99 (1H, dd, J 9.6, 9.3, H-6), 3.84 (3H, s, OCH3 H-12), 3.34 (1H, dd, J 
9.6, 2.1, H-1), 3.25 (1H, dd, J 9.4, 9.3, H-5), 3.18 (1H, dd, J 9.8, 2.1, H-3), 2.25 
(1H, br s, OH-4); 13C NMR (125 MHz; CDCl3) ! 159.2 (C-11 Ar), 138.9 (C-14 Ph 
and C-21 Ph overlap), 137.9 (C-21 Ph), 135.5 (CH C-18), 130.4 (C-8 Ar), 129.2 
(CH-9,9’ Ar), 128.5, 128.3, 128.2, 128.1, 127.9, 127.7, 127.6, 127.4, 116.8 (CH2 
C-19), 113.8 (CH-10,10’ Ar), 83.0 (CH-5), 81.4 (CH-6), 80.8 (CH-1), 80.0 (CH-
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3), 75.8 (CH2 C-20), 74.2 (CH2 C-17), 74.0 (CH2 C-13), 73.7 (CH-2), 72.7 (CH-
4), 72.6 (CH2 C-7), 72.3 (CH2 C-15), 55.3 (OCH3 C-12); m/z (ES
+) 633 
([M+Na]+, 100%).  The data were in good agreement with the literature values.45 
 
6.3.56. (-)-D-5-O-Allyl-2,3,6-tris-O-benzyl-1-O-(4-methoxybenzyl)-myo-
  inositol 4-(dibenzyl phosphate) 219 
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To a solution of bis(benzyloxy)-N,N-diisopropylamino phosphine 168 (1.17 g, 
3.4 mmol, 3 eq) in CH2Cl2 (10 mL) was added a solution of 1H-tetrazole in 
acetonitrile (0.43 M, 7.9 mL, 3.4 mmol, 3 eq).  The solution was stirred for 
15 min, turning opaque.  To this mixture was added a solution of (-)-D-5-O-allyl-
2,3,6-tris-O-benzyl-1-O-(4-methoxybenzyl)-myo-inositol 218 (690 mg, 1.1 mmol, 
1 eq) in CH2Cl2 (20 mL) dropwise via a pressure equalised dropping funnel over 
1 h.  The resulting solution was stirred for 18 h at RT, after which time TLC 
analysis indicated consumption of the starting material.  The mixture was 
cooled to -78 ˚C and 3-chloroperoxybenzoic acid (585 mg, 3.4 mmol, 3 eq) was 
added in a single portion.  The mixture was stirred for 15 min at -78 ˚C, then 
allowed to warm to RT over 2 h, after which time TLC indicated consumption of 
the intermediate.  The reaction was quenched by the addition of aqueous 
sodium sulfite solution (10% w/v, 40 mL) and CH2Cl2 (40 mL).  The layers were 
separated and the aqueous phase was re-extracted with CH2Cl2 (3 ! 40 mL).  
The combined organic extracts were washed with saturated aqueous sodium 
bicarbonate solution (2 ! 40 mL) and brine (40 mL), dried over magnesium 
sulfate, filtered and concentrated in vacuo, affording a colourless oil.  
Purification of the oil by silica gel chromatography, eluting with hexane and 
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ethyl acetate (90:10, 85:15, 80:20), furnished (-)-D-5-O-allyl-2,3,6-tris-O-benzyl-
1-O-(4-methoxybenzyl)-myo-inositol 4-(dibenzyl phosphate) 219 (849 mg, 86%) 
as a colourless crystalline solid: Rf 0.29 (hexane/ethyl acetate 70:30); 
  
! 
"[ ]
D
20
 -4.20 (c 1.0 in CHCl3); mp 112-114 ˚C (from ethyl acetate and hexane); 
!max (KBr disc) /cm
-1 3449 (w), 3065 (m), 3033 (m), 2916 (m), 1612 (m), 1515 
(s), 1497 (m), 1455 (s), 1362 (m), 1305 (w), 1253 (s), 1172 (m), 1135 (s), 1087 
(s), 1014 (s), 977 (s), 915 (m), 872 (m), 822 (m), 798 (w), 736 (s), 696 (s) and 
605 (w); 1H NMR (400 MHz; CDCl3) ! 7.39-7.19 (27H, m, Ar H), 6.87-6.84 (2H, 
m, H-10,10’ Ar H), 5.90 (1H, dddd, J 17.3, 10.6, 5.5, 5.5, CH-20), 5.19 (1H, 
dddd, J 17.3, 1.7, 1.5, 1.5, CHXHY H-21), 5.05 (1H, dddd, J 10.6, 1.7, 1.5, 1.5, 
CHXHY H-21’), 5.02-4.95 (4H, m, 2 " CH2-17,17’), 4.91 (1H, ddd, J 9.8, 9.6, 9.3, 
H-4), 4.89 (1H, d, J 10.4, CHAHB H-22), 4.84 (1H, d, J 12.0, CHA’HB’ H-13), 4.80 
(1H, d, J 10.4, CHAHB H-22’), 4.79 (1H, d, J 12.0, CHA’HB’ H-13’), 4.59 (1H, d, J 
12.2, CHA’’HB’’ H-15), 4.55 (1H, d, J 11.6, CHA’’’HB’’’ H-7), 4.52 (1H, d, J 12.2, 
CHA’’HB’’ H-15’), 4.51 (1H, d, J 11.6, CHA’’’HB’’’ H-7’), 4.31 (2H, ddd, J 5.5, 1.5, 
1.5, H-19,19’), 4.03 (1H, dd, J 9.7, 9.4, H-6), 3.97 (1H, dd, J 2.3, 2.3, H-2), 3.83 
(3H, s, OCH3 H-12), 3.38 (1H, dd, J 9.4, 9.3, H-5), 3.33 (1H, dd, J 9.8, 2.3, H-3) 
and 3.31 (1H, dd, J 9.7, 2.3, H-1); 13C NMR (100 MHz; CDCl3) ! 159.2 (C-11 
Ar), 138.7 (C-23 Ph and C-14 Ph), 137.8 (C-16 Ph), 136.3 (d, J 7.7, C-18 and 
C-18’ Ph), 135.2 (CH C-20), 130.3 (C-8 Ar), 129.3 (CH-9,9’ Ar), 128.4, 128.2, 
128.1, 127.8, 127.76, 127.7, 127.68, 127.6, 127.4, 116.5 (CH2 C-21), 113.8 
(CH-10,10’ Ar), 81.4 (CH-6), 81.35 (CH-5), 80.2 (CH-1), 80.0 (d, J 7.3, CH-4), 
78.9 (d, J 2.7, CH-3), 75.8 (CH2 C-22), 74.2 (CH2 C-19), 74.1 (CH2 C-13), 73.6 
(CH-2), 72.5 (CH2 C-15), 72.4 (CH2 C-7), 69.2 (d, J 5.2, CH2 C-17), 69.0 (d, J 
5.2, CH2 C-17’) and 55.3 (OCH3 C-12); 
31P NMR (162 MHz; CDCl3) ! -1.71 (P-
4); HRMS m/z (ES+) [Found: (M+Na)+ 893.3427. C52H55O10PNa requires M
+, 
893.3431]; m/z (ES+) 893 ([M+Na]+, 100%); Anal. Calcd. for C52H55O10P: C, 
71.71; H, 6.37. Found: C, 71.52; H, 6.32. 
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6.3.57. (-)-D-5-O-Allyl-2,3,6-tris-O-benzyl-myo-inositol 4-(dibenzyl  
  phosphate) 220 
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In an open flask, to a solution of (-)-D-5-O-allyl-2,3,6-tris-O-benzyl-1-O-(4-
methoxybenzyl)-myo-inositol 4-(dibenzyl phosphate) 219 (849 mg, 0.97 mmol, 
1 eq) in acetonitrile (48 mL) and water (12 mL) was added ceric ammonium 
nitrate (1.87 g, 3.41 mmol, 3.5 eq) in a single portion.  The bright orange 
solution lightened to pale yellow over 30 min stirring, after which time TLC 
analysis indicated consumption of the starting material.  The volatile 
components were removed in vacuo, providing a dark orange solution that was 
partitioned between water (80 mL) and ethyl acetate (80 mL).  The layers were 
separated and the aqueous phase was re-extracted with ethyl acetate (3 ! 
80 mL).  The combined organic phases were washed with brine (80 mL), dried 
over magnesium sulfate, filtered and concentrated in vacuo, affording a 
colourless oil.  Purification by silica gel chromatography, eluting with hexane 
and ethyl acetate (80:20, 70:30, 60:40), furnished (-)-D-5-O-allyl-2,3,6-tris-O-
benzyl-myo-inositol 4-(dibenzyl phosphate) 220 (580 mg, 80%) as a colourless 
solid: Rf 0.20 (hexane/ethyl acetate 70:30); 
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-4.9 (c 0.86 in CHCl3); mp 
84-87 ˚C (from diethyl ether); "max (KBr disc) /cm
-1 3370 (s), 3033 (w), 2893 (m), 
1497 (w), 1455 (m), 1356 (w), 1252 (s), 1133 (m), 1074 (s), 1021 (s), 902 (w), 
735 (s), 698 (s), and 494 (w); 1H NMR (400 MHz; CDCl3) ! 7.42-7.21 (25H, m, 
Ar H), 5.94 (1H, dddd, J 17.2, 10.6, 5.6, 5.5, CH-14), 5.24 (1H, dddd, J 17.2, 
1.6, 1.5, 1.4, CHXHY H-15), 5.10 (1H, dddd, J 10.6, 1.6, 1.4, 1.4, CHXHY H-15’), 
5.07-4.95 (4H, m, CH2-11,11’), 4.95 (1H, d, J 11.6, CHAHB H-7), 4.93 (1H, ddd, 
J 9.8, 9.6, 9.5, H-4), 4.90 (1H, d, J 11.2, CHA’HB’ H-16), 4.78 (1H, d, J 11.2, 
CHA’HB’ H-16’), 4.69 (1H, d, J 11.6, CHA’’HB’’ H-9), 4.68 (1H, d, J 11.6, CHAHB H-
7’), 4.65 (1H, d, J 11.6, CHA’’HB’’ H-9’), 4.38 (1H, dddd, J 12.1, 5.5, 1.5, 1.4, 
CHA’’’HB’’’ H-13), 4.31 (1H, dddd, J 12.1, 5.6, 1.4, 1.4, CHA’’’HB’’’ H-13’), 4.05 (1H, 
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dd, J 2.4, 2.3, H-2), 3.80 (1H, dd, J 9.4, 9.4, H-6), 3.54-3.47 (1H, m, H-1), 3.46 
(1H, dd, J 9.8, 2.3, H-3) 3.41 (1H, dd, J 9.5, 9.4, H-5) and 2.22 (1H, br s, OH-1); 
13C NMR (75 MHz; CDCl3) ! 138.8 (2C, C-8 Ph and C-17 Ph), 138.1 (C-10 Ph), 
136.7 (2C, C-12 Ph and C-12’ Ph), 135.4 (CH C-14), 128.9, 128.84, 128.8, 
128.6, 128.56, 128.3, 128.24, 128.23, 128.2, 128.1, 117.2 (CH2 C-15), 82.2 
(CH-6), 81.6 (d, J 3.5, CH-5), 80.3 (d, J 7.2, CH-4), 76.7 (CH-2), 75.9 (CH2 C-
16), 75.2 (CH2 C-7), 74.6 (CH2 C-13), 73.1 (CH2 C-9), 72.6 (CH-1), 69.6 (d, J 
5.3, CH2 C-11) and 69.5 (d, J 5.2, CH2 C-11’); 
31P NMR (162 MHz; CDCl3) 
! -1.49 (P-4); HRMS m/z (ES+) [Found: (M+Na)+ 773.2866. C44H47O9PNa 
requires M+, 773.2855]; m/z (ES+) 773 ([M+Na]+, 100%). 
 
6.3.58. 3-Benzyloxycarbonylaminopropan-1-ol 222 
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To a solution of 3-aminopropan-1-ol (10.0 g, 133 mmol, 1.0 eq) in water 
(250 mL) was added sodium hydrogen carbonate (16.8 g, 200 mmol, 1.5 eq).  
To this solution was added benzyl chloroforamte (22.7 g, 19.0 mL, 133 mmol, 
1.0 eq) dropwise via a pressure equalised dropping funnel over 20 min.  The 
resulting mixture was stirred for 18 h at RT, after which time TLC analysis 
indicated consumption of the starting material.  The solution was extracted with 
CH2Cl2 (3 ! 250 mL).  The combined organic layers were washed with brine 
(250 mL), dried over magnesium sulfate, filtered and concentrated in vacuo to 
afford a sticky colourless solid.  Recrystallisation of the solid from ethyl acetate 
and hexane, provided 3-benzyloxycarbonylaminopropan-1-ol 222 (20.4 g, 43%) 
as colourless crystalline plates: Rf 0.52 (ethyl acetate); mp 50-51 ˚C (from ethyl 
acetate and hexane) [lit.191 50-51 ˚C]; 1H NMR (300 MHz; CDCl3) ! 7.69-7.31 
(5H, m, Ar H), 5.41 (1H, br s, NH), 5.10 (2H, s, CH2-5), 3.69-3.62 (2H, m, CH2-
1), 3.37-3.26 (3H, m, CH2-3 and OH) and 1.74-1.64 (2H, m, CH2-2); 
13C NMR 
(75 MHz; CDCl3) ! 157.8 (C=O C-4), 136.9 (C-6 Ph), 129.0 (CH-7,7’ Ph), 128.6 
(CH-9 Ph), 128.5 (CH-8,8’ Ph), 67.2 (CH2 C-5), 59.9 (CH2 C-1), 38.2 (CH2 C-3) 
and 32.8 (CH2 C-2).  The data are in good agreement with the literature 
values.191 
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6.3.59. (Benzyloxy)(3-benzyloxycarbonylaminopropan-1-ol)-N,N- 
  diisopropylamino phosphine 223 
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To a solution of (benzyloxy) bis(N,N-diisopropylamino) phosphine 167 (5.0 g, 
14.8 mmol, 1.0 eq) in CH2Cl2 (100 mL) at RT was added a solution of 1H-
tetrazole in acetonitrile (0.43 M, 13.7 mL, 5.9 mmol, 0.4 eq), turning the solution 
partially cloudy.  To this solution was added a solution of 3-
benzyloxycarbonylaminopropan-1-ol 222 (3.1 g, 14.8 mmol, 1 eq) in CH2Cl2 
(100 mL) dropwise over 4 h, via a pressure equalised dropping funnel.  The 
mixture was stirred for a further 2 h, after which time TLC analysis indicated 
consumption of the starting material.  The volatile components were removed in 
vacuo, affording a sticky light brown oil.  Purification of the material by silica gel 
chromatography, eluting with hexane, ethyl acetate and triethylamine (65:30:5), 
afforded (benzyloxy)(3-benzyloxycarbonylaminopropan-1-ol)- N,N-
diisopropylamino phosphine 223 (4.28 g, 65%) as a colourless oil; Rf 0.70 
(hexane/ethyl acetate/triethylamine 65:30:5); 1H NMR (300 MHz; CDCl3) ! 7.38-
7.23 (10H, m, Ar H), 5.26 (1H, br s, NH), 5.09 (2H, s, CH2-5), 4.76 (1H, dd, J 
12.6, 8.4, CHAHB H-7), 4.66 (1H, dd, J 12.6, 9.0, CHAHB H-7’), 3.81-3.69 (2H, m 
CH2-1), 3.69-3.58 (2H, m, CH(CH3)2 H-9), 3.39-3.28 (2H, m, CH2-3), 1.87-1.77 
(2H, m, CH2-2) and 1.19 (12H, dd, J 6.8, 1.5, CH3 H-10); 
31P NMR (121 MHz; 
CDCl3) ! 147.01.  The data are in good agreement with the literature values.
170 
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6.3.60. (-)-D-5-O-Allyl-2,3,6-tris-O-benzyl-myo-inositol 1-(benzyl-(3- 
  benzylcarbonylaminopropan-1-ol) phosphate)-4-(dibenzyl 
  phosphate) 224 
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To a solution of (benzyloxy)(3-benzyloxycarbonylaminopropan-1-ol)- N,N-
diisopropylamino phosphine 223 (773 mg, 1.7 mmol, 2.5 eq) in CH2Cl2 (10 mL) 
was added a solution of 1H-tetrazole in acetonitrile (0.43 M, 4.0 mL, 1.7 mmol, 
2.5 eq).  The solution was stirred for 20 min at RT, then a solution of (-)-D-5-O-
allyl-2,3,6-tris-O-benzyl-myo-inositol 4-(dibenzyl phosphate) 220 (520 mg, 
0.7 mmol, 1.0 eq) in CH2Cl2 (20 mL) was added dropwise over 2 h via a 
pressure equalised dropping funnel.  The resulting solution was stirred for a 
further 2 h, after which time TLC analysis showed consumption of the starting 
material.  The mixture was cooled to -78 ˚C and 3-chloroperoxybenzoic acid 
(299 mg, 1.7 mmol, 2.5 eq) was added in a single portion.  The mixture was 
stirred at -78 ˚C for 30 min, then allowed to warm to RT and stirred for a further 
30 min.  TLC analysis indicated consumption of the intermediate.  The reaction 
was quenched by the addition of aqueous sodium sulfite solution (10% w/v, 
60 mL) and the layers were separated.  The aqueous phase was re-extracted 
with CH2Cl2 (3 ! 60 mL).  The combined organic layers were washed with 
saturated aqueous sodium bicarbonate solution (2 ! 60 mL) and brine (60 mL), 
dried over magnesium sulfate, filtered and concentrated in vacuo affording a 
pale brown oil.  Purification of the oil by silica gel chromatography, eluting with 
first with hexane and ethyl acetate (60:40, 50:50, 40:60, 0:100) then secondly 
with chloroform and acetone (100:0 to 80:20), provided (-)-D-5-O-allyl-2,3,6-tris-
O-benzyl-myo-inositol 1-(benzyl-(3-benzylcarbonylaminopropan-1-ol) 
phosphate)-4-(dibenzyl phosphate) 224 (601 mg, 78%) as a colourless oil and a 
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2:1 mixture of diastereoisomers (adjudged by 1H NMR); Rf 0.11 (hexane/ethyl 
acetate 60:40); !max (KBr disc) /cm
-1 3422 (m), 3033 (m), 2945 (m), 1719 (s), 
1540 (m), 1497 (m), 1456 (s), 1359 (m), 1266 (s), 1215 (m), 1128 (m), 1017 (s), 
919 (w), 737 (s), 697 (s), 600 (w) and 501 (m); 1H NMR (500 MHz; CDCl3) ! 
7.38-7.15 (35H, m, Ar H), 5.91-5.80 (1H, m, CH-18), 5.19-5.12 (1H, m, CHXHY 
H-19), 5.08-4.81 (13H, m, CHXHY H-19’, CHAHB H-20 and 6 " CH2), 5.06 (2H, s, 
CH2 H-11,11’), 4.76-4.64 (2H, m, CHAHB H-20’ and CHA’HB’ H-13’), 4.58 (2H, s, 
CH2 H-15,15’ diastereoisomer 1), 4.55 (2H, s, CH2 H-15,15’ diastereoisomer 2), 
4.34-4.24 (3H, m, H-2 and CH2 H-17,17’), 4.27-4.22 (1H, m, H-1 
diastereoisomer 1), 4.18-4.13 (1H, m, H-1 diastereoisomer 2), 4.05-4.00 (1H, m, 
H-6), 3.97-3.82 (2H, m, CH2 H-7,7’), 3.47-3.35 (2H, m, H-3 and H-5), 3.18-2.98 
(2H, m, CH2 H-9,9’), 1.74 (1H, br s, NH) and 1.69-1.51 (2H, m, CH2 H-8,8’); 
13C 
NMR (125 MHz; CDCl3) ! 156.3 (C=O, C-10), 138.3 (C-14 Ph), 138.2 (C-21 Ph 
diastereoisomer 1), 138.1 (C-21 Ph diastereoisomer 2), 137.5 (C-16 Ph 
diastereoisomer 1), 137.4 (C-16 Ph diastereoisomer 2), 136.6 (C-12 Ph 
diastereoisomer 1), 136.5 (C-12 Ph diastereoisomer 1), 136.2 (d, J 7.6, 2 " C 
on P-4), 135.7 (d, J 5.4, C on P-1 diastereoisomer 2), 135.6 (d, J, C on P-1 
diastereoisomer 1), 128.7, 128.6, 128.58, 128.5, 128.4, 128.23, 128.3, 128.27, 
128.25, 128.23, 128.2, 128.13, 128.1, 127.9, 127.8, 127.7, 127.68, 127.65, 
127.6, 127.5, 127.46, 116.8 (CH2 C-19 diastereoisomer 1), 116.78 (CH2 C-19 
minor), 80.9 (CH-5), 79.7 (d, J 6.8, CH-6), 79.4 (d, J 6.9, CH-4), 78.5 (d, J 2.4, 
CH-3 diastereoisomer 1), 78.4 (d, J 2.5, CH-3 diastereoisomer 2), 78.0 (d, J 6.3, 
CH-1 diastereoisomer 2), 77.9 (d, J 5.9, CH-1 diastereoisomer 1), 75.7 (CH2 C-
20), 75.5 (CH-2), 75.1 (CH2 C-13 diastereoisomer 1), 75.0 (CH2 C-13 
diastereoisomer 2), 74.3 (CH2 C-17), 72.5 (CH2 C-15 diastereoisomer 1), 72.4 
(CH2 C-15 diastereoisomer 2), 69.5 (d, J 5.6, CH2Ph on P-1 diastereoisomer 2), 
69.3 (d, J 5.5, CH2Ph on P-1 diastereoisomer 1), 69.2 (d, J 5.3, CH2Ph on P-4), 
69.0 (d, J 5.1, CH2Ph on P-4), 66.6 (CH2 C-11), 65.4 (d, J 5.9, CH2 C-7 
diastereoisomer 1), 65.3 (d, J 6.0, CH2 C-7 diastereoisomer 2), 37.1 (CH2 C-9 
minor), 37.0 (CH2 C-9 diastereoisomer 1), 30.0 (d, J 7.1, CH2 C-8 
diastereoisomer 2) and 29.9 (d, J 6.7, CH2 C-8 diastereoisomer 1); 
31P NMR 
(202 MHz; CDCl3) ! -0.92 (P-1 diastereoisomer 1), -1.30 (P-1 diastereoisomer 
2), -1.41 (P-4 diastereoisomer 1) and -1.45 (P-4 diastereoisomer 2); isotope 
distribution m/z (ES+) [Found: (M+Na)+ 1134.3655 (100), 1135.3685 (67), 
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1136.3695 (24) and 1137.3741 (6). C62H67O14NP2Na requires M
+, 1134.3929 
(100), 1135.3963 (69), 1136.3996 (26), 1137.4029 (7) and 1138.4063 (2)]; m/z 
(ES+) 1134 ([M+Na]+, 100%); Anal. Calcd. for C62H67O14NP2: C, 66.96; H, 6.07; 
N, 1.26. Found: C, 66.66; H, 6.09; N, 1.30. 
 
6.3.61. 2-benzyloxypyridine 153 
NO
 
A mixture of benzyl alcohol (2.00 g, 1.92 mL, 18.5 mmol, 1.0 eq), 2-
chloropyridine (3.47 g, 2.9 mL, 30.5 mmol, 1.7 eq), powdered potassium 
hydroxide (3.42 g, 61.0 mmol, 3.3 eq), 18-crown-6 (244 mg, 0.9 mmol, 0.05 eq) 
and toluene (37 mL) was heated under reflux with the azeotropic removal of 
water via Dean and Stark apparatus for 1 h.  The light brown solution was 
cooled to RT, then partitioned between ethyl acetate (35 mL) and water 
(15 mL).  The organic phase was washed with brine (15 mL), dried over 
magnesium sulfate, filtered and concentrated in vacuo to provide a yellow oil.  
Purification of the oil by silica gel chromatography, eluting with hexane and 
ethyl acetate (50:50), provided 2-benzyloxypyridine 153 (3.42 g, 100%) as a 
colourless oil: Rf 0.43 (hexane/ethyl acetate 90:10); 
1H NMR (400 MHz; CDCl3) 
! 8.22 (1H, ddd, J 5.1, 2.0, 0.7), 7.60  (1H, td, J 7.0, 2.0), 7.54-7.49 (2H, m), 
7.45-7.33 (3H, m), 6.92 (1H, ddd, J 7.1, 5.1, 0.9), 6.85 (1H, dt, J 8.4, 0.8) and 
5.43 (2H, s); 13C NMR (100 MHz; CDCl3) ! 163.7 (C-2 py), 146.9, 137.4 (C-1 
Ph), 128.5 (Ph), 128.0 (Ph), 127.9 (Ph), 116.9, 111.4 and 67.6 (CH2).  These 
data are in agreement with the literature values.145 
 
6.3.62. 2-benzyloxy-1-methylpyridinium triflate 154 
NO
CH3
OTf
 
To a solution of 2-benxyloxypyridine 153 (3.42 g, 18.5 mmol, 1 eq) in toluene 
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(20 mL) cooled to 0 ˚C was added methyl triflate (3.19 g, 2.1 mL, 19.4 mmol, 
1.05 eq) dropwise via a syringe.  After 2 min stirring a colourless gel was 
observed, which halted the magnetic stirrer.  The flask was removed from the 
cooling bath and allowed to warm to RT with stirring, forming a colourless paste.  
The volatile components were removed in vacuo, providing a colourless solid, 
which was dried in vacuo for 3 days.  Grinding the solid with a mortar and pestle 
furnished 2-benzyloxy-1-methylpyridinium triflate 154 (6.23 g, 97%) as an 
amorphous colourless solid:  mp 91-92 ˚C (from toluene) [lit.145 82-86 ˚C]; 1H 
NMR (400 MHz; CDCl3) ! 8.46 (1H, dd, J 6.4, 1.6), 8.30 (1H, td, J 8.7, 1.7), 
7.68 (1H, d, J 8.8), 7.50-7.46 (2H, m), 7.42-7.34 (4H, m), 5.52 (2H, s, CH2) and 
4.02 (3H, s, CH3); 
13C NMR (100 MHz; CDCl3) ! 159.8 (C-2 Py), 148.1, 143.8, 
132.6 (C-1 Ph), 129.6 (Ph), 129.1 (Ph), 128.6 (Ph), 120.7 (CF3, JC-F 320.6), 
119.1, 117.4, 74.5 (CH2), 42.0 (CH3); 
19F NMR (282 MHz; CDCl3): ! -78.8 (CF3).  
These data are in agreement with the literature values.145!
 
6.3.63. Iodoxybenzoic acid (IBX) 
O
I
O
O
OH
 
2-Iodobenzoic acid (50.0 g, 200 mmol, 1 eq) was added via a powder funnel to 
a mechanically stirred solution of oxone (181.0 g, 290 mmol, 1.3 eq) in distilled 
water (650 mL) in a 2 L round bottom flask.  The mixture was warmed to 70 ˚C 
and vigorously stirred for 4 hours, resulting in a clear solution with a small 
amount of colourless solid at the bottom.  As the reaction proceeded the 
suspension became easier to stir.  The mixture was cooled to 0 ˚C for 2 h with 
slow stirring, precipitating a colourless solid, which was isolated by filtration.  
The residue was washed with distilled water (6 ! 100 mL) and acetone (2 ! 
100 mL) then dried in vacuo for 24 h to afford 2-iodoxybenzoic acid (47.39 g, 
85%) as a white crystalline solid: mp (water) 230-231 ˚ C dec. (lit.192 232-
233 ˚C); 1H NMR (300 MHz; d6-DMSO) ! 8.17-8.12 (1H, m, Ar H), 8.07-7.97 
(2H, m, Ar H) and 7.88-7.81  (1H, m, Ar H).  The data were in good agreement 
with the literature values.193 
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6.3.64. Dess Martin periodinane 
O
I
O
OAc
AcO OAc
 
2-iodoxybenzoic acid (100 g, 0.36 mol) was suspended in acetic anhydride 
(400 mL) and 4-TsOH·H2O (0.5 g) was added.  The mixture was heated to 
80 ˚C for 2.5 h, causing rapid dissolution of the solids.  The solution was then 
allowed to cool to RT over 3 h, before being cooled further to 0 ˚C, precipitating 
a colourless solid.  The solid was isolated by filtration and washed with 
anhydrous diethyl ether (300 mL) under a stream of nitrogen gas, affording 
Dess Martin periodinane (120.8 g, 80%) as a colourless crystalline solid: mp 
132-134 ˚C (from acetic anhydride). [lit.192, 194 133-134 ˚C] 
 
6.3.65. Benzyl-2,2,2-trichloroacetimidate 
O CCl3
NH
 
A solution of benzyl alcohol (4.00 g, 3.8 mL, 37.0 mmol, 1 eq) in tetrahydrofuran 
(20 mL) was transferred via cannula into a flask containing a suspension of 
sodium hydride (148 mg, 3.7 mmol, 0.1 eq) in tetrahydrofuran (10 mL).  The 
suspension was stirred for 20 min at RT then cooled to 0 ˚C.  
Trichloroacetonitrile (5.87 g, 4.1 mL, 40.7 mmol, 1.1 eq) was added dropwise 
over 15 min at 0 ˚C before the solution was allowed to warm to RT over 90 min.  
The solvent was removed in vacuo, providing a pale brown oil, which was 
mixed with pentane (15 mL) and anhydrous methanol (150 !L), causing a 
brown solid to precipitate.  The solid was removed by filtration through a pad of 
Celite, and the filtrate was concentrated in vacuo providing a yellow oil.  The oil 
was taken up in a further portion of pentane (15 mL), causing further brown 
solid to precipitate.  This solid was removed by filtration through a fresh pad of 
Celite.  The residue was washed with pentane (2 ! 15 mL) and the combined 
filtrates was concentrated in vacuo to give a pale yellow oil.  Purification of the 
oil by neutral alumina chromatography, eluting with hexane and ethyl acetate 
Experimental Section 
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(95:5), yielded benzyl 2,2,2-trichloroacetimidate (6.93 g, 74%) as a colourless 
oil:  Rf 0.26 (hexane/ethyl acetate 95:5); 
1H NMR (400 MHz; CDCl3) ! 8.41 (1H, 
br s, NH), 7.48-7.37 (5H, m, Ph ring) and 5.36 (2H, s, CH2).  The data are in 
good agreement with the literature values.144  
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Appendix 1 
NMR spectra of compounds for biological evaluation 
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Appendix 2 
NMR spectra of novel compounds  
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8.1. (+)-Methyl 2-O-benzyl-4,6-O-anisylidene-!-D-glucopyranoside 138 
 
 
Figure 8.1.1.  VMD representation of crystal structure of 138. 
 
Table 8.1.1.  Crystal data and structure refinement for nksc6. 
Identification 
code 
nksc6 
Theta range for data 
collection 
1.75 to 25.34  ˚
Empirical 
formula 
C22H26O7 Index ranges 
-5<=h<=7  
-32<=k<=27  
-14<=l<=13 
Formula 
weight 
402.43 Reflections collected 12800 
Temperature 93(2) K Independent reflections 
5808 
[R(int) = 0.0364] 
Wavelength 0.71073 Å 
Completeness to  
theta = 25.00˚ 
95.1 % 
Crystal 
system 
Monoclinic Absorption correction Multiscan 
Space group P2(1) 
Max. and min. 
transmission 
1.0000 and 0.9158 
Unit cell 
dimensions 
a = 6.2977(7) Å 
b = 27.328(3) Å 
c = 11.7306(14) Å 
! = 90˚ 
" = 97.914(3)  ˚
# = 90˚ 
Refinement method 
Full-matrix least-
squares on F2 
Volume 1999.6(4) Å3 
Data 
Restraints 
Parameters 
5808  
3 
536 
Z 4 Goodness-of-fit on F2 1.020 
Density 
(calculated) 
1.337 mg/m3 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0470 
wR2 = 0.0978 
Absorption 
coefficient 
0.099 mm-1 
R indices 
(all data) 
R1 = 0.0589 
wR2 = 0.1049 
F(000) 856 
Absolute structure 
parameter 
0.7(8) 
Crystal size 0.1500 ! 0.0300 ! 0.0300 mm
3 Largest diff. peak and hole 
0.175 and  
-0.256 e.Å-3 
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Table 8.1.2.  Atomic coordinates (! 104) and equivalent isotropic displacement parameters (Å2 ! 103) for nksc6.  U(eq) 
is defined as one third of  the trace of the orthogonalised Uij tensor. 
 x y z U(eq) 
O(1) 3659(3) 2435(1) -563(2) 25(1) 
C(1) 3157(5) 2857(1) -1205(3) 22(1) 
O(2) 6694(3) 2737(1) -1856(2) 24(1) 
C(2) 5237(5) 3092(1) -1509(3) 20(1) 
O(3) 8045(3) 3680(1) -1008(2) 25(1) 
C(3) 6519(5) 3384(1) -535(3) 18(1) 
O(4) 6112(3) 3966(1) 985(2) 21(1) 
C(4) 5001(5) 3711(1) 7(3) 19(1) 
O(5) 1976(3) 3200(1) -625(2) 22(1) 
C(5) 3232(5) 3399(1) 398(3) 20(1) 
O(6) 3098(3) 3961(1) 1949(2) 24(1) 
C(6) 1775(5) 3701(1) 1043(3) 24(1) 
C(7) 4601(5) 4262(1) 1471(3) 22(1) 
O(8) 7996(3) 5481(1) 5174(2) 28(1) 
C(8) 1859(6) 2104(1) -621(3) 31(1) 
C(9) 5817(5) 2467(1) -2859(3) 30(1) 
C(10) 7497(5) 2128(1) -3198(3) 24(1) 
C(11) 7397(6) 1627(1) -3001(3) 32(1) 
C(12) 8941(6) 1315(2) -3341(3) 40(1) 
C(13) 10591(6) 1499(2) -3878(3) 38(1) 
C(14) 10691(5) 1990(1) -4078(3) 29(1) 
C(15) 9168(5) 2309(1) -3741(3) 26(1) 
C(16) 5672(5) 4581(1) 2421(3) 21(1) 
C(17) 7795(5) 4541(1) 2895(3) 24(1) 
C(18) 8668(5) 4837(1) 3815(3) 24(1) 
C(19) 7365(5) 5178(1) 4261(3) 22(1) 
C(20) 5245(5) 5237(1) 3750(3) 30(1) 
C(21) 4414(5) 4940(1) 2852(3) 28(1) 
C(22) 10127(5) 5416(1) 5786(3) 34(1) 
O(31) 6354(4) 1484(1) 3099(2) 31(1) 
C(31) 5628(5) 1808(1) 2216(3) 26(1) 
O(32) 8707(3) 1554(1) 1311(2) 26(1) 
C(32) 7544(5) 1968(1) 1620(3) 23(1) 
O(33) 10571(3) 2510(1) 1699(2) 26(1) 
C(33) 9127(5) 2291(1) 2389(3) 21(1) 
O(34) 9311(3) 2962(1) 3738(2) 21(1) 
C(34) 7898(5) 2692(1) 2888(3) 20(1) 
O(35) 4620(3) 2230(1) 2639(2) 24(1) 
C(35) 6073(5) 2498(1) 3472(3) 19(1) 
O(36) 6443(3) 3189(1) 4713(2) 25(1) 
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C(36) 4900(5) 2927(1) 3920(3) 25(1) 
C(37) 8178(5) 3359(1) 4165(3) 22(1) 
C(38) 4653(6) 1253(2) 3608(4) 48(1) 
C(39) 7700(6) 1314(1) 292(3) 33(1) 
C(40) 8847(5) 836(1) 177(3) 30(1) 
C(41) 8370(6) 427(1) 782(3) 34(1) 
C(42) 9463(6) -6(1) 710(3) 38(1) 
C(43) 11069(6) -39(2) 13(4) 42(1) 
C(44) 11551(6) 368(2) -587(4) 48(1) 
C(45) 10479(6) 803(1) -516(3) 39(1) 
C(46) 9733(5) 3635(1) 5028(3) 22(1) 
C(47) 11583(5) 3823(1) 4686(3) 24(1) 
C(48) 13015(5) 4095(1) 5450(3) 25(1) 
O(49) 13817(4) 4460(1) 7366(2) 32(1) 
C(49) 12573(5) 4180(1) 6548(3) 25(1) 
C(50) 10742(5) 3986(1) 6908(3) 29(1) 
C(51) 9323(5) 3716(1) 6142(3) 27(1) 
C(52) 15587(6) 4721(2) 7002(3) 38(1) 
 
 
Table 8.1.3.  Bond lengths [Å] and angles [˚] for nksc6 
O(1)-C(1) 1.388(4) O(49)-C(52) 1.437(4) H(22A)-C(22)-H(22B) 109.5000 
O(1)-C(8) 1.445(4) C(49)-C(50) 1.387(4) O(8)-C(22)-H(22C) 109.5000 
C(1)-O(5) 1.428(4) C(50)-C(51) 1.388(5) H(22A)-C(22)-H(22C) 109.5000 
C(1)-C(2) 1.545(4) C(50)-H(50A) 0.9500 H(22B)-C(22)-H(22C) 109.5000 
C(1)-H(1A) 1.0000 C(51)-H(51A) 0.9500 C(31)-O(31)-C(38) 113.6(3) 
O(2)-C(2) 1.431(3) C(52)-H(52A) 0.9800 O(31)-C(31)-O(35) 111.7(3) 
O(2)-C(9) 1.434(4) C(52)-H(52B) 0.9800 O(31)-C(31)-C(32) 108.7(2) 
C(2)-C(3) 1.530(4) C(52)-H(52C) 0.9800 O(35)-C(31)-C(32) 110.0(3) 
C(2)-H(2A) 1.0000 C(1)-O(1)-C(8) 112.0(2) O(31)-C(31)-H(31A) 108.8000 
O(3)-C(3) 1.427(3) O(1)-C(1)-O(5) 112.4(2) O(35)-C(31)-H(31A) 108.8000 
O(3)-H(3O) 0.970(19) O(1)-C(1)-C(2) 109.5(2) C(32)-C(31)-H(31A) 108.8000 
C(3)-C(4) 1.512(4) O(5)-C(1)-C(2) 110.5(3) C(32)-O(32)-C(39) 113.1(2) 
C(3)-H(3A) 1.0000 O(1)-C(1)-H(1A) 108.1000 O(32)-C(32)-C(33) 107.1(2) 
O(4)-C(7) 1.427(3) O(5)-C(1)-H(1A) 108.1000 O(32)-C(32)-C(31) 110.8(3) 
O(4)-C(4) 1.438(4) C(2)-C(1)-H(1A) 108.1000 C(33)-C(32)-C(31) 112.5(3) 
C(4)-C(5) 1.523(4) C(2)-O(2)-C(9) 113.1(2) O(32)-C(32)-H(32A) 108.8000 
C(4)-H(4A) 1.0000 O(2)-C(2)-C(3) 105.8(2) C(33)-C(32)-H(32A) 108.8000 
O(5)-C(5) 1.448(4) O(2)-C(2)-C(1) 112.4(3) C(31)-C(32)-H(32A) 108.8000 
C(5)-C(6) 1.513(4) C(3)-C(2)-C(1) 114.9(2) C(33)-O(33)-H(33O) 110(3) 
C(5)-H(5A) 1.0000 O(2)-C(2)-H(2A) 107.8000 O(33)-C(33)-C(34) 108.5(3) 
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O(6)-C(7) 1.426(3) C(3)-C(2)-H(2A) 107.8000 O(33)-C(33)-C(32) 108.7(2) 
O(6)-C(6) 1.444(4) C(1)-C(2)-H(2A) 107.8000 C(34)-C(33)-C(32) 108.8(2) 
C(6)-H(6A) 0.9900 C(3)-O(3)-H(3O) 105(3) O(33)-C(33)-H(33A) 110.3000 
C(6)-H(6B) 0.9900 O(3)-C(3)-C(4) 109.1(2) C(34)-C(33)-H(33A) 110.3000 
C(7)-C(16) 1.500(4) O(3)-C(3)-C(2) 108.6(2) C(32)-C(33)-H(33A) 110.3000 
C(7)-H(7A) 1.0000 C(4)-C(3)-C(2) 108.9(2) C(37)-O(34)-C(34) 109.9(2) 
O(8)-C(19) 1.369(4) O(3)-C(3)-H(3A) 110.1000 O(34)-C(34)-C(33) 109.8(2) 
O(8)-C(22) 1.443(4) C(4)-C(3)-H(3A) 110.1000 O(34)-C(34)-C(35) 107.5(2) 
C(8)-H(8A) 0.9800 C(2)-C(3)-H(3A) 110.1000 C(33)-C(34)-C(35) 112.6(3) 
C(8)-H(8B) 0.9800 C(7)-O(4)-C(4) 108.4(2) O(34)-C(34)-H(34A) 109.0000 
C(8)-H(8C) 0.9800 O(4)-C(4)-C(3) 110.8(2) C(33)-C(34)-H(34A) 109.0000 
C(9)-C(10) 1.502(4) O(4)-C(4)-C(5) 109.0(2) C(35)-C(34)-H(34A) 109.0000 
C(9)-H(9A) 0.9900 C(3)-C(4)-C(5) 109.0(3) C(31)-O(35)-C(35) 111.9(2) 
C(9)-H(9B) 0.9900 O(4)-C(4)-H(4A) 109.3000 O(35)-C(35)-C(34) 108.7(2) 
C(10)-C(11) 1.389(5) C(3)-C(4)-H(4A) 109.3000 O(35)-C(35)-C(36) 109.5(2) 
C(10)-C(15) 1.393(4) C(5)-C(4)-H(4A) 109.3000 C(34)-C(35)-C(36) 108.9(3) 
C(11)-C(12) 1.393(5) C(1)-O(5)-C(5) 112.4(2) O(35)-C(35)-H(35A) 109.9000 
C(11)-H(11A) 0.9500 O(5)-C(5)-C(6) 108.6(2) C(34)-C(35)-H(35A) 109.9000 
C(12)-C(13) 1.382(5) O(5)-C(5)-C(4) 107.4(2) C(36)-C(35)-H(35A) 109.9000 
C(12)-H(12A) 0.9500 C(6)-C(5)-C(4) 111.3(3) C(37)-O(36)-C(36) 111.3(2) 
C(13)-C(14) 1.365(5) O(5)-C(5)-H(5A) 109.8000 O(36)-C(36)-C(35) 106.9(2) 
C(13)-H(13A) 0.9500 C(6)-C(5)-H(5A) 109.8000 O(36)-C(36)-H(36A) 110.3000 
C(14)-C(15) 1.392(5) C(4)-C(5)-H(5A) 109.8000 C(35)-C(36)-H(36A) 110.3000 
C(14)-H(14A) 0.9500 C(7)-O(6)-C(6) 109.9(2) O(36)-C(36)-H(36B) 110.3000 
C(15)-H(15A) 0.9500 O(6)-C(6)-C(5) 108.0(2) C(35)-C(36)-H(36B) 110.3000 
C(16)-C(17) 1.380(4) O(6)-C(6)-H(6A) 110.1000 H(36A)-C(36)-H(36B) 108.6000 
C(16)-C(21) 1.397(4) C(5)-C(6)-H(6A) 110.1000 O(36)-C(37)-O(34) 111.4(3) 
C(17)-C(18) 1.398(4) O(6)-C(6)-H(6B) 110.1000 O(36)-C(37)-C(46) 109.1(2) 
C(17)-H(17A) 0.9500 C(5)-C(6)-H(6B) 110.1000 O(34)-C(37)-C(46) 107.8(2) 
C(18)-C(19) 1.391(4) H(6A)-C(6)-H(6B) 108.4000 O(36)-C(37)-H(37A) 109.5000 
C(18)-H(18A) 0.9500 O(6)-C(7)-O(4) 110.2(2) O(34)-C(37)-H(37A) 109.5000 
C(19)-C(20) 1.395(5) O(6)-C(7)-C(16) 107.3(2) C(46)-C(37)-H(37A) 109.5000 
C(20)-C(21) 1.375(5) O(4)-C(7)-C(16) 111.8(2) O(31)-C(38)-H(38A) 109.5000 
C(20)-H(20A) 0.9500 O(6)-C(7)-H(7A) 109.2000 O(31)-C(38)-H(38B) 109.5000 
C(21)-H(21A) 0.9500 O(4)-C(7)-H(7A) 109.2000 H(38A)-C(38)-H(38B) 109.5000 
C(22)-H(22A) 0.9800 C(16)-C(7)-H(7A) 109.2000 O(31)-C(38)-H(38C) 109.5000 
C(22)-H(22B) 0.9800 C(19)-O(8)-C(22) 117.7(2) H(38A)-C(38)-H(38C) 109.5000 
C(22)-H(22C) 0.9800 O(1)-C(8)-H(8A) 109.5000 H(38B)-C(38)-H(38C) 109.5000 
O(31)-C(31) 1.392(4) O(1)-C(8)-H(8B) 109.5000 O(32)-C(39)-C(40) 107.9(3) 
O(31)-C(38) 1.441(4) H(8A)-C(8)-H(8B) 109.5000 O(32)-C(39)-H(39A) 110.1000 
C(31)-O(35) 1.437(4) O(1)-C(8)-H(8C) 109.5000 C(40)-C(39)-H(39A) 110.1000 
C(31)-C(32) 1.538(4) H(8A)-C(8)-H(8C) 109.5000 O(32)-C(39)-H(39B) 110.1000 
C(31)-H(31A) 1.0000 H(8B)-C(8)-H(8C) 109.5000 C(40)-C(39)-H(39B) 110.1000 
Appendix 3 – X-ray crystal structure data 
 
A327 
O(32)-C(32) 1.421(4) O(2)-C(9)-C(10) 109.2(2) H(39A)-C(39)-H(39B) 108.4000 
O(32)-C(39) 1.432(4) O(2)-C(9)-H(9A) 109.8000 C(41)-C(40)-C(45) 118.4(3) 
C(32)-C(33) 1.530(4) C(10)-C(9)-H(9A) 109.8000 C(41)-C(40)-C(39) 121.0(3) 
C(32)-H(32A) 1.0000 O(2)-C(9)-H(9B) 109.8000 C(45)-C(40)-C(39) 120.6(3) 
O(33)-C(33) 1.429(3) C(10)-C(9)-H(9B) 109.8000 C(42)-C(41)-C(40) 121.2(3) 
O(33)-H(33O) 0.965(19) H(9A)-C(9)-H(9B) 108.3000 C(42)-C(41)-H(41A) 119.4000 
C(33)-C(34) 1.505(4) C(11)-C(10)-C(15) 118.7(3) C(40)-C(41)-H(41A) 119.4000 
C(33)-H(33A) 1.0000 C(11)-C(10)-C(9) 120.9(3) C(41)-C(42)-C(43) 120.2(4) 
O(34)-C(37) 1.426(4) C(15)-C(10)-C(9) 120.4(3) C(41)-C(42)-H(42A) 119.9000 
O(34)-C(34) 1.444(4) C(10)-C(11)-C(12) 120.4(3) C(43)-C(42)-H(42A) 119.9000 
C(34)-C(35) 1.513(4) C(10)-C(11)-H(11A) 119.8000 C(44)-C(43)-C(42) 118.7(4) 
C(34)-H(34A) 1.0000 C(12)-C(11)-H(11A) 119.8000 C(44)-C(43)-H(43A) 120.7000 
O(35)-C(35) 1.443(4) C(13)-C(12)-C(11) 120.4(4) C(42)-C(43)-H(43A) 120.7000 
C(35)-C(36) 1.517(4) C(13)-C(12)-H(12A) 119.8000 C(43)-C(44)-C(45) 121.6(4) 
C(35)-H(35A) 1.0000 C(11)-C(12)-H(12A) 119.8000 C(43)-C(44)-H(44A) 119.2000 
O(36)-C(37) 1.419(3) C(14)-C(13)-C(12) 119.5(3) C(45)-C(44)-H(44A) 119.2000 
O(36)-C(36) 1.440(4) C(14)-C(13)-H(13A) 120.3000 C(44)-C(45)-C(40) 119.9(4) 
C(36)-H(36A) 0.9900 C(12)-C(13)-H(13A) 120.3000 C(44)-C(45)-H(45A) 120.1000 
C(36)-H(36B) 0.9900 C(13)-C(14)-C(15) 121.0(3) C(40)-C(45)-H(45A) 120.1000 
C(37)-C(46) 1.510(4) C(13)-C(14)-H(14A) 119.5000 C(47)-C(46)-C(51) 119.3(3) 
C(37)-H(37A) 1.0000 C(15)-C(14)-H(14A) 119.5000 C(47)-C(46)-C(37) 119.0(3) 
C(38)-H(38A) 0.9800 C(14)-C(15)-C(10) 120.1(3) C(51)-C(46)-C(37) 121.7(3) 
C(38)-H(38B) 0.9800 C(14)-C(15)-H(15A) 120.0000 C(46)-C(47)-C(48) 120.5(3) 
C(38)-H(38C) 0.9800 C(10)-C(15)-H(15A) 120.0000 C(46)-C(47)-H(47A) 119.8000 
C(39)-C(40) 1.508(5) C(17)-C(16)-C(21) 118.5(3) C(48)-C(47)-H(47A) 119.8000 
C(39)-H(39A) 0.9900 C(17)-C(16)-C(7) 124.3(3) C(49)-C(48)-C(47) 119.7(3) 
C(39)-H(39B) 0.9900 C(21)-C(16)-C(7) 117.2(3) C(49)-C(48)-H(48A) 120.1000 
C(40)-C(41) 1.380(5) C(16)-C(17)-C(18) 121.4(3) C(47)-C(48)-H(48A) 120.1000 
C(40)-C(45) 1.398(5) C(16)-C(17)-H(17A) 119.3000 C(49)-O(49)-C(52) 117.2(3) 
C(41)-C(42) 1.376(5) C(18)-C(17)-H(17A) 119.3000 C(48)-C(49)-O(49) 125.1(3) 
C(41)-H(41A) 0.9500 C(19)-C(18)-C(17) 119.2(3) C(48)-C(49)-C(50) 120.2(3) 
C(42)-C(43) 1.389(5) C(19)-C(18)-H(18A) 120.4000 O(49)-C(49)-C(50) 114.6(3) 
C(42)-H(42A) 0.9500 C(17)-C(18)-H(18A) 120.4000 C(49)-C(50)-C(51) 119.7(3) 
C(43)-C(44) 1.372(6) O(8)-C(19)-C(18) 125.2(3) C(49)-C(50)-H(50A) 120.2000 
C(43)-H(43A) 0.9500 O(8)-C(19)-C(20) 115.1(3) C(51)-C(50)-H(50A) 120.2000 
C(44)-C(45) 1.375(5) C(18)-C(19)-C(20) 119.7(3) C(46)-C(51)-C(50) 120.5(3) 
C(44)-H(44A) 0.9500 C(21)-C(20)-C(19) 120.1(3) C(46)-C(51)-H(51A) 119.7000 
C(45)-H(45A) 0.9500 C(21)-C(20)-H(20A) 119.9000 C(50)-C(51)-H(51A) 119.7000 
C(46)-C(47) 1.383(4) C(19)-C(20)-H(20A) 119.9000 O(49)-C(52)-H(52A) 109.5000 
C(46)-C(51) 1.384(4) C(20)-C(21)-C(16) 121.1(3) O(49)-C(52)-H(52B) 109.5000 
C(47)-C(48) 1.396(4) C(20)-C(21)-H(21A) 119.5000 H(52A)-C(52)-H(52B) 109.5000 
C(47)-H(47A) 0.9500 C(16)-C(21)-H(21A) 119.5000 O(49)-C(52)-H(52C) 109.5000 
C(48)-H(48A) 0.9500 O(8)-C(22)-H(22B) 109.5000 H(52B)-C(52)-H(52C) 109.5000 
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Table 8.1.4.  Anisotropic displacement parameters (Å2 ! 103) for nksc6.  The anisotropic displacement 
factor exponent takes the form:  -2!2[h2 a*2U11 + ... + 2 h k a* b* U12] 
 U
11
 U
22
 U
33
 U
23
 U
13
 U
12
 
O(1) 26(1) 24(1) 26(1) 2(1) 5(1) -3(1) 
C(1) 23(2) 20(2) 24(2) 1(1) 7(1) 1(1) 
O(2) 24(1) 30(2) 17(1) -9(1) 1(1) 2(1) 
C(2) 23(2) 22(2) 17(2) -1(1) 6(1) 1(1) 
O(3) 24(1) 28(1) 24(1) -1(1) 9(1) -4(1) 
C(3) 17(2) 19(2) 20(2) -2(1) 4(1) -2(1) 
O(4) 23(1) 21(1) 20(1) -5(1) 4(1) 0(1) 
C(4) 20(2) 21(2) 16(2) 0(1) 1(1) -1(1) 
O(5) 22(1) 26(1) 20(1) -6(1) 4(1) 0(1) 
C(5) 23(2) 24(2) 14(2) -5(1) 3(1) -1(1) 
O(6) 24(1) 30(2) 19(1) -4(1) 5(1) -7(1) 
C(6) 20(2) 31(2) 21(2) -8(2) 4(1) -7(1) 
C(7) 23(2) 24(2) 20(2) 0(1) 7(1) 0(1) 
O(8) 29(1) 26(1) 27(1) -10(1) 1(1) 1(1) 
C(8) 43(2) 23(2) 27(2) -3(2) 8(2) -10(2) 
C(9) 28(2) 39(2) 24(2) -13(2) 5(1) -3(2) 
C(10) 25(2) 28(2) 18(2) -10(1) -1(1) -3(1) 
C(11) 33(2) 37(2) 26(2) 0(2) 0(2) -4(2) 
C(12) 50(3) 23(2) 44(3) -10(2) -8(2) 2(2) 
C(13) 33(2) 38(3) 44(2) -15(2) 2(2) 6(2) 
C(14) 23(2) 41(2) 22(2) -8(2) 2(1) 0(2) 
C(15) 27(2) 32(2) 17(2) -2(2) -2(1) 0(2) 
C(16) 23(2) 23(2) 18(2) 0(1) 4(1) 2(1) 
C(17) 28(2) 21(2) 24(2) -1(1) 8(1) 3(1) 
C(18) 23(2) 24(2) 25(2) -3(2) 0(1) 1(1) 
C(19) 29(2) 20(2) 18(2) 0(1) 3(1) 0(1) 
C(20) 26(2) 32(2) 33(2) -8(2) 7(2) 6(2) 
C(21) 29(2) 29(2) 26(2) -5(2) 3(1) 4(2) 
C(22) 33(2) 39(2) 28(2) -7(2) -6(2) 1(2) 
O(31) 34(1) 28(2) 32(2) 5(1) 11(1) 1(1) 
C(31) 28(2) 22(2) 27(2) -4(2) 4(1) 0(1) 
O(32) 29(1) 25(1) 22(1) -9(1) 3(1) 5(1) 
C(32) 24(2) 24(2) 20(2) -3(2) 4(1) 2(1) 
O(33) 22(1) 34(2) 23(1) -1(1) 7(1) -3(1) 
C(33) 18(2) 24(2) 20(2) 3(1) 4(1) 1(1) 
C(48)-C(49) 1.375(4) O(8)-C(22)-H(22A) 109.5000 H(52A)-C(52)-H(52C) 109.5000 
O(49)-C(49) 1.382(4)     
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O(34) 21(1) 23(1) 20(1) -4(1) 5(1) 2(1) 
C(34) 22(2) 23(2) 16(2) -1(1) 4(1) 0(1) 
O(35) 20(1) 28(1) 24(1) -7(1) 3(1) 3(1) 
C(35) 20(2) 21(2) 17(2) -2(1) 0(1) 0(1) 
O(36) 21(1) 30(1) 23(1) -6(1) 6(1) -1(1) 
C(36) 23(2) 31(2) 21(2) 0(2) 3(1) 2(2) 
C(37) 23(2) 23(2) 21(2) -3(1) 5(1) 1(1) 
C(38) 50(2) 46(3) 54(3) 9(2) 28(2) -8(2) 
C(39) 39(2) 29(2) 25(2) -10(2) -8(2) 5(2) 
C(40) 40(2) 24(2) 26(2) -7(2) 5(2) -4(2) 
C(41) 37(2) 38(3) 27(2) -5(2) 10(2) -8(2) 
C(42) 53(2) 28(2) 29(2) 2(2) -1(2) -3(2) 
C(43) 48(3) 27(2) 51(3) -12(2) 5(2) 2(2) 
C(44) 49(2) 37(3) 63(3) -15(2) 23(2) -3(2) 
C(45) 60(3) 23(2) 38(2) -7(2) 23(2) -5(2) 
C(46) 27(2) 19(2) 21(2) 0(1) 1(1) 3(1) 
C(47) 27(2) 25(2) 19(2) 1(1) 1(1) 6(1) 
C(48) 25(2) 26(2) 25(2) -1(2) 8(1) 2(1) 
O(49) 38(1) 36(2) 23(1) -5(1) 3(1) -8(1) 
C(49) 29(2) 24(2) 19(2) -5(1) -1(1) 2(1) 
C(50) 42(2) 21(2) 24(2) 1(2) 7(2) -2(2) 
C(51) 35(2) 21(2) 27(2) -2(2) 10(1) -3(2) 
C(52) 29(2) 46(3) 38(2) -5(2) 2(2) -6(2) 
 
 
Table 8.1.5.  Hydrogen coordinates (! 104) and isotropic displacement parameters (Å2 ! 103) for nksc6. 
 x y z U(eq) 
H(1A) 2252 2761 -1939 26 
H(2A) 4834 3320 -2171 24 
H(3O) 9200(50) 3458(13) -1110(40) 66(14) 
H(3A) 7270 3156 55 22 
H(4A) 4350 3955 -575 23 
H(5A) 3878 3126 899 24 
H(6A) 947 3936 513 29 
H(6B) 752 3486 1374 29 
H(7A) 3818 4473 855 26 
H(8A) 598 2281 -436 46 
H(8B) 2203 1837 -68 46 
H(8C) 1553 1968 -1400 46 
H(9A) 5342 2696 -3498 36 
H(9B) 4558 2277 -2694 36 
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H(11A) 6269 1498 -2632 39 
H(12A) 8859 973 -3204 48 
H(13A) 11647 1286 -4106 46 
H(14A) 11818 2117 -4453 35 
H(15A) 9268 2650 -3881 31 
H(17A) 8683 4307 2591 29 
H(18A) 10133 4805 4132 29 
H(20A) 4374 5482 4024 36 
H(21A) 2962 4979 2519 34 
H(22A) 10266 5085 6109 51 
H(22B) 10379 5656 6410 51 
H(22C) 11182 5463 5254 51 
H(31A) 4563 1636 1642 31 
H(32A) 6995 2154 906 27 
H(33O) 12010(40) 2391(17) 1930(40) 80(16) 
H(33A) 9938 2092 3019 25 
H(34A) 7307 2920 2256 24 
H(35A) 6645 2278 4124 23 
H(36A) 4303 3143 3277 30 
H(36B) 3708 2809 4316 30 
H(37A) 7623 3581 3515 27 
H(38A) 3894 1500 4003 72 
H(38B) 5259 1005 4163 72 
H(38C) 3648 1097 3004 72 
H(39A) 7791 1522 -390 39 
H(39B) 6169 1253 349 39 
H(41A) 7266 444 1257 40 
H(42A) 9117 -283 1139 45 
H(43A) 11819 -338 -47 50 
H(44A) 12652 348 -1064 58 
H(45A) 10847 1080 -936 47 
H(47A) 11881 3766 3925 29 
H(48A) 14289 4221 5212 30 
H(50A) 10460 4037 7674 34 
H(51A) 8061 3585 6386 32 
H(52A) 16596 4488 6738 57 
H(52B) 16318 4911 7650 57 
H(52C) 15055 4943 6371 57 
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Table 8.1.6.  Torsion angles [˚] for nksc6. 
C(8)-O(1)-C(1)-O(5) 78.9(3) C(38)-O(31)-C(31)-O(35) 67.2(4) 
C(8)-O(1)-C(1)-C(2) -157.8(2) C(38)-O(31)-C(31)-C(32) -171.2(3) 
C(9)-O(2)-C(2)-C(3) -173.2(2) C(39)-O(32)-C(32)-C(33) -158.6(3) 
C(9)-O(2)-C(2)-C(1) 60.6(3) C(39)-O(32)-C(32)-C(31) 78.4(3) 
O(1)-C(1)-C(2)-O(2) 42.6(3) O(31)-C(31)-C(32)-O(32) 50.8(3) 
O(5)-C(1)-C(2)-O(2) 166.9(2) O(35)-C(31)-C(32)-O(32) 173.4(3) 
O(1)-C(1)-C(2)-C(3) -78.5(3) O(31)-C(31)-C(32)-C(33) -69.0(3) 
O(5)-C(1)-C(2)-C(3) 45.9(4) O(35)-C(31)-C(32)-C(33) 53.6(3) 
O(2)-C(2)-C(3)-O(3) 70.4(3) O(32)-C(32)-C(33)-O(33) 70.9(3) 
C(1)-C(2)-C(3)-O(3) -165.0(2) C(31)-C(32)-C(33)-O(33) -167.1(2) 
O(2)-C(2)-C(3)-C(4) -170.9(2) O(32)-C(32)-C(33)-C(34) -171.1(2) 
C(1)-C(2)-C(3)-C(4) -46.3(3) C(31)-C(32)-C(33)-C(34) -49.2(3) 
C(7)-O(4)-C(4)-C(3) -179.1(3) C(37)-O(34)-C(34)-C(33) 176.8(2) 
C(7)-O(4)-C(4)-C(5) -59.1(3) C(37)-O(34)-C(34)-C(35) -60.4(3) 
O(3)-C(3)-C(4)-O(4) -66.0(3) O(33)-C(33)-C(34)-O(34) -69.7(3) 
C(2)-C(3)-C(4)-O(4) 175.6(2) C(32)-C(33)-C(34)-O(34) 172.1(2) 
O(3)-C(3)-C(4)-C(5) 174.0(2) O(33)-C(33)-C(34)-C(35) 170.6(2) 
C(2)-C(3)-C(4)-C(5) 55.6(3) C(32)-C(33)-C(34)-C(35) 52.4(3) 
O(1)-C(1)-O(5)-C(5) 66.4(3) O(31)-C(31)-O(35)-C(35) 60.1(3) 
C(2)-C(1)-O(5)-C(5) -56.2(3) C(32)-C(31)-O(35)-C(35) -60.7(3) 
C(1)-O(5)-C(5)-C(6) -172.1(3) C(31)-O(35)-C(35)-C(34) 63.3(3) 
C(1)-O(5)-C(5)-C(4) 67.4(3) C(31)-O(35)-C(35)-C(36) -177.9(3) 
O(4)-C(4)-C(5)-O(5) 172.6(2) O(34)-C(34)-C(35)-O(35) 179.5(2) 
C(3)-C(4)-C(5)-O(5) -66.3(3) C(33)-C(34)-C(35)-O(35) -59.4(3) 
O(4)-C(4)-C(5)-C(6) 53.8(3) O(34)-C(34)-C(35)-C(36) 60.3(3) 
C(3)-C(4)-C(5)-C(6) 174.9(3) C(33)-C(34)-C(35)-C(36) -178.6(3) 
C(7)-O(6)-C(6)-C(5) 58.5(3) C(37)-O(36)-C(36)-C(35) 59.5(3) 
O(5)-C(5)-C(6)-O(6) -170.7(2) O(35)-C(35)-C(36)-O(36) -178.0(2) 
C(4)-C(5)-C(6)-O(6) -52.6(3) C(34)-C(35)-C(36)-O(36) -59.2(3) 
C(6)-O(6)-C(7)-O(4) -67.2(3) C(36)-O(36)-C(37)-O(34) -61.7(3) 
C(6)-O(6)-C(7)-C(16) 170.9(2) C(36)-O(36)-C(37)-C(46) 179.4(3) 
C(4)-O(4)-C(7)-O(6) 66.8(3) C(34)-O(34)-C(37)-O(36) 61.6(3) 
C(4)-O(4)-C(7)-C(16) -173.9(3) C(34)-O(34)-C(37)-C(46) -178.8(2) 
C(2)-O(2)-C(9)-C(10) 176.6(3) C(32)-O(32)-C(39)-C(40) -169.9(3) 
O(2)-C(9)-C(10)-C(11) 105.9(3) O(32)-C(39)-C(40)-C(41) 81.9(4) 
O(2)-C(9)-C(10)-C(15) -75.5(4) O(32)-C(39)-C(40)-C(45) -95.7(4) 
C(15)-C(10)-C(11)-C(12) 0.0(5) C(45)-C(40)-C(41)-C(42) -0.1(5) 
C(9)-C(10)-C(11)-C(12) 178.7(3) C(39)-C(40)-C(41)-C(42) -177.8(3) 
C(10)-C(11)-C(12)-C(13) 0.0(5) C(40)-C(41)-C(42)-C(43) -0.5(6) 
C(11)-C(12)-C(13)-C(14) -0.3(5) C(41)-C(42)-C(43)-C(44) 0.7(6) 
C(12)-C(13)-C(14)-C(15) 0.6(5) C(42)-C(43)-C(44)-C(45) -0.3(6) 
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C(13)-C(14)-C(15)-C(10) -0.5(5) C(43)-C(44)-C(45)-C(40) -0.4(6) 
C(11)-C(10)-C(15)-C(14) 0.2(5) C(41)-C(40)-C(45)-C(44) 0.5(6) 
C(9)-C(10)-C(15)-C(14) -178.4(3) C(39)-C(40)-C(45)-C(44) 178.2(4) 
O(6)-C(7)-C(16)-C(17) 111.3(3) O(36)-C(37)-C(46)-C(47) 178.4(3) 
O(4)-C(7)-C(16)-C(17) -9.6(4) O(34)-C(37)-C(46)-C(47) 57.3(4) 
O(6)-C(7)-C(16)-C(21) -68.3(4) O(36)-C(37)-C(46)-C(51) -3.5(4) 
O(4)-C(7)-C(16)-C(21) 170.8(3) O(34)-C(37)-C(46)-C(51) -124.5(3) 
C(21)-C(16)-C(17)-C(18) 2.5(5) C(51)-C(46)-C(47)-C(48) -0.6(5) 
C(7)-C(16)-C(17)-C(18) -177.1(3) C(37)-C(46)-C(47)-C(48) 177.7(3) 
C(16)-C(17)-C(18)-C(19) 0.0(5) C(46)-C(47)-C(48)-C(49) -0.5(5) 
C(22)-O(8)-C(19)-C(18) -5.3(5) C(47)-C(48)-C(49)-O(49) -177.3(3) 
C(22)-O(8)-C(19)-C(20) 176.0(3) C(47)-C(48)-C(49)-C(50) 1.7(5) 
C(17)-C(18)-C(19)-O(8) 178.3(3) C(52)-O(49)-C(49)-C(48) 6.6(5) 
C(17)-C(18)-C(19)-C(20) -3.1(5) C(52)-O(49)-C(49)-C(50) -172.4(3) 
O(8)-C(19)-C(20)-C(21) -177.7(3) C(48)-C(49)-C(50)-C(51) -1.8(5) 
C(18)-C(19)-C(20)-C(21) 3.6(5) O(49)-C(49)-C(50)-C(51) 177.3(3) 
C(19)-C(20)-C(21)-C(16) -1.0(5) C(47)-C(46)-C(51)-C(50) 0.5(5) 
C(17)-C(16)-C(21)-C(20) -2.0(5) C(37)-C(46)-C(51)-C(50) -177.7(3) 
C(7)-C(16)-C(21)-C(20) 177.7(3) C(49)-C(50)-C(51)-C(46) 0.7(5) 
 
 
Table 8.1.7. Hydrogen bonds for nksc6  [Å and ˚]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
O(3)-H(3O)...O(5)   #1 0.970(19) 1.90(3) 2.783(3) 150(4) 
O(33)-H(33O)...O(35)   #1 0.965(19) 1.79(2) 2.744(3) 168(4) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z  
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8.2.  (-)-3-O-Benzyl-2-hydroxy-5-O-(4-methoxybenzyl)-4-O- 
  triisopropylsilyl-6-oxocyclohexyl acetate 147 
 
Figure 8.2.1.  VMD representation of crystal structure of 147. 
 
Crystal structure data for nksc10 was deposited at the Cambridge Crystallographic Data Centre 
as supplementary publication number CCDC 718377. 
Table 8.2.1.  Crystal data and structure refinement for nksc10. 
Identification 
code 
nksc10 
Theta range for data 
collection 
1.87 to 25.31  ˚
Empirical 
formula 
C32H46O8Si Index ranges 
-13<=h<=12 
-9<=k<=9 
-26<=l<=26 
Formula 
weight 586.78 
Reflections collected 18396 
Temperature 93(2) K Independent reflections 
10355 
[R(int) = 0.0889] 
Wavelength 0.71073 Å 
Completeness to  
theta = 25.00˚ 
96.5 % 
Crystal 
system 
Monoclinic Absorption correction Multiscan 
Space group P2(1) 
Max. and min. 
transmission 
1.0000 and 0.9710 
Unit cell 
dimensions 
a = 11.478(3) Å 
b = 8.219(2) Å  
c = 34.195(9) Å 
!= 90˚ 
"= 90.187(6)˚ 
# = 90˚ 
Refinement method 
Full-matrix least-
squares on F2 
Volume 3225.8(14) Å3 
Data 
Restraints 
Parameters 
10355 
3  
753 
Z 4 Goodness-of-fit on F2 0.949 
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Density 
(calculated) 
1.208 mg/m3 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0832 
wR2 = 0.1699 
Absorption 
coefficient 
0.120 mm-1 
R indices 
(all data) 
R1 = 0.1572 
wR2 = 0.2079 
F(000) 1264 
Absolute structure 
parameter 
-0.1(2) 
Crystal size 0.3500 ! 0.1000 ! 0.0100 mm
3 Extinction coefficient 0.0040(6) 
  Largest diff. peak and hole 
0.428 and  
-0.408 e.Å-3 
 
 
Table 8.2.2. Atomic coordinates (! 104) and equivalent isotropic displacement parameters (Å2 ! 103) for 
nksc10.  U(eq) is defined as one third of  the trace of the orthogonalised Uij tensor. 
 x y z U(eq) 
C(1) 6815(5) 7750(8) 4701(2) 31(2) 
O(1) 7548(4) 8223(6) 5019(1) 36(1) 
C(2) 7516(5) 6693(8) 4419(2) 34(2) 
O(2) 8448(4) 7586(6) 4252(1) 39(1) 
C(3) 6715(5) 6102(7) 4089(2) 29(2) 
O(3) 7346(4) 5179(5) 3808(1) 35(1) 
C(4) 6162(5) 7513(7) 3863(2) 28(2) 
O(4) 5329(3) 6903(5) 3595(1) 32(1) 
Si(4) 5368(2) 6667(2) 3112(1) 31(1) 
C(5) 5540(5) 8637(8) 4144(2) 30(2) 
O(5) 5060(4) 9959(5) 3932(1) 33(1) 
C(6) 6389(5) 9142(8) 4460(2) 30(2) 
O(6) 6729(4) 10537(6) 4510(1) 40(1) 
C(7) 6973(7) 9017(8) 5318(2) 38(2) 
O(7) 5941(4) 9282(6) 5300(1) 44(1) 
C(8) 7796(6) 9405(9) 5646(2) 45(2) 
C(9) 7570(5) 3519(8) 3926(2) 34(2) 
C(10) 8633(5) 2891(8) 3721(2) 34(2) 
C(11) 9546(5) 3964(9) 3623(2) 40(2) 
C(12) 10534(6) 3345(11) 3437(2) 46(2) 
C(13) 10643(6) 1724(10) 3353(2) 46(2) 
C(14) 9751(6) 665(10) 3450(2) 47(2) 
C(15) 8762(6) 1262(9) 3630(2) 40(2) 
C(16) 5595(6) 4431(7) 3013(2) 32(2) 
C(17) 5316(6) 3907(8) 2595(2) 42(2) 
C(18) 4945(6) 3326(9) 3311(2) 50(2) 
C(19) 6565(5) 7955(8) 2886(2) 33(2) 
C(20) 7818(5) 7234(9) 2946(2) 45(2) 
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C(21) 6375(6) 8243(10) 2451(2) 48(2) 
C(22) 3923(6) 7419(8) 2942(2) 41(2) 
C(23) 3772(6) 9259(8) 3000(2) 43(2) 
C(24) 2896(6) 6532(10) 3135(2) 49(2) 
C(25) 4286(5) 10954(8) 4170(2) 37(2) 
C(26) 3270(5) 9989(8) 4336(2) 34(2) 
C(27) 2264(5) 9808(8) 4117(2) 37(2) 
C(28) 1327(5) 8955(8) 4269(2) 36(2) 
C(29) 1397(5) 8267(8) 4632(2) 32(2) 
O(29) 404(4) 7435(5) 4758(1) 38(1) 
C(30) 2400(5) 8369(7) 4857(2) 31(2) 
C(31) 3323(6) 9289(8) 4700(2) 34(2) 
C(32) 396(6) 6901(10) 5160(2) 47(2) 
C(41) 11915(5) 7298(8) 9696(2) 30(2) 
O(41) 12658(3) 7775(5) 10013(1) 35(1) 
C(42) 12595(5) 6241(8) 9408(2) 28(2) 
O(42) 13514(4) 7181(6) 9238(1) 39(1) 
C(43) 11775(5) 5671(7) 9091(2) 27(2) 
O(43) 12404(4) 4748(5) 8797(1) 34(1) 
C(44) 11187(5) 7043(7) 8868(2) 25(1) 
O(44) 10313(3) 6390(5) 8621(1) 32(1) 
Si(44) 10101(2) 6501(2) 8142(1) 30(1) 
C(45) 10604(5) 8221(8) 9155(2) 30(2) 
O(45) 10124(3) 9537(5) 8943(1) 35(1) 
C(46) 11464(5) 8737(8) 9462(2) 31(2) 
O(46) 11828(4) 10111(6) 9506(1) 38(1) 
C(47) 12079(6) 8555(8) 10313(2) 38(2) 
O(47) 11043(4) 8813(6) 10303(1) 41(1) 
C(48) 12888(6) 8973(9) 10640(2) 44(2) 
C(49) 12605(5) 3075(8) 8904(2) 36(2) 
C(50) 13695(5) 2496(8) 8703(2) 31(2) 
C(51) 14567(5) 3564(9) 8587(2) 40(2) 
C(52) 15558(6) 2984(10) 8404(2) 45(2) 
C(53) 15685(6) 1324(10) 8328(2) 46(2) 
C(54) 14821(6) 262(10) 8442(2) 45(2) 
C(55) 13836(6) 830(9) 8622(2) 42(2) 
C(56) 11375(5) 7518(8) 7905(2) 30(2) 
C(57) 11521(6) 7180(9) 7468(2) 44(2) 
C(58) 11396(6) 9375(8) 7976(2) 44(2) 
C(59) 9970(6) 4313(8) 7982(2) 36(2) 
C(60) 9475(6) 3192(9) 8307(2) 43(2) 
C(61) 9298(6) 4021(9) 7595(2) 46(2) 
C(62) 8718(5) 7762(8) 8083(2) 38(2) 
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C(63) 8398(6) 8271(9) 7669(2) 50(2) 
C(64) 7659(5) 6913(9) 8280(2) 47(2) 
C(65) 9373(5) 10600(7) 9182(2) 34(2) 
C(66) 8357(5) 9640(8) 9348(2) 28(2) 
C(67) 7323(5) 9546(8) 9135(2) 34(2) 
C(68) 6372(5) 8713(9) 9279(2) 38(2) 
O(69) 5429(3) 7177(6) 9762(1) 37(1) 
C(69) 6432(5) 7966(8) 9639(2) 33(2) 
C(70) 7460(5) 8020(7) 9858(2) 29(2) 
C(71) 8402(5) 8886(7) 9707(2) 27(2) 
C(72) 5426(5) 6545(9) 10160(2) 43(2) 
 
 
Table 8.2.3.  Bond lengths [Å] and angles [˚] for nksc10 
C(1)-O(1) 1.426(7) C(68)-H(68A) 0.950 H(32A)-C(32)-H(32B) 109.500 
C(1)-C(6) 1.492(9) O(69)-C(69) 1.387(7) O(29)-C(32)-H(32C) 109.500 
C(1)-C(2) 1.530(9) O(69)-C(72) 1.457(8) H(32A)-C(32)-H(32C) 109.500 
C(1)-H(1A) 1.000 C(69)-C(70) 1.395(8) H(32B)-C(32)-H(32C) 109.500 
O(1)-C(7) 1.381(8) C(70)-C(71) 1.395(8) O(41)-C(41)-C(46) 112.8(5) 
C(2)-O(2) 1.419(7) C(70)-H(70A) 0.950 O(41)-C(41)-C(42) 109.8(5) 
C(2)-C(3) 1.532(8) C(71)-H(71A) 0.950 C(46)-C(41)-C(42) 106.1(5) 
C(2)-H(2A) 1.000 C(72)-H(72A) 0.980 O(41)-C(41)-H(41A) 109.400 
O(2)-H(2O) 0.98(2) C(72)-H(72B) 0.980 C(46)-C(41)-H(41A) 109.400 
C(3)-O(3) 1.425(7) C(72)-H(72C) 0.980 C(42)-C(41)-H(41A) 109.400 
C(3)-C(4) 1.529(8) O(1)-C(1)-C(6) 113.8(5) C(47)-O(41)-C(41) 113.7(5) 
C(3)-H(3A) 1.000 O(1)-C(1)-C(2) 109.0(5) O(42)-C(42)-C(43) 109.6(5) 
O(3)-C(9) 1.446(7) C(6)-C(1)-C(2) 105.0(5) O(42)-C(42)-C(41) 109.5(5) 
C(4)-O(4) 1.414(7) O(1)-C(1)-H(1A) 109.600 C(43)-C(42)-C(41) 108.7(5) 
C(4)-C(5) 1.514(8) C(6)-C(1)-H(1A) 109.600 O(42)-C(42)-H(42A) 109.700 
C(4)-H(4A) 1.000 C(2)-C(1)-H(1A) 109.600 C(43)-C(42)-H(42A) 109.700 
O(4)-Si(4) 1.665(5) C(7)-O(1)-C(1) 114.2(5) C(41)-C(42)-H(42A) 109.700 
Si(4)-C(22) 1.860(7) O(2)-C(2)-C(3) 108.7(5) C(42)-O(42)-H(42O) 103(6) 
Si(4)-C(16) 1.888(6) O(2)-C(2)-C(1) 111.0(5) O(43)-C(43)-C(42) 110.4(5) 
Si(4)-C(19) 1.901(6) C(3)-C(2)-C(1) 109.2(5) O(43)-C(43)-C(44) 105.0(5) 
C(5)-O(5) 1.416(7) O(2)-C(2)-H(2A) 109.300 C(42)-C(43)-C(44) 114.0(5) 
C(5)-C(6) 1.511(8) C(3)-C(2)-H(2A) 109.300 O(43)-C(43)-H(43A) 109.100 
C(5)-H(5A) 1.000 C(1)-C(2)-H(2A) 109.300 C(42)-C(43)-H(43A) 109.100 
O(5)-C(25) 1.458(7) C(2)-O(2)-H(2O) 110(5) C(44)-C(43)-H(43A) 109.100 
C(6)-O(6) 1.223(7) O(3)-C(3)-C(4) 105.9(5) C(49)-O(43)-C(43) 113.6(5) 
C(7)-O(7) 1.205(8) O(3)-C(3)-C(2) 111.1(5) O(44)-C(44)-C(43) 109.4(5) 
C(7)-C(8) 1.500(9) C(4)-C(3)-C(2) 112.2(5) O(44)-C(44)-C(45) 108.1(4) 
C(8)-H(8A) 0.980 O(3)-C(3)-H(3A) 109.200 C(43)-C(44)-C(45) 109.8(5) 
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C(8)-H(8B) 0.980 C(4)-C(3)-H(3A) 109.200 O(44)-C(44)-H(44A) 109.800 
C(8)-H(8C) 0.980 C(2)-C(3)-H(3A) 109.200 C(43)-C(44)-H(44A) 109.800 
C(9)-C(10) 1.500(9) C(3)-O(3)-C(9) 113.8(5) C(45)-C(44)-H(44A) 109.800 
C(9)-H(9A) 0.990 O(4)-C(4)-C(5) 107.9(5) C(44)-O(44)-Si(44) 132.1(4) 
C(9)-H(9B) 0.990 O(4)-C(4)-C(3) 109.7(5) O(44)-Si(44)-C(56) 109.8(3) 
C(10)-C(15) 1.383(10) C(5)-C(4)-C(3) 109.8(5) O(44)-Si(44)-C(59) 104.3(3) 
C(10)-C(11) 1.411(9) O(4)-C(4)-H(4A) 109.800 C(56)-Si(44)-C(59) 111.2(3) 
C(11)-C(12) 1.397(9) C(5)-C(4)-H(4A) 109.800 O(44)-Si(44)-C(62) 104.7(3) 
C(11)-H(11A) 0.950 C(3)-C(4)-H(4A) 109.800 C(56)-Si(44)-C(62) 111.3(3) 
C(12)-C(13) 1.370(11) C(4)-O(4)-Si(4) 131.6(4) C(59)-Si(44)-C(62) 115.0(3) 
C(12)-H(12A) 0.950 O(4)-Si(4)-C(22) 104.2(3) O(45)-C(45)-C(46) 113.4(5) 
C(13)-C(14) 1.385(10) O(4)-Si(4)-C(16) 107.2(3) O(45)-C(45)-C(44) 108.8(5) 
C(13)-H(13A) 0.950 C(22)-Si(4)-C(16) 113.0(3) C(46)-C(45)-C(44) 109.8(5) 
C(14)-C(15) 1.384(10) O(4)-Si(4)-C(19) 111.2(3) O(45)-C(45)-H(45A) 108.200 
C(14)-H(14A) 0.950 C(22)-Si(4)-C(19) 109.4(3) C(46)-C(45)-H(45A) 108.200 
C(15)-H(15A) 0.950 C(16)-Si(4)-C(19) 111.6(3) C(44)-C(45)-H(45A) 108.200 
C(16)-C(17) 1.526(9) O(5)-C(5)-C(6) 113.8(5) C(45)-O(45)-C(65) 113.3(5) 
C(16)-C(18) 1.558(9) O(5)-C(5)-C(4) 109.1(5) O(46)-C(46)-C(45) 125.2(6) 
C(16)-H(16A) 1.000 C(6)-C(5)-C(4) 108.5(5) O(46)-C(46)-C(41) 122.8(6) 
C(17)-H(17A) 0.980 O(5)-C(5)-H(5A) 108.400 C(45)-C(46)-C(41) 111.7(5) 
C(17)-H(17B) 0.980 C(6)-C(5)-H(5A) 108.400 O(47)-C(47)-O(41) 122.5(6) 
C(17)-H(17C) 0.980 C(4)-C(5)-H(5A) 108.400 O(47)-C(47)-C(48) 126.2(7) 
C(18)-H(18A) 0.980 C(5)-O(5)-C(25) 112.4(5) O(41)-C(47)-C(48) 111.3(6) 
C(18)-H(18B) 0.980 O(6)-C(6)-C(1) 122.5(6) C(47)-C(48)-H(48A) 109.500 
C(18)-H(18C) 0.980 O(6)-C(6)-C(5) 124.2(6) C(47)-C(48)-H(48B) 109.500 
C(19)-C(21) 1.520(9) C(1)-C(6)-C(5) 113.2(5) H(48A)-C(48)-H(48B) 109.500 
C(19)-C(20) 1.568(8) O(7)-C(7)-O(1) 121.4(6) C(47)-C(48)-H(48C) 109.500 
C(19)-H(19A) 1.000 O(7)-C(7)-C(8) 127.9(7) H(48A)-C(48)-H(48C) 109.500 
C(20)-H(20A) 0.980 O(1)-C(7)-C(8) 110.7(6) H(48B)-C(48)-H(48C) 109.500 
C(20)-H(20B) 0.980 C(7)-C(8)-H(8A) 109.500 O(43)-C(49)-C(50) 108.5(5) 
C(20)-H(20C) 0.980 C(7)-C(8)-H(8B) 109.500 O(43)-C(49)-H(49A) 110.000 
C(21)-H(21A) 0.980 H(8A)-C(8)-H(8B) 109.500 C(50)-C(49)-H(49A) 110.000 
C(21)-H(21B) 0.980 C(7)-C(8)-H(8C) 109.500 O(43)-C(49)-H(49B) 110.000 
C(21)-H(21C) 0.980 H(8A)-C(8)-H(8C) 109.500 C(50)-C(49)-H(49B) 110.000 
C(22)-C(23) 1.535(9) H(8B)-C(8)-H(8C) 109.500 H(49A)-C(49)-H(49B) 108.400 
C(22)-C(24) 1.537(10) O(3)-C(9)-C(10) 109.8(5) C(51)-C(50)-C(55) 118.4(7) 
C(22)-H(22A) 1.000 O(3)-C(9)-H(9A) 109.700 C(51)-C(50)-C(49) 122.0(6) 
C(23)-H(23A) 0.980 C(10)-C(9)-H(9A) 109.700 C(55)-C(50)-C(49) 119.6(6) 
C(23)-H(23B) 0.980 O(3)-C(9)-H(9B) 109.700 C(50)-C(51)-C(52) 120.3(7) 
C(23)-H(23C) 0.980 C(10)-C(9)-H(9B) 109.700 C(50)-C(51)-H(51A) 119.900 
C(24)-H(24A) 0.980 H(9A)-C(9)-H(9B) 108.200 C(52)-C(51)-H(51A) 119.900 
C(24)-H(24B) 0.980 C(15)-C(10)-C(11) 118.1(6) C(51)-C(52)-C(53) 120.4(7) 
C(24)-H(24C) 0.980 C(15)-C(10)-C(9) 121.7(6) C(51)-C(52)-H(52A) 119.800 
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C(25)-C(26) 1.521(9) C(11)-C(10)-C(9) 120.1(6) C(53)-C(52)-H(52A) 119.800 
C(25)-H(25A) 0.990 C(12)-C(11)-C(10) 119.1(7) C(54)-C(53)-C(52) 119.5(7) 
C(25)-H(25B) 0.990 C(12)-C(11)-H(11A) 120.500 C(54)-C(53)-H(53A) 120.300 
C(26)-C(31) 1.371(9) C(10)-C(11)-H(11A) 120.500 C(52)-C(53)-H(53A) 120.300 
C(26)-C(27) 1.383(8) C(13)-C(12)-C(11) 121.6(7) C(55)-C(54)-C(53) 120.4(7) 
C(27)-C(28) 1.387(9) C(13)-C(12)-H(12A) 119.200 C(55)-C(54)-H(54A) 119.800 
C(27)-H(27A) 0.950 C(11)-C(12)-H(12A) 119.200 C(53)-C(54)-H(54A) 119.800 
C(28)-C(29) 1.366(9) C(12)-C(13)-C(14) 119.5(7) C(54)-C(55)-C(50) 121.1(7) 
C(28)-H(28A) 0.950 C(12)-C(13)-H(13A) 120.200 C(54)-C(55)-H(55A) 119.500 
C(29)-C(30) 1.385(8) C(14)-C(13)-H(13A) 120.200 C(50)-C(55)-H(55A) 119.500 
C(29)-O(29) 1.399(7) C(15)-C(14)-C(13) 119.5(7) C(57)-C(56)-C(58) 109.3(6) 
O(29)-C(32) 1.444(7) C(15)-C(14)-H(14A) 120.200 C(57)-C(56)-Si(44) 115.4(4) 
C(30)-C(31) 1.410(9) C(13)-C(14)-H(14A) 120.200 C(58)-C(56)-Si(44) 112.7(5) 
C(30)-H(30A) 0.950 C(10)-C(15)-C(14) 122.1(7) C(57)-C(56)-H(56A) 106.300 
C(31)-H(31A) 0.950 C(10)-C(15)-H(15A) 118.900 C(58)-C(56)-H(56A) 106.300 
C(32)-H(32A) 0.980 C(14)-C(15)-H(15A) 118.900 Si(44)-C(56)-H(56A) 106.300 
C(32)-H(32B) 0.980 C(17)-C(16)-C(18) 110.5(5) C(56)-C(57)-H(57A) 109.500 
C(32)-H(32C) 0.980 C(17)-C(16)-Si(4) 114.5(4) C(56)-C(57)-H(57B) 109.500 
C(41)-O(41) 1.434(7) C(18)-C(16)-Si(4) 112.5(5) H(57A)-C(57)-H(57B) 109.500 
C(41)-C(46) 1.519(9) C(17)-C(16)-H(16A) 106.200 C(56)-C(57)-H(57C) 109.500 
C(41)-C(42) 1.528(8) C(18)-C(16)-H(16A) 106.200 H(57A)-C(57)-H(57C) 109.500 
C(41)-H(41A) 1.000 Si(4)-C(16)-H(16A) 106.200 H(57B)-C(57)-H(57C) 109.500 
O(41)-C(47) 1.380(8) C(16)-C(17)-H(17A) 109.500 C(56)-C(58)-H(58A) 109.500 
C(42)-O(42) 1.432(7) C(16)-C(17)-H(17B) 109.500 C(56)-C(58)-H(58B) 109.500 
C(42)-C(43) 1.507(8) H(17A)-C(17)-H(17B) 109.500 H(58A)-C(58)-H(58B) 109.500 
C(42)-H(42A) 1.000 C(16)-C(17)-H(17C) 109.500 C(56)-C(58)-H(58C) 109.500 
O(42)-H(42O) 0.98(2) H(17A)-C(17)-H(17C) 109.500 H(58A)-C(58)-H(58C) 109.500 
C(43)-O(43) 1.454(7) H(17B)-C(17)-H(17C) 109.500 H(58B)-C(58)-H(58C) 109.500 
C(43)-C(44) 1.519(8) C(16)-C(18)-H(18A) 109.500 C(61)-C(59)-C(60) 109.7(5) 
C(43)-H(43A) 1.000 C(16)-C(18)-H(18B) 109.500 C(61)-C(59)-Si(44) 115.8(5) 
O(43)-C(49) 1.441(8) H(18A)-C(18)-H(18B) 109.500 C(60)-C(59)-Si(44) 112.7(4) 
C(44)-O(44) 1.414(7) C(16)-C(18)-H(18C) 109.500 C(61)-C(59)-H(59A) 105.900 
C(44)-C(45) 1.536(8) H(18A)-C(18)-H(18C) 109.500 C(60)-C(59)-H(59A) 105.900 
C(44)-H(44A) 1.000 H(18B)-C(18)-H(18C) 109.500 Si(44)-C(59)-H(59A) 105.900 
O(44)-Si(44) 1.657(4) C(21)-C(19)-C(20) 108.4(6) C(59)-C(60)-H(60A) 109.500 
Si(44)-C(56) 1.872(6) C(21)-C(19)-Si(4) 112.5(4) C(59)-C(60)-H(60B) 109.500 
Si(44)-C(59) 1.885(7) C(20)-C(19)-Si(4) 113.5(5) H(60A)-C(60)-H(60B) 109.500 
Si(44)-C(62) 1.906(7) C(21)-C(19)-H(19A) 107.300 C(59)-C(60)-H(60C) 109.500 
C(45)-O(45) 1.414(7) C(20)-C(19)-H(19A) 107.300 H(60A)-C(60)-H(60C) 109.500 
C(45)-C(46) 1.498(8) Si(4)-C(19)-H(19A) 107.300 H(60B)-C(60)-H(60C) 109.500 
C(45)-H(45A) 1.000 C(19)-C(20)-H(20A) 109.500 C(59)-C(61)-H(61A) 109.500 
O(45)-C(65) 1.477(7) C(19)-C(20)-H(20B) 109.500 C(59)-C(61)-H(61B) 109.500 
C(46)-O(46) 1.213(7) H(20A)-C(20)-H(20B) 109.500 H(61A)-C(61)-H(61B) 109.500 
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C(47)-O(47) 1.208(7) C(19)-C(20)-H(20C) 109.500 C(59)-C(61)-H(61C) 109.500 
C(47)-C(48) 1.493(9) H(20A)-C(20)-H(20C) 109.500 H(61A)-C(61)-H(61C) 109.500 
C(48)-H(48A) 0.980 H(20B)-C(20)-H(20C) 109.500 H(61B)-C(61)-H(61C) 109.500 
C(48)-H(48B) 0.980 C(19)-C(21)-H(21A) 109.500 C(63)-C(62)-C(64) 109.8(6) 
C(48)-H(48C) 0.980 C(19)-C(21)-H(21B) 109.500 C(63)-C(62)-Si(44) 116.5(5) 
C(49)-C(50) 1.508(9) H(21A)-C(21)-H(21B) 109.500 C(64)-C(62)-Si(44) 111.2(5) 
C(49)-H(49A) 0.990 C(19)-C(21)-H(21C) 109.500 C(63)-C(62)-H(62A) 106.200 
C(49)-H(49B) 0.990 H(21A)-C(21)-H(21C) 109.500 C(64)-C(62)-H(62A) 106.200 
C(50)-C(51) 1.390(9) H(21B)-C(21)-H(21C) 109.500 Si(44)-C(62)-H(62A) 106.200 
C(50)-C(55) 1.406(9) C(23)-C(22)-C(24) 108.9(6) C(62)-C(63)-H(63A) 109.500 
C(51)-C(52) 1.386(9) C(23)-C(22)-Si(4) 112.8(5) C(62)-C(63)-H(63B) 109.500 
C(51)-H(51A) 0.950 C(24)-C(22)-Si(4) 113.1(5) H(63A)-C(63)-H(63B) 109.500 
C(52)-C(53) 1.396(11) C(23)-C(22)-H(22A) 107.200 C(62)-C(63)-H(63C) 109.500 
C(52)-H(52A) 0.950 C(24)-C(22)-H(22A) 107.200 H(63A)-C(63)-H(63C) 109.500 
C(53)-C(54) 1.378(10) Si(4)-C(22)-H(22A) 107.200 H(63B)-C(63)-H(63C) 109.500 
C(53)-H(53A) 0.950 C(22)-C(23)-H(23A) 109.500 C(62)-C(64)-H(64A) 109.500 
C(54)-C(55) 1.370(9) C(22)-C(23)-H(23B) 109.500 C(62)-C(64)-H(64B) 109.500 
C(54)-H(54A) 0.950 H(23A)-C(23)-H(23B) 109.500 H(64A)-C(64)-H(64B) 109.500 
C(55)-H(55A) 0.950 C(22)-C(23)-H(23C) 109.500 C(62)-C(64)-H(64C) 109.500 
C(56)-C(57) 1.531(9) H(23A)-C(23)-H(23C) 109.500 H(64A)-C(64)-H(64C) 109.500 
C(56)-C(58) 1.546(9) H(23B)-C(23)-H(23C) 109.500 H(64B)-C(64)-H(64C) 109.500 
C(56)-H(56A) 1.000 C(22)-C(24)-H(24A) 109.500 O(45)-C(65)-C(66) 110.5(5) 
C(57)-H(57A) 0.980 C(22)-C(24)-H(24B) 109.500 O(45)-C(65)-H(65A) 109.600 
C(57)-H(57B) 0.980 H(24A)-C(24)-H(24B) 109.500 C(66)-C(65)-H(65A) 109.600 
C(57)-H(57C) 0.980 C(22)-C(24)-H(24C) 109.500 O(45)-C(65)-H(65B) 109.600 
C(58)-H(58A) 0.980 H(24A)-C(24)-H(24C) 109.500 C(66)-C(65)-H(65B) 109.600 
C(58)-H(58B) 0.980 H(24B)-C(24)-H(24C) 109.500 H(65A)-C(65)-H(65B) 108.100 
C(58)-H(58C) 0.980 O(5)-C(25)-C(26) 112.7(5) C(71)-C(66)-C(67) 118.1(6) 
C(59)-C(61) 1.546(9) O(5)-C(25)-H(25A) 109.100 C(71)-C(66)-C(65) 122.7(5) 
C(59)-C(60) 1.555(9) C(26)-C(25)-H(25A) 109.100 C(67)-C(66)-C(65) 119.2(6) 
C(59)-H(59A) 1.000 O(5)-C(25)-H(25B) 109.100 C(68)-C(67)-C(66) 121.0(6) 
C(60)-H(60A) 0.980 C(26)-C(25)-H(25B) 109.100 C(68)-C(67)-H(67A) 119.500 
C(60)-H(60B) 0.980 H(25A)-C(25)-H(25B) 107.800 C(66)-C(67)-H(67A) 119.500 
C(60)-H(60C) 0.980 C(31)-C(26)-C(27) 118.8(7) C(67)-C(68)-C(69) 120.1(6) 
C(61)-H(61A) 0.980 C(31)-C(26)-C(25) 121.7(6) C(67)-C(68)-H(68A) 119.900 
C(61)-H(61B) 0.980 C(27)-C(26)-C(25) 119.6(6) C(69)-C(68)-H(68A) 119.900 
C(61)-H(61C) 0.980 C(28)-C(27)-C(26) 119.9(6) C(69)-O(69)-C(72) 117.0(5) 
C(62)-C(63) 1.519(10) C(28)-C(27)-H(27A) 120.000 C(68)-C(69)-O(69) 116.1(5) 
C(62)-C(64) 1.557(9) C(26)-C(27)-H(27A) 120.000 C(68)-C(69)-C(70) 120.3(6) 
C(62)-H(62A) 1.000 C(29)-C(28)-C(27) 120.4(6) O(69)-C(69)-C(70) 123.7(6) 
C(63)-H(63A) 0.980 C(29)-C(28)-H(28A) 119.800 C(69)-C(70)-C(71) 118.2(6) 
C(63)-H(63B) 0.980 C(27)-C(28)-H(28A) 119.800 C(69)-C(70)-H(70A) 120.900 
C(63)-H(63C) 0.980 C(28)-C(29)-C(30) 121.8(6) C(71)-C(70)-H(70A) 120.900 
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C(64)-H(64A) 0.980 C(28)-C(29)-O(29) 115.9(5) C(66)-C(71)-C(70) 122.3(6) 
C(64)-H(64B) 0.980 C(30)-C(29)-O(29) 122.4(6) C(66)-C(71)-H(71A) 118.900 
C(64)-H(64C) 0.980 C(29)-O(29)-C(32) 116.7(5) C(70)-C(71)-H(71A) 118.900 
C(65)-C(66) 1.520(8) C(29)-C(30)-C(31) 116.4(6) O(69)-C(72)-H(72A) 109.500 
C(65)-H(65A) 0.990 C(29)-C(30)-H(30A) 121.800 O(69)-C(72)-H(72B) 109.500 
C(65)-H(65B) 0.990 C(31)-C(30)-H(30A) 121.800 H(72A)-C(72)-H(72B) 109.500 
C(66)-C(71) 1.374(9) C(26)-C(31)-C(30) 122.6(6) O(69)-C(72)-H(72C) 109.500 
C(66)-C(67) 1.392(8) C(26)-C(31)-H(31A) 118.700 H(72A)-C(72)-H(72C) 109.500 
C(67)-C(68) 1.380(9) C(30)-C(31)-H(31A) 118.700 H(72B)-C(72)-H(72C) 109.500 
C(67)-H(67A) 0.950 O(29)-C(32)-H(32A) 109.500   
C(68)-C(69) 1.379(9) O(29)-C(32)-H(32B) 109.500   
 
 
Table 8.2.4. Anisotropic displacement parameters (Å2 ! 103) for nksc10.  The anisotropic displacement 
factor exponent takes the form:  -2!2[h2 a*2U11 + ... + 2 h k a* b* U12] 
 U
11 
U
22 
U
33 
U
23 
U
13 
U
12 
C(1) 26(4) 36(4) 31(4) 4(3) -1(3) -7(3) 
O(1) 30(2) 48(3) 29(3) 3(2) -8(2) -8(2) 
C(2) 15(3) 34(4) 53(5) 11(3) -4(3) -7(3) 
O(2) 25(3) 52(3) 41(3) 6(2) -1(2) -6(2) 
C(3) 19(3) 34(4) 33(4) -8(3) 2(3) 2(3) 
O(3) 33(3) 36(3) 35(3) 0(2) 5(2) 6(2) 
C(4) 17(3) 31(4) 35(4) 4(3) -6(3) 3(3) 
O(4) 22(2) 42(3) 31(3) -3(2) -6(2) -2(2) 
Si(4) 26(1) 36(1) 32(1) 0(1) -5(1) -2(1) 
C(5) 26(4) 35(4) 28(4) -2(3) -1(3) 4(3) 
O(5) 30(3) 37(3) 33(3) -1(2) -1(2) 1(2) 
C(6) 25(4) 38(4) 27(4) -3(3) 4(3) -9(3) 
O(6) 40(3) 41(3) 40(3) 0(2) 0(2) -12(2) 
C(7) 50(5) 38(4) 25(4) 9(3) 3(3) -18(4) 
O(7) 43(3) 46(3) 43(3) -5(2) 2(2) -3(3) 
C(8) 51(5) 52(5) 34(5) 4(4) -9(4) -21(4) 
C(9) 30(4) 31(4) 41(4) 4(3) 0(3) 1(3) 
C(10) 31(4) 43(4) 28(4) 3(3) 0(3) 4(3) 
C(11) 26(4) 51(5) 43(5) 6(4) 3(3) -1(4) 
C(12) 24(4) 76(6) 38(5) 9(4) -2(3) -1(4) 
C(13) 45(5) 61(6) 33(4) 3(4) 2(3) 27(4) 
C(14) 43(5) 51(5) 46(5) 9(4) -12(4) 19(4) 
C(15) 46(4) 42(5) 33(4) 5(3) -11(3) 3(4) 
C(16) 31(4) 25(4) 39(4) -1(3) -3(3) -1(3) 
C(17) 47(5) 31(4) 47(5) -5(3) -3(4) -7(3) 
C(18) 56(5) 34(4) 61(6) 8(4) 0(4) -9(4) 
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C(19) 16(3) 47(4) 36(4) 7(3) -4(3) -6(3) 
C(20) 28(4) 60(5) 47(5) -2(4) 8(3) -6(4) 
C(21) 39(4) 55(5) 50(5) 5(4) -5(4) -14(4) 
C(22) 37(4) 32(4) 54(5) -7(3) -6(4) -5(3) 
C(23) 40(4) 42(4) 48(5) -2(4) -4(3) -3(4) 
C(24) 33(4) 62(5) 51(5) 0(4) -11(3) 1(4) 
C(25) 30(4) 34(4) 46(5) 1(3) 10(3) 2(3) 
C(26) 25(4) 39(4) 37(4) -3(3) -4(3) 7(3) 
C(27) 32(4) 37(4) 40(5) 4(3) 1(3) 7(3) 
C(28) 29(4) 50(5) 29(4) 6(3) -10(3) 4(3) 
C(29) 15(3) 40(4) 42(4) -9(3) 6(3) 2(3) 
O(29) 25(3) 48(3) 39(3) 3(2) -3(2) 0(2) 
C(30) 27(4) 27(4) 39(4) 3(3) 2(3) 3(3) 
C(31) 26(4) 39(4) 37(4) -6(3) -3(3) 8(3) 
C(32) 35(4) 71(6) 37(5) 16(4) 1(3) -12(4) 
C(41) 20(3) 39(4) 30(4) 1(3) -4(3) -3(3) 
O(41) 24(2) 51(3) 31(3) -1(2) -8(2) 2(2) 
C(42) 15(3) 37(4) 32(4) 6(3) 1(3) -1(3) 
O(42) 23(2) 56(3) 37(3) 0(2) -2(2) -5(2) 
C(43) 19(3) 34(4) 27(4) 0(3) 0(3) -3(3) 
O(43) 37(3) 36(3) 29(3) 1(2) 0(2) 9(2) 
C(44) 12(3) 29(4) 35(4) 2(3) -2(3) -1(3) 
O(44) 29(2) 38(3) 30(3) 0(2) -8(2) 1(2) 
Si(44) 25(1) 34(1) 30(1) 1(1) -4(1) -2(1) 
C(45) 22(3) 38(4) 29(4) 7(3) -5(3) 3(3) 
O(45) 23(2) 38(3) 43(3) -1(2) 3(2) 2(2) 
C(46) 20(4) 33(4) 40(4) -8(3) 0(3) 1(3) 
O(46) 36(3) 37(3) 40(3) 3(2) -3(2) -10(2) 
C(47) 32(4) 33(4) 49(5) 5(3) -7(4) -13(3) 
O(47) 39(3) 43(3) 41(3) -3(2) 2(2) -4(2) 
C(48) 39(4) 47(5) 45(5) -4(4) -4(4) -3(4) 
C(49) 29(4) 36(4) 44(5) 3(3) 1(3) 8(3) 
C(50) 24(4) 38(4) 31(4) 11(3) -2(3) 5(3) 
C(51) 24(4) 52(5) 46(5) 1(4) -3(3) -1(4) 
C(52) 24(4) 63(6) 48(5) 8(4) -1(3) -3(4) 
C(53) 29(4) 65(6) 44(5) 8(4) -8(3) 23(4) 
C(54) 39(5) 54(5) 42(5) -1(4) -5(4) 22(4) 
C(55) 34(4) 55(5) 38(5) -3(4) -14(3) 8(4) 
C(56) 17(3) 35(4) 38(4) 4(3) -2(3) -11(3) 
C(57) 36(4) 61(5) 35(4) -3(4) 8(3) -6(4) 
C(58) 43(5) 45(4) 45(5) 0(4) 2(4) -14(4) 
C(59) 41(4) 34(4) 32(4) -2(3) 4(3) -2(3) 
C(60) 52(5) 42(4) 37(4) -4(3) -3(3) -4(4) 
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C(61) 42(4) 56(5) 40(5) -3(4) 2(3) 0(4) 
C(62) 28(4) 45(4) 41(5) -1(3) -7(3) -4(3) 
C(63) 35(4) 52(5) 62(6) 5(4) 0(4) 8(4) 
C(64) 21(4) 49(5) 72(6) 10(4) 12(3) -4(4) 
C(65) 24(4) 24(4) 54(5) -2(3) 3(3) -2(3) 
C(66) 12(3) 34(4) 39(4) -5(3) 2(3) -1(3) 
C(67) 28(4) 29(4) 43(5) 2(3) 0(3) 1(3) 
C(68) 18(4) 52(5) 42(5) -9(4) -7(3) 11(3) 
O(69) 19(2) 56(3) 37(3) 4(2) -4(2) -10(2) 
C(69) 24(4) 37(4) 37(4) 1(3) -2(3) 1(3) 
C(70) 23(3) 32(4) 31(4) -1(3) -8(3) 6(3) 
C(71) 26(4) 28(4) 27(4) -4(3) -1(3) 1(3) 
C(72) 26(4) 43(4) 61(5) 15(4) -2(3) -8(4) 
 
 
Table 8.2.5.  Hydrogen coordinates (! 104) and isotropic  displacement parameters (Å2 ! 103) for nksc10. 
 x y z U(eq) 
H(1A) 6136 7118 4803 37 
H(2A) 7835 5732 4563 41 
H(2O) 9130(40) 7560(90) 4426(19) 70(30) 
H(3A) 6085 5409 4202 34 
H(4A) 6778 8128 3720 34 
H(5A) 4888 8021 4269 36 
H(8A) 7430 10189 5824 68 
H(8B) 8514 9873 5540 68 
H(8C) 7981 8406 5790 68 
H(9A) 6891 2829 3859 41 
H(9B) 7690 3472 4212 41 
H(11A) 9489 5090 3682 48 
H(12A) 11146 4068 3368 55 
H(13A) 11326 1328 3229 56 
H(14A) 9817 -462 3392 56 
H(15A) 8151 528 3693 48 
H(16A) 6445 4220 3052 38 
H(17A) 5459 2737 2567 63 
H(17B) 5814 4507 2412 63 
H(17C) 4497 4141 2536 63 
H(18A) 5092 2181 3248 76 
H(18B) 4106 3542 3296 76 
H(18C) 5227 3559 3576 76 
H(19A) 6547 9042 3017 40 
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H(20A) 8392 7952 2823 68 
H(20B) 7859 6153 2826 68 
H(20C) 7984 7145 3226 68 
H(21A) 7009 8916 2348 72 
H(21B) 5630 8803 2410 72 
H(21C) 6363 7196 2314 72 
H(22A) 3874 7204 2654 50 
H(23A) 3006 9593 2903 65 
H(23B) 4381 9839 2857 65 
H(23C) 3834 9518 3279 65 
H(24A) 2161 6968 3032 73 
H(24B) 2927 6697 3418 73 
H(24C) 2943 5366 3077 73 
H(25A) 3978 11857 4009 44 
H(25B) 4737 11435 4389 44 
H(27A) 2215 10268 3862 44 
H(28A) 631 8847 4119 43 
H(30A) 2462 7846 5104 37 
H(31A) 4010 9430 4852 41 
H(32A) 1024 6113 5202 71 
H(32B) -355 6388 5219 71 
H(32C) 512 7840 5333 71 
H(41A) 11240 6664 9800 36 
H(42A) 12931 5281 9548 34 
H(42O) 14050(70) 7350(120) 9457(19) 110(40) 
H(43A) 11164 4961 9210 32 
H(44A) 11777 7639 8708 30 
H(45A) 9952 7632 9288 36 
H(48A) 12468 9602 10838 66 
H(48B) 13538 9622 10539 66 
H(48C) 13190 7971 10758 66 
H(49A) 11933 2397 8824 44 
H(49B) 12699 2983 9192 44 
H(51A) 14484 4697 8635 48 
H(52A) 16155 3720 8328 54 
H(53A) 16360 930 8199 55 
H(54A) 14909 -872 8396 54 
H(55A) 13239 87 8692 51 
H(56A) 12086 7072 8036 36 
H(57A) 12206 7762 7370 66 
H(57B) 10826 7553 7326 66 
H(57C) 11623 6009 7426 66 
H(58A) 12076 9849 7846 67 
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H(58B) 11440 9592 8257 67 
H(58C) 10684 9863 7869 67 
H(59A) 10784 3930 7934 43 
H(60A) 9427 2073 8210 65 
H(60B) 8697 3569 8381 65 
H(60C) 9991 3228 8536 65 
H(61A) 9286 2853 7537 69 
H(61B) 9685 4603 7382 69 
H(61C) 8498 4420 7622 69 
H(62A) 8853 8792 8232 45 
H(63A) 7682 8919 7674 75 
H(63B) 8276 7300 7508 75 
H(63C) 9031 8923 7558 75 
H(64A) 6962 7589 8246 71 
H(64B) 7818 6765 8559 71 
H(64C) 7529 5850 8157 71 
H(65A) 9073 11504 9019 41 
H(65B) 9835 11074 9399 41 
H(67A) 7271 10064 8887 40 
H(68A) 5675 8655 9129 45 
H(70A) 7517 7480 10103 35 
H(71A) 9098 8958 9856 32 
H(72A) 6008 5678 10184 65 
H(72B) 4653 6109 10221 65 
H(72C) 5616 7424 10343 65 
 
 
Table 8.2.6.  Torsion angles [˚] for nksc10. 
C(6)-C(1)-O(1)-C(7) 70.6(7) C(46)-C(41)-O(41)-C(47) 69.9(7) 
C(2)-C(1)-O(1)-C(7) -172.5(5) C(42)-C(41)-O(41)-C(47) -172.0(5) 
O(1)-C(1)-C(2)-O(2) -63.4(6) O(41)-C(41)-C(42)-O(42) -63.9(6) 
C(6)-C(1)-C(2)-O(2) 59.0(6) C(46)-C(41)-C(42)-O(42) 58.3(6) 
O(1)-C(1)-C(2)-C(3) 176.8(5) O(41)-C(41)-C(42)-C(43) 176.5(5) 
C(6)-C(1)-C(2)-C(3) -60.8(6) C(46)-C(41)-C(42)-C(43) -61.4(6) 
O(2)-C(2)-C(3)-O(3) 55.8(7) O(42)-C(42)-C(43)-O(43) 56.7(6) 
C(1)-C(2)-C(3)-O(3) 177.0(5) C(41)-C(42)-C(43)-O(43) 176.3(5) 
O(2)-C(2)-C(3)-C(4) -62.6(7) O(42)-C(42)-C(43)-C(44) -61.3(6) 
C(1)-C(2)-C(3)-C(4) 58.7(7) C(41)-C(42)-C(43)-C(44) 58.3(7) 
C(4)-C(3)-O(3)-C(9) -158.5(5) C(42)-C(43)-O(43)-C(49) 81.6(6) 
C(2)-C(3)-O(3)-C(9) 79.3(6) C(44)-C(43)-O(43)-C(49) -155.1(5) 
O(3)-C(3)-C(4)-O(4) 65.6(6) O(43)-C(43)-C(44)-O(44) 67.8(6) 
C(2)-C(3)-C(4)-O(4) -173.0(5) C(42)-C(43)-C(44)-O(44) -171.2(5) 
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O(3)-C(3)-C(4)-C(5) -175.9(5) O(43)-C(43)-C(44)-C(45) -173.7(4) 
C(2)-C(3)-C(4)-C(5) -54.5(7) C(42)-C(43)-C(44)-C(45) -52.6(7) 
C(5)-C(4)-O(4)-Si(4) 135.9(5) C(43)-C(44)-O(44)-Si(44) -122.8(5) 
C(3)-C(4)-O(4)-Si(4) -104.5(6) C(45)-C(44)-O(44)-Si(44) 117.6(5) 
C(4)-O(4)-Si(4)-C(22) -136.1(5) C(44)-O(44)-Si(44)-C(56) 7.0(6) 
C(4)-O(4)-Si(4)-C(16) 103.9(5) C(44)-O(44)-Si(44)-C(59) 126.3(5) 
C(4)-O(4)-Si(4)-C(19) -18.4(6) C(44)-O(44)-Si(44)-C(62) -112.5(5) 
O(4)-C(4)-C(5)-O(5) -62.0(6) O(44)-C(44)-C(45)-O(45) -64.2(6) 
C(3)-C(4)-C(5)-O(5) 178.4(5) C(43)-C(44)-C(45)-O(45) 176.5(5) 
O(4)-C(4)-C(5)-C(6) 173.4(5) O(44)-C(44)-C(45)-C(46) 171.1(5) 
C(3)-C(4)-C(5)-C(6) 53.9(7) C(43)-C(44)-C(45)-C(46) 51.8(7) 
C(6)-C(5)-O(5)-C(25) -68.2(6) C(46)-C(45)-O(45)-C(65) -67.2(6) 
C(4)-C(5)-O(5)-C(25) 170.5(5) C(44)-C(45)-O(45)-C(65) 170.3(4) 
O(1)-C(1)-C(6)-O(6) 6.6(9) O(45)-C(45)-C(46)-O(46) -7.4(9) 
C(2)-C(1)-C(6)-O(6) -112.6(7) C(44)-C(45)-C(46)-O(46) 114.6(7) 
O(1)-C(1)-C(6)-C(5) -175.5(5) O(45)-C(45)-C(46)-C(41) 177.3(5) 
C(2)-C(1)-C(6)-C(5) 65.3(6) C(44)-C(45)-C(46)-C(41) -60.7(7) 
O(5)-C(5)-C(6)-O(6) -6.6(9) O(41)-C(41)-C(46)-O(46) 9.8(9) 
C(4)-C(5)-C(6)-O(6) 115.0(7) C(42)-C(41)-C(46)-O(46) -110.4(7) 
O(5)-C(5)-C(6)-C(1) 175.5(5) O(41)-C(41)-C(46)-C(45) -174.7(5) 
C(4)-C(5)-C(6)-C(1) -62.8(7) C(42)-C(41)-C(46)-C(45) 65.0(6) 
C(1)-O(1)-C(7)-O(7) -0.6(8) C(41)-O(41)-C(47)-O(47) -0.5(9) 
C(1)-O(1)-C(7)-C(8) 177.5(5) C(41)-O(41)-C(47)-C(48) 178.1(5) 
C(3)-O(3)-C(9)-C(10) -154.6(5) C(43)-O(43)-C(49)-C(50) -152.3(5) 
O(3)-C(9)-C(10)-C(15) -149.8(6) O(43)-C(49)-C(50)-C(51) 25.2(9) 
O(3)-C(9)-C(10)-C(11) 31.4(8) O(43)-C(49)-C(50)-C(55) -153.8(6) 
C(15)-C(10)-C(11)-C(12) 0.2(10) C(55)-C(50)-C(51)-C(52) -1.2(10) 
C(9)-C(10)-C(11)-C(12) 179.1(6) C(49)-C(50)-C(51)-C(52) 179.8(6) 
C(10)-C(11)-C(12)-C(13) -0.7(10) C(50)-C(51)-C(52)-C(53) 0.8(10) 
C(11)-C(12)-C(13)-C(14) 0.6(11) C(51)-C(52)-C(53)-C(54) -0.7(11) 
C(12)-C(13)-C(14)-C(15) 0.0(10) C(52)-C(53)-C(54)-C(55) 1.2(10) 
C(11)-C(10)-C(15)-C(14) 0.4(10) C(53)-C(54)-C(55)-C(50) -1.7(10) 
C(9)-C(10)-C(15)-C(14) -178.5(6) C(51)-C(50)-C(55)-C(54) 1.6(10) 
C(13)-C(14)-C(15)-C(10) -0.5(10) C(49)-C(50)-C(55)-C(54) -179.3(6) 
O(4)-Si(4)-C(16)-C(17) 163.6(4) O(44)-Si(44)-C(56)-C(57) 159.1(5) 
C(22)-Si(4)-C(16)-C(17) 49.5(6) C(59)-Si(44)-C(56)-C(57) 44.2(6) 
C(19)-Si(4)-C(16)-C(17) -74.4(5) C(62)-Si(44)-C(56)-C(57) -85.4(6) 
O(4)-Si(4)-C(16)-C(18) 36.4(5) O(44)-Si(44)-C(56)-C(58) -74.4(5) 
C(22)-Si(4)-C(16)-C(18) -77.8(5) C(59)-Si(44)-C(56)-C(58) 170.7(5) 
C(19)-Si(4)-C(16)-C(18) 158.4(4) C(62)-Si(44)-C(56)-C(58) 41.1(6) 
O(4)-Si(4)-C(19)-C(21) -160.1(5) O(44)-Si(44)-C(59)-C(61) 156.4(5) 
C(22)-Si(4)-C(19)-C(21) -45.6(6) C(56)-Si(44)-C(59)-C(61) -85.3(6) 
C(16)-Si(4)-C(19)-C(21) 80.2(5) C(62)-Si(44)-C(59)-C(61) 42.3(6) 
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O(4)-Si(4)-C(19)-C(20) 76.2(5) O(44)-Si(44)-C(59)-C(60) 28.9(5) 
C(22)-Si(4)-C(19)-C(20) -169.2(5) C(56)-Si(44)-C(59)-C(60) 147.2(5) 
C(16)-Si(4)-C(19)-C(20) -43.4(6) C(62)-Si(44)-C(59)-C(60) -85.2(5) 
O(4)-Si(4)-C(22)-C(23) 67.5(6) O(44)-Si(44)-C(62)-C(63) 171.6(5) 
C(16)-Si(4)-C(22)-C(23) -176.5(5) C(56)-Si(44)-C(62)-C(63) 53.0(6) 
C(19)-Si(4)-C(22)-C(23) -51.5(6) C(59)-Si(44)-C(62)-C(63) -74.5(6) 
O(4)-Si(4)-C(22)-C(24) -56.6(5) O(44)-Si(44)-C(62)-C(64) -61.5(5) 
C(16)-Si(4)-C(22)-C(24) 59.4(6) C(56)-Si(44)-C(62)-C(64) 179.9(5) 
C(19)-Si(4)-C(22)-C(24) -175.6(5) C(59)-Si(44)-C(62)-C(64) 52.4(6) 
C(5)-O(5)-C(25)-C(26) -58.9(7) C(45)-O(45)-C(65)-C(66) -60.0(6) 
O(5)-C(25)-C(26)-C(31) 93.2(8) O(45)-C(65)-C(66)-C(71) 91.3(7) 
O(5)-C(25)-C(26)-C(27) -86.9(7) O(45)-C(65)-C(66)-C(67) -90.4(7) 
C(31)-C(26)-C(27)-C(28) 1.1(10) C(71)-C(66)-C(67)-C(68) -0.4(10) 
C(25)-C(26)-C(27)-C(28) -178.9(6) C(65)-C(66)-C(67)-C(68) -178.7(6) 
C(26)-C(27)-C(28)-C(29) -1.1(10) C(66)-C(67)-C(68)-C(69) 0.5(10) 
C(27)-C(28)-C(29)-C(30) -1.2(10) C(67)-C(68)-C(69)-O(69) 179.2(6) 
C(27)-C(28)-C(29)-O(29) 180.0(6) C(67)-C(68)-C(69)-C(70) -1.3(10) 
C(28)-C(29)-O(29)-C(32) -171.4(6) C(72)-O(69)-C(69)-C(68) -173.0(6) 
C(30)-C(29)-O(29)-C(32) 9.7(9) C(72)-O(69)-C(69)-C(70) 7.5(9) 
C(28)-C(29)-C(30)-C(31) 3.2(9) C(68)-C(69)-C(70)-C(71) 2.0(9) 
O(29)-C(29)-C(30)-C(31) -178.0(5) O(69)-C(69)-C(70)-C(71) -178.5(6) 
C(27)-C(26)-C(31)-C(30) 1.1(10) C(67)-C(66)-C(71)-C(70) 1.1(9) 
C(25)-C(26)-C(31)-C(30) -179.0(6) C(65)-C(66)-C(71)-C(70) 179.4(6) 
C(29)-C(30)-C(31)-C(26) -3.2(9) C(69)-C(70)-C(71)-C(66) -1.9(9) 
 
 
Table 8.2.7.  Hydrogen bonds for nksc10 [Å and ˚]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
O(2)-H(2O)...O(29)  #1 0.98(2) 1.85(2) 2.831(6) 178(7) 
O(42)-H(42O)...O(69)  #1 0.98(2) 1.90(4) 2.831(6) 159(9) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z 
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8.3. (-)-D-1-O-Acetyl-3-O-benzyl-2,6-bis-O-benzyloxymethyl-5-O- 
(4-methoxybenzyl)-4-O-triisopropylsilyl-myo-inositol 162 
 
 
Figure 8.3.1.  VMD representation of crystal structure of 162. 
 
Table 8.3.1.  Crystal data and structure refinement for nksc14. 
Identification 
code 
nksc14 
Theta range for data 
collection 
2.53 to 68.08˚ 
Empirical 
formula 
C48H64O10Si Index ranges 
-41<=h<=41 
-11<=k<=11 
-17<=l<=17 
Formula 
weight 
829.08 Reflections collected 32515 
Temperature 173(2) K Independent reflections 
8568 
[R(int) = 0.0961] 
Wavelength 1.54178 Å 
Completeness to  
theta = 25.00  ˚
99.6 % 
Crystal 
system 
Monoclinic Absorption correction Multiscan 
Space group C2 
Max. and min. 
transmission 
1.0000 and 0.7687 
Unit cell 
dimensions 
a = 35.085(15) Å 
b = 9.425(5) Å 
c = 14.725(8) Å 
! = 90˚ 
" = 
95.240(14)˚ 
#  = 90˚ 
Refinement method 
Full-matrix least-
squares on F2 
Volume 4849(4) Å3 
Data 
Restraints 
Parameters 
8568 
4 
482 
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Z 4 Goodness-of-fit on F2 1.408 
Density 
(calculated) 
1.136 mg/m3 
Final R indices 
[I>2sigma(I)] 
R1 = 0.1396 
wR2 = 0.3555 
Absorption 
coefficient 
0.855 mm-1 
R indices 
(all data) 
R1 = 0.1511 
wR2 = 0.3819 
F(000) 1784 
Absolute structure 
parameter 
0.05(7) 
Crystal size 0.3000 ! 0.0500 ! 0.0500 mm
3 Extinction coefficient 0.0079(8) 
  Largest diff. peak and hole 
1.058 and -0.616 
e.Å-3 
 
 
Table 8.3.2.  Atomic coordinates (! 104) and equivalent isotropic displacement parameters (Å2 ! 103) for 
nksc14.  U(eq) is defined as one third of  the trace of the orthogonalised Uij tensor. 
 x y z U(eq) 
O(1) 8338(2) 5558(6) 5881(3) 102(1) 
C(1) 8309(2) 6352(7) 6714(4) 90(2) 
O(2) 8996(2) 6247(5) 7081(3) 98(1) 
C(2) 8679(2) 7186(8) 6918(4) 88(2) 
O(3) 8981(1) 8878(5) 8017(3) 91(1) 
C(3) 8646(2) 8074(7) 7766(4) 87(2) 
O(4) 8514(1) 7993(5) 9362(3) 87(1) 
C(4) 8572(2) 7125(8) 8576(4) 89(2) 
O(5) 8146(1) 5383(5) 9106(3) 90(1) 
C(5) 8212(2) 6243(7) 8335(4) 85(2) 
O(6) 7899(1) 4577(5) 7269(3) 93(1) 
C(6) 8247(2) 5349(7) 7500(4) 86(2) 
O(7) 7813(2) 6612(8) 5228(4) 132(2) 
C(7) 8073(2) 5780(8) 5172(4) 98(2) 
O(8) 7608(2) 2982(5) 12844(3) 97(1) 
C(8) 8150(4) 4943(10) 4347(6) 133(3) 
C(9) 9012(3) 10140(8) 7453(6) 110(2) 
C(10) 9295(2) 11141(7) 7918(5) 92(2) 
C(11) 9217(2) 12570(9) 7898(6) 102(2) 
C(12) 9463(3) 13529(11) 8342(7) 122(3) 
C(13) 9808(3) 13070(11) 8792(7) 130(3) 
C(14) 9890(3) 11625(13) 8813(7) 123(3) 
C(15) 9628(2) 10667(11) 8399(6) 113(2) 
Si(1) 8789(1) 8296(2) 10287(1) 92(1) 
C(16) 8926(2) 10245(11) 10253(6) 112(3) 
C(17) 8643(3) 11163(9) 9722(8) 126(3) 
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C(18) 9043(3) 10907(12) 11186(8) 135(4) 
C(19) 9224(3) 7085(9) 10333(7) 120(3) 
C(20) 9124(4) 5526(12) 10460(6) 139(4) 
C(21) 9582(3) 7648(18) 10903(11) 175(6) 
C(22) 8487(2) 7849(8) 11213(4) 102(2) 
C(23) 8655(3) 7783(15) 12212(5) 139(4) 
C(24) 8119(2) 8733(9) 11185(6) 107(2) 
C(25) 7803(2) 5799(8) 9507(4) 87(2) 
C(26) 7778(2) 4995(7) 10401(4) 84(2) 
C(27) 8018(2) 3972(8) 10709(4) 94(2) 
C(28) 7984(2) 3257(8) 11535(4) 92(2) 
C(29) 7688(2) 3632(7) 12028(4) 87(2) 
C(30) 7434(2) 4696(7) 11733(5) 90(2) 
C(31) 7483(2) 5382(7) 10910(4) 88(2) 
C(32) 7845(2) 1795(9) 13139(5) 104(2) 
C(33) 7919(2) 3150(7) 7591(5) 96(2) 
O(33) 8144(2) 2277(5) 7085(3) 96(1) 
C(34) 7951(3) 1948(9) 6212(5) 114(3) 
C(35) 8255(3) 1247(9) 5657(5) 107(2) 
C(36) 8178(4) -33(10) 5229(5) 124(3) 
C(37) 8425(6) -656(14) 4695(8) 151(5) 
C(38) 8743(7) -55(18) 4578(8) 172(6) 
C(39) 8853(5) 1309(15) 5004(7) 151(4) 
C(40) 8594(3) 1928(10) 5540(5) 113(2) 
C(41) 9305(4) 6570(30) 6637(14) 217(9) 
O(41) 9357(4) 6598(15) 5884(7) 210(5) 
C(42) 9372(5) 5247(19) 5405(11) 200 
C(43) 9376(4) 5619(16) 4368(6) 200 
C(44) 9272(3) 4537(13) 3753(9) 200 
C(45) 9430(4) 4476(14) 2923(8) 200 
C(46) 9693(4) 5498(16) 2707(7) 200 
C(47) 9798(3) 6580(14) 3322(9) 200 
C(48) 9639(4) 6640(14) 4152(8) 200 
 
 
Table 8.3.3.  Bond lengths [Å] and angles [˚] for nksc14. 
O(1)-C(7) 1.348(8) C(44)-H(44A) 0.950 H(20B)-C(20)-H(20C) 109.500 
O(1)-C(1) 1.450(7) C(45)-C(46) 1.390 C(19)-C(21)-H(21A) 109.500 
C(1)-C(2) 1.522(10) C(45)-H(45A) 0.950 C(19)-C(21)-H(21B) 109.500 
C(1)-C(6) 1.526(9) C(46)-C(47) 1.390 H(21A)-C(21)-H(21B) 109.500 
C(1)-H(1A) 1.000 C(46)-H(46A) 0.950 C(19)-C(21)-H(21C) 109.500 
O(2)-C(41) 1.352(15) C(47)-C(48) 1.390 H(21A)-C(21)-H(21C) 109.500 
Appendix 3 – X-ray crystal structure data 
 
A350 
O(2)-C(2) 1.426(8) C(47)-H(47A) 0.950 H(21B)-C(21)-H(21C) 109.500 
C(2)-C(3) 1.516(9) C(48)-H(48A) 0.950 C(24)-C(22)-C(23) 107.3(7) 
C(2)-H(2A) 1.000 C(7)-O(1)-C(1) 118.6(6) C(24)-C(22)-Si(1) 113.2(5) 
O(3)-C(3) 1.418(8) O(1)-C(1)-C(2) 108.0(6) C(23)-C(22)-Si(1) 121.3(7) 
O(3)-C(9) 1.460(8) O(1)-C(1)-C(6) 110.4(5) C(24)-C(22)-H(22A) 104.500 
C(3)-C(4) 1.532(9) C(2)-C(1)-C(6) 110.4(5) C(23)-C(22)-H(22A) 104.500 
C(3)-H(3A) 1.000 O(1)-C(1)-H(1A) 109.300 Si(1)-C(22)-H(22A) 104.500 
O(4)-C(4) 1.447(7) C(2)-C(1)-H(1A) 109.300 C(22)-C(23)-H(23A) 109.500 
O(4)-Si(1) 1.620(4) C(6)-C(1)-H(1A) 109.300 C(22)-C(23)-H(23B) 109.500 
C(4)-C(5) 1.526(10) C(41)-O(2)-C(2) 115.2(8) H(23A)-C(23)-H(23B) 109.500 
C(4)-H(4A) 1.000 O(2)-C(2)-C(3) 108.7(5) C(22)-C(23)-H(23C) 109.500 
O(5)-C(5) 1.431(7) O(2)-C(2)-C(1) 110.6(5) H(23A)-C(23)-H(23C) 109.500 
O(5)-C(25) 1.440(8) C(3)-C(2)-C(1) 108.7(5) H(23B)-C(23)-H(23C) 109.500 
C(5)-C(6) 1.505(8) O(2)-C(2)-H(2A) 109.600 C(22)-C(24)-H(24A) 109.500 
C(5)-H(5A) 1.000 C(3)-C(2)-H(2A) 109.600 C(22)-C(24)-H(24B) 109.500 
O(6)-C(33) 1.426(8) C(1)-C(2)-H(2A) 109.600 H(24A)-C(24)-H(24B) 109.500 
O(6)-C(6) 1.435(8) C(3)-O(3)-C(9) 112.9(5) C(22)-C(24)-H(24C) 109.500 
C(6)-H(6A) 1.000 O(3)-C(3)-C(2) 112.8(6) H(24A)-C(24)-H(24C) 109.500 
O(7)-C(7) 1.213(10) O(3)-C(3)-C(4) 107.7(5) H(24B)-C(24)-H(24C) 109.500 
C(7)-C(8) 1.493(11) C(2)-C(3)-C(4) 110.5(5) O(5)-C(25)-C(26) 109.6(5) 
O(8)-C(29) 1.400(7) O(3)-C(3)-H(3A) 108.600 O(5)-C(25)-H(25A) 109.800 
O(8)-C(32) 1.437(9) C(2)-C(3)-H(3A) 108.600 C(26)-C(25)-H(25A) 109.800 
C(8)-H(8A) 0.980 C(4)-C(3)-H(3A) 108.600 O(5)-C(25)-H(25B) 109.800 
C(8)-H(8B) 0.980 C(4)-O(4)-Si(1) 131.0(4) C(26)-C(25)-H(25B) 109.800 
C(8)-H(8C) 0.980 O(4)-C(4)-C(5) 108.7(5) H(25A)-C(25)-H(25B) 108.200 
C(9)-C(10) 1.491(10) O(4)-C(4)-C(3) 109.8(6) C(27)-C(26)-C(31) 119.2(6) 
C(9)-H(9A) 0.990 C(5)-C(4)-C(3) 109.4(5) C(27)-C(26)-C(25) 124.6(6) 
C(9)-H(9B) 0.990 O(4)-C(4)-H(4A) 109.600 C(31)-C(26)-C(25) 116.2(5) 
C(10)-C(11) 1.374(11) C(5)-C(4)-H(4A) 109.600 C(26)-C(27)-C(28) 122.9(7) 
C(10)-C(15) 1.385(10) C(3)-C(4)-H(4A) 109.600 C(26)-C(27)-H(27A) 118.600 
C(11)-C(12) 1.374(12) C(5)-O(5)-C(25) 111.9(5) C(28)-C(27)-H(27A) 118.600 
C(11)-H(11A) 0.950 O(5)-C(5)-C(6) 111.2(5) C(29)-C(28)-C(27) 117.6(6) 
C(12)-C(13) 1.395(15) O(5)-C(5)-C(4) 108.4(5) C(29)-C(28)-H(28A) 121.200 
C(12)-H(12A) 0.950 C(6)-C(5)-C(4) 111.6(6) C(27)-C(28)-H(28A) 121.200 
C(13)-C(14) 1.392(17) O(5)-C(5)-H(5A) 108.500 C(28)-C(29)-C(30) 121.3(6) 
C(13)-H(13A) 0.950 C(6)-C(5)-H(5A) 108.500 C(28)-C(29)-O(8) 124.4(6) 
C(14)-C(15) 1.388(13) C(4)-C(5)-H(5A) 108.600 C(30)-C(29)-O(8) 114.3(6) 
C(14)-H(14A) 0.950 C(33)-O(6)-C(6) 112.6(5) C(29)-C(30)-C(31) 118.7(7) 
C(15)-H(15A) 0.950 O(6)-C(6)-C(5) 110.3(5) C(29)-C(30)-H(30A) 120.700 
Si(1)-C(22) 1.849(9) O(6)-C(6)-C(1) 108.2(5) C(31)-C(30)-H(30A) 120.700 
Si(1)-C(16) 1.900(11) C(5)-C(6)-C(1) 107.5(5) C(26)-C(31)-C(30) 120.4(6) 
Si(1)-C(19) 1.904(8) O(6)-C(6)-H(6A) 110.300 C(26)-C(31)-H(31A) 119.800 
C(16)-C(17) 1.483(13) C(5)-C(6)-H(6A) 110.300 C(30)-C(31)-H(31A) 119.800 
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C(16)-C(18) 1.530(11) C(1)-C(6)-H(6A) 110.300 O(8)-C(32)-H(32A) 109.500 
C(16)-H(16A) 1.000 O(7)-C(7)-O(1) 121.1(6) O(8)-C(32)-H(32B) 109.500 
C(17)-H(17A) 0.980 O(7)-C(7)-C(8) 126.1(7) H(32A)-C(32)-H(32B) 109.500 
C(17)-H(17B) 0.980 O(1)-C(7)-C(8) 112.7(8) O(8)-C(32)-H(32C) 109.500 
C(17)-H(17C) 0.980 C(29)-O(8)-C(32) 116.3(6) H(32A)-C(32)-H(32C) 109.500 
C(18)-H(18A) 0.980 C(7)-C(8)-H(8A) 109.500 H(32B)-C(32)-H(32C) 109.500 
C(18)-H(18B) 0.980 C(7)-C(8)-H(8B) 109.500 O(33)-C(33)-O(6) 113.0(6) 
C(18)-H(18C) 0.980 H(8A)-C(8)-H(8B) 109.500 O(33)-C(33)-H(33A) 109.000 
C(19)-C(20) 1.526(16) C(7)-C(8)-H(8C) 109.500 O(6)-C(33)-H(33A) 109.000 
C(19)-C(21) 1.539(13) H(8A)-C(8)-H(8C) 109.500 O(33)-C(33)-H(33B) 109.000 
C(19)-H(19A) 1.000 H(8B)-C(8)-H(8C) 109.500 O(6)-C(33)-H(33B) 109.000 
C(20)-H(20A) 0.980 O(3)-C(9)-C(10) 109.6(6) H(33A)-C(33)-H(33B) 107.800 
C(20)-H(20B) 0.980 O(3)-C(9)-H(9A) 109.800 C(33)-O(33)-C(34) 111.3(6) 
C(20)-H(20C) 0.980 C(10)-C(9)-H(9A) 109.800 O(33)-C(34)-C(35) 105.9(6) 
C(21)-H(21A) 0.980 O(3)-C(9)-H(9B) 109.800 O(33)-C(34)-H(34A) 110.500 
C(21)-H(21B) 0.980 C(10)-C(9)-H(9B) 109.800 C(35)-C(34)-H(34A) 110.600 
C(21)-H(21C) 0.980 H(9A)-C(9)-H(9B) 108.200 O(33)-C(34)-H(34B) 110.600 
C(22)-C(24) 1.535(11) C(11)-C(10)-C(15) 118.9(8) C(35)-C(34)-H(34B) 110.600 
C(22)-C(23) 1.537(9) C(11)-C(10)-C(9) 119.2(7) H(34A)-C(34)-H(34B) 108.700 
C(22)-H(22A) 1.000 C(15)-C(10)-C(9) 121.8(7) C(36)-C(35)-C(40) 119.1(9) 
C(23)-H(23A) 0.980 C(12)-C(11)-C(10) 121.3(8) C(36)-C(35)-C(34) 119.9(10) 
C(23)-H(23B) 0.980 C(12)-C(11)-H(11A) 119.300 C(40)-C(35)-C(34) 120.8(7) 
C(23)-H(23C) 0.980 C(10)-C(11)-H(11A) 119.300 C(37)-C(36)-C(35) 122.4(13) 
C(24)-H(24A) 0.980 C(11)-C(12)-C(13) 120.2(9) C(37)-C(36)-H(36A) 118.800 
C(24)-H(24B) 0.980 C(11)-C(12)-H(12A) 119.900 C(35)-C(36)-H(36A) 118.800 
C(24)-H(24C) 0.980 C(13)-C(12)-H(12A) 119.900 C(38)-C(37)-C(36) 119.9(14) 
C(25)-C(26) 1.528(8) C(14)-C(13)-C(12) 118.8(9) C(38)-C(37)-H(37A) 120.000 
C(25)-H(25A) 0.990 C(14)-C(13)-H(13A) 120.600 C(36)-C(37)-H(37A) 120.000 
C(25)-H(25B) 0.990 C(12)-C(13)-H(13A) 120.600 C(37)-C(38)-C(39) 122.0(14) 
C(26)-C(27) 1.331(9) C(15)-C(14)-C(13) 120.0(9) C(37)-C(38)-H(38A) 119.000 
C(26)-C(31) 1.383(10) C(15)-C(14)-H(14A) 120.000 C(39)-C(38)-H(38A) 119.000 
C(27)-C(28) 1.404(9) C(13)-C(14)-H(14A) 120.000 C(40)-C(39)-C(38) 116.9(15) 
C(27)-H(27A) 0.950 C(10)-C(15)-C(14) 120.6(9) C(40)-C(39)-H(39A) 121.500 
C(28)-C(29) 1.366(10) C(10)-C(15)-H(15A) 119.700 C(38)-C(39)-H(39A) 121.500 
C(28)-H(28A) 0.950 C(14)-C(15)-H(15A) 119.700 C(35)-C(40)-C(39) 119.7(10) 
C(29)-C(30) 1.387(9) O(4)-Si(1)-C(22) 104.0(3) C(35)-C(40)-H(40A) 120.200 
C(30)-C(31) 1.397(9) O(4)-Si(1)-C(16) 106.3(3) C(39)-C(40)-H(40A) 120.200 
C(30)-H(30A) 0.950 C(22)-Si(1)-C(16) 113.8(4) O(41)-C(41)-O(2) 133(2) 
C(31)-H(31A) 0.950 O(4)-Si(1)-C(19) 109.7(3) O(41)-C(41)-H(41A) 104.000 
C(32)-H(32A) 0.980 C(22)-Si(1)-C(19) 110.4(5) O(2)-C(41)-H(41A) 104.000 
C(32)-H(32B) 0.980 C(16)-Si(1)-C(19) 112.1(4) O(41)-C(41)-H(41B) 104.000 
C(32)-H(32C) 0.980 C(17)-C(16)-C(18) 110.3(8) O(2)-C(41)-H(41B) 104.000 
C(33)-O(33) 1.400(9) C(17)-C(16)-Si(1) 114.8(6) H(41A)-C(41)-H(41B) 105.500 
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C(33)-H(33A) 0.990 C(18)-C(16)-Si(1) 114.8(8) C(41)-O(41)-C(42) 118.0(18) 
C(33)-H(33B) 0.990 C(17)-C(16)-H(16A) 105.300 O(41)-C(42)-C(43) 106.2(12) 
O(33)-C(34) 1.430(7) C(18)-C(16)-H(16A) 105.300 O(41)-C(42)-H(42A) 110.500 
C(34)-C(35) 1.550(13) Si(1)-C(16)-H(16A) 105.300 C(43)-C(42)-H(42A) 110.500 
C(34)-H(34A) 0.990 C(16)-C(17)-H(17A) 109.500 O(41)-C(42)-H(42B) 110.500 
C(34)-H(34B) 0.990 C(16)-C(17)-H(17B) 109.500 C(43)-C(42)-H(42B) 110.500 
C(35)-C(36) 1.376(12) H(17A)-C(17)-H(17B) 109.500 H(42A)-C(42)-H(42B) 108.700 
C(35)-C(40) 1.377(13) C(16)-C(17)-H(17C) 109.500 C(44)-C(43)-C(48) 120.000 
C(36)-C(37) 1.358(18) H(17A)-C(17)-H(17C) 109.500 C(44)-C(43)-C(42) 116.4(11) 
C(36)-H(36A) 0.950 H(17B)-C(17)-H(17C) 109.500 C(48)-C(43)-C(42) 116.2(11) 
C(37)-C(38) 1.28(2) C(16)-C(18)-H(18A) 109.500 C(45)-C(44)-C(43) 120.000 
C(37)-H(37A) 0.950 C(16)-C(18)-H(18B) 109.500 C(45)-C(44)-H(44A) 120.000 
C(38)-C(39) 1.47(2) H(18A)-C(18)-H(18B) 109.500 C(43)-C(44)-H(44A) 120.000 
C(38)-H(38A) 0.950 C(16)-C(18)-H(18C) 109.500 C(46)-C(45)-C(44) 120.000 
C(39)-C(40) 1.384(15) H(18A)-C(18)-H(18C) 109.500 C(46)-C(45)-H(45A) 120.000 
C(39)-H(39A) 0.950 H(18B)-C(18)-H(18C) 109.500 C(44)-C(45)-H(45A) 120.000 
C(40)-H(40A) 0.950 C(20)-C(19)-C(21) 116.8(10) C(45)-C(46)-C(47) 120.000 
C(41)-O(41) 1.140(19) C(20)-C(19)-Si(1) 112.9(7) C(45)-C(46)-H(46A) 120.000 
C(41)-H(41A) 0.990 C(21)-C(19)-Si(1) 115.1(7) C(47)-C(46)-H(46A) 120.000 
C(41)-H(41B) 0.990 C(20)-C(19)-H(19A) 103.200 C(46)-C(47)-C(48) 120.000 
O(41)-C(42) 1.458(16) C(21)-C(19)-H(19A) 103.200 C(46)-C(47)-H(47A) 120.000 
C(42)-C(43) 1.569(16) Si(1)-C(19)-H(19A) 103.200 C(48)-C(47)-H(47A) 120.000 
C(42)-H(42A) 0.990 C(19)-C(20)-H(20A) 109.500 C(47)-C(48)-C(43) 120.000 
C(42)-H(42B) 0.990 C(19)-C(20)-H(20B) 109.500 C(47)-C(48)-H(48A) 120.000 
C(43)-C(44) 1.390 H(20A)-C(20)-H(20B) 109.500 C(43)-C(48)-H(48A) 120.000 
C(43)-C(48) 1.390 C(19)-C(20)-H(20C) 109.500   
C(44)-C(45) 1.390 H(20A)-C(20)-H(20C) 109.500   
 
 
Table 8.3.4.  Anisotropic displacement parameters  (Å2 ! 103) for nksc14.  The anisotropic displacement 
factor exponent takes the form:  -2!2[h2 a*2U11 + ... + 2 h k a* b* U12] 
 U
11
 U
22
 U
33
 U
23
 U
13
 U
12
 
O(1) 155(4) 90(3) 57(2) -8(2) -4(2) -2(3) 
C(1) 142(5) 79(3) 46(2) -12(2) -15(3) 5(4) 
O(2) 134(3) 90(3) 71(2) -3(2) 7(2) 4(3) 
C(2) 118(4) 82(4) 62(3) 6(3) -4(3) -3(3) 
O(3) 123(3) 74(2) 72(2) 13(2) -16(2) -7(2) 
C(3) 114(4) 78(4) 65(3) 1(3) -10(3) -5(3) 
O(4) 117(3) 82(3) 59(2) -14(2) -9(2) 6(2) 
C(4) 115(4) 83(4) 68(3) -10(3) -6(3) 6(3) 
O(5) 132(3) 72(2) 63(2) 5(2) -5(2) 6(2) 
C(5) 134(4) 66(3) 51(3) -4(2) -9(3) -14(3) 
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O(6) 133(3) 66(2) 75(3) -5(2) -12(2) -5(2) 
C(6) 117(4) 79(3) 59(3) -5(3) -11(3) -3(3) 
O(7) 200(6) 118(4) 69(3) -10(3) -38(3) 28(5) 
C(7) 147(5) 76(3) 62(3) -11(3) -27(3) 5(4) 
O(8) 146(3) 77(3) 64(2) 9(2) -9(2) -1(2) 
C(8) 232(10) 92(5) 72(4) -13(4) -12(5) 12(6) 
C(9) 152(6) 78(4) 93(5) 24(4) -20(4) -27(4) 
C(10) 113(4) 77(4) 83(4) 4(3) -2(3) -5(3) 
C(11) 122(5) 84(4) 98(5) 5(4) 2(4) 2(4) 
C(12) 164(7) 94(5) 105(6) -7(5) -13(5) -14(5) 
C(13) 173(8) 104(6) 112(6) -3(5) 12(6) -42(6) 
C(14) 115(5) 128(7) 122(7) 4(6) -16(5) -13(5) 
C(15) 117(5) 110(6) 109(5) 7(5) -4(4) 13(5) 
Si(1) 114(1) 83(1) 74(1) -18(1) -17(1) 10(1) 
C(16) 111(4) 117(6) 107(5) -43(5) -1(4) 14(4) 
C(17) 152(7) 77(4) 148(8) -10(5) 10(6) -2(5) 
C(18) 137(6) 128(8) 137(7) -62(7) -9(5) -32(6) 
C(19) 136(6) 96(5) 118(6) -28(5) -48(5) 20(5) 
C(20) 204(9) 121(7) 87(5) -5(5) -13(5) 69(7) 
C(21) 134(7) 175(12) 204(13) -65(11) -48(8) 29(7) 
C(22) 155(6) 85(4) 60(3) -8(3) -20(3) 5(4) 
C(23) 183(8) 169(10) 60(4) -19(5) -17(4) 24(8) 
C(24) 146(6) 87(4) 90(5) -10(4) 15(4) 12(4) 
C(25) 103(4) 83(4) 74(3) 15(3) 2(3) -2(3) 
C(26) 112(4) 71(3) 65(3) 7(3) -13(3) -2(3) 
C(27) 140(5) 78(4) 62(3) 7(3) 2(3) -1(4) 
C(28) 130(4) 74(3) 72(3) 11(3) -1(3) 9(4) 
C(29) 125(4) 75(3) 57(3) 8(2) -10(3) -12(3) 
C(30) 111(4) 81(4) 76(4) -1(3) -6(3) 0(3) 
C(31) 110(4) 80(4) 71(3) 11(3) -5(3) 0(3) 
C(32) 138(5) 89(4) 79(4) 15(3) -11(4) -5(4) 
C(33) 134(4) 64(3) 86(4) -4(3) -11(3) -3(3) 
O(33) 147(4) 75(2) 60(2) -13(2) -16(2) 3(2) 
C(34) 168(7) 91(5) 72(4) -25(3) -42(4) 23(5) 
C(35) 172(7) 83(4) 61(3) -3(3) -16(4) 23(5) 
C(36) 215(9) 90(5) 64(4) -5(3) -9(5) 34(6) 
C(37) 260(15) 100(7) 90(6) 15(5) 5(8) 25(9) 
C(38) 292(18) 134(10) 89(7) -3(7) 14(9) 85(12) 
C(39) 230(11) 138(9) 89(5) 15(6) 27(6) 33(9) 
C(40) 165(7) 100(5) 73(4) -5(4) 3(4) 20(5) 
C(41) 161(9) 270(20) 224(18) 130(17) 54(11) 76(12) 
O(41) 285(11) 220(11) 143(7) -34(7) 118(8) -15(10) 
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Table 8.3.5.  Hydrogen coordinates (! 104) and isotropic displacement parameters (Å2 ! 103) for nksc14. 
 x y z U(eq) 
H(1A) 8089 7027 6626 109 
H(2A) 8719 7820 6391 106 
H(3A) 8425 8741 7648 104 
H(4A) 8795 6480 8722 107 
H(5A) 7990 6903 8210 102 
H(6A) 8467 4679 7606 104 
H(8A) 7927 4350 4159 200 
H(8B) 8374 4338 4490 200 
H(8C) 8198 5592 3850 200 
H(9A) 8759 10608 7350 131 
H(9B) 9095 9865 6853 131 
H(11A) 8989 12902 7570 123 
H(12A) 9399 14508 8342 147 
H(13A) 9984 13732 9081 156 
H(14A) 10125 11293 9109 148 
H(15A) 9678 9678 8447 135 
H(16A) 9161 10276 9918 135 
H(17A) 8737 12143 9738 189 
H(17B) 8398 11120 9990 189 
H(17C) 8609 10832 9089 189 
H(18A) 9112 11904 11106 203 
H(18B) 9263 10393 11481 203 
H(18C) 8829 10850 11567 203 
H(19A) 9300 7118 9695 145 
H(20A) 9357 4950 10467 208 
H(20B) 8941 5220 9956 208 
H(20C) 9010 5408 11038 208 
H(21A) 9793 6974 10873 262 
H(21B) 9526 7763 11538 262 
H(21C) 9655 8567 10660 262 
H(22A) 8397 6861 11070 122 
H(23A) 8453 7528 12600 209 
H(23B) 8762 8712 12397 209 
H(23C) 8859 7067 12277 209 
H(24A) 7970 8446 11686 161 
H(24B) 7966 8578 10602 161 
H(24C) 8184 9741 11248 161 
H(25A) 7576 5584 9081 105 
H(25B) 7808 6833 9626 105 
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H(27A) 8220 3715 10355 112 
H(28A) 8161 2537 11742 111 
H(30A) 7230 4954 12083 108 
H(31A) 7312 6118 10700 105 
H(32A) 7892 1209 12610 155 
H(32B) 7715 1226 13574 155 
H(32C) 8089 2140 13432 155 
H(33A) 8027 3146 8236 115 
H(33B) 7657 2754 7567 115 
H(34A) 7849 2822 5906 137 
H(34B) 7736 1288 6278 137 
H(36A) 7943 -497 5311 149 
H(37A) 8362 -1539 4408 181 
H(38A) 8914 -505 4205 206 
H(39A) 9090 1749 4915 182 
H(40A) 8651 2816 5825 136 
H(41A) 9376 7541 6856 260 
H(41B) 9509 5944 6916 260 
H(42A) 9146 4661 5507 240 
H(42B) 9606 4715 5624 240 
H(44A) 9092 3839 3901 240 
H(45A) 9359 3737 2503 240 
H(46A) 9802 5456 2140 240 
H(47A) 9977 7278 3174 240 
H(48A) 9710 7380 4572 240 
 
 
Table 8.3.6.  Torsion angles [˚] for nksc14. 
C(7)-O(1)-C(1)-C(2) -121.6(7) C(22)-Si(1)-C(16)-C(18) 42.6(7) 
C(7)-O(1)-C(1)-C(6) 117.5(7) C(19)-Si(1)-C(16)-C(18) -83.6(7) 
C(41)-O(2)-C(2)-C(3) -107.6(14) O(4)-Si(1)-C(19)-C(20) -68.0(8) 
C(41)-O(2)-C(2)-C(1) 133.1(14) C(22)-Si(1)-C(19)-C(20) 46.1(8) 
O(1)-C(1)-C(2)-O(2) -63.2(6) C(16)-Si(1)-C(19)-C(20) 174.0(7) 
C(6)-C(1)-C(2)-O(2) 57.6(7) O(4)-Si(1)-C(19)-C(21) 154.4(10) 
O(1)-C(1)-C(2)-C(3) 177.5(5) C(22)-Si(1)-C(19)-C(21) -91.5(11) 
C(6)-C(1)-C(2)-C(3) -61.7(7) C(16)-Si(1)-C(19)-C(21) 36.5(12) 
C(9)-O(3)-C(3)-C(2) 77.4(8) O(4)-Si(1)-C(22)-C(24) -59.2(6) 
C(9)-O(3)-C(3)-C(4) -160.4(6) C(16)-Si(1)-C(22)-C(24) 56.1(6) 
O(2)-C(2)-C(3)-O(3) 58.8(7) C(19)-Si(1)-C(22)-C(24) -176.9(5) 
C(1)-C(2)-C(3)-O(3) 179.2(5) O(4)-Si(1)-C(22)-C(23) 171.2(7) 
O(2)-C(2)-C(3)-C(4) -61.8(7) C(16)-Si(1)-C(22)-C(23) -73.6(8) 
C(1)-C(2)-C(3)-C(4) 58.6(7) C(19)-Si(1)-C(22)-C(23) 53.5(8) 
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Si(1)-O(4)-C(4)-C(5) 134.1(5) C(5)-O(5)-C(25)-C(26) -171.9(5) 
Si(1)-O(4)-C(4)-C(3) -106.2(6) O(5)-C(25)-C(26)-C(27) -5.9(9) 
O(3)-C(3)-C(4)-O(4) 60.5(7) O(5)-C(25)-C(26)-C(31) 174.1(6) 
C(2)-C(3)-C(4)-O(4) -175.9(5) C(31)-C(26)-C(27)-C(28) 0.1(11) 
O(3)-C(3)-C(4)-C(5) 179.7(5) C(25)-C(26)-C(27)-C(28) -179.9(7) 
C(2)-C(3)-C(4)-C(5) -56.7(7) C(26)-C(27)-C(28)-C(29) 0.7(11) 
C(25)-O(5)-C(5)-C(6) -124.2(6) C(27)-C(28)-C(29)-C(30) -1.0(10) 
C(25)-O(5)-C(5)-C(4) 112.9(6) C(27)-C(28)-C(29)-O(8) 177.5(6) 
O(4)-C(4)-C(5)-O(5) -59.2(7) C(32)-O(8)-C(29)-C(28) -3.5(9) 
C(3)-C(4)-C(5)-O(5) -179.1(5) C(32)-O(8)-C(29)-C(30) 175.0(6) 
O(4)-C(4)-C(5)-C(6) 178.0(5) C(28)-C(29)-C(30)-C(31) 0.5(10) 
C(3)-C(4)-C(5)-C(6) 58.1(7) O(8)-C(29)-C(30)-C(31) -178.2(6) 
C(33)-O(6)-C(6)-C(5) -98.6(6) C(27)-C(26)-C(31)-C(30) -0.7(10) 
C(33)-O(6)-C(6)-C(1) 144.1(6) C(25)-C(26)-C(31)-C(30) 179.3(6) 
O(5)-C(5)-C(6)-O(6) 61.3(7) C(29)-C(30)-C(31)-C(26) 0.4(10) 
C(4)-C(5)-C(6)-O(6) -177.6(5) C(6)-O(6)-C(33)-O(33) -74.1(7) 
O(5)-C(5)-C(6)-C(1) 179.0(6) O(6)-C(33)-O(33)-C(34) -73.7(8) 
C(4)-C(5)-C(6)-C(1) -59.9(7) C(33)-O(33)-C(34)-C(35) 169.0(6) 
O(1)-C(1)-C(6)-O(6) -59.8(7) O(33)-C(34)-C(35)-C(36) 128.7(7) 
C(2)-C(1)-C(6)-O(6) -179.2(5) O(33)-C(34)-C(35)-C(40) -55.1(9) 
O(1)-C(1)-C(6)-C(5) -178.9(6) C(40)-C(35)-C(36)-C(37) 0.2(12) 
C(2)-C(1)-C(6)-C(5) 61.7(7) C(34)-C(35)-C(36)-C(37) 176.4(8) 
C(1)-O(1)-C(7)-O(7) -0.9(11) C(35)-C(36)-C(37)-C(38) 0.3(16) 
C(1)-O(1)-C(7)-C(8) 177.2(7) C(36)-C(37)-C(38)-C(39) -0.2(19) 
C(3)-O(3)-C(9)-C(10) 162.7(6) C(37)-C(38)-C(39)-C(40) -0.2(18) 
O(3)-C(9)-C(10)-C(11) -139.2(8) C(36)-C(35)-C(40)-C(39) -0.6(12) 
O(3)-C(9)-C(10)-C(15) 38.5(11) C(34)-C(35)-C(40)-C(39) -176.9(8) 
C(15)-C(10)-C(11)-C(12) 0.1(12) C(38)-C(39)-C(40)-C(35) 0.6(14) 
C(9)-C(10)-C(11)-C(12) 177.9(9) C(2)-O(2)-C(41)-O(41) -66(3) 
C(10)-C(11)-C(12)-C(13) 2.8(14) O(2)-C(41)-O(41)-C(42) -70(3) 
C(11)-C(12)-C(13)-C(14) -2.5(16) C(41)-O(41)-C(42)-C(43) 170.6(14) 
C(12)-C(13)-C(14)-C(15) -0.9(16) O(41)-C(42)-C(43)-C(44) -160.7(10) 
C(11)-C(10)-C(15)-C(14) -3.5(12) O(41)-C(42)-C(43)-C(48) 49.1(15) 
C(9)-C(10)-C(15)-C(14) 178.8(9) C(48)-C(43)-C(44)-C(45) 0 
C(13)-C(14)-C(15)-C(10) 3.9(15) C(42)-C(43)-C(44)-C(45) -149.0(12) 
C(4)-O(4)-Si(1)-C(22) -126.3(6) C(43)-C(44)-C(45)-C(46) 0 
C(4)-O(4)-Si(1)-C(16) 113.3(6) C(44)-C(45)-C(46)-C(47) 0 
C(4)-O(4)-Si(1)-C(19) -8.1(7) C(45)-C(46)-C(47)-C(48) 0 
O(4)-Si(1)-C(16)-C(17) 27.1(7) C(46)-C(47)-C(48)-C(43) 0 
C(22)-Si(1)-C(16)-C(17) -86.8(7) C(44)-C(43)-C(48)-C(47) 0 
C(19)-Si(1)-C(16)-C(17) 147.1(7) C(42)-C(43)-C(48)-C(47) 149.0(12) 
O(4)-Si(1)-C(16)-C(18) 156.5(6)   
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8.4. (-)-D-5-O-Allyl-2,3,6-tris-O-benzyl-myo-inositol 4-(dibenzyl phosphate)
  220 
 
Figure 8.4.1.  VMD representation of crystal structure of 220. 
 
Table 8.4.1.  Crystal data and structure refinement for nksc15. 
Identification 
code 
nksc15 
Theta range for data 
collection 
3.97 to 68.11˚ 
Empirical 
formula 
C44H47O9P Index ranges 
-11<=h<=11 
-22<=k<=22 
-26<=l<=26 
Formula 
weight 
750.79 Reflections collected 52624 
Temperature 173(2) K Independent reflections 
7210 
[R(int) = 0.0660] 
Wavelength 1.54178 Å 
Completeness to  
theta = 25.00  ˚
99.3 % 
Crystal 
system 
Orthorhombic Absorption correction Multiscan 
Space group P2(1)2(1)2(1) 
Max. and min. 
transmission 
1.0000 and 0.7965 
Unit cell 
dimensions 
a = 9.639(6) Å 
b = 18.816(9) Å  
c = 22.243(11) Å 
! = 90˚ 
" = 90˚ 
# = 90˚ 
Refinement method 
Full-matrix least-
squares on F2 
Volume 4034(4) Å3 
Data 
Restraints 
Parameters 
7210 
2  
493 
Z 4 Goodness-of-fit on F2 0.993 
Density 
(calculated) 
1.236 mg/m3 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0488 
wR2 = 0.1372 
Absorption 
coefficient 
1.051 mm-1 
R indices 
(all data) 
R1 = 0.0568 
wR2 = 0.1577 
F(000) 1592 
Absolute structure 
parameter 
-0.01(3) 
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Crystal size 0.3000 ! 0.1000 ! 0.1000 mm
3 Extinction coefficient 0.0013(2) 
  Largest diff. peak and hole 
0.390 and  
-0.358 e.Å-3 
 
 
Table 8.4.2.  Atomic coordinates (! 104) and equivalent  isotropic displacement parameters (Å2 ! 103) for 
nksc15.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
O(1) 5982(2) 6139(1) 4611(1) 48(1) 
C(1) 4736(3) 6451(2) 4824(1) 35(1) 
O(2) 4582(2) 5578(1) 5614(1) 39(1) 
C(2) 4548(3) 6339(1) 5500(1) 33(1) 
O(3) 2924(2) 6487(1) 6337(1) 36(1) 
C(3) 3160(3) 6649(1) 5720(1) 32(1) 
O(4) 713(2) 6651(1) 5573(1) 37(1) 
C(4) 1978(3) 6307(1) 5367(1) 32(1) 
O(5) 1039(2) 6064(1) 4396(1) 40(1) 
C(5) 2160(3) 6417(2) 4696(1) 34(1) 
O(6) 3654(2) 6210(1) 3855(1) 40(1) 
C(6) 3542(3) 6104(1) 4486(1) 34(1) 
C(7) 5333(3) 5379(2) 6134(1) 45(1) 
C(8) 5336(3) 4576(2) 6199(1) 42(1) 
C(9) 6113(4) 4271(2) 6659(2) 64(1) 
C(10) 6140(5) 3531(2) 6740(2) 76(1) 
C(11) 5381(5) 3093(2) 6371(2) 70(1) 
C(12) 4582(4) 3390(2) 5922(2) 64(1) 
C(13) 4563(4) 4130(2) 5835(2) 52(1) 
C(14) 3578(4) 6982(2) 6741(1) 47(1) 
C(15) 3217(3) 6755(2) 7370(1) 42(1) 
C(16) 4148(3) 6368(2) 7720(1) 47(1) 
C(17) 3803(4) 6152(2) 8297(1) 54(1) 
C(18) 2494(4) 6319(2) 8525(1) 54(1) 
C(19) 1573(4) 6702(2) 8186(2) 55(1) 
C(20) 1922(3) 6924(2) 7609(1) 47(1) 
P(1) -794(1) 6340(1) 5528(1) 37(1) 
O(7) -1673(2) 6704(1) 5084(1) 47(1) 
O(8) -630(2) 5506(1) 5472(1) 41(1) 
O(9) -1408(2) 6466(1) 6171(1) 42(1) 
C(21) -1349(3) 5061(2) 5024(1) 47(1) 
C(22) -833(3) 4301(2) 5096(1) 39(1) 
C(23) 517(4) 4129(2) 4937(1) 52(1) 
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C(24) 1027(5) 3446(2) 5026(2) 67(1) 
C(25) 196(6) 2919(2) 5278(2) 70(1) 
C(26) -1153(5) 3081(2) 5435(2) 65(1) 
C(27) -1658(4) 3772(2) 5346(2) 54(1) 
C(28) -815(3) 6089(2) 6685(1) 46(1) 
C(29) -1482(3) 6339(2) 7257(1) 45(1) 
C(30) -1625(3) 5857(2) 7726(2) 53(1) 
C(31) -2147(4) 6085(3) 8279(2) 65(1) 
C(32) -2516(4) 6788(3) 8364(2) 69(1) 
C(33) -2397(4) 7277(2) 7894(2) 68(1) 
C(34) -1873(3) 7056(2) 7342(2) 55(1) 
C(35) 484(3) 6461(2) 3895(1) 47(1) 
C(36) -406(6) 6009(3) 3547(2) 112(2) 
C(37) -1355(11) 5847(3) 3348(4) 200(6) 
C(38) 4105(7) 5575(2) 3552(2) 87(2) 
C(39) 4114(4) 5704(2) 2882(1) 50(1) 
C(40) 3250(4) 5299(2) 2519(2) 60(1) 
C(41) 3306(5) 5379(2) 1894(2) 67(1) 
C(42) 4215(5) 5862(2) 1655(2) 68(1) 
C(43) 5051(4) 6259(2) 2009(2) 69(1) 
C(44) 5004(4) 6173(2) 2612(2) 63(1) 
 
 
Table 8.4.3.  Bond lengths [Å] and angles [˚] for nksc15 
O(1)-C(1) 1.419(3) C(39)-C(40) 1.386(5) C(20)-C(19)-H(19A) 119.7 
O(1)-H(1O) 0.962(19) C(40)-C(41) 1.401(5) C(19)-C(20)-C(15) 120.0(3) 
C(1)-C(6) 1.523(4) C(40)-H(40A) 0.95 C(19)-C(20)-H(20A) 120 
C(1)-C(2) 1.529(4) C(41)-C(42) 1.369(6) C(15)-C(20)-H(20A) 120 
C(1)-H(1A) 1 C(41)-H(41A) 0.95 O(7)-P(1)-O(9) 109.03(13) 
O(2)-C(7) 1.414(3) C(42)-C(43) 1.351(6) O(7)-P(1)-O(4) 113.74(12) 
O(2)-C(2) 1.454(3) C(42)-H(42A) 0.95 O(9)-P(1)-O(4) 103.63(11) 
C(2)-C(3) 1.540(4) C(43)-C(44) 1.353(6) O(7)-P(1)-O(8) 117.81(12) 
C(2)-H(2A) 1 C(43)-H(43A) 0.95 O(9)-P(1)-O(8) 105.00(11) 
O(3)-C(3) 1.425(3) C(44)-H(44A) 0.95 O(4)-P(1)-O(8) 106.38(11) 
O(3)-C(14) 1.439(3) C(1)-O(1)-H(1O) 110(3) C(21)-O(8)-P(1) 124.65(18) 
C(3)-C(4) 1.527(4) O(1)-C(1)-C(6) 107.2(2) C(28)-O(9)-P(1) 119.57(18) 
C(3)-H(3A) 1 O(1)-C(1)-C(2) 111.8(2) O(8)-C(21)-C(22) 108.0(2) 
O(4)-C(4) 1.455(3) C(6)-C(1)-C(2) 109.7(2) O(8)-C(21)-H(21A) 110.1 
O(4)-P(1) 1.569(2) O(1)-C(1)-H(1A) 109.3 C(22)-C(21)-H(21A) 110.1 
C(4)-C(5) 1.517(4) C(6)-C(1)-H(1A) 109.3 O(8)-C(21)-H(21B) 110.1 
C(4)-H(4A) 1 C(2)-C(1)-H(1A) 109.3 C(22)-C(21)-H(21B) 110.1 
O(5)-C(5) 1.434(3) C(7)-O(2)-C(2) 114.5(2) H(21A)-C(21)-H(21B) 108.4 
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O(5)-C(35) 1.444(3) O(2)-C(2)-C(1) 107.8(2) C(23)-C(22)-C(27) 118.1(3) 
C(5)-C(6) 1.530(4) O(2)-C(2)-C(3) 109.7(2) C(23)-C(22)-C(21) 120.0(3) 
C(5)-H(5A) 1 C(1)-C(2)-C(3) 111.2(2) C(27)-C(22)-C(21) 121.8(3) 
O(6)-C(6) 1.422(3) O(2)-C(2)-H(2A) 109.4 C(22)-C(23)-C(24) 120.8(3) 
O(6)-C(38) 1.439(4) C(1)-C(2)-H(2A) 109.4 C(22)-C(23)-H(23A) 119.6 
C(6)-H(6A) 1 C(3)-C(2)-H(2A) 109.4 C(24)-C(23)-H(23A) 119.6 
C(7)-C(8) 1.519(4) C(3)-O(3)-C(14) 113.2(2) C(25)-C(24)-C(23) 120.8(4) 
C(7)-H(7A) 0.99 O(3)-C(3)-C(4) 106.7(2) C(25)-C(24)-H(24A) 119.6 
C(7)-H(7B) 0.99 O(3)-C(3)-C(2) 111.3(2) C(23)-C(24)-H(24A) 119.6 
C(8)-C(13) 1.384(5) C(4)-C(3)-C(2) 109.0(2) C(24)-C(25)-C(26) 119.2(3) 
C(8)-C(9) 1.392(4) O(3)-C(3)-H(3A) 109.9 C(24)-C(25)-H(25A) 120.4 
C(9)-C(10) 1.403(5) C(4)-C(3)-H(3A) 109.9 C(26)-C(25)-H(25A) 120.4 
C(9)-H(9A) 0.95 C(2)-C(3)-H(3A) 109.9 C(25)-C(26)-C(27) 119.7(4) 
C(10)-C(11) 1.374(7) C(4)-O(4)-P(1) 126.13(16) C(25)-C(26)-H(26A) 120.1 
C(10)-H(10A) 0.95 O(4)-C(4)-C(5) 110.2(2) C(27)-C(26)-H(26A) 120.1 
C(11)-C(12) 1.378(6) O(4)-C(4)-C(3) 106.0(2) C(22)-C(27)-C(26) 121.4(4) 
C(11)-H(11A) 0.95 C(5)-C(4)-C(3) 111.2(2) C(22)-C(27)-H(27A) 119.3 
C(12)-C(13) 1.407(5) O(4)-C(4)-H(4A) 109.8 C(26)-C(27)-H(27A) 119.3 
C(12)-H(12A) 0.95 C(5)-C(4)-H(4A) 109.8 O(9)-C(28)-C(29) 110.1(2) 
C(13)-H(13A) 0.95 C(3)-C(4)-H(4A) 109.8 O(9)-C(28)-H(28A) 109.6 
C(14)-C(15) 1.504(4) C(5)-O(5)-C(35) 113.4(2) C(29)-C(28)-H(28A) 109.6 
C(14)-H(14A) 0.99 O(5)-C(5)-C(4) 107.9(2) O(9)-C(28)-H(28B) 109.6 
C(14)-H(14B) 0.99 O(5)-C(5)-C(6) 109.6(2) C(29)-C(28)-H(28B) 109.6 
C(15)-C(20) 1.394(5) C(4)-C(5)-C(6) 110.4(2) H(28A)-C(28)-H(28B) 108.2 
C(15)-C(16) 1.393(5) O(5)-C(5)-H(5A) 109.7 C(30)-C(29)-C(34) 119.8(3) 
C(16)-C(17) 1.387(5) C(4)-C(5)-H(5A) 109.7 C(30)-C(29)-C(28) 118.3(3) 
C(16)-H(16A) 0.95 C(6)-C(5)-H(5A) 109.7 C(34)-C(29)-C(28) 121.8(3) 
C(17)-C(18) 1.395(5) C(6)-O(6)-C(38) 111.6(2) C(29)-C(30)-C(31) 119.8(4) 
C(17)-H(17A) 0.95 O(6)-C(6)-C(1) 111.8(2) C(29)-C(30)-H(30A) 120.1 
C(18)-C(19) 1.371(5) O(6)-C(6)-C(5) 108.2(2) C(31)-C(30)-H(30A) 120.1 
C(18)-H(18A) 0.95 C(1)-C(6)-C(5) 110.0(2) C(32)-C(31)-C(30) 120.4(4) 
C(19)-C(20) 1.390(5) O(6)-C(6)-H(6A) 108.9 C(32)-C(31)-H(31A) 119.8 
C(19)-H(19A) 0.95 C(1)-C(6)-H(6A) 108.9 C(30)-C(31)-H(31A) 119.8 
C(20)-H(20A) 0.95 C(5)-C(6)-H(6A) 108.9 C(33)-C(32)-C(31) 120.4(4) 
P(1)-O(7) 1.470(2) O(2)-C(7)-C(8) 110.1(2) C(33)-C(32)-H(32A) 119.8 
P(1)-O(9) 1.565(2) O(2)-C(7)-H(7A) 109.6 C(31)-C(32)-H(32A) 119.8 
P(1)-O(8) 1.583(2) C(8)-C(7)-H(7A) 109.6 C(32)-C(33)-C(34) 119.6(4) 
O(8)-C(21) 1.474(3) O(2)-C(7)-H(7B) 109.6 C(32)-C(33)-H(33A) 120.2 
O(9)-C(28) 1.462(4) C(8)-C(7)-H(7B) 109.6 C(34)-C(33)-H(33A) 120.2 
C(21)-C(22) 1.523(4) H(7A)-C(7)-H(7B) 108.2 C(33)-C(34)-C(29) 119.9(4) 
C(21)-H(21A) 0.99 C(13)-C(8)-C(9) 118.1(3) C(33)-C(34)-H(34A) 120 
C(21)-H(21B) 0.99 C(13)-C(8)-C(7) 123.1(3) C(29)-C(34)-H(34A) 120 
C(22)-C(23) 1.387(5) C(9)-C(8)-C(7) 118.8(3) C(36)-C(35)-O(5) 109.3(3) 
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C(22)-C(27) 1.391(4) C(8)-C(9)-C(10) 120.9(4) C(36)-C(35)-H(35A) 109.8 
C(23)-C(24) 1.390(5) C(8)-C(9)-H(9A) 119.6 O(5)-C(35)-H(35A) 109.8 
C(23)-H(23A) 0.95 C(10)-C(9)-H(9A) 119.6 C(36)-C(35)-H(35B) 109.8 
C(24)-C(25) 1.393(6) C(11)-C(10)-C(9) 120.5(4) O(5)-C(35)-H(35B) 109.8 
C(24)-H(24A) 0.95 C(11)-C(10)-H(10A) 119.8 H(35A)-C(35)-H(35B) 108.3 
C(25)-C(26) 1.380(7) C(9)-C(10)-H(10A) 119.8 C(37)-C(36)-C(35) 155.7(9) 
C(25)-H(25A) 0.95 C(10)-C(11)-C(12) 119.2(3) C(37)-C(36)-H(36A) 102.2 
C(26)-C(27) 1.403(5) C(10)-C(11)-H(11A) 120.4 C(35)-C(36)-H(36A) 102.2 
C(26)-H(26A) 0.95 C(12)-C(11)-H(11A) 120.4 C(36)-C(37)-H(37A) 120 
C(27)-H(27A) 0.95 C(11)-C(12)-C(13) 120.5(4) C(36)-C(37)-H(37B) 120 
C(28)-C(29) 1.503(4) C(11)-C(12)-H(12A) 119.7 H(37A)-C(37)-H(37B) 120 
C(28)-H(28A) 0.99 C(13)-C(12)-H(12A) 119.7 O(6)-C(38)-C(39) 109.3(3) 
C(28)-H(28B) 0.99 C(8)-C(13)-C(12) 120.8(3) O(6)-C(38)-H(38A) 109.8 
C(29)-C(30) 1.389(5) C(8)-C(13)-H(13A) 119.6 C(39)-C(38)-H(38A) 109.8 
C(29)-C(34) 1.413(5) C(12)-C(13)-H(13A) 119.6 O(6)-C(38)-H(38B) 109.8 
C(30)-C(31) 1.397(5) O(3)-C(14)-C(15) 107.2(2) C(39)-C(38)-H(38B) 109.8 
C(30)-H(30A) 0.95 O(3)-C(14)-H(14A) 110.3 H(38A)-C(38)-H(38B) 108.3 
C(31)-C(32) 1.384(6) C(15)-C(14)-H(14A) 110.3 C(44)-C(39)-C(40) 118.4(3) 
C(31)-H(31A) 0.95 O(3)-C(14)-H(14B) 110.3 C(44)-C(39)-C(38) 122.6(4) 
C(32)-C(33) 1.396(6) C(15)-C(14)-H(14B) 110.3 C(40)-C(39)-C(38) 118.8(4) 
C(32)-H(32A) 0.95 H(14A)-C(14)-H(14B) 108.5 C(39)-C(40)-C(41) 119.7(3) 
C(33)-C(34) 1.392(5) C(20)-C(15)-C(16) 119.0(3) C(39)-C(40)-H(40A) 120.2 
C(33)-H(33A) 0.95 C(20)-C(15)-C(14) 119.8(3) C(41)-C(40)-H(40A) 120.2 
C(34)-H(34A) 0.95 C(16)-C(15)-C(14) 121.2(3) C(42)-C(41)-C(40) 118.8(3) 
C(35)-C(36) 1.434(5) C(17)-C(16)-C(15) 121.0(3) C(42)-C(41)-H(41A) 120.6 
C(35)-H(35A) 0.99 C(17)-C(16)-H(16A) 119.5 C(40)-C(41)-H(41A) 120.6 
C(35)-H(35B) 0.99 C(15)-C(16)-H(16A) 119.5 C(43)-C(42)-C(41) 121.4(3) 
C(36)-C(37) 1.061(7) C(16)-C(17)-C(18) 119.2(3) C(43)-C(42)-H(42A) 119.3 
C(36)-H(36A) 0.95 C(16)-C(17)-H(17A) 120.4 C(41)-C(42)-H(42A) 119.3 
C(37)-H(37A) 0.95 C(18)-C(17)-H(17A) 120.4 C(44)-C(43)-C(42) 119.5(4) 
C(37)-H(37B) 0.95 C(19)-C(18)-C(17) 120.3(3) C(44)-C(43)-H(43A) 120.3 
C(38)-C(39) 1.510(5) C(19)-C(18)-H(18A) 119.9 C(42)-C(43)-H(43A) 120.3 
C(38)-H(38A) 0.99 C(17)-C(18)-H(18A) 119.9 C(43)-C(44)-C(39) 122.2(4) 
C(38)-H(38B) 0.99 C(18)-C(19)-C(20) 120.6(3) C(43)-C(44)-H(44A) 118.9 
C(39)-C(44) 1.369(5) C(18)-C(19)-H(19A) 119.7 C(39)-C(44)-H(44A) 118.9 
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Table 8.4.4.  Anisotropic displacement parameters (Å2 ! 103) for nksc15.  The anisotropic displacement 
factor exponent takes the form:  -2!2[h2 a*2U11 + ... + 2 h k a* b* U12] 
 U
11
 U
22
 U
33 
U
23
 U
13
 U
12
 
O(1) 31(1) 62(1) 52(1) -12(1) 0(1) 6(1) 
C(1) 28(1) 37(1) 39(1) 2(1) -1(1) -2(1) 
O(2) 41(1) 32(1) 44(1) 3(1) -14(1) 3(1) 
C(2) 30(1) 29(1) 40(1) 1(1) -4(1) -1(1) 
O(3) 37(1) 40(1) 30(1) -2(1) -3(1) -5(1) 
C(3) 31(1) 30(1) 35(1) 4(1) -4(1) -5(1) 
O(4) 28(1) 35(1) 49(1) -3(1) 0(1) -1(1) 
C(4) 26(1) 31(1) 39(1) 2(1) -3(1) 0(1) 
O(5) 36(1) 43(1) 40(1) 6(1) -13(1) -4(1) 
C(5) 27(1) 36(1) 38(1) 3(1) -9(1) -2(1) 
O(6) 43(1) 44(1) 32(1) 0(1) -1(1) 3(1) 
C(6) 34(1) 36(1) 33(1) 4(1) -6(1) 0(1) 
C(7) 48(2) 43(2) 45(2) 4(1) -15(1) 5(1) 
C(8) 34(1) 45(2) 47(2) 8(1) -1(1) 3(1) 
C(9) 66(2) 53(2) 71(2) 21(2) -17(2) 1(2) 
C(10) 68(2) 60(2) 100(3) 40(2) -14(2) 1(2) 
C(11) 68(2) 47(2) 94(3) 24(2) 15(2) 12(2) 
C(12) 67(2) 43(2) 82(3) -1(2) 1(2) -5(2) 
C(13) 56(2) 43(2) 58(2) -1(1) -3(2) 3(2) 
C(14) 56(2) 42(2) 43(2) -5(1) -1(1) -13(1) 
C(15) 46(2) 40(2) 38(1) -10(1) 0(1) -12(1) 
C(16) 45(2) 51(2) 45(2) -8(1) -1(1) -3(2) 
C(17) 61(2) 55(2) 46(2) -3(1) -10(2) -6(2) 
C(18) 62(2) 61(2) 38(2) -3(1) -1(1) -14(2) 
C(19) 48(2) 67(2) 50(2) -16(2) 11(2) -15(2) 
C(20) 48(2) 49(2) 45(2) -9(1) -7(1) -6(1) 
P(1) 28(1) 34(1) 49(1) 1(1) -2(1) 0(1) 
O(7) 36(1) 44(1) 60(1) 6(1) -13(1) 2(1) 
O(8) 39(1) 34(1) 48(1) -1(1) -6(1) -3(1) 
O(9) 32(1) 42(1) 53(1) 0(1) 5(1) 2(1) 
C(21) 44(2) 42(2) 54(2) -3(1) -13(1) -4(1) 
C(22) 44(2) 37(1) 37(1) -6(1) -4(1) -2(1) 
C(23) 55(2) 56(2) 44(2) -3(1) 7(1) 4(2) 
C(24) 73(2) 68(2) 59(2) -7(2) 7(2) 24(2) 
C(25) 107(3) 42(2) 61(2) -9(2) -10(2) 20(2) 
C(26) 88(3) 41(2) 66(2) 5(2) -2(2) -12(2) 
C(27) 55(2) 44(2) 62(2) -3(1) 3(2) -10(2) 
C(28) 38(2) 46(2) 54(2) 0(1) 2(1) 5(1) 
C(29) 34(1) 51(2) 51(2) -8(1) 3(1) -5(1) 
Appendix 3 – X-ray crystal structure data 
 
A363 
C(30) 43(2) 60(2) 55(2) -3(2) 5(1) -2(2) 
C(31) 47(2) 94(3) 54(2) -3(2) 8(2) -4(2) 
C(32) 48(2) 95(3) 64(2) -24(2) 10(2) -3(2) 
C(33) 44(2) 71(2) 87(3) -32(2) 7(2) 0(2) 
C(34) 41(2) 53(2) 70(2) -11(2) 9(2) -3(2) 
C(35) 45(2) 54(2) 44(2) 11(1) -15(1) 2(2) 
C(36) 130(4) 104(4) 103(4) 58(3) -90(4) -57(3) 
C(37) 289(11) 87(4) 223(9) 62(5) -214(9) -70(6) 
C(38) 158(5) 64(2) 41(2) -4(2) -5(2) 38(3) 
C(39) 64(2) 48(2) 37(1) -2(1) 1(1) 14(2) 
C(40) 51(2) 63(2) 66(2) 14(2) 4(2) -11(2) 
C(41) 70(2) 66(2) 64(2) -13(2) -23(2) -1(2) 
C(42) 97(3) 66(2) 40(2) 6(2) 14(2) 21(2) 
C(43) 63(2) 68(2) 76(2) 11(2) 15(2) -6(2) 
C(44) 62(2) 51(2) 76(2) 1(2) -18(2) -6(2) 
 
 
Table 8.4.5.  Hydrogen coordinates (! 104) and isotropic displacement parameters (Å2 ! 103) for nksc15. 
 x y z U(eq) 
H(1O) 6770(30) 6380(20) 4783(18) 77(13) 
H(1A) 4747 6972 4735 42 
H(2A) 5329 6573 5721 39 
H(3A) 3150 7176 5659 38 
H(4A) 1936 5787 5458 38 
H(5A) 2132 6937 4602 40 
H(6A) 3547 5582 4571 41 
H(7A) 4905 5598 6493 54 
H(7B) 6299 5554 6102 54 
H(9A) 6632 4567 6922 76 
H(10A) 6687 3332 7053 91 
H(11A) 5407 2593 6424 83 
H(12A) 4039 3091 5670 77 
H(13A) 4014 4326 5521 63 
H(14A) 3236 7470 6665 56 
H(14B) 4597 6976 6684 56 
H(16A) 5033 6250 7560 56 
H(17A) 4449 5894 8534 65 
H(18A) 2240 6166 8917 64 
H(19A) 687 6818 8346 66 
H(20A) 1277 7191 7378 57 
H(21A) -1148 5236 4614 56 
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H(21B) -2364 5082 5090 56 
H(23A) 1100 4482 4766 62 
H(24A) 1954 3337 4913 80 
H(25A) 552 2454 5341 84 
H(26A) -1737 2726 5603 78 
H(27A) -2584 3881 5460 64 
H(28A) 197 6175 6702 55 
H(28B) -966 5571 6637 55 
H(30A) -1370 5374 7670 63 
H(31A) -2249 5755 8599 78 
H(32A) -2854 6940 8744 83 
H(33A) -2671 7757 7951 81 
H(34A) -1777 7387 7022 65 
H(35A) -46 6875 4044 57 
H(35B) 1252 6638 3640 57 
H(36A) 210 5643 3424 135 
H(37A) -2167 6126 3401 240 
H(37B) -1393 5423 3117 240 
H(38A) 3470 5178 3648 105 
H(38B) 5048 5444 3689 105 
H(40A) 2623 4970 2695 72 
H(41A) 2725 5104 1640 80 
H(42A) 4258 5920 1231 81 
H(43A) 5667 6595 1835 83 
H(44A) 5609 6447 2857 76 
 
 
Table 8.4.6.  Torsion angles [˚] for nksc15. 
C(7)-O(2)-C(2)-C(1) 138.9(2) C(15)-C(16)-C(17)-C(18) 0.9(5) 
C(7)-O(2)-C(2)-C(3) -99.9(3) C(16)-C(17)-C(18)-C(19) -1.2(5) 
O(1)-C(1)-C(2)-O(2) -57.0(3) C(17)-C(18)-C(19)-C(20) 0.7(5) 
C(6)-C(1)-C(2)-O(2) 61.9(3) C(18)-C(19)-C(20)-C(15) 0.2(5) 
O(1)-C(1)-C(2)-C(3) -177.3(2) C(16)-C(15)-C(20)-C(19) -0.5(4) 
C(6)-C(1)-C(2)-C(3) -58.4(3) C(14)-C(15)-C(20)-C(19) 178.7(3) 
C(14)-O(3)-C(3)-C(4) -156.6(2) C(4)-O(4)-P(1)-O(7) -109.0(2) 
C(14)-O(3)-C(3)-C(2) 84.6(3) C(4)-O(4)-P(1)-O(9) 132.8(2) 
O(2)-C(2)-C(3)-O(3) 55.5(3) C(4)-O(4)-P(1)-O(8) 22.3(2) 
C(1)-C(2)-C(3)-O(3) 174.6(2) O(7)-P(1)-O(8)-C(21) -3.1(3) 
O(2)-C(2)-C(3)-C(4) -61.9(3) O(9)-P(1)-O(8)-C(21) 118.4(2) 
C(1)-C(2)-C(3)-C(4) 57.2(3) O(4)-P(1)-O(8)-C(21) -132.1(2) 
P(1)-O(4)-C(4)-C(5) 81.8(3) O(7)-P(1)-O(9)-C(28) 172.7(2) 
P(1)-O(4)-C(4)-C(3) -157.74(18) O(4)-P(1)-O(9)-C(28) -65.8(2) 
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O(3)-C(3)-C(4)-O(4) 62.8(2) O(8)-P(1)-O(9)-C(28) 45.6(2) 
C(2)-C(3)-C(4)-O(4) -176.9(2) P(1)-O(8)-C(21)-C(22) 176.19(19) 
O(3)-C(3)-C(4)-C(5) -177.4(2) O(8)-C(21)-C(22)-C(23) -69.3(3) 
C(2)-C(3)-C(4)-C(5) -57.1(3) O(8)-C(21)-C(22)-C(27) 107.4(3) 
C(35)-O(5)-C(5)-C(4) 139.6(2) C(27)-C(22)-C(23)-C(24) 0.1(5) 
C(35)-O(5)-C(5)-C(6) -100.2(3) C(21)-C(22)-C(23)-C(24) 176.9(3) 
O(4)-C(4)-C(5)-O(5) -64.6(3) C(22)-C(23)-C(24)-C(25) -0.2(6) 
C(3)-C(4)-C(5)-O(5) 178.2(2) C(23)-C(24)-C(25)-C(26) 0.6(6) 
O(4)-C(4)-C(5)-C(6) 175.8(2) C(24)-C(25)-C(26)-C(27) -0.8(6) 
C(3)-C(4)-C(5)-C(6) 58.5(3) C(23)-C(22)-C(27)-C(26) -0.3(5) 
C(38)-O(6)-C(6)-C(1) 105.0(4) C(21)-C(22)-C(27)-C(26) -177.1(3) 
C(38)-O(6)-C(6)-C(5) -133.7(3) C(25)-C(26)-C(27)-C(22) 0.7(6) 
O(1)-C(1)-C(6)-O(6) -59.8(3) P(1)-O(9)-C(28)-C(29) 175.10(19) 
C(2)-C(1)-C(6)-O(6) 178.5(2) O(9)-C(28)-C(29)-C(30) 148.2(3) 
O(1)-C(1)-C(6)-C(5) 179.9(2) O(9)-C(28)-C(29)-C(34) -36.2(4) 
C(2)-C(1)-C(6)-C(5) 58.3(3) C(34)-C(29)-C(30)-C(31) -0.4(5) 
O(5)-C(5)-C(6)-O(6) 60.4(3) C(28)-C(29)-C(30)-C(31) 175.3(3) 
C(4)-C(5)-C(6)-O(6) 179.1(2) C(29)-C(30)-C(31)-C(32) -0.3(5) 
O(5)-C(5)-C(6)-C(1) -177.2(2) C(30)-C(31)-C(32)-C(33) 1.2(6) 
C(4)-C(5)-C(6)-C(1) -58.6(3) C(31)-C(32)-C(33)-C(34) -1.4(6) 
C(2)-O(2)-C(7)-C(8) -178.4(2) C(32)-C(33)-C(34)-C(29) 0.8(5) 
O(2)-C(7)-C(8)-C(13) -7.0(4) C(30)-C(29)-C(34)-C(33) 0.1(5) 
O(2)-C(7)-C(8)-C(9) 175.2(3) C(28)-C(29)-C(34)-C(33) -175.4(3) 
C(13)-C(8)-C(9)-C(10) 1.6(6) C(5)-O(5)-C(35)-C(36) 167.5(4) 
C(7)-C(8)-C(9)-C(10) 179.6(4) O(5)-C(35)-C(36)-C(37) 119.5(15) 
C(8)-C(9)-C(10)-C(11) -0.9(7) C(6)-O(6)-C(38)-C(39) 176.3(3) 
C(9)-C(10)-C(11)-C(12) -0.6(7) O(6)-C(38)-C(39)-C(44) 66.3(6) 
C(10)-C(11)-C(12)-C(13) 1.3(6) O(6)-C(38)-C(39)-C(40) -117.9(4) 
C(9)-C(8)-C(13)-C(12) -0.9(5) C(44)-C(39)-C(40)-C(41) -0.1(6) 
C(7)-C(8)-C(13)-C(12) -178.8(3) C(38)-C(39)-C(40)-C(41) -176.0(4) 
C(11)-C(12)-C(13)-C(8) -0.6(6) C(39)-C(40)-C(41)-C(42) -0.4(6) 
C(3)-O(3)-C(14)-C(15) 178.8(2) C(40)-C(41)-C(42)-C(43) 0.1(6) 
O(3)-C(14)-C(15)-C(20) -79.3(3) C(41)-C(42)-C(43)-C(44) 0.8(6) 
O(3)-C(14)-C(15)-C(16) 99.8(3) C(42)-C(43)-C(44)-C(39) -1.3(6) 
C(20)-C(15)-C(16)-C(17) 0.0(4) C(40)-C(39)-C(44)-C(43) 0.9(6) 
C(14)-C(15)-C(16)-C(17) -179.2(3) C(38)-C(39)-C(44)-C(43) 176.7(4) 
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Table 8.4.7.  Hydrogen bonds for nksc15 [Å and ˚]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
O(1)-H(1O)...O(7)   #1 0.962(19) 1.75(2) 2.710(3) 172(4) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z 
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8.5. (-)-D-5-O-Allyl-2,3,6-tris-O- benzyl-myo-inositol 1,4-bis-O- 
(dibenzylphosphate) 203 
 
 
Figure 8.5.1.  VMD stick representation of crystal structure of 203. 
 
Table 8.5.1.  Crystal data and structure refinement for 6075. 
Identification 
code 
6075 
Theta range for data 
collection 
5.107 to 26.370  ˚
Empirical 
formula 
C58H60O12P2 Index ranges 
-7<=h<=7 
-43<=k<=44 
-15<=l<=15 
Formula 
weight 
1011.05 Reflections collected 9515 
Temperature 150 K Independent reflections 
9515 
[R(int) = 0.083] 
Wavelength 0.71073 Å 
Completeness to  
theta = 25.00  ˚
98.4 % 
Crystal 
system 
Monoclinic Absorption correction 
Semi-empirical from 
equivalents  
Space group P 1 21 1 
Max. and min. 
transmission 
1.00 and 0.76 
Unit cell 
dimensions 
a = 5.96290(10) Å 
b = 35.5152(7) Å 
c = 12.5277(2) Å 
!= 90˚ 
"= 
101.1369(7)˚ 
# = 90˚ 
Refinement method 
Full-matrix least-
squares on F2 
Volume 2603.08(8)3 Å3 
Data 
Restraints 
Parameters 
5255 
650 
647 
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Z 2 Goodness-of-fit on F2 1.0746 
Density 
(calculated) 
1.290 mg/m3 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0645 
wR2 = 0.0515 
Absorption 
coefficient 
0.147 mm-1 
R indices 
(all data) 
R1 = 0.1403 
wR2 = 0.0772  
F(000) 1068.000  
Absolute structure 
parameter 
0.00(13) 
Crystal size 0.42 ! 0.05 ! 0.02 mm
3 
Largest diff. peak and 
hole 
0.43 and -0.34 e.Å-3 
 
 
Table 8.5.2. Atomic coordinates (! 104) and equivalent isotropic displacement parameters (Å2 ! 103) for 
6075.  U(eq) is defined as one third of  the trace of the orthogonalised Uij tensor. 
 x y z U(eq) 
P(1) 5677(3) 4780(1) 483(1) 38 
O(2) 4266(6) 5153(1) 155(3) 33 
C(3) 5109(9) 5519(1) 555(4) 31 
C(4) 3491(9) 5686(1) 1222(4) 31 
O(5) 3544(6) 5449(1) 2145(3) 31 
C(6) 1526(10) 5482(2) 2606(5) 51 
C(7) 1691(10) 5229(2) 3575(4) 37 
C(8) -272(11) 5043(2) 3725(5) 49 
C(9) -193(11) 4815(2) 4626(5) 60 
C(10) 1813(12) 4763(2) 5357(6) 71 
C(11) 3736(11) 4948(2) 5207(5) 69 
C(12) 3673(10) 5182(2) 4317(5) 50 
C(13) 4211(9) 6090(2) 1552(4) 31 
O(14) 6460(6) 6093(1) 2176(3) 37 
C(16) 8873(11) 6244(2) 3886(5) 53 
C(17) 10037(10) 6534(2) 3552(5) 57 
C(18) 12088(11) 6641(2) 4122(5) 60 
C(19) 13022(11) 6461(2) 5077(5) 63 
C(20) 11913(11) 6161(2) 5435(5) 68 
C(21) 9818(11) 6054(2) 4823(5) 63 
C(22) 4151(9) 6327(1) 536(4) 30 
O(23) 4846(6) 6707(1) 857(3) 33 
P(24) 3024(2) 7028(1) 872(1) 31 
O(25) 4324(6) 7317(1) 1718(3) 35 
C(26) 6512(9) 7480(2) 1630(5) 39 
C(27) 7492(9) 7678(2) 2659(4) 33 
C(28) 6167(10) 7936(2) 3099(5) 38 
C(29) 7085(11) 8120(2) 4056(5) 45 
Appendix 3 – X-ray crystal structure data 
 
A369 
C(30) 9295(11) 8053(2) 4572(5) 52 
C(31) 10610(11) 7799(2) 4130(5) 54 
C(32) 9711(10) 7615(2) 3177(5) 43 
O(33) 2839(7) 7198(1) -303(3) 38 
C(34) 1131(10) 7488(2) -700(5) 43 
C(35) 2093(10) 7872(2) -383(5) 38 
C(36) 3823(11) 8019(2) -848(5) 46 
C(37) 4777(12) 8362(2) -540(6) 57 
C(38) 3982(13) 8571(2) 251(6) 62 
C(39) 2269(13) 8422(2) 704(6) 61 
C(40) 1322(10) 8082(2) 398(5) 50 
O(41) 851(6) 6915(1) 1149(3) 36 
C(42) 5805(9) 6176(2) -132(4) 31 
C(43) 5255(9) 5763(2) -436(4) 32 
O(44) 7038(6) 5615(1) -941(3) 42 
O(48) 5623(6) 6383(1) -1117(3) 31 
C(49) 7703(10) 6557(2) -1247(5) 47 
C(50) 7309(9) 6805(2) -2238(4) 36 
C(51) 8836(10) 6803(2) -2932(5) 44 
C(52) 8563(10) 7037(2) -3824(5) 52 
C(53) 6762(11) 7287(2) -4021(5) 53 
C(54) 5198(12) 7288(2) -3321(5) 52 
C(55) 5481(10) 7049(2) -2452(4) 44 
O(56) 7767(6) 4834(1) 1296(3) 45 
O(57) 6049(7) 4613(1) -624(3) 56 
C(58) 8381(12) 4591(2) -829(5) 63 
C(59) 8387(11) 4361(2) -1821(5) 41 
C(60) 10486(11) 4183(2) -1900(6) 54 
C(61) 10534(12) 3961(2) -2804(6) 58 
C(62) 8629(13) 3921(2) -3603(6) 65 
C(63) 6661(12) 4107(2) -3523(5) 58 
C(64) 6554(11) 4315(2) -2634(5) 48 
O(65) 3872(7) 4496(1) 770(3) 44 
C(66) 3232(11) 4528(2) 1842(5) 47 
C(67) 3171(10) 4140(2) 2314(4) 37 
C(68) 1216(10) 3931(2) 2118(5) 47 
C(69) 1165(14) 3573(2) 2503(6) 68 
C(70) 3040(15) 3421(2) 3107(6) 69 
C(71) 5088(13) 3624(2) 3343(5) 65 
C(72) 5108(11) 3989(2) 2930(5) 51 
C(150) 6340(20) 6228(5) 3269(9) 48(1) 
C(151) 6780(30) 6007(5) 3317(11) 48(1) 
C(450) 6165(12) 5593(5) -2095(7) 50(2) 
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C(460) 8091(19) 5472(4) -2669(6) 52(2) 
C(470) 9964(17) 5377(4) -2155(9) 56(2) 
C(451) 6612(12) 5538(5) -2072(7) 53(3) 
C(461) 8830(20) 5593(3) -2506(8) 53(2) 
C(471) 9642(19) 5340(3) -2972(10) 55(3) 
 
 
Table 8.5.3.  Bond lengths [Å] and angles [˚] for 6075. 
P(1)-O(2) 1.581(4) C(450)-H(4501) 0.972 C(38)-C(37)-H(371) 120.3 
P(1)-O(56) 1.461(4) C(450)-H(4502) 0.969 C(37)-C(38)-C(39) 118.4(6) 
P(1)-O(57) 1.564(4) C(460)-C(470) 1.224(8) C(37)-C(38)-H(381) 120.8 
P(1)-O(65) 1.568(4) C(460)-H(4601) 0.932 C(39)-C(38)-H(381) 120.7 
O(2)-C(3) 1.446(6) C(470)-H(4701) 0.934 C(38)-C(39)-C(40) 121.9(6) 
C(3)-C(4) 1.513(7) C(470)-H(4702) 0.934 C(38)-C(39)-H(391) 118.6 
C(3)-C(43) 1.530(7) C(451)-C(461) 1.539(8) C(40)-C(39)-H(391) 119.5 
C(3)-H(31) 0.975 C(451)-H(4511) 0.971 C(35)-C(40)-C(39) 120.3(6) 
C(4)-O(5) 1.425(6) C(451)-H(4512) 0.973 C(35)-C(40)-H(401) 120 
C(4)-C(13) 1.533(7) C(461)-C(471) 1.220(8) C(39)-C(40)-H(401) 119.7 
C(4)-H(41) 0.972 C(461)-H(4611) 0.933 C(22)-C(42)-C(43) 110.2(4) 
O(5)-C(6) 1.436(6) C(471)-H(4711) 0.935 C(22)-C(42)-O(48) 110.4(4) 
C(6)-C(7) 1.497(8) C(471)-H(4712) 0.938 C(43)-C(42)-O(48) 107.7(4) 
C(6)-H(61) 0.983 O(2)-P(1)-O(56) 114.3(2) C(22)-C(42)-H(421) 108.7 
C(6)-H(62) 0.983 O(2)-P(1)-O(57) 104.3(2) C(43)-C(42)-H(421) 109.5 
C(7)-C(8) 1.389(8) O(56)-P(1)-O(57) 114.8(2) O(48)-C(42)-H(421) 110.4 
C(7)-C(12) 1.366(8) O(2)-P(1)-O(65) 104.2(2) C(42)-C(43)-C(3) 112.5(4) 
C(8)-C(9) 1.382(8) O(56)-P(1)-O(65) 117.0(2) C(42)-C(43)-O(44) 108.5(4) 
C(8)-H(81) 0.922 O(57)-P(1)-O(65) 100.3(2) C(3)-C(43)-O(44) 108.2(4) 
C(9)-C(10) 1.372(9) P(1)-O(2)-C(3) 122.0(3) C(42)-C(43)-H(431) 108.7 
C(9)-H(91) 0.922 O(2)-C(3)-C(4) 109.1(4) C(3)-C(43)-H(431) 109.1 
C(10)-C(11) 1.365(9) O(2)-C(3)-C(43) 107.2(4) O(44)-C(43)-H(431) 109.8 
C(10)-H(101) 0.931 C(4)-C(3)-C(43) 111.6(4) C(43)-O(44)-C(450) 107.8(4) 
C(11)-C(12) 1.385(8) O(2)-C(3)-H(31) 110.4 C(42)-O(48)-C(49) 113.6(4) 
C(11)-H(111) 0.934 C(4)-C(3)-H(31) 108.5 O(48)-C(49)-C(50) 110.3(5) 
C(12)-H(121) 0.933 C(43)-C(3)-H(31) 110 O(48)-C(49)-H(491) 109.9 
C(13)-O(14) 1.416(6) C(3)-C(4)-O(5) 107.5(4) C(50)-C(49)-H(491) 110.2 
C(13)-C(22) 1.520(7) C(3)-C(4)-C(13) 109.9(4) O(48)-C(49)-H(492) 108.7 
C(13)-H(131) 0.982 O(5)-C(4)-C(13) 111.9(4) C(50)-C(49)-H(492) 109 
O(14)-C(150) 1.465(12) C(3)-C(4)-H(41) 108.9 H(491)-C(49)-H(492) 108.5 
C(16)-C(17) 1.351(6) O(5)-C(4)-H(41) 110.7 C(49)-C(50)-C(51) 120.2(5) 
C(16)-C(21) 1.377(7) C(13)-C(4)-H(41) 107.9 C(49)-C(50)-C(55) 121.4(5) 
C(16)-C(150) 1.561(13) C(4)-O(5)-C(6) 112.9(4) C(51)-C(50)-C(55) 118.4(5) 
C(17)-C(18) 1.347(6) O(5)-C(6)-C(7) 110.4(5) C(50)-C(51)-C(52) 121.4(6) 
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  O(5)-C(6)-H(61) 107.9 C(50)-C(51)-H(511) 119.1 
C(18)-C(19) 1.376(7) C(7)-C(6)-H(61) 109.5 C(52)-C(51)-H(511) 119.5 
C(18)-H(181) 0.936 O(5)-C(6)-H(62) 109.8 C(51)-C(52)-C(53) 120.0(6) 
C(19)-C(20) 1.375(7) C(7)-C(6)-H(62) 109.6 C(51)-C(52)-H(521) 121.1 
C(19)-H(191) 0.936 H(61)-C(6)-H(62) 109.6 C(53)-C(52)-H(521) 118.9 
C(20)-C(21) 1.386(7) C(6)-C(7)-C(8) 118.1(5) C(52)-C(53)-C(54) 118.7(6) 
C(20)-H(201) 0.926 C(6)-C(7)-C(12) 122.6(6) C(52)-C(53)-H(531) 121.3 
C(21)-H(211) 0.921 C(8)-C(7)-C(12) 119.3(5) C(54)-C(53)-H(531) 120 
C(22)-O(23) 1.448(6) C(7)-C(8)-C(9) 119.6(6) C(53)-C(54)-C(55) 120.3(6) 
C(22)-C(42) 1.509(7) C(7)-C(8)-H(81) 120.7 C(53)-C(54)-H(541) 120.1 
C(22)-H(221) 0.982 C(9)-C(8)-H(81) 119.7 C(55)-C(54)-H(541) 119.6 
O(23)-P(24) 1.576(4) C(8)-C(9)-C(10) 120.7(6) C(50)-C(55)-C(54) 121.2(5) 
P(24)-O(25) 1.569(4) C(8)-C(9)-H(91) 119.5 C(50)-C(55)-H(551) 119 
P(24)-O(33) 1.577(4) C(10)-C(9)-H(91) 119.7 C(54)-C(55)-H(551) 119.8 
P(24)-O(41) 1.461(4) C(9)-C(10)-C(11) 119.4(6) P(1)-O(57)-C(58) 118.5(4) 
O(25)-C(26) 1.451(6) C(9)-C(10)-H(101) 120.5 O(57)-C(58)-C(59) 109.3(5) 
C(26)-C(27) 1.486(7) C(11)-C(10)-H(101) 120 O(57)-C(58)-H(581) 110.1 
C(26)-H(261) 0.974 C(10)-C(11)-C(12) 120.4(6) C(59)-C(58)-H(581) 109.4 
C(26)-H(262) 0.975 C(10)-C(11)-H(111) 120 O(57)-C(58)-H(582) 108.5 
C(27)-C(28) 1.391(7) C(12)-C(11)-H(111) 119.6 C(59)-C(58)-H(582) 111.5 
C(27)-C(32) 1.375(8) C(11)-C(12)-C(7) 120.5(6) H(581)-C(58)-H(582) 108 
C(28)-C(29) 1.383(7) C(11)-C(12)-H(121) 120.2 C(58)-C(59)-C(60) 116.5(6) 
C(28)-H(281) 0.947 C(7)-C(12)-H(121) 119.3 C(58)-C(59)-C(64) 124.3(6) 
C(29)-C(30) 1.372(8) C(4)-C(13)-O(14) 109.9(4) C(60)-C(59)-C(64) 119.2(6) 
C(29)-H(291) 0.939 C(4)-C(13)-C(22) 109.4(4) C(59)-C(60)-C(61) 117.8(6) 
C(30)-C(31) 1.379(9) O(14)-C(13)-C(22) 109.0(4) C(59)-C(60)-H(601) 121 
C(30)-H(301) 0.931 C(4)-C(13)-H(131) 109.6 C(61)-C(60)-H(601) 121.1 
C(31)-C(32) 1.375(8) O(14)-C(13)-H(131) 109.5 C(60)-C(61)-C(62) 120.8(6) 
C(31)-H(311) 0.928 C(22)-C(13)-H(131) 109.3 C(60)-C(61)-H(611) 119.9 
C(32)-H(321) 0.93 C(13)-O(14)-C(150) 107.8(6) C(62)-C(61)-H(611) 119.2 
O(33)-C(34) 1.467(6) C(17)-C(16)-C(21) 119.1(6) C(61)-C(62)-C(63) 119.9(7) 
C(34)-C(35) 1.502(8) C(17)-C(16)-C(150) 112.5(7) C(61)-C(62)-H(621) 120.2 
C(34)-H(341) 0.957 C(21)-C(16)-C(150) 127.0(7) C(63)-C(62)-H(621) 119.9 
C(34)-H(342) 0.969 C(16)-C(17)-C(18) 121.3(6) C(62)-C(63)-C(64) 120.2(7) 
C(35)-C(36) 1.380(8) C(16)-C(17)-H(171) 119 C(62)-C(63)-H(631) 120.1 
C(35)-C(40) 1.377(8) C(18)-C(17)-H(171) 119.7 C(64)-C(63)-H(631) 119.7 
C(36)-C(37) 1.370(9) C(17)-C(18)-C(19) 120.2(6) C(59)-C(64)-C(63) 121.9(6) 
C(36)-H(361) 0.928 C(17)-C(18)-H(181) 119.4 C(59)-C(64)-H(641) 118.2 
C(37)-C(38) 1.391(9) C(19)-C(18)-H(181) 120.4 C(63)-C(64)-H(641) 119.9 
C(37)-H(371) 0.938 C(18)-C(19)-C(20) 120.3(6) P(1)-O(65)-C(66) 118.0(3) 
C(38)-C(39) 1.366(9) C(18)-C(19)-H(191) 119.6 O(65)-C(66)-C(67) 108.5(4) 
C(38)-H(381) 0.934 C(20)-C(19)-H(191) 120 O(65)-C(66)-H(661) 110.1 
C(39)-C(40) 1.358(9) C(19)-C(20)-C(21) 118.0(6) C(67)-C(66)-H(661) 109.5 
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C(39)-H(391) 0.926 C(19)-C(20)-H(201) 120.3 O(65)-C(66)-H(662) 108.3 
C(40)-H(401) 0.92 C(21)-C(20)-H(201) 121.6 C(67)-C(66)-H(662) 109.9 
C(42)-C(43) 1.536(7) C(20)-C(21)-C(16) 121.0(6) H(661)-C(66)-H(662) 110.5 
C(42)-O(48) 1.423(6) C(20)-C(21)-H(211) 119.3 C(66)-C(67)-C(68) 121.0(6) 
C(42)-H(421) 0.975 C(16)-C(21)-H(211) 119.8 C(66)-C(67)-C(72) 119.9(6) 
C(43)-O(44) 1.437(6) C(13)-C(22)-O(23) 108.9(4) C(68)-C(67)-C(72) 119.1(6) 
C(43)-H(431) 0.981 C(13)-C(22)-C(42) 110.9(4) C(67)-C(68)-C(69) 121.5(6) 
O(44)-C(450) 1.441(7) O(23)-C(22)-C(42) 107.6(4) C(67)-C(68)-H(681) 119.3 
O(48)-C(49) 1.421(6) C(13)-C(22)-H(221) 110.3 C(69)-C(68)-H(681) 119.2 
C(49)-C(50) 1.504(8) O(23)-C(22)-H(221) 109.3 C(68)-C(69)-C(70) 120.2(7) 
C(49)-H(491) 0.973 C(42)-C(22)-H(221) 109.8 C(68)-C(69)-H(691) 119.8 
C(49)-H(492) 0.964 C(22)-O(23)-P(24) 121.1(3) C(70)-C(69)-H(691) 119.9 
C(50)-C(51) 1.375(7) O(23)-P(24)-O(25) 103.2(2) C(69)-C(70)-C(71) 120.8(7) 
C(50)-C(55) 1.379(8) O(23)-P(24)-O(33) 101.0(2) C(69)-C(70)-H(701) 119.5 
C(51)-C(52) 1.378(8) O(25)-P(24)-O(33) 108.4(2) C(71)-C(70)-H(701) 119.7 
C(51)-H(511) 0.944 O(23)-P(24)-O(41) 116.7(2) C(70)-C(71)-C(72) 118.0(6) 
C(52)-C(53) 1.378(9) O(25)-P(24)-O(41) 111.4(2) C(70)-C(71)-H(711) 121.8 
C(52)-H(521) 0.946 O(33)-P(24)-O(41) 115.0(2) C(72)-C(71)-H(711) 120.2 
C(53)-C(54) 1.398(9) P(24)-O(25)-C(26) 123.0(3) C(71)-C(72)-C(67) 120.4(6) 
C(53)-H(531) 0.939 O(25)-C(26)-C(27) 109.4(4) C(71)-C(72)-H(721) 119.6 
C(54)-C(55) 1.363(8) O(25)-C(26)-H(261) 107.4 C(67)-C(72)-H(721) 120 
C(54)-H(541) 0.938 C(27)-C(26)-H(261) 109.8 C(16)-C(150)-O(14) 104.8(8) 
C(55)-H(551) 0.932 O(25)-C(26)-H(262) 108.4 C(16)-C(150)-H(1501) 109.9 
O(57)-C(58) 1.464(7) C(27)-C(26)-H(262) 111 O(14)-C(150)-H(1501) 109.5 
C(58)-C(59) 1.488(8) H(261)-C(26)-H(262) 110.9 C(16)-C(150)-H(1502) 110.9 
C(58)-H(581) 0.984 C(26)-C(27)-C(28) 119.8(5) O(14)-C(150)-H(1502) 111.9 
C(58)-H(582) 0.99 C(26)-C(27)-C(32) 120.9(5) H(1501)-C(150)-H(1502) 109.7 
C(59)-C(60) 1.423(8) C(28)-C(27)-C(32) 119.2(5) C(16)-C(151)-O(14) 106.4(9) 
C(59)-C(64) 1.352(8) C(27)-C(28)-C(29) 119.7(5) C(16)-C(151)-H(1511) 109.9 
C(60)-C(61) 1.384(9) C(27)-C(28)-H(281) 119.4 O(14)-C(151)-H(1511) 110.6 
C(60)-H(601) 0.922 C(29)-C(28)-H(281) 121 C(16)-C(151)-H(1512) 111 
C(61)-C(62) 1.369(9) C(28)-C(29)-C(30) 120.6(6) O(14)-C(151)-H(1512) 109.7 
C(61)-H(611) 0.927 C(28)-C(29)-H(291) 119.6 H(1511)-C(151)-H(1512) 109.3 
C(62)-C(63) 1.368(9) C(30)-C(29)-H(291) 119.8 O(44)-C(450)-C(460) 
109.16(9
) 
C(62)-H(621) 0.922 C(29)-C(30)-C(31) 119.6(6) O(44)-C(450)-H(4501) 110 
C(63)-C(64) 1.348(8) C(29)-C(30)-H(301) 119.5 C(460)-C(450)-H(4501) 108.9 
C(63)-H(631) 0.931 C(31)-C(30)-H(301) 120.8 O(44)-C(450)-H(4502) 109.6 
C(64)-H(641) 0.938 C(30)-C(31)-C(32) 120.1(6) C(460)-C(450)-H(4502) 109.5 
O(65)-C(66) 1.470(7) C(30)-C(31)-H(311) 120.2 H(4501)-C(450)-H(4502) 109.6 
C(66)-C(67) 1.502(8) C(32)-C(31)-H(311) 119.7 C(450)-C(460)-C(470) 
121.44(1
0) 
C(66)-H(661) 0.969 C(31)-C(32)-C(27) 120.7(6) C(450)-C(460)-H(4601) 119.1 
C(66)-H(662) 0.969 C(31)-C(32)-H(321) 119.8 C(470)-C(460)-H(4601) 119.5 
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C(67)-C(68) 1.364(8) C(27)-C(32)-H(321) 119.5 C(460)-C(470)-H(4701) 120.6 
C(67)-C(72) 1.369(8) P(24)-O(33)-C(34) 120.4(3) C(460)-C(470)-H(4702) 121.9 
C(68)-C(69) 1.361(9) O(33)-C(34)-C(35) 110.1(5) H(4701)-C(470)-H(4702) 117.5 
C(68)-H(681) 0.938 O(33)-C(34)-H(341) 108.2 O(44)-C(451)-C(461) 
109.16(1
0) 
C(69)-C(70) 1.337(10) C(35)-C(34)-H(341) 109.7 O(44)-C(451)-H(4511) 109.4 
C(69)-H(691) 0.936 O(33)-C(34)-H(342) 109.4 C(461)-C(451)-H(4511) 109.1 
C(70)-C(71) 1.399(10) C(35)-C(34)-H(342) 109.5 O(44)-C(451)-H(4512) 109.1 
C(70)-H(701) 0.926 H(341)-C(34)-H(342) 109.9 C(461)-C(451)-H(4512) 111.1 
C(71)-C(72) 1.397(9) C(34)-C(35)-C(36) 120.6(5) H(4511)-C(451)-H(4512) 109 
C(71)-H(711) 0.925 C(34)-C(35)-C(40) 121.0(5) C(451)-C(461)-C(471) 
121.45(1
0) 
C(72)-H(721) 0.931 C(36)-C(35)-C(40) 118.4(5) C(451)-C(461)-H(4611) 119.6 
C(150)-H(1501) 0.978 C(35)-C(36)-C(37) 121.4(6) C(471)-C(461)-H(4611) 118.9 
C(150)-H(1502) 0.977 C(35)-C(36)-H(361) 119 C(461)-C(471)-H(4711) 120.1 
C(151)-H(1511) 0.978 C(37)-C(36)-H(361) 119.6 C(461)-C(471)-H(4712) 120.2 
C(151)-H(1512) 0.975 C(36)-C(37)-C(38) 119.6(6) H(4711)-C(471)-H(4712) 119.7 
C(450)-C(460) 1.530(7) C(36)-C(37)-H(371) 120.1   
 
 
Table 8.5.4.  Anisotropic displacement parameters (Å2 ! 103) for 6075.  The anisotropic displacement 
factor exponent takes the form:  -2!2[h2 a*2U11 + ... + 2 h k a* b* U12] 
 U
11
 U
22
 U
33
 U
23
 U
13
 U
12
 
P(1) 47(1) 29(1) 38(1) 1(1) 12(1) 12(1) 
O(2) 33(2) 25(1) 41(2) 0(1) 5(2) 2(1) 
C(3) 33(3) 24(2) 35(3) 1(2) 5(2) 5(2) 
C(4) 28(3) 29(2) 34(3) 7(2) 5(2) 8(2) 
O(5) 31(2) 32(2) 32(2) 4(1) 9(2) 6(2) 
C(6) 44(3) 57(4) 59(4) 23(3) 29(3) 19(3) 
C(7) 40(2) 39(3) 34(3) 1(2) 16(2) 6(2) 
C(8) 43(3) 61(4) 44(3) 0(3) 9(3) -9(3) 
C(9) 48(3) 72(5) 63(4) 13(3) 21(3) -13(4) 
C(10) 60(3) 93(6) 62(4) 33(4) 19(3) 4(4) 
C(11) 42(3) 107(6) 55(4) 29(3) -1(3) 4(3) 
C(12) 36(3) 59(4) 57(4) 9(3) 12(2) 1(3) 
C(13) 28(2) 30(2) 36(2) 2(2) 10(2) 11(2) 
O(14) 34(2) 36(2) 39(2) 0(2) 4(1) 8(2) 
C(16) 49(2) 75(4) 37(3) -20(2) 10(2) -4(3) 
C(17) 51(3) 64(4) 53(4) 3(3) 6(2) 13(3) 
C(18) 63(4) 49(4) 68(4) -12(3) 10(3) -2(3) 
C(19) 50(4) 72(5) 58(4) -26(3) -11(3) 1(3) 
C(20) 83(5) 62(4) 49(4) 0(3) -9(3) 19(3) 
C(21) 79(4) 66(5) 45(4) -6(3) 19(3) -13(3) 
Appendix 3 – X-ray crystal structure data 
 
A374 
C(22) 29(3) 23(2) 36(3) -2(2) 4(2) 1(2) 
O(23) 31(2) 26(2) 43(2) -4(2) 6(2) 0(1) 
P(24) 33(1) 25(1) 36(1) -3(1) 9(1) 1(1) 
O(25) 31(2) 34(2) 42(2) -7(2) 9(2) -3(2) 
C(26) 32(3) 40(3) 49(3) -12(2) 14(2) -5(2) 
C(27) 35(2) 27(3) 38(3) -1(2) 11(2) -4(2) 
C(28) 40(3) 27(3) 46(3) -1(2) 8(2) 1(2) 
C(29) 61(3) 29(3) 48(3) -6(2) 21(2) -9(3) 
C(30) 58(3) 61(4) 38(3) -8(3) 13(2) -29(3) 
C(31) 39(3) 81(5) 41(3) 4(3) 5(2) -11(3) 
C(32) 33(2) 44(4) 54(3) -1(2) 11(2) -2(3) 
O(33) 49(2) 29(2) 36(2) -3(1) 9(2) 4(2) 
C(34) 44(3) 35(2) 48(4) 7(2) 3(3) -1(2) 
C(35) 39(3) 29(2) 45(3) 5(2) 5(2) 6(2) 
C(36) 59(4) 37(3) 47(4) 5(3) 22(3) 5(2) 
C(37) 57(4) 43(3) 72(5) 12(3) 19(3) -8(3) 
C(38) 79(5) 30(3) 72(5) -5(3) 6(3) -13(3) 
C(39) 87(5) 38(3) 62(5) -8(3) 24(4) 6(3) 
C(40) 52(4) 38(3) 66(4) 5(3) 29(3) 5(3) 
O(41) 30(2) 36(2) 42(2) -5(2) 9(2) 0(2) 
C(42) 34(3) 31(2) 28(3) 2(2) 5(2) 3(2) 
C(43) 32(3) 27(2) 36(3) 3(2) 5(2) 8(2) 
O(44) 47(2) 38(2) 44(2) 3(2) 18(2) 10(2) 
O(48) 31(2) 30(2) 32(2) 5(1) 2(2) 1(2) 
C(49) 35(3) 63(4) 43(3) 5(2) 5(3) -10(3) 
C(50) 32(3) 37(3) 40(3) -5(2) 7(2) -15(2) 
C(51) 38(3) 43(3) 52(3) 3(2) 15(2) -3(3) 
C(52) 53(3) 57(4) 50(3) 5(3) 22(3) -12(3) 
C(53) 64(4) 40(4) 57(4) 18(3) 17(3) -13(3) 
C(54) 59(4) 40(4) 59(4) 6(3) 16(3) 1(3) 
C(55) 53(3) 41(3) 44(3) -3(2) 24(3) -1(2) 
O(56) 39(2) 39(2) 57(2) -2(2) 8(1) 17(2) 
O(57) 62(2) 59(3) 49(2) -12(2) 17(2) 17(2) 
C(58) 64(3) 75(5) 56(4) -18(3) 23(3) -2(4) 
C(59) 52(3) 38(3) 39(3) 3(2) 22(2) -5(3) 
C(60) 49(3) 53(4) 62(4) -4(3) 18(3) -2(3) 
C(61) 57(3) 42(4) 83(4) -11(3) 35(3) 3(3) 
C(62) 78(4) 52(4) 70(4) -23(4) 30(3) -5(3) 
C(63) 67(4) 57(4) 52(4) -4(3) 14(3) -3(3) 
C(64) 49(3) 56(4) 42(3) 9(2) 17(2) 9(3) 
O(65) 56(2) 31(2) 45(2) 5(2) 9(2) 3(2) 
C(66) 45(4) 43(3) 57(3) -1(3) 19(3) 6(3) 
C(67) 35(2) 41(3) 38(3) -4(2) 13(2) 4(2) 
Appendix 3 – X-ray crystal structure data 
 
A375 
C(68) 34(3) 53(3) 57(4) -4(3) 16(3) 1(2) 
C(69) 73(4) 62(4) 74(5) 5(3) 27(4) -21(3) 
C(70) 110(5) 51(4) 53(5) 14(3) 37(4) 9(3) 
C(71) 77(4) 71(4) 43(4) 8(3) 4(4) 34(3) 
C(72) 44(3) 63(3) 42(4) -8(3) 0(3) 7(3) 
 
 
Table 8.5.5.  Hydrogen coordinates (! 104) and isotropic displacement parameters (Å2 ! 103) for 6075. 
 x y z U(eq) 
H(31) 6617 5495 1019 36 
H(41) 1963 5694 779 37 
H(61) 1401 5745 2831 61 
H(62) 173 5414 2058 61 
H(81) -1625 5070 3233 59 
H(91) -1505 4696 4733 71 
H(101) 1865 4607 5957 85 
H(111) 5108 4915 5702 83 
H(121) 4991 5307 4217 60 
H(131) 3153 6198 1981 36 
H(171) 9396 6661 2916 68 
H(181) 12866 6840 3864 72 
H(191) 14410 6546 5487 76 
H(201) 12564 6034 6066 81 
H(211) 9050 5853 5050 75 
H(221) 2600 6330 94 35 
H(261) 6236 7659 1030 47 
H(262) 7519 7278 1485 47 
H(281) 4647 7983 2737 46 
H(291) 6193 8295 4351 54 
H(301) 9869 8171 5231 62 
H(311) 12104 7750 4476 65 
H(321) 10608 7445 2880 52 
H(341) 741 7470 -1476 52 
H(342) -214 7448 -388 52 
H(361) 4322 7883 -1390 55 
H(371) 5963 8456 -859 68 
H(381) 4602 8806 467 74 
H(391) 1749 8559 1237 74 
H(401) 165 7991 717 60 
H(421) 7351 6194 296 38 
H(431) 3789 5752 -950 38 
Appendix 3 – X-ray crystal structure data 
 
A376 
H(491) 8332 6703 -602 57 
H(492) 8784 6363 -1334 57 
H(511) 10094 6637 -2794 53 
H(521) 9595 7030 -4311 62 
H(531) 6581 7456 -4607 63 
H(541) 3951 7454 -3444 62 
H(551) 4427 7051 -1992 52 
H(581) 8954 4846 -937 77 
H(582) 9378 4480 -182 76 
H(601) 11772 4214 -1366 65 
H(611) 11865 3836 -2870 69 
H(621) 8669 3769 -4196 78 
H(631) 5385 4090 -4081 70 
H(641) 5178 4432 -2566 58 
H(661) 4343 4680 2322 56 
H(662) 1730 4642 1744 56 
H(681) -122 4035 1708 57 
H(691) -188 3433 2344 82 
H(701) 2981 3178 3371 83 
H(711) 6407 3521 3748 78 
H(721) 6454 4129 3069 61 
H(1501) 5669 6480 3219 57 
H(1502) 5437 6060 3638 57 
H(1511) 5422 6078 3603 57 
H(1512) 7066 5739 3431 57 
H(4501) 5602 5838 -2371 59 
H(4502) 4936 5411 -2239 59 
H(4601) 7821 5467 -3427 62 
H(4701) 11093 5287 -2514 66 
H(4702) 10326 5391 -1397 66 
H(4511) 5460 5711 -2444 64 
H(4512) 6046 5281 -2193 64 
H(4611) 9569 5826 -2426 65 
H(4711) 10968 5382 -3249 67 
H(4712) 8949 5102 -3045 67 
 
 
Table 8.5.6.  Hydrogen bonds for 6075 [Å and ˚]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
C(6)-H(62)...O(56)  #1 0.98 2.59 3.405(10) 141 
C(8)-H(81)...O(56)  #1 0.92 2.53 3.132(10) 124 
C(26)-H(262)...O(41)  #2 0.97 2.47 3.419(10) 164 
Appendix 3 – X-ray crystal structure data 
 
A377 
C(49)-H(491)...O(41)  #2 0.97 2.52 3.460(10) 162 
C(55)-H(551)...O(33) 0.93 2.53 3.413(10) 157 
C(58)-H(581)...C(470) 0.98 2.57 3.470(10) 152 
C(66)-H(662)...O(56)  #1 0.97 2.42 3.377(10) 170 
C(450)-H(4501)...O(48) 0.97 2.49 3.104(10) 121 
 
Symmetry transformations used to generate equivalent atoms:  
#1 x-1,y,z    #2 x+1,y,z 
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